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ABBREVIATIONS
ActD Actinomycin D
BPI Bactericidal permeability increasing protein
CARS Compensatory anti-inflammatory response syndrome
ConA Concanavalin A
CT Cocktail
DMEM Dulbeccos modified eagles medium
DMPC Dimyristoyl phosphatidyl choline
DMPG Dimyristoyl phosphatidyl glycerol
DNA Deoxyribonucleic acid
DOC Deoxycholate
DTH Delayed type hypersensitivity
EDTA Ethylene diamine tetraacetic acid
ELISA Enzyme linked immunosorbant assay
EndoCAb Endogenous core antibodies
EtBr Ethidium bromide
EU Endotoxin units
FACS Fluorescence activated cell sorting
FCS Foetal calf serum
GlcN Glucosamine
GM-CSF Granulocyte monocyte colony stimulating factor
HDL High density lipoprotein
HEK Human embryonic kidney
HK Heat killed





IRAK lnterleukin-1 receptor associated kinase
Ill International units
Kdo 2-keto-3-deoxyoctonic acid
KLH Keyhole limpet haemocyanin
LAL Limulus Amoebocyte Lysate





MHC Major histocompatibility complex
Mit-C Mitomycin-C
MOF Multiple organ failure




NRS Normal rabbit serum
PAGE Polyacrylamide gel electrophoresis
PBMC Peripheral blood mononuclear cells
PBS Phosphate buffered saline
PCP Phenol / chloroform / petroleum




PSG Penicillin, Streptomycin, Glutamine





SDS Sodium dodecyl sulphate
SI Stimulation index
SIRS Systemic inflammatory response syndrome
SOFA Sepsis - related organ failure assessment
SRBC Sheep red blood cells
TBS Tris buffered saline




TNF Tumour necrosis factor
TTBS Tween tris buffered saline
ABSTRACT
For all naturally occurring Gram-negative bacteria, lipopolysaccharide (LPS) is
an indispensible component of the outer membrane. As such, LPS has
represented a relatively immobile target for the defences of the mammalian
innate immune system and, in particular, the cellular LPS receptor Toll-like
receptor 4 (TLR-4). Under most circumstances, TLR-4 mediated recognition of
LPS provides a strongly protective benefit on the host by initiating a rapid
inflammatory response in response to Gram-negative infection. However,
systemic inflammation occuring in response to large amounts of LPS can lead to
excessive vascular permeability, activation of the clotting cascades, circulatory
collapse, shock, multiple organ failure and potentially death. It has been
hypothesised that high levels of antibodies towards LPS may provide some
protective benefit in patients at risk of endotoxin exposure, and a vaccine based
on a liposomal encapsulation of LPS has been proposed as a prophylactic agent
to induce such antibodies in high risk groups. This thesis investigates the
potential of the vaccine and the role of LPS signaling and T-cell and antibody
responses towards LPS in the pathogenesis of sepsis.
The toxicity of LPS is mediated by its capacity to induce pro-inflammatory
cytokines in the host. For this reason, the capacity of the vaccine to induce pro¬
inflammatory cytokines from murine macrophages and human monocytes was
assessed. Incorporation of LPS into liposomes was found to reduce its capacity
to induce nitric oxide from murine macrophages by approximately 3,200 fold,
TNF-a from murine macrophages by approximately 1,000,000 fold and TNF-a
from human monocytes by approximately 100,000 fold, suggesting that the
vaccine may demonstrate low enough toxicity for use in preliminary clinical trials.
The signaling of liposomal LPS was found to be dependent on the serum
proteins LBP and CD14.
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Two point mutations in the TLR-4 gene were found to be present at a frequency
of 10% in a screen of 80 Scottish residents. Monocytes derived from individuals
heterozygous for the mutations were not found to exhibit any defecit in capacity
to recognise LPS of seven different organisms.
T-cell responses to LPS have received very little investigation. The present
study investigated LPS induced proliferative responses of T-cells derived from
mouse spleen and lymph node and human peripheral blood. Proliferative
responses of human peripheral blood mononuclear cells challenged with LPS
were seen to peak at seven days and individual responses to particular core
types were seen to vary with time. The requirement of the lipid presentation
molecule CD1 could not be demonstrated using either CD1 upregulation or
antibody blocking experiments. Of 40 healthy volunteers tested, only 50%
exhibited T-cells capable of responding to LPS.
In order to investigate the clinical relevance of T-cells reactive to LPS, 27
patients admitted to hospital with inflammatory disease associated with
endotoxin exposure were assessed for T-cell and antibody responses to LPS.
Patient T-cell responses to most LPS were not significantly lower than those
displayed by healthy controls, though responses to E.coli R1 LPS were
significantly blunted (p<0.01). Patient T-cell responses to ConA were also
strongly blunted (p<0.05), as were levels of IgG antibodies specific for core
epitopes of LPS (p<0.05). The TLR-4 mutations did not appear at a higher
frequency in the patient group than in the healthy population.
The implications of these findings in the context of potential treatments for
diseases associated with endotoxin exposure is discussed.
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1.1 Structure of Lipopolvsaccharide
1.1.1 History of LPS structural studies
The history of research into the structure and function of LPS is a complex and
intriguing one, beginning more than a hundred years ago. Around the late
1870s, investigators were beginning to realise that some bacteria were capable
of excreting toxic compounds. Termed "exotoxins" to describe the fact that they
were excreted by the bacteria into their environment, these compounds gained
widespread interest when they were shown to be produced by the bacteria
responsible for diphtheria, tetanus and botulism (Rietschel et al 1999).
However, it was not until the early 1890s that the first descriptions of endotoxin
appear. In 1892 Pfeiffer and Centanni independently described pyrogenic toxins
intrinsic to the bacteria Vibrio cholerae and Salmonella typhi, each capable of
eliciting pyrexia and irreversible shock in animal models (reviewed in Rietschel
et al 1992). In contrast to the exotoxins previously described, these researchers
were able to show that these bacterial products were heat-stable and instead of
being actively extruded from the bacteria, remained associated with them. Using
the Greek word for within ("endo-") to describe the internal nature of this new
class of toxin, the term "endotoxin" was therefore applied to the compound
(Pfeiffer 1892).
Efforts to elucidate the chemical nature of the newly discovered endotoxins had
to wait another forty years or so, before analytical chemists - working with the
relatively impure crude extracts of the time - were able to hypothesise that the
heat stable compound consisted of polysaccharide, lipid and protein
constituents. However, the protein component described in these early reports
could not be detected by Shear et al (1943), whose more stringent purifications
of Serratia marcescens endotoxin allowed him to deduce that this endotoxin
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consisted of only lipid and polysaccharide, thereby leading to the coinage of the
term lipopolysaccharide.
The idea that protein was not required for the toxic activity of lipopolysaccharide
gained further support following the efforts of Luderitz and Westphal in the late
1940s, whose very pure extracts of endotoxin (lacking protein completely), again
proved able to retain all biological activity (Westphal et al 1952). By this time,
endotoxins from a wide range of different Gram-negative bacteria had been
extracted and evidence was beginning to accumulate to suggest that not only
were they all nearly identical in basic chemical composition, but each isolated
endotoxin led to identical pyrogenic responses when administered to animals
(Westphal et al 1977). These findings suggested that endotoxins most likely
existed as variants of a common molecule. Insight into this hypothesis came
with early attempts at elucidation of the structure of the molecule. The first of
these came in the 1950s with the efforts of Luderitz and Westphal, whose acid
treatment of LPS preparations yielded the first carbohydrate-free portions of LPS
(termed Lipid A), a product which also retained strong biological activity
(Westphal et al 1954).
By the 1960s, further evidence came to light to suggest that it was this lipid
portion of the molecule that contained the endotoxic activity, as so called 'deep-
rough' mutants (lacking the major part of the oligosaccharide portion of the
molecule) were found to retain strong biological activity. Other experiments,
such as mild alkali removal of fatty acids and protein binding experiments
pointed towards the same conclusion (reviewed in Rietschei et al 1994).
However, it was not until 1983 that the correct structure of Salmonella lipid A
was elucidated by Takayama and Raetz in the USA (Takayama et al 1983) and
that of Escherichia coli by Imoto et al in Europe (1983). Following these
advances, the chemical synthesis of pure lipid A allowed experimenters to
confirm that it was indeed this portion of the molecule that was responsible for
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the biological activity of the whole molecule (Galanos et al 1985, Kusumoto et al
1992).
1.1.2 General structure of LPS
Today, with procedures such as NMR, HPLC and epitope studies, the structure
of the lipopolysaccharides of many Gram-negative organisms have been
characterised, and they have all been seen to conform to a common general
architecture (Figure 1.1). Modifications of this basic structure account for the
endotoxins of all Gram-negative organisms so far investigated and can be
formally classified as containing three separate regions. Lipid A is the highly
hydrophobic and endotoxically active part of the molecule. Covalently attached
to this is the core section of the molecule which can itself be formally divided into
inner and outer core. The inner core is proximal to the lipid A and contains a
high proportion of unusual sugars such as 3-deoxy-D-manno-octulosonic acid
(Kdo) and L-glycero-D-manno heptose (Hep). The outer core extends further
from the bacterial surface and is more likely to consist of more common sugars
such as hexoses and hexosamines. Onto this is attached, in most cases, a
polymer of repeating saccharide subunits called the O-polysaccharide, or O-
chain, also typically composed of common hexoses. This O-chain is not
ubiquitous, however, as it is seen to be truncated or lacking in a number of
Gram-negative strains. Bacteria which colonise mucosal surfaces, for example,
often express LPS with a truncated non-repeating O-chain known as lipo-
oligosaccharide (LOS) (Kosma 1999, Brandtzaeg et al 2001). In addition, certain
strains carry mutations in the otherwise well conserved 'rfb' locus (which
contains a selection of genes involved in O-chain synthesis and attachment) and
are termed 'Rough mutants' to differentiate them from the wild type 'smooth'
strains which express O-chain bearing LPS.
4
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Figure 1.1 General structure of lipopolvsaccharides
1.1.3 O-polvsaccharide
The repeating units of the O-polysaccharide region consist of between one and
eight glycosyl residues and differ between strains by means of the sugars,
sequence, chemical linkage, substitution and ring forms utilised. As can be
expected, this leads to an almost limitless diversity of O-chain structure and is
verified in nature with the observation of hundreds of serotypes for particular
Gram-negative species. In addition, the number of units used to complete the
chain varies between 0 and ~ 50 and a single organism will produce a wide
range of these lengths as a result of incomplete synthesis of the chains. This
gives rise to the classical ladder pattern of molecular weights seen when smooth
LPS is visualised by SDS-PAGE (Hancock and Poxton 1998).
The O-polysaccharide is also the outermost part of the LPS molecule expressed
on bacteria and is therefore the major antigen targeted by host antibody
responses. These responses can be highly O-chain specific, and for this reason
the O-chain is often also referred to as the O-antigen. As a result of this,
serology of O-antigens has become a useful tool in typing strains of organisms
and LPS.
The O-polysaccharide region is also recognised by the innate arm of the
immune system, playing a role in both the activation and inhibition of
complement activation (Joiner et al 1986). For many organisms, eg Salmonella,
the O-chain is essential for survival in host serum as it prevents penetration of
the complement membrane attack complex (Joiner et al 1984).
1.1.4 Core polysaccharide
While the O-polysaccharide region of bacterial endotoxins is extremely variable,
the oligosaccharide structures in the core part of the molecule are much more
limited, with some regions being highly conserved between different strains and
species. As an illustration, while there are now over 160 identified O-serotypes
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for E. coli, only five unique core structures have so far been determined (R1-R4
and K12) (Rietschel et al 1993). Figure 1.2 shows some examples of the range
of core structures seen in a selection of wild type and 'rough' strain Gram-
negative bacteria.
The outer core typically consists of common hexose sugars such as glucose,
galactose, N-acetyl galactosamine and N-acetyl glucosamine (hence
alternatively referred to as the hexose region) and is generally more variable
than the inner core.
The inner core is characterised by more unusual sugars, particularly 2-keto-3-
deoxyoctonic acid (Kdo) and heptose. The former of these is seen in almost
every LPS looked at to date, being a-bound to the carbohydrate backbone of
lipid A in every case. The only exceptions yet seen to this rule are Acinetobacter
and Burkholderia cepacia LPS which employ the alternative 2-keto-D-glycero-D-
talo-octonic acid (Ko) in its place (Rietschel et al 1994, Cox et al 1995). The
bond between the lipid A and this first Kdo residue is normally very acid-labile
with moderate pH (<4.4) easily hydrolysing the bond to release the core (and
with it the O-antigen) from the lipid A (Morrison et al 1999).
Interestingly, while the O-chain and the majority of the core can be dispensed
with in some viable mutants, this Kdo residue is always absolutely required for
bacterial viability. Evidence for this is seen in the fact that the smallest
saccharide component seen in the LPS of any organism is that of a deep rough
mutant of Haemophilus influenzae (Helander et al 1988) which has only one Kdo
residue attached to its lipid A. Of the naturally-occurring bacteria, the smallest
core yet seen is that of Chlamydia spp, which consists of only a triplet of Kdo
units (Brade et al 1987) (Figure 1.2). This primary Kdo residue always has a
negatively charged substituent on it (such as phosphate, typically at position 4)
and it appears that this is also essential for viability.
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Figure 1.2 Core structures of selected lipopolvsaccharides
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The fact, therefore, that Kdo synthesis is absolutely essential for Gram-negative
bacterial viability presents rational drug designers with a tantalising opportunity.
Drugs targeting the Kdo synthesis enzymes would show not only a wide
specificity towards Gram-negative organisms but would also represent an
entirely new class of antibiotics (Hammond et al 1987).
A second unusual sugar seen in the inner core is heptose, typically in the L-
glycero-D-manno configuration, but also occasionally as D-glycero- D-manno
heptose. Yersinia strains, for example, use this isomer exclusively (Venezia et al
1985).
Both inner and outer core sugar residues can be substituted with charged
groups like phosphate, pyrophosphate, 2-aminoethylphosphate and 2-
aminoethylpyrophosphate. In the inner core it is thought that these substituents
maintain a close association with the Ca2+ and Mg2+ ions that are required for
membrane structure and function (Rietschel et al 1994).
Since the inner core is reasonably well conserved (the structure is identical, for
example, for all strains of E. coli and Salmonella) this provides the possibility of
an epitope capable of inducing an antibody response of broad enough specificity
to be cross reactive antigenically with the LPS of many different strains of Gram-
negative bacteria. This thought has already been applied in the consideration of
a new vaccine to elicit such widely cross reactive antibodies in human sera
(Bennett-Guerrero et al 2000, Erridge et al 2002b) and in the production of a
monoclonal antibody capable of binding to a wide range of E. coli and
Salmonella LPSs (Di Padova et al 1993).
Finally, it should be pointed out that while the endotoxically active part of the
molecule is lipid A, the nature and number of attached saccharide residues and
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substituents do have considerable impact on modulating this activity. The
mechanisms for this will be discussed later.
1.1.5 Lipid A
In 1985 it was shown that synthetic lipid A exhibits identical biological properties
to E. coli lipid A. (Galanos et al 1985), thus proving that lipid A is the part of the
molecule responsible for its endotoxic activity. Structurally, lipid A is typically
composed of a p- D-GlcN-(1-6)-a- D -GlcN disaccharide carrying two phosphoryl
groups (at positions 1 and 4'). Both phosphates can be further substituted with
groups such as phosphate, ethanolamine, ethanolamine phosphate,
ethanolamine diphosphate, GlcN, 4-amino-4-deoxy-L-arabino-pyranose and D-
arabino-furanose.
To this structure are attached up to 4 acyl chains by ester or amide linkage.
These chains can then in turn be substituted by further fatty acids to provide
LPS molecules with up to 7 acyl substituents, which vary quite considerably
between species in nature, number, length, order and saturation (Kosma 1999,
Venezia et al 1985, Goldberg et al 1996). These can be attached to the lipid A
either symmetrically (3+3, e.g. Neisseria meningitidis) (Brandtzaeg 2001) or
asymmetrically (4+2, e.g. E. coli) (Alexander et al 2001). Unsaturated fatty acids
are rarely seen in lipid A, but have been reported in Rhodobacter sphaeroides
and Rhodobacter capsulatus LPS and in Enterobacteriaceae grown at low
temperature. It is possible though not yet proven that this helps the bacteria
regulate membrane fluidity.
The polysaccharide portion of the molecule is almost invariably linked (see
above) to the lipid A by means of a linking Kdo residue at position 6'. This
portion of the molecule therefore constitutes the most highly conserved region
seen between LPS molecules: a phosphorylated di-glucosamine backbone
attached to at least one Kdo (or Ko) residue. (Campylobacter jejuni LPS is the
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notable exception to this rule, in which GlcN II is replaced by the related
molecule 2,3-diamino-2,3-dideoxy- D-glucose (GlcN3N) - Moran et al 1997).
Some examples of lipid As from selected human pathogens and chemically
synthesised derivatives are depicted in Figure 1.3. These are the chemically-
elucidated complete structures of lipid A, though it should be borne in mind that
like O-chain, extracted lipid A often possesses a considerable proportion of
partial or incomplete structures as a result of incomplete biosynthesis. In
addition to this intrinsic variation, it can be seen that the number, nature and
lengths of the acyl chains varies quite substantially between the LPS of different
organisms. Of particular significance may be the observation that lipid As
substituted with only five acyl chains - such as those of C.trachomatis, B.fragilis,
P.gingivalis or P.aeruginosa - tend to be the ones expressing low biological
activity in vitro.
1.2 Innate immune responses to LPS
The innate immune recognition of molecules associated with pathogenic
organisms has evolved over the millenia to provide the host with an immediate
and tailored defence against microbial invasion. In the main, the targets
recognised by these defences tend to be molecules which are absolutely
required by the pathogen for virulence or survival but which are also highly
conserved among species and strains of those organisms. In the case of Gram-
negative bacteria, the most potent and well studied activator of the innate
immune response is LPS.
Decades before the chemical structure of LPS was identified, its biological
effects in humans or animal models were well established. Administration of
even small amounts of LPS was seen to result in fever, tachycardia, shock and
potentially multiple organ failure (Redl et al 1993, Martich et al 1993, Glauser et
li
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Figure 1.3 Lipid A structures of selected lipopolysaccharides and synthetic analogues
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al 1991, Suffredini et al 1989, Galanos et al 1993, Michie et al 1988, Taveira
daSilva et al 1993). This reaction towards LPS is now established to be a direct
response of the cells of the immune system to the lipid A component of the
molecule. Exactly how the recognition of this component of LPS is achieved has
proven difficult to decipher, but the last five years or so have shown
considerable advancement in our understanding of the receptors and signalling
pathways for LPS.
1.2.1 Cellular responses to LPS
LPS in the host is dealt with at the cellular level via two distinct pathways, as
summarised in Figure 1.4. In some cell types and via some receptors, it can be
merely removed from the circulation and degraded without any stimulatory
action. Such non-stimulatory pathways exist in macrophages and Kupffer cells
and are present to remove and detoxify LPS from either the local environment or
the circulation (Wright 1991). In the main, it is thought that these activities are
mediated by the surface proteins CD18 and scavenger receptor, though it
should also be pointed out that some lipid-binding proteins in the serum are also
capable of binding LPS for direction towards the non-stimulatory degradative
pathway (Kohn and Kung 1995).
On the other hand, specific receptors exist on other cell types which are
exquisitely sensitive to the presence of LPS and engagement of these receptors
results in the eliciting of a strongly pro-inflammatory reaction. Cells of the
myeloid lineage in particular are capable of responding to even minute
concentrations of LPS with near immediate release of pro-inflammatory
cytokines (Martich et al 1993, Pugin et al 1993, Mayeux et al 1997). The role of
these in the host is to provide rapid recognition of the presence of Gram-















Mediators released by cells such as monocytes in response to recognition of
LPS include the pro-inflammatory cytokines IL-ip, TNF-a, IL-8, IL-6, IL-12, IL-
15, IL-18; the colony stimulating factors M-CSF, G-CSF and GM-CSF; lipid-
derived mediators such as platelet activating factor, prostaglandin E2 and
thromboxane; and several reactive oxygen intermediates such as the
superoxide anion (02~) and hydroxyl radicals (Alexander et al 2001). The
function of these molecules are to (i) induce local inflammation (ii) recruit further
immune cells to the environment (iii) activate nearby cells to take action and (iv)
kill the microbes directly. Further to these cellular responses, it should also be
pointed out that activation of both the classical and alternative complement
pathways can be achieved via direct molecular recognition of lipid A (Galanos et
al 1971).
In most situations involving a local point of infection, this rapid and inherent
response to LPS is extremely effective, with the invaders being swiftly dealt with
as a result of the aggressive inflammatory reaction mounted against them.
However, while this reaction is obviously of great benefit to the host under
normal conditions, it can become life-threatening when expressed systemically.
As will be discussed later, if the body is exposed systemically to LPS the
resulting overwhelming pro-inflammatory reaction can have deadly
consequences.
1.2.2 Role of LBP and CD14 in LPS recognition
The typical conformation of naturally-occurring LPS presents something of a
problem for the receptors of the immune system. Naturally-occurring endotoxin
exists as large conglomerates of LPS monomers, either as part of intact
bacterial membranes, as part of membrane fragments, or as part of free-floating
micelles of LPS shed from dying or dividing bacteria (Manthey and Vogel 1994,
Mainous et al 1991). Within these structures, the hydrophobic lipid A
components of the LPS monomers are effectively shielded from recognition by
15
mammalian receptors, so a mechanism is required by the mammalian immune
system to retreive monomeric LPS from these hydrophobic domains for
presentation to the various cellular receptors for LPS. Without such a
mechanism, free LPS monomers would be unable to cross the large
thermodynamic barrier of the aqueous environment between receptor and
target.
As such, mammalian serum contains many proteins dedicated to the shuttling of
lipids from cell to cell. Of these, investigators have shown that while some are
able to slightly inhibit or upregulate LPS signalling others appear crucial for LPS
recognition.
High density lipoprotein (HDL), for example, is typically associated with so-called
reverse cholesterol transport, but it is also a major binding protein for circulating
LPS (Wurfel et al 1995) serving to reduce the amount of LPS available in the
serum for activation of inflammatory cells. Bactericidal permeability increasing
protein (BPI) similarly reduces activity of avilable LPS by binding it and
effectively sequestering it away from the serum lipoproteins that stimulate LPS
mediated activation - an activity which can also be demonstrated in vitro (Weiss
et al 1992).
Sharing approximately 45% amino acid homolgy with BPI, however, LPS binding
protein (LBP) performs the opposite role. LBP acts to shuttle LPS monomers
from bacterial membranes and other multimeric LPS structures to the lipoprotein
required for sensitive recognition of LPS, CD14 (Hailman et al 1994, Shumann
et al 1990). LBP knockout mice are only slightly hyporesponsive to LPS however
(Wurfel et al 1997), suggesting that it does not play an entirely essential role in
sensitive recognition of LPS.
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CD14, on the other hand has been shown to be absolutely required for sensitive
recognition of LPS (Wright et al 1990). CD14 is expressed primarily on
monocytes and neutrophils as a phosphatidyl-inositol anchored cell surface
membrane protein. However, enzymic cleavage of the lipid anchor results in the
release of an LPS binding soluble CD14 (sCD14) into the serum. Here, sCD14
acts to shuttle monomeric LPS from bacterial membranes and from LBP to the
cell surface of other cell types. It has been shown capable of inserting LPS
monomers directly into the plasma membrane of host cells (a function it shares
with LBP) (Wurfel et al 1997). Cells from CD14 knockout mice show greatly
blunted responses to LPS, though it should be pointed out that they can still
respond to very high concentrations of LPS (Haziot et al 1996), suggesting that
presence of CD14 is not an absolutely necessary component of the cellular LPS
receptor.
1.2.3 Receptors for LPS
While it had been recognised for some time that CD14 was required by cells to
confer sensitive responses to LPS, it was reasoned that it could not function as
the sole receptor molecule for LPS. Being a phosphatidyl-inositol anchored
protein, CD14 lacks a transmembrane domain with which to facilitate
intracellular signalling. In addition to this, it was noted that CD14 deficient
human cells could still respond to LPS even in serum-free conditions lacking
soluble CD14 (Akashi et al 2000).
This mystery remained unsolved until 1999, when the Ips gene responsible for
the LPS hyporesponsive phenotype of C3H/HeJ mouse was at last identified
and shown to code for a mutated version of the protein TLR-4 (Toll-like receptor,
so called because of its homology with the Drosophila Toll protein) (Qureshi et al
1999, Poltorak et al 1998). Examination of the TLR-4 knockout mouse
generated the same year revealed a phenotype similar to that of the C3H/HeJ
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mouse, and thus the function of TLR-4 as an essential component of the LPS
receptor was confirmed (Hoshino et al 1999).
However, it was soon realised that this was not yet the complete picture.
Transfection of some TLR-4 deficient cell lines with TLR-4 was not in itself
sufficient to render them sensitive to LPS (Qureshi et al 1999, Hoshino et al
1999). Thus at least one further molecule was seen to be required to complete
the LPS receptor complex. This was discovered shortly afterwards to be the
protein MD-2 when it was seen that co-transfection of these cells with MD-2
restored LPS sensitivity (Shimazu et al 1999). An extracellular protein lacking a
transmembrane domain, MD-2 remains attached to the cell surface via its
interaction with TLR-4.
However, this hypothesis of the TLR-4/MD-2 complex being the sole signalling
receptor for LPS went through a period of some controversy. Many groups were
able to show responses to their LPS preparations that were independent of TLR-
4. Moreover, it appeared that another Toll like receptor, TLR-2, was critical in
these responses. Only stringent purification protocols capable of providing LPS
extracts free from protein contaminants were finally able to reveal that the
majority of LPSs signal solely through TLR4, while the TLR-2 signalling
previously seen appeared to be due to lipoprotein contamination of those
preparations (Shimazu et al 1999).
Nevertheless, two very interesting exceptions to this rule have recently been
described. The LPSs from Porphyromonas gingivalis and Leptospira interrogans
have both been shown to be recognised not by TLR-4, but by TLR-2 (Hirschfield
et al 2001, Werts et al 2001). Interestingly, the five branched acyl chains and
mono-phosphorylated lipid-A of P. gingivalis differs substantially from the typical
hexa-acyl di-phosporylated E.coli lipid-A like template recognised by TLR-4
(Kumada et al 1995). While the structure of Leptospira interrogans lipid-A has
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yet to be determined, it is tempting to speculate that it may share structural
features with P. gingivalis lipid A. Further, it is interesting to note that LPS
extracted from Bacteroides fragilis has already been shown capable of activating
TLR-4 mutant mouse (C3H/HeJ) cells and shares a lipid A of striking
resemblance (see Figure 1.3) to that of P. gingivalis lipid A (Delahooke et al
1996). Determining the chemical structures of lipid A from other organisms with
LPS capable of stimulating TLR-4 deficient cells (such as that of Treponema
denticola - Rosen et al 1990) may well shed some light on the matter of which
domains or particular three dimensional arrangements of LPS are differentiated
by TLR-2 and TLR-4.
1.2.4 Mechanisms for recognition of LPS by TLR-4/MD-2
Much evidence has recently emerged to shed some light on the mechanisms by
which the TLR-4/MD-2 complex might recognise LPS. Firstly, it appears that the
main role of LPS binding protein (LBP) in the serum is to deliver LPS to either
soluble or membrane bound CD14 (Flailman et al 1994). Then, as it is now
becoming clearer that CD14 does not play an essential role in the TLR-4/MD-2
receptor complex (see above), it seems that the likely role of CD14 is to catalyse
insertion of LPS molecules into either the plasma membrane (a function of CD14
demonstrated by Wurfel et al 1997) or directly into the receptor complex. In
support of this hypothesis, Ulevitch and co-workers have used photo-activated
cross-linking to reveal LPS in close proximity with both TLR-4 and MD-2, but
only when in the presence of CD14 (da Silva Correia et al 2001). In addition, it
has been shown that LPS is removed from mCD14 before it is internalised
(Vasselon 1999).
As for which of TLR-4 and MD-2 participate in the discrimination of active lipid
As, evidence is now emerging to suggest a role for both of these proteins in this
function. For example, it has been shown that expression of murine TLR-4 in
human cells renders them sensitive to the partial structure lipid IVa, whereas
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expression of human TLR-4 in unresponsive C3H/HeJ mouse cells does not
(Lien et al 2000, Poltorak et al 2000). On the other hand, Akashi et al have
shown that while transfection of Ba/F3 cells with murine TLR-4 and MD-2 allows
them to respond to the partial structure lipid IVa, replacement of the murine MD-
2 with the human equivalent removes this ability (Akashi et al 2001). In addition,
this chimaeric complex was seen to confer an antagonistic effect on lipid IVa,
while it remains an agonist in cells expressing the purely murine complex
(Akashi et al 2001). MD-2 has also been shown to have a direct effect on the
discrimination of another TLR-4 ligand, the anti-mitotic compound Taxol.
Signalling in response to Taxol has been shown to be ablated following the
mutation of a single glycine residue in MD-2, whereas LPS signalling remains
unaffected (Kawasaki et al 2001). Further, distinct differences have been
observed in the abilities of human and mouse MD-2 molecules to recognise
Taxol (Kawasaki et al 2000).
Nevertheless, it seems clear that dimerisation of TLR-4 appears to be the key to
activation of the complex, as chimaeric constructs of TLR-4/CD4 have been
shown to dimerise at the cytosolic domains and induce cellular activation
(Medzhitov et al 1997). Flowever, the question of how LPS is able to induce
dimerisation of TLR-4 remains as yet unclear. Depicted in Figure 1.5 are three
models which suggest how particular types of LPS may result in dimerisation of
TLR4 monomers and ultimately cellular activation.
In the first model (Figure 1,5a), LPS is recognised within the complex of MD-2
and TLR-4. MD-2 has been shown to have a high affinity for LPS (Kd = 65 nM,
similar to that of CD14 - Viriyakosul et al, 2001) and may function to hold LPS
molecules in place for TLR-4 mediated pattern recognition. Alternatively, the
incorporation of the LPS into either molecule may induce a conformational
change which then promotes dimerisation of TLR-4. In this model, LPS
molecules are delivered directy to the complex by CD14.
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Alternatively, since it has been shown that CD14 rapidly catalyses the insertion
of LPS into the plasma membrane of host cells (Wurfel et al 1997), it may be
possible that this is where TLR-4 and MD-2 encounter the LPS (Figure 1.5b). In
this scenario, the shape of the lipid A is recognised by the transmembrane
domains of TLR-4, while the (exposed) charged head group may be recognised
by MD-2.
Finally, it is possible that disruptions to the physical properties of the host cell
membrane occurring as a result of the incorporation of the unusual lipid-A are
recognised by TLR-4/MD-2, as first suggested by Samuel Wright (Wright 1999).
Evidence for this include the striking correlation between lipid A phase transition
temperature (Tc) and toxicity (Seydel et al 1993) and the fact that the membrane
active agent chlorpromazine is able to render cells sensitive to the inactive lipid
IVa (Thiemblemont et al 1998). The effects of lipid A antagonists can also be
explained in this model by functioning to counteract the physical changes in the
membrane caused by lipid A. In this model, local membrane architecture is
altered in such a way as to dimerise the TLR subunits with the assistance of
MD-2 resulting in signalling (Figure 1.5c).
1.2.5 Intracellular signalling of the TLR-4/MD-2 complex
The TLR-4 signalling pathway shows striking similarities to that employed by the
IL-1 receptor (IL-1R). In both pathways, the adaptor protein MyD88 (myeloid
differentiation factor 88) is thought to be recruited to activated (i.e. dimerised) IL-
1R or TLR-4 cytosolic domains where it catalyses the activation of
serine/threonine kinases of the IRAK family. These then act through TNF-
receptor associated factor 6 (TRAF-6) to promote both MAP kinase cascades
and the NF-kB inducing cascade (reviewed in Underhill et al 2002).
Recently a protein has also been identified that interacts both with the
cytoplasmic tail of the IL1 receptor and with IRAKs. Termed Tollip this protein
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has also been shown to co-precipitate with TLR-2 and TLR-4 (Bulut et al 2001),
and is also likely to play a role in recruiting IRAKs to the dimerised Toll receptors
(as depicted in Figure 1.6).
Evidence is accumulating, however, to suggest that LPS signalling may proceed
along alternative parallel pathways. For example, certain cellular responses
towards LPS do not require MyD88, and while the activation of NF-kB in
response to LPS is merely delayed in MyD88 deficient cells, it is completely
abolished in TLR-4 deficient cells (Kawei 1999). Another recently discovered
protein TIRAP (or MAL) has been shown to interact with both TLR-4 and IRAK-2
and on over-expression also activates NF-kB (Fitzgerald et al 2001, Florng et al
2001). It is therefore possible that this adaptor protein is responsible for at least
one MyD88-independent signalling pathway, though its full function remains to
be determined.
1.2.6 Roles of other Toll like receptors
At least ten Toll-like receptors have now been seen to be expressed in human
cells, and appear to be used to recognise particular "pathogen associated
molecular patterns" (PAMPs) contained in highly conserved molecules. Table
1.1 shows some of the molecules recently shown to be recognised by the
various Toll-like receptors. Interestingly, it has recently been shown that
recognition of some molecules is achieved via heterodimers of different Toll-like
receptors. For example, TLR-2 has been shown to co-operate with at least TLR-
6, and possibly other TLRs in the recognition of molecules (Ozinsky et al 2000).
Indeed, it has even been shown that dimerisation of TLR-2 as a homodimer
does not result in cellular activation (Ozinsky et al 2000). If this co-operation
between receptor molecules turns out to be more widespread among the TLRs,









Figure1.6Proposedcompon ntsfTLR4/MD2intracellularsi nal ingc p ex Tollip- linteractingprote ,TIRAP-oll/lnterleukin-1rec ptorassociat d protein,IRAK-lnterleukin-1receptorassocia dkinas ,MAPi s-mit gen activatedproteinkinas ,NF-kB-nuclearfactorkB.
However, of more interest is the fact that the signalling via different TLRs can
result in differential gene expression. For example, macrophages stimulated via
TLR-2 can be triggered to release TNF-a, IL-113 and MIP-2, whereas
macrophages stimulated via TLR-4 are triggered to release all of these
cytokines, but also IL-12 p40, IFN-y and macrophage chemotactic protein 5
(Hirschfield et al 2001). If this observation transpires to be relevant for all the
TLRs, or even possible pairings of the TLRs, it may turn out that the innate
immune response is capable of producing very specialised actions tailored to
each individual pathogen.
Table 1.1: Identified ligands of the Toll-like receptors
Toll receptor Ligand
TLR-1 Unknown
TLR-2 Peptidoglycan, bacterial lipoproteins, Leptospira and
(+TLR-6 / Porphyromonas LPS, S. cerevisiae zymosan, T.cruzii GPI
unidentified anchor, M. tuberculosis lipoarabinomannan and
TLR) phosphatidylinositol dimannoside
TLR-3 Double stranded (ds) RNA
TLR-4 Most LPS, Taxol, HSP-60 (human and chlamydial), fibronectin







1.2.7 Signaling of liposomal LPS
The idea of using LPS as either an adjuvant or a vaccine has over the years
received a great deal of interest (Cryz et al 1987, Barclay et al 1986, Cryz et al
1991, Bhattercharjee et al 1996, McCabe et al 1972, McCabe et al 1977,
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Bhattacharjee et al 1999). That the O-chain and core epitopes of LPS are highly
immunoreactive and capable of eliciting both specific and broadly cross-reactive
antibody responses are undoubted (Ziegler et al 1979, Teng et al 1985, Ziegler
et al 1982, Scott and Barclay 1987, Di Padova et al 1993) - only the inherent
toxicity of LPS (as discussed above) precludes its widespread use as an agent
for vaccination. For this reason, ways of reducing the biological activity of LPS
by avoiding the TLR-mediated pro-inflammatory response have deservedly
received much attention.
Encouraged by the reduction in activity seen when LPS was allowed to integrate
into the plasma membrane of sheep red blood cells (Galanos et al 1971, Pollack
et al 1989), people sought other ways of reducing the activity of LPS. Dijkstra
was the first to show that incorporation of LPS into liposomal vesicles was able
to mask the toxic lipid A and reduce its biological activity by up to a thousand¬
fold (Dijkstra et al 1987).
Since that initial observation, considerable interest has been shown in liposomal
LPS, and each study has shown a significant reduction in toxicity. For example,
studies of S. minnesota rough (Re) and wild-type LPS showed that incorporation
of LPS into liposomes according to the method of Dijkstra et al (1988) results in
the reduction of IL-1 p secretion from RAW 264.7 macrophages by between 100-
and 1000-fold, (Dijkstra et al 1987) and TNF-a release of 100-1000-fold
(Dijkstra et al 1988b). A reduction in activity as measured by limulus
amoebocyte lysate assay has been observed to be in the order of between 100-
and 1000- fold (Dijkstra et al 1988a), and actinomycin D-sensitized mice have
been shown to have a 10-fold reduction in lethality when challenged with
liposomal lipid A compared with native lipid A (Dijkstra et al 1989). Finally,
encapsulation of Neisseria meningitidis LPS within liposomes has been shown
to reduce the pyrogenicity of LPS in rabbits by up to 1000-fold (Petrov et al
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1992). These findings offer promise for the concept of a lipopolysaccharide-
based vaccine.
1.3 Antibody responses to LPS
1.3.1 History
While the innate immune response to LPS is focused on the lipid A component
of the molecule, it remains for the adaptive immune response to react to the
polysaccharide component. As long ago as the 1960s, it was shown by Luderitz
and Westphal that strong variation exists between the O-polysaccarides of
various bacterial strains and that the antibodies raised against these O-chains
are rarely cross-reactive. The early nineteen-seventies saw several groups
demonstrating that antibodies raised against particular O-chains could protect
animals from infection or endotoxaemia from bacteria of the same O-antigen.
However, the early studies of Braude and McCabe and others demonstrated
that antibodies raised against the core-structures of LPS could cross-react with
LPS from heterologous strains and these antibodies appeared capable of
protecting animals from challenge with heterologous Gram-negative bacteria
(Braude et al 1972, McCabe et al 1972).
Encouraged by these findings, these researchers and others raced to produce
therapeutic preparations of these antibodies for use in human clinical trials. The
resulting monoclonals and hyperimmune sera tested revealed ambiguous
results in preliminary trials, leading to a great deal of controversy and ultimately
the removal of one such drug (HA1A) from the market (Baumgartner 1994).
This section will now discuss the role of anti-LPS antibodies in protection from
LPS-mediated pathologies and review the events that led to the removal of one
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such preparation from the marketplace and the prospects for a better designed
vaccine approach.
1.3.2 Antibodies to O-polysaccharide
The O-polysaccharide of LPS demonstrates incredible diversity. More than a
hundred different sugars have so far been found to contribute to their structure,
and each of these may combine with several others to create unique 0-
polysaccharide subunits. Further to this, these sugars can of course be joined in
any order and vary considerably in their use of glycosidic linkages. Thus the
possibility for variation of the O-antigen tertiary structure is immense, and by
direct correlation so must the potential range of antibodies directed against
these O-chains. However, since the O-chain is seen to adopt an irregular spiral
shape, it is probable that particular O-chains display a particular series of
repeating epitopes and one or more terminal epitopes that provide
immunodominant motifs for antibody formation and recognition (Barclay 1990).
Around the early seventies, several groups were beginning to show that
antibodies directed against the polysaccharide (O-antigen) of LPS were able to
protect against infection and shock in animal models when challenged with
bacteria of homologous serotype (Kirkland et al 1984, Barclay et al 1986, Cross
et al 1988). Unsurprisingly, however, given the vast diversity seen in the O-
polysacchirides of different strains and species of Gram-negative bacteria, these
antibodies could not be shown to protect against challenge with heterologous 0-
serotypes (Kirkland et al 1984, Barclay et al 1986, Cross et al 1988).
More recently, direct evidence has emerged to show that O-polysaccharide
directed anibodies can decrease the toxicity of LPS. For example, Burd et al
(1993) have shown that an lgG3 monoclonal antibody directed against the 0-
chain of E.coli 0111 is able to enhance uptake of that LPS by macrophages and
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also reduces resultant TNF secretion of these cells. These authors concluded
that Fc-mediated uptake was bypassing the mechanism of TNF secretion.
In terms of clinical benefit, however, it was realised that to provide humoral
immunity against the LPSs from a wide range of LPSs, O-polysaccharide-
directed antibodies would not work as they were simply too strain-specific.
Instead, a much more widely cross-reactive antibody would have to be found
capable of neutralising the LPSs from many different strains and species.
1.3.3 Antibodies to core epitopes
In contrast to O-polysaccharide, the core glycolipid structures of LPS are
relatively conserved between different serotypes and species of Gram-negative
bacteria (Jansson et al 1981, Westphal et al 1983, Barclay 1990). All strains of
E.coli, for example, express one of only five distinct core types (R1-4 and K12)
(Jansson et al 1981). For this reason, it was suggested by Chedid as far back as
1968 that a small number of antibodies directed against this core structure of the
LPS molecule might act as 'masterkeys', being able to react with the LPS from
an extensive range of strains (Chedid et al 1968).
Certainly, the structural properties of core LPS lend themselves to this
hypothesis. Different core types tend to share more structural features between
themselves than the highly diverse O-chains, and the relatively well conserved
sugars, phosphoryl residues and other charged substituents (such as
ethanolamine) of the inner core therefore represent particularly good targets for
potentially cross-reacting antibodies. On the other hand, it is clear that while
some antibodies raised against core epitopes may react well with both rough
and smooth LPS (Di Padova et al 1993), others may fail to react with complete
S-LPS, as evidenced by Western blots (DeJongh-Leuvenink et al 1986, Pollack
et al 1989), presumably representing those antibodies directed against core
epitopes masked by O-polysaccharide substitution.
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Nevertheless, the cross-protection hypothesis gained further credence with the
demonstration in 1972 by both Braude and McCabe that antibodies directed
against inner core epitopes were able to protect against bacterial challenge from
heterologous strains in animal models (Braude et al 1972, McCabe et al 1972).
As most pathogenic bacteria typically express smooth LPS, however, these
findings may at first seem contra-intuitive. However, since it has been shown
that the LPS extracted from S-strain bacteria contains considerable amounts of
unsubstituted core (R-LPS) without polysaccharide (Westphal et al 1983), it is
thought that these epitopes are expressed on the surface of all wild type
bacteria. Thus, covering a considerable proportion of the bacterial surface,
antibodies directed against these core epitopes should be able to bind to all
bacteria expressing either that core type or a closely related one, regardless of
the O-chain substitution in that strain. Figure 1.7 summarises the potential
binding sites for antibodies to LPS molecules.
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Antibodies to Lipid-A may react with
phosphate, glucosamine or even lipid
component, but may suffer from non¬
specific binding to hydrophobic
surfaces.
Antibodies to O-polvsaccharide may bind to
repeating epitopes, but are unlikely to cross react
between strains and species.
Antibodies to Core-saccharides are much
more likely to cross react between strains
and species.
Figure 1.7 Potential binding sites for antibodies directed against LPS
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1.3.4 Core antibodies in sepsis
Antibodies to core saccharides are not merely laboratory artefacts. Many studies
have been able to show that antibodies directed against core epitopes occur
naturally and exist in the sera of healthy subjects (Barclay et al 1987, Scott et al
1987, Barclay et al 1989). Indeed it was the opinion of Barclay (1990) that "there
is now significant evidence to suggest that natural LPS-cross-reactive IgG
antibodies to common shared epitope structures of the Gram-negative endotoxin
core emerge as a result of continuous exposure to endotoxins, and that these
antibodies may constitute a significant component of the host defence against
Gram-negative bacteraemia and endotoxaemia."
Measurement of anti-core antibodies has been assisted by the development of
an ELISA based on four rough mutant LPS (approximately Rb-Rc) from the
organisms Escherichia coli K12, Pseudomonas aeruginosa PAC611, Klebsiella
pneumoniae KaM10b and Salmonella typhimurium 878. (Barclay et al 1987).
Developed to provide a measurement of the titre of cross-reacting anti-core
antibodies in human subjects, this test has been used as the basis of the
investigations into the role played by anti-core antibodies in various disease
processes.
For example, anti-core antibodies were seen to be depleted during episodes of
endotoxaemia, then restored in 2 of 3 patients studied with septic shock (Barclay
et al 1989). The same protocol has been used to measure LPS antibody kinetics
in pancreatitis patients (Windsor et al 1993), surgical patients with gut mucosal
hypoperfusion (Mythen et al 1993), sepsis patients (Barclay et al 1989) and
patients with haemolytic uraemic syndrome (Heydermann et al 1994), with each
of these studies suggesting that depletion of anti-core LPS antibodies can occur
in these patient groups. Further, recent studies of anti-LPS antibodies in the
sera of pre- and post-surgery patients have revealed a correlation between high
endogenous levels of anti-core LPS antibodies and protection from adverse
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post-operative outcome (Freeman et at 1985, Bennett-Guerrero et at 1997,
Hamilton-Davies et al 1997, Bennett-Guerrero et al 2001).
Taken together, the data from these studies provide further support for the
hypothesis that augmentation of levels of anti-core antibodies in patients may
provide some protective benefit in disease processes involving either Gram-
negative infection or endotoxaemia.
1.3.5 Clinical trials of anti-LPS antibodies
The succesful application of anti-LPS antibodies to animal models of disease in
the laboratory led to a strong interest among researchers in the clinical
application of such antibodies. As it is extremely difficult to condense the
sequence of events and reports that accompanied these efforts, I have listed the
majority of these in Table 1.2 (at the end of this chapter) with the more
significant ones being reviewed as follows.
In the early seventies, two groups in particular focussed their interests on the
clinical applications of passive transfer of LPS-reactive antibodies. McCabe and
colleagues measured the titres of naturally-occurring antibodies to S. minnesota
Re chemotype LPS in cases of Gram-negative bacteraemia. They found that
high titres of anti-Re-LPS were associated with a decreased frequency of shock
or fatal outcome, whereas no protection was observed from O-specific
antibodies (McCabe et al 1972). Subsequent animal studies performed by the
same group appeared to show that antibodies raised against E.coli J5 (Rc
chemotype) LPS or S. minnesota Re LPS could protect those animals against
heterologous Gram-negative bacterial infection (McCabe et al 1977).
Then in 1979, Ziegler and colleagues were able to show that antibodies raised
against certain R-mutant LPS (in particular that of E.coli J5) were capable of
protecting animals against challenge from both infection and endotoxin from
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heterologous smooth bacteria (Ziegler et al 1979). This demonstration led the
same group to attempt in 1982 the therapeutic passive transfer of plasma from
donors immunised with J5 to patients with sepsis (Ziegler et al 1982). Their
initial interpretation of the data was that a beneficial effect was observed on
treated patients. However, later interpretation of the same data (Baumgartner
1994) questioned the validity of their assumptions. In particular, concerns were
voiced over the lack of evaluation of the severity of illnesses among the patients
at entry other than by listing underlying diseases, and the unusually high
mortality shown in the control group of patients with septic shock (77%). The
following year saw the first openly negative result for passive transfer of J5
human antiserum when McCutchan et al were unable to show any protective
benefit from the administration of a single prophylactic dose of human antiserum
to J5 in Gram-negative-infected patients with prolonged neutropenia
(McCutchan et al 1983).
Nevertheless, two years later Baumgartner et al attempted prophylactic passive
transfer of antibody raised in human volunteers immunised with E.coli J5 to
high-risk surgery patients (Baumgartner et al 1985). In this small preliminary
study, some degree of protection was observed against septic shock, raising
hopes that larger trials of the antibody would demonstrate the same benefit
(Baumgartner et al 1985). However subsequent re-analysis of the results of this
initial study were later questioned by the same authors (Baumgartner et al 1987)
- their main concerns being the small sample size and the fact that while the
one-tailed statistical test was significant, the more appropriate two-tailed test
was not.
In the same year (1985), the study of Teng et al showed protection against
Gram-negative bacteraemia and endotoxaemia with the administration of human
monoclonal IgM antibodies (Teng et al 1985). However, later analysts suggested
that these data should be interpreted with caution, as they were performed with
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ascites or hybridoma fluids, not with purified antibodies (Baumgartner 1994). To
add to the controversy, Calandra et al wrote in 1988 that they had been unable
to demonstrate a benefit when anti-J5 intravenous immune globulin was used in
the treatment of Gram-negative septic shock (Calandra et al 1988).
Further concerned at the lack of unequivocal evidence as to the efficacy of anti-
LPS antibodies in the treatment of these conditions, Baumgartner's group
attempted to repeat some of the earlier animal studies. They reported their
inability to reproduce the results of the early J5 antiserum cross-protection
studies in animals (Baumgartner et al 1990, Baumgartner 1991).
Meanwhile, two large pharmaceutical companies had purchased the rights to
two monoclonals derived from E. coli J5 immunisations - termed E5 and HA1 A.
Human IgMs directed against lipid A, both E5 and HA1A had shown initially
promising results in animal models (Teng et al 1985, Young et al 1989). Eager
to be the first to the marketplace, Centocor rushed HA1A into clinical trials, the
first of which showed ambiguous results but which was nevertheless granted
approval for sale by a panel of experts in the USA in September 1991. HA1A
became available for sale in the USA and in Europe very shortly afterwards.
However, doubts were soon raised as to the validity of the conclusions from this
initial trial when Baumgartner showed that HA1A was able to bind non-
specifically to hydrophobic surfaces such as Gram-negative and Gram-positive
bacterial membranes, yeasts, high density lipoproteins and cardiolipin but only
very poorly to its purported ligand, lipid A (Baumgartner et al 1991).
Concerned by this and the inability of others to repeat animal protection studies,
a number of authors wrote letters of concern to the New England Journal of
Medicine demanding a re-examination of Centocor's initial study (Various
authors, 1991). Following this, the US FDA used the freedom of information act
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to obtain Centocor's initial data for re-analysis and deduced that the null
hypothesis had not been convincingly rejected (Wenzel 1992). However, since it
appeared that when compared with the placebo group, a significant decrease in
the mortality of 200 patients with Gram-negative bacteraemia in shock at study
entry had been seen (Ziegler et al 1991, Warren et al 1992), a second trial was
demanded. Interim analysis of the results from this second trial, however,
revealed a slightly higher mortality in the HA1A-treated cohort than in the
controls and the trial was aborted (Baumgartner 1994). Concurrently, HA1A was
also immediately removed from the marketplace.
In parallel, the competing anti lipid-A monoclonal E5 had also entered
preliminary clincal trials. No change in mortality in patients with documented
Gram-negative infection was observed in the first trial, though it seemed clear
that in one subgroup (patients without shock at entry) a decrease in mortality
was observed. For this reason a second study of E5 was called for. This second
study looked at over 800 patients with sepsis syndrome without shock, but failed
to show any reduction in mortality (Wenzel et al 1991), and investigations into
the clinical applications of E5 were also ceased.
The failure of these two antibodies has left pharmaceutical companies and
researchers an interesting question. Were these failures due to the poor
binding/cross reactivity of these antibodies? Or have the protective benefits of
anti-LPS antibodies been overstated?
Certainly, some researchers are of the opinion that neither of these two
antibodies had been shown capable of binding well enough to their range of
target ligands (Baumgertner 1994). One particular criticism has been the
assertion that immunoglobulin of the IgM subclass has a natural tendency to
bind non-specifically to hydrophobic substances. This binding, they suggest,
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may have been misinterpreted as cross-reactivity to lipid A or rough LPS in
preliminary investigations of these antibodies (Heumann et al 1991).
If these assertions are assumed to be correct, then it remains to be seen
whether or not a broadly cross-reactive monoclonal antibody is capable of
providing a benefit in patients at risk of Gram-negative infection or
endotoxaemia. One potentially significant newly developed monoclonal
antibody, WN1-222.5 has been reported to react with all smooth and most rough
LPS from all E.coli and Salmonella strains so far investigated (Di Padova et al
1993). Immunoblots using this antibody reveal a clear ladder pattern, indicating
that it reacts with both substituted and unsubstituted LPS. In bioassays too, this
antibody has been shown able to inhibit LPS activity in LAL assay, and TNF and
IL-6 release from LPS-challenged murine peritoneal macrophages. In animal
models it has been shown to neutralise the pyrogenic response to LPS in rabbits
and protects D-galactosamine-treated mice from the lethal effects of both E.coli
and S.abortus-equi. However it has not been shown able to bind LPS from
Enterobacter, Klebsiella, Serratia, Proteus or Pseudomonas spp. Nevertheless,
such broad reactivity between strains suggests that administration of a mixture
of similarly derived antibodies may provide the broad spectrum of reactivity
required to provide protection against infections in the natural setting.
1.3.6 Vaccination for LPS?
An active immunisation strategy has several theoretical advantages over
monoclonal antibody-based treatments. Of these, the most pertinent are low
production costs and the ability of the vaccine to generate high titre endogenous
antibodies in recipients. Indeed it could be argued that such a prophylactic
treatment for high risk patients would be more desirable than treatment with
passive immunisation, as it is difficult clinically to detect the early signs of
endotoxaemia in time to effectively intervene with a specific anti-endotoxin
therapy (Cross et al 1994, Opal 1995).
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However, since administration of even as little as several nanograms of LPS is
enough to induce symptoms of systemic inflammation (Suffredini et al 1989,
Martich et al 1993), ways must be sought to reduce the biological activity of
LPS-based vaccines for them to work effectively. Further, since it is generally
considered that purified LPS is poorly immunogenic, strategies must be devised
to enhance the immunogenicity of the LPS used in the vaccine.
In murine systems, one approach is to add pure LPS to sheep red blood cells.
Since the lipid A is incorporated into the plasma membrane of the red blood
cells, the toxicity of the LPS is reduced while the preparation remains
immunogenic (Pollack et al 1989, Heumann et al 1991). However, in terms of
human vaccination, approaches to date have typically involved covalent
attachment of various O-polysaccharides to carrier proteins. Since these
preparations contain no lipid A, the toxicity of the LPS is effectively neutralised
and the protein remains available for MHC-mediated induction of T-dependent
help. Examples of this approach include P.aeruginosa or E.coli 018 O-chain
linked to toxin A of P. aeruginosa (Cryz et al 1987, Schiff et al 1993) and E.coli
018 O-chain linked to cholera toxin (Cryz et al 1991). Covalent attachment of
E.coli J5 LPS to the outer membrane protein from group B meningococcus has
resulted in a vaccine that has been shown to be highly immunogenic and well
tolerated in experimental animal systems (Bhattercharjee et al 1996).
Polyclonal antibodies produced in response to this vaccine appear able to bind
to LPS from a number of Gram-negative bacteria and protect animals from lethal
endotoxin challenge and infection with Gram-negative bacteria (Bhattercharjee
et al 1994).
In summary, these findings suggest that induction of high levels of broadly
cross-reactive antibodies towards LPS may potentially be more easily and/or
effectively achieved using a vaccine strategy than by the passive
immunotherapy alternatives previously attempted.
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Table 1.2: History to date of development of LPS antibody therapies
Author (Year) Outcome* Study
McCabe (1972) High titres of anti-S.m/nnesofa Re-LPS in septic patients is
associated with a decreased frequency of shock or fatal
outcome, whereas no protection was observed from O-
specific antibodies.
McCabe (1977) Positive Animal studies show antibodies raised against E.coli J5 LPS
or S. minnesota Re LPS protect those animals against
heterologous Gram-negative bacterial infection.
Ziegler (1979) Positive Anti- rough mutant LPS (especially against J5) were
capable of protecting animals against challenge from both
infection and endotoxin of heterologous smooth bacteria.
Ziegler (1982) Positive? Therapeutic passive transfer of plasma from donors
immunised with J5 had a beneficial effect on patients with
sepsis. Later analysis (Baumgartner 1994) revealed that this
study was limited because there was no evaluation of the
severity of illnesses among the patients at entry other than
by listing underlying diseases. Also an unusually high
percentage of mortality was observed in the control group of
patients with septic shock (77%).
Pollack (1983) High levels of antibodies to endotoxin correlate with
improved outcome in sepsis patients.
McCutchan (1983) Negative Prophylactic use of single dose human antiserum to J5 in
Gram-negative infected patients with prolonged neutropenia
is ineffective.
Baumgartner (1985) Positive? Prophylactic passive transfer of antibody raised in human
volunteers immunised with E.coli J5 protects patients from
Gram-negative shock and death in surgical patients.
Criticisms are that only a small number of patients
developed septic shock and the statistics were only
significant using the one-tailed statistical test, while the
more appropriate two-tailed test was not significant.
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Table 1.2 (continued)













Protection against Gram-negative bacteraemia and
endotoxaemia with human monoclonal anti-LPS IgM
antibodies. Should be interpreted with caution however, as
they were performed with ascites or hybridoma fluids and
not with purified antibodies.
Baumgartner's reanalysis of their own 1985 findings - casts
doubt on validity of their earlier deductions.
Barclay's EndoCAb ELISA screens blood donors for high
levels of cross reactive antibodies for preparation of
hyperimmune intravenous IgG.
No benefit seen when anti-J5 intravenous immune globulin
used in treatment of Gram-negative septic shock.
Anti-core antibodies seen to be depleted during episodes of
endotoxaemia, then restored in 2/3 patients studied with
septic shock.
Baumgartner's group failed to reproduce the results of the
early J5 antiserum cross-protection studies in animals.
Unable to reproduce protection seen in early animal studies
with antisera against J5 or Re mutants.
Immunisation of volunteers with E.coli J5 vaccine induced
an increase in IgG and IgM type specific anti-J5 LPS
antibodies, but no increase seen in antibodies directed
against other epitopes of the core LPS or against lipid A.
Baumgartner writes to editor of NEJM to point out that their
tests of HA1A shows it binds non-specifically to hydrophobic
molecules such as Gram-negative and Gram positive
bacterial membranes, yeasts, high density lipoproteins and
cardiolipin. It bound only very weakly to lipid A.
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Table 1.2 (continued)











Clinical trial of treatment of Gram-negative bacteraemia and
septic shock with HA1A did not reduce mortality in either
overall patients or patients with proven Gram-negative
sepsis. However, compared with placebo group, there was a
significant decrease in the mortality in 200 patients with
Gram-negative bacteraemia. Later analysis (Warren et al
1992) also suggested a protective effect limited to patients
who were in shock at study entry.
Second study of the human monoclonal IgM E5 (Xoma
corp) looked at over 800 patients with sepsis syndrome
without shock, but failed to show any reduction in mortality.
A string of letters written by various researchers to Eng
J Med urging caution as to the interpretation of data for the
anti-LPS trials.
Treatment of severe infectious purpura in children with
human E. coli J5 antisera reveals no protective benefit.
No benefit seen when anti-core LPS intravenous immune
globulin administered to patients at high risk of post surgical
infection.
Unable to reproduce protection seen in early animal studies
with antisera against E. coli J5 or Re mutants.
Independent re-analysis of the early HA1A data deduced
that the null hypothesis had not been convincingly rejected.
Patients who undergo major surgery were less likely to
succumb to sepsis if they maintained high levels of anti-core
glycolipid antibodies.
Used cyclic immunisation of heat killed bacteria with
different Ra chemotypes to create the widely cross reactive
murine monoclonal antibody WN1 222-5.
EndoCAb measurement in pancreatitis patients reveals




Author (Year) Outcome* Study
Heyderman (1994) EndoCAb measurement in haemolytic uraemic syndrome
patients.
Bhatt (1994) Affinity purified anti-E. coli J5 LPS IgG protects neutropenic
Baumgartner (1994)
rats against Gram-negative spesis.
Baumgartner's review of failures of clinical trials for anti-
LPS.
* For all of the studies which involved human or animal trials of transfer of
antibody or hyper-immune plasma, a brief summary of whether a protective
benefit was observed is listed in the 'Outcome' column. For sake of clarity,
studies providing indirect evidence of LPS antibody function {i.e. those involving
measurement of antibodies but not passive transfer) have not been summarised
in this column and are indicated by a dash.
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1.4 T-cell responses to LPS
1.4.1 Overview of T-cell responses to LPS
In the traditionally accepted view of T-cell immunology, the role of the T-cell is to
recognise peptide presented to them by the MHC molecules of presenting cells.
Then, depending on the type of T-cell and the secondary signals present at the
time of antigen recognition, appropriate cytokines are released to orchestrate an
immune response, or the cell is targeted for apoptosis or lysis. This rather
narrow view of the T-cells capabilities has been expanded somewhat in the last
decade or so by some novel discoveries.
The first of these occurred in 1992 when it was discovered for the first time that
protein-derived antigens were not the only type of antigen capable of being
presented to and recognised by T-cells. Lipid antigens too, were shown to be a
viable T-cell substrate. Mediated by the non-polymorphic MHC-like CD1
molecules, this interaction led to new insights into the role of the T-cell in both
innate and acquired immunity. Then in 1994 it was shown for the first time that
human T-cells could mount a response towards LPS.
Together these two findings opened up new questions for the role of lipid
reactive T-cells in the human host in health and disease.
1.4.2 Early evidence for LPS reactive T-cells
The significance of T-cell responses in human immunity cannot be
overestimated. The almost complete lack of capacity to defend against infection
seen in nude mice or athymic human patients need only be considered to realise
how significant an effect on the immune system a loss of these cells have.
Together, the various subsets of T-cells protect against viral challenge, assist in
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the class switching and activation of B-cells and produce the cytokines essential
to orchestrate the whole immune response.
In terms of LPS recognition, however, while other cell types have been
intensively studied, T-cells have remained largely uninvestigated. The
responses of monocytes, macrophages, dendritic cells and B-cells in particular
to LPS have been very well characterised while surprisingly little is known of the
responses made by T-cells to LPS. This lack of interest in LPS-reactive T-cells
may have been precipitated by the long held (and false) conception that
peripheral T-cells were largely refractory to the effects of LPS. Only a small
number of murine studies showed any reaction at all, and none of these were
extensively pursued (Tough et al 1997, Vogel et al 1983, Andersson et al 1977).
For example, as far back as 1977, the proliferation of a cloned murine IL-2-
dependent cytotoxic T cell (line CT6) in response to LPS was demonstrated
(Andersson et al 1977). This response turned out to be dose- and time-
dependent and blocked by polymyxin B. In addition, stimulation of highly purified
murine splenic T-cells showed that 3% of this population were capable of
proliferating in response to LPS. However, the same study also revealed that
this population was missing in the C3H/HeJ mouse strain, allowing the
deduction with hindsight that this T-cell proliferation is dependent on the Toll-like
receptor mediated innate recognition of LPS.
Other than infrequent articles like these, very little attention was paid to the
study of T-cells responsive to lipid antigens. This remained the case until an
interesting discovery was made in 1992.
1.4.3 The CD1 story
For some time, the CD1 molecules had presented something of a mystery to
geneticists and immunologists alike. Genomic analysis revealed that they
existed in every mammalian species looked at (Calabi et al 1989) while
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immunological and sequence analysis revealed striking similarities to the MHC
class of molecules (being 30% identical to MHC class I heavy chain and
similarly associated with p2-microglobulin) (Park et al 2000). However, unlike
MHC molecules, they did not show the high degree of polymorphism observed
in MHC molecules to present diverse peptides, nor had they ever been shown
capable of presenting peptides to T-cells.
Comprising five distinct genes (isotypes) in humans, the CD1 molecules can be
separated into two groups on the basis of homology (Calabi et al 1989). Group 1
CD1 molecules are found in humans but are absent from mouse and rat and
comprise CD1a,b,c and e. Group 2 comprises only CD1d and is found in all
species studied so far. Human CD1e has been seen to be transcribed but no
protein product has yet been seen (Cattoretti et al 1989).
The first direct evidence implicating CD1 in the regulation of T-cell function was
provided in 1989 with the observation of a subset of human circulating CD4"
CD8" T-cell clones expressing either aP or y8 TCRs which were capable of lysing
tumor cells expressing specific isoforms of human CD1 (Porcelli et al 1989).
This mystery became all the more tantalising when in 1992 Porcelli et al
demonstrated a human T-cell clone capable of recognising an antigen from
Mycobacterium tuberculosis that was restricted not by MHC-I or MHC-II, but by
the CD1 molecule CD1b (Porcelli et al 1992). With an immunological function
finally suggested for this molecule, the same group set about purifying their
mycobacterial extracts to determine what type of antigen was being presented
by the CD1 molecule. Proteolysis of the sample had no effect on antigenicity,
suggesting that a peptide antigen was not involved. More curiously, the antigen
appeared to be eluting within the hydrophobic fractions of their purifications.
HPLC analysis was finally able to narrow down the antigen to the mycobacterial
lipid mycolic acid (Beckman et al 1994) - a member of the a-branched, p-
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hydroxy family of long chain fatty acids expressed by mycobacteria (Minnikin
1982).
This was the first demonstation of any lipid antigen being presented to T-cells
and other labs scrambled to discover other lipids capable of being presented by
CD1. In 1995, Sieling et al managed to show CD1 b presentation of another
mycobacterial lipid, lipoarabinomannan (LAM) (Sieling et al 1995). Further to
this, they were able to show that glutaraldehyde fixation of the monocytes
prevented presentation (suggesting that internalisation of antigen was required),
as did chloroquine treatment, suggesting that endosomal acidification was also
required for antigen loading (Sieling et al 1995). The T-cells responding to this
antigen were shown to express ap TCRs, produce IFN-y and mediate cytolytic
effects on activation.
In 1997, a further lipid antigen of mycobacterial origin was seen to bind CD1 -
glucose monomycolate (GMM). Moody et al investigated the structural
requirements for binding of this antigen and found that substantial alteration of
its lipid tails did not affect presentation (Moody et al 1997). On the other hand,
antigenic recognition appeared to be extremely sensitive to variations in its
carbohydrate portion or other polar substituents (Moody et al 1997). At this
stage the idea was put forward that the lipid region was simply held in place
non-specifically by the CD1 molecule, while the polar headgroup was left to
interact with (and be recognised by) the T-cell receptor (Moody et al 1997).
By this stage, and with a handful of further CD1 presented mycobacterium-
derived lipids discovered, a pattern was beginning to emerge. It was noted that
the general architecture of the CD1 ligand appeared to be a di-acyl lipid
attached to a strongly polar headgroup (Park et al 2000). Only CD1c proved
capable of binding a mono-acyl template (Moody et al 2000).
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Determination of the crystal structure of murine CD1d brought credence to this
idea when it emerged that the CD1 molecules contain a long groove,
reminiscent of the peptide binding groove of MHC-I, but with a lining from end to
end of highly hydrophobic residues. This hydrophobic binding pocket was shown
to be approximately 30A long by 10-15A wide, giving further support to the idea
that the optimum molecular template structure for potential CD1 antigens is a di-
acyl lipid format (Zeng et al 1997). The current model suggests that the structure
and position of the polar head group is crucial for recognition by the TCR
(Porcelli et al 1997). Closer analysis of where the hydrophilic interactions took
place have suggested that the TCR should be optimally exposed to between
one and four carbohydrate residues extending from the head of the lipid (Moody
et al 1997).
This predominance of mycobacterial lipid antigens continued for some time until
recently, when different classes of lipids have been shown capable of binding
CD1. Self ceramides such as gangliosides, for example, can also be presented
by CD1b (Shamshiev et al 1999), suggesting a role for these antigens in the
autoimmune dysfunctions of diseases such as multiple sclerosis.
Of considerable interest is the very unusual lipid a-Galactosylceramide (a-
GalCer). This glycolipid has only been seen in extracts from marine sponges
(Natori et al 1994), but seems exquisitely capable of stimulating an entire
population of human CD1d-restricted T-cells. These T-cells express a semi-
invariant TCR which can recognise a-GalCer in even picomolar concentrations
and exert potent effector and regulatory functions (Kawano et al 1997).
There is some evidence that hydrophobic peptides might also be presented by
CD1 (Castano et al 1997), but given the variability of antigenic peptides and the
non-polymorphic nature of CD1, it is more likely that it has evolved to present
lipid antigens. In addition, human cellular GPI has been suggested to bind CD1d
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(Joyce et al 1998), but this has yet to be confirmed. Finally, a recent study has
indicated that a non-protein antigen derived from Haemophilus influenzae
serotype b is also presented to CD1-restricted T-cells (Fairhurst et al 1998).
It has been suggested that the different CD1 molecules exist to sample different
subcellular compartments for microbial lipids. Certainly, the different CD1
molecules are seen to take remarkably defined different routes through the cell.
CD1b and CD1d are concentrated mainly in the late endosome or lysosome,
CD1c in the late endosome and CD1a in the early or recycling endosome,
lending credence to the idea that the different CD1 isotypes have evolved to
sample different intracellular compartments (Sugita et al 1999, Schaible et al
2000).
One common event must occur, however, for ligand loading of all four isotypes
of expressed CD1. Studies have shown that acidification of the ligand loading
compartment is essential for antigen binding, as a low pH is required to open the
CD1 ligand binding groove for insertion of antigen. Following this, CD1 binds
lipids stably, with half lives ranging from a half hour to over twelve hours, an
affinity reminiscent of that observed for MFIC presentation of peptides (Naidenko
et al 1999, Benlagha et al 2000).
1.4.4 Cellular expression of CD1 isotypes
Perhaps unusually, CD1 genes are poorly expressed in unstimulated human
peripheral blood cells. However, stimulation of resting human monocytes with
GM-CSF is capable of inducing strong expression of the group 1 CD1 molecules
(Porcelli et al 1992, Kasinerk et al 1993), suggesting a role for these tissue
macrophages in inflammatory lesions. Further, CD1 isotypes are expressed by
antigen presenting cells, such as dendritic cells and macrophages (Porcelli et al
1999, Cattoretti et al 1989, Porcelli et al 1995). A subset of human B-cells also
express CD1c (Small et al 1987) which seems to be, for some reason, much
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more prominent on the circulating B-cells of infants than adults (Plebani et al
1993). In addition, CD1c has been shown to be upregulated on the marginal
zone B-cells of lymphoid follicles (Cattoretti et al 1987).
Several studies have shown expression of CD1d on normal human gastric
epithelia (Blumberg et al 1991, Balk et al 1994, Canchis et al 1993). These
molecules seem to lack glycosylation and association with (32-microglobulin
(Balk et al 1994). Interestingly, no group 1 CD1 molecules (ie CD1a,b or c) are
expressed here. Human CD1d has also been seen to be expressed at low levels
on circulating T- and B- cells and resting monocytes and at moderate levels on
Langerhans' cells (Porcelli et al 1999). Murine CD1d, on the other hand, is
expressed constitutively at low levels by most B-cells and is upregulated on
splenic marginal zone B-cells (Roark et al 1998).
1.4.5 CD1 restricted T-cell phenotypes and function
The first CD1-reactive T-cell clones were seen to express neither CD4 or CD8
molecules (Porcelli et al 1989, Beckman et al 1994, Porcelli et al 1992), but it is
now seen that CD1 restriction is broadly distributed among all of the T-cell
subsets. In particular, there is evidence for CD1 recognition in both innate and
acquired T-cell responses. For example, in their studies of patients recently
infected with M. tuberculosis, Moody et al showed that the T-cells of these
patients had enhanced CD1 regulated responses to synthetic mycobacterial
lipids, suggesting a role for memory T-cells and acquired immunity in these
infections (Moody et al 2000). Further, the T-cell receptors of these T-cells
showed a wide diversity of peptide sequence, suggesting a clonal selection
origin rather than a germline-encoded innate receptor.
As for innate immune responses, the CD1 work has thrown up some very
interesting and unexpected new insights into naturally-occurring T-cell
populations in humans that seem to offer a lymphocyte bridge between the
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innate and acquired immune systems. CD1c, for example, is recognised by a
major subset of cytolytic y8 T-cells, found in high numbers in the gut, that
express V51 y5 TCRs of limited diversity (Beldjford et al 1993). The antigens
being presented by these CD1c molecules have yet to be discovered, though
are considered likely to play a role in mucosal immunity (Spada et al 2000).
Another curious T-cell subtype is the NK-T-cell. It is not clear whether these
cells are derived from the NK cell lineage or from the T-cell lineage as they are
seen to express cell surface markers from both lineages (Godefroy et al 2000).
These cells seem inherently capable of recognising CD1d and express strikingly
conserved T-cell receptors (Va24-JaQ in humans, Exley et al 1997, and
Va14Ja28 in mice, Bendelac et al 1997). Together they represent a not
inconsiderable proportion of the T-cell population, accounting for up to 20-30%
of T-cells in the liver and bone marrow, and 1% of total splenocytes in mice.
Virtually all NK-T-cells are capable of reacting strongly to the unusual lipid a-
GalCer expressed in the context of CD1d. This finding has been particularly
unexpected as a-GalCer has only been seen to be expressed in marine
sponges. Nevertheless, it is tempting to speculate that a mammalian lipid
homologue exists that is either expressed and released by cells under certain
pathological or inflammatory conditions or that a breakdown product of some
other microbial lipid resembling a-GalCer exists, indicating infection requiring
the actions of NK-T-cells.
As for the role of these cells in the wider immune response against pathogens,
multiple suggestions have been put forward on the basis of their ability to
secrete both IL-4 and IFN^y upon activation (Godefroy et al 2000). Indeed,
recent studies have linked reduction in NK-T-cell numbers and alterations in
their cytokine secretion patterns to progression of human autoimmune diabetes
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and other disorders (Sumida et al 1995, Hammond et al 1998). A role also
seems to be played by these cells in the recognition and rejection of tumours
(Smyth et al 2000).
The CD1-restricted T-cells capable of recognising mycobacterial infection, on
the other hand, are seen to react differently. CD1-restricted CD4" CD8" T-cells
have been shown able to induce apoptosis of presenting cells via Fas ligand
(Stenger et al 1997) and some CD8+ CD1-restricted cells have been
demonstrated to be able to employ perforin and granulysin to induce apoptosis
and kill mycobacteria respectively (Park et al 2000, Stenger et al 1997). CD4+,
CD8+ and double-negative CD1 restricted cells all appear to produce low levels
of IL-4 but high levels of IFN-y, a significant anti-mycobacterial cytokine which is
thought to be required for activation of macrophage-mediated killing of
intracellular pathogens and development of effective cell mediated immunity
against these organisms (Porcelli et al 1999).
1.4.6 Can LPS bind to CD1?
As mentioned above, most of the lipid ligands so far discovered for the CD1
molecules have been of the format of a diacyl lipid attached to a polar head
group (Sieling et al 1995, Shamshiev et al 1999, Naidenko et al 1999, Benlagha
et al 2000). CD1c is so far the only exception to this rule, having been proven
capable of binding the mono-acyl isporenyl glycolipids of M. tuberculosis (Moody
et al 2000).
However, while LPS molecules certainly conform to the more general picture of
potential CD1 antigens, (a hydrophobic region attached to a polar headgroup),
they do not conform to the proposed optimum diacyl structure as a result of their
typical substitution of between 5 and 7 acyl chains. Thus the question emerges
of whether or not native LPS monomers are too bulky to fit inside the groove of
CD1. As mentioned above, the groove of CD1 is approximately 10-15A wide by
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30A long (Zeng et al 1997), while the width and length of enterobacterial LPS
molecules, for example, have been calculated at 20-24A in width by 12-14A in
length respectively (Alexander et al 2001). This suggests that some processing
of LPS molecules via degradative enzymes in cells would be required to
produce a ligand suitable for presentation by any of the isotypes of CD1.
It has also been suggested, after consideration of the hydrophilic areas of CD1
and the T-cell receptor, that between only one and four carbohydrate residues
extending from the head of the CD1 ligand can be recognised by the T-cell
receptor (Moody et al 1997). In terms of LPS, this would represent the minimum
structure required for bacterial viability (one to three Kdo residues attached to
Lipid A), and since only a very small number of bacteria naturally express LPS
with carbohydrate portions this small, some enzymatic glycan trimming of most
naturally-occurring LPS would also be required to produce a ligand suitable for
expression on CD1.
This then leads to the question of whether or not antigen presenting cells
express enzymes capable of this type of degradation? And by extrapolation
whether or not such degraded LPS molecules pass through an intermediate
structural form capable of being presented on CD1? Some lines of evidence
exist to suggest that this is possible. Firstly, CD1b, for example, is seen to be
strongly expressed in MIICs, the intracellular compartments where MHC-II is
loaded with peptide (Sugita et al 1999). Moreover, these compartments are also
seen to be lipid-rich (Prigozy et al 1997, Sugita et al 1996) and possess many
degradative enzymes capable of glycan trimming etc (Ernst et al 1998). It has
also been shown that LPS passes through these vesicles following cellular
ingestion (Thiemblemont et al 1998, Detmers et al 1996).
Further, it has been seen that the enzyme acyloxyhydrolase, an enzyme
strongly expressed by neutrophils, is capable of trimming the secondary
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substituted acyl chains of LPS to provide a tetra-acyl breakdown product
(Rietschel et al 1994). This molecule has the interesting property of being an
antagonist of native LPS, thereby contributing to LPS tolerance in these cells.
However, this precedent suggests that further acyl trimming or other enzymic
activity may result in the formation of LPS derived molecules capable of binding
to CD1, as depicted in Figure 1.8.
1.4.7 T-ceH responses to LPS
Concurrently to the progress being made in the understanding of CD1 restricted
T-cells, another group was looking at the possibility of T-cells reactive towards
LPS. Mattern et al, working in Germany showed in 1994 for the first time that
human T-cells can in fact become activated in response to LPS (Mattern et al
1994) - a finding in direct contrast with earlier work suggesting that human
peripheral lymphocytes could not proliferate in response to LPS (Peavy et al
1970, Greaves et al 1974, Ellner et al 1989, Fauci et al 1976). Their explanation
for this was that while the proliferation in response to LPS they had observed
occured after an unusual delay of around seven days, previous investigators
had been looking for this proliferation around the more typical period of 3-4 days
incubation (Peavy et al 1970, Greaves et al 1974, Ellner et al 1989, Fauci et al
1976).
Further investigation of this response revealed that the proliferation required
contact with accessory monocytes, as proliferation was abolished in transwell
culture. This proliferation was proven to be due to the lipid component and not
some protein or lipoprotein contaminant of their preparations when it was shown
that the chemically synthesised compound 506, equivalent to E.coli lipid A,
stimulated cells as readily as the native LPS of Salmonella friedenau.
Interestingly, estimates of the frequency of responding T-cells ranged between
1:400 and 1:1100, thereby excluding the possibilty that the LPS was acting
merely as a T-cell mitogen. However, both memory and naive T-cells were
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Glycan trimming enzymes may be required to
reduce length of carbohydrate portion to 3-4
residues - hypothesised to be the optimum length
required for TCR engagement.
Di-glucosamine bond must be cleaved,
enzyme performing this function not yet
determined.
ry acyl chains must be
removed by cleavage of ester
bonds. This function is achieved
by mammalian enzyme
acyloxyhydrolase.
Figure 1.8 Enzymic modifications of LPS required for production of potential
CD1 liqands
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shown able to proliferate in response to LPS, suggesting a further example of T-
cell-mediated crossover between the innate and acquired immune systems.
Of most interest to this group was, however, the fact that only around 50% of the
healthy volunteers they looked at demonstrated T-cell responses to LPS - a
phenotype which had no correlation with HLA haplotype.
The same group then followed up this line of investigation four years later by
reporting that the proliferation is absolutely dependent on the interaction
between T-cell CD28 and monocyte CD80 (Mattern et al 1998). Pre-treatment of
monocytes with ammonium chloride prevents acidification of vesicles, and
hence enzymic antigen processing such as proteolysis (Bauer et al 1988). This
treatment abolished LPS-induced proliferation, lending further credence to the
idea that the LPS was involved in some kind of presentation pathway.
Both autologous (same donor) and heterlogous monocytes were seen able to
induce T-cell proliferation, indicating a likelihood that the response is MHC-
independent, and it was noted that T-cells from non-responders could be made
to respond if incubated with monocyte preparations from responders (which
were shown to have strongly upregulated CD80). Antibody blocking experiments
further confirmed that these responses are not MHC-restricted (Mattern et al
1998).
Then the following year, the same group showed that while only around 50% of
samples from the peripheral blood of healthy controls responded, 100% of
samples of PBMCs extracted from cord blood did. As a result of this finding they
were able to pinpoint that the cell type required for the stimulation of the T-cells
was not the monocyte, but the CD34+ blood stem cell, a contaminating cell in
their original monocyte preparations (Mattern et al 1999). This cell type was
deduced to be present in responders and missing in non-responders as antibody
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mediated depletion of CD34+ cells abolished T-cell proliferation from responders'
PBMC, while addition of CD34+ cells to cell preparations from non-responders
allowed them to respond to LPS. Further evidence for the critical role of CD34+
cells in this process became clear when they showed that purified T-cells could
be made to proliferate in response to LPS if incubated with irradiated KG-1a
cells (a CD34+ cell line).
Despite all of these advances, however, the group did not speculate as to how
the LPS was being presented to the T-cells in their experiments other than to
rule out the possibility of CD1-mediated presentation on the basis of their belief
that CD1 is not expressed on monocytes, CD34+ blood stem cells or KG-1a
cells. However, since other studies have shown CD1 to be expressed
constitutively at least at low levels on monocytes (Porcelli et al 1999), and
CD1a, b and c on cytokine differentiated monocytes (Porcelli et al 1992,
Kasinerk et al 1993), the possibility that LPS may interact with CD1 in this
proliferation should not be discounted.
1.4.8 Potential implications of LPS-reactive T-cells
Every group working on lipid-reactive T-cells has been quick to speculate on the
clinical relevance of their interactions. While the protective value of CD1-
restricted antimycobacterial responses remains to be evaluated, evidence
certainly exists to suggest that they play a role in natural mycobacterial infection.
For example, patients recently infected with M. tuberculosis show enhanced
responses to synthetic mycobacterial lipids, suggesting a role for CD1-restricted
memory T-cells in these infections (Moody et al 2000). Further, the CD1-
restricted T-cell clones reactive for mycobacterial lipids have all shown a
phenotype capable of mounting a response suitable for the clearance of this
type of bacteria (Beckman et al 1994, Porcelli et al 1992, Park et al 2000,
Stenger et al 1997).
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As for the LPS-reactive T-cells, while the mechanism behind this interaction has
not been fully elucidated, it is clear that these T-cells should have some role to
play in the immunity against Gram-negative infection. Not only are they activated
to proliferate in response to LPS, but they display a clearly Th1 phenotype,
quickly expressing and releasing IL-2 and IFN-y, but not the Th2 cytokines IL-4,
IL-5 or IL-10.
If responding populations of these T-cells are eventually shown to confer some
benefit on particular patient groups (such as those at risk from Gram-negative
infection, sepsis syndrome or endotoxaemia), then vaccination with LPS may
become a useful prophylactic option. In terms of vaccines or adjuvants in
particular, lipid based antigens should offer a significant advantage over
equivalent protein based vaccines. Since the CD1 molecules are shown to be
non-polymorphic between individuals, inter-person variablilty in MHC haplotype
is avoided, greatly simplifying the selection of suitable lipid vaccine candidates.
Nevertheless, of most interest in the following study is the role of LPS reactive
T-cells in endotoxaemia and sepsis syndrome and in particular the relationship
between T-cell responses to LPS and clinical outcome.
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1.5 Role of LPS in disease
1.5.1 Role of LPS in disease
In addition to their role as essential structural components of the Gram-negative
outer membrane, the lipopolysaccharides of many bacteria have been seen to
play a distinct role in the pathogenesis of a number of disease processes.
Surprisingly diverse applications have been seen for LPS in this capacity, with,
for example, some types of LPS acting as cellular adhesins, others protecting
against complement-mediated attack or even providing the bacteria with a
mechanism for host antigen mimicry in immune evasion (reviewed in Erridge et
al 2002a). However, it is the host response to LPS during endotoxaemia that is
associated with by far the most morbidity and mortality in human patients
(Wenzel et al 1988). For this reason, the following section will discuss the role of
LPS in the initiation and resultant pathology of sepsis syndrome.
1.5.2 Incidence of sepsis
Despite ongoing progress in the development of antibiotics and other supportive
care therapies, sepsis syndrome continues to carry a high mortality rate (40-
50%) (Wakefield et al 1988), which has not seen significant improvement in the
past 50 years (Wheeler et al 1999). Reported to affect more than 500,000
patients in the United States annually (Wheeler et al 1999, Various authors
1990), the incidence of sepsis syndrome is, if anything, thought to be becoming
yet more frequent (Wheeler et al 1999, Various authors 1990). While it is difficult
to place accurate figures on the incidence and outcome of sepsis syndrome, it
has been suggested that sepsis syndrome and its related sequelae together
account for the thirteenth most common preventable cause of death in the USA
(Knuefermann et al 2002).
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Patients at risk of sepsis syndrome include those undergoing high risk surgical
procedures, trauma patients, those presenting with abdominal complications
such as pancreatitis, appendicitis or diverticulitis and those exposed to severe
microbial infection, especially of the abdominal cavity (Bahrami et al 1995,
Callery et al 1991, Gibb 1993).
1.5.3 Systemic inflammatory response syndrome and sepsis terminology
The history of sepsis syndrome is littered with fairly loose definitions and terms
which were used interchangably in the literature and which were not clearly
enough defined to allow accurate comparisons between various studies. This
led a number of clinicians to call for better definitions of the vaguely used term
"sepsis" (Various authors, 1991). Prompted by this concern, Bone and
colleagues subsequently proposed a list of clearly defined clinical definitions for
the diagnosis of the various conditions seen in patients at risk of sepsis
syndrome (Bone 1991, Bone et al 1997).
In brief, these definitions consisted of the following: Systemic inflammatory
response syndrome (SIRS) is defined as clinical evidence of a systemic
inflammatory response. Sepsis is defined as a SIRS response that can be
shown to be derived from an infective source. The term sepsis syndrome (often
refered to as 'severe sepsis') is applied to those patients exhibiting sepsis
together with evidence of organ hypoperfusion, while septic shock describes
sepsis syndrome in conjunction with low blood pressure.
The clinical parameters of these definitions are summarised in Table 1.3 (taken
from American College of Chest Physicians, 1992).
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...is defined as the presence of viable bacteria in the circulating blood, and
as such can therefore only be determined by blood culture.
...has been used to describe the "systemic disease caused by the spread
of microorganisms and their toxins in the circulating blood.". This term is
misleading and should therefore no longer be used.
...is defined as the systemic inflammatory response to a wide variety of
severe clinical insults (ie not necessarily infection). SIRS is characterised
by a diagnosis of two or more of the following:
• Core temperature >38.3 or <35.6°C
• Heart rate > 90 beats per minute
• Respiratory rate > 20 breaths per minute or PaC02 < 32mm Hg
• White blood cell count > 12,000/mm3 or < 4,000/mm3, or > 10%
immature (band) forms.
...is defined as the systemic inflammatory response to infection.
Manifestations of sepsis are identical to those listed above for SIRS, but
with the addition of clinical evidence of infection.
(also frequently refered to as 'Sepsis syndrome') ...is defined as sepsis
combined with evidence of altered organ perfusion. Altered organ perfusion
may be diagnosed if the patient exhibits the following clinical indicators:
• Pa02/F|02 <=280 (without other pulmonary or cardiovascular disease as
the cause)
• Elevated lactate level (> upper limits of normal for the laboratory)
• Oliguria (documented urine output < 0.5 ml/kg body weight) for at least
one hour (in patients with catheters)
• Acute changes in mental status
...is defined as sepsis syndrome with hypotension: ie a systolic blood
pressure < 90mm Hg, or decrease from baseline systolic blood pressure >
40mm Hg that is responsive to intravenous fluids or pharmacologic
intervention.
Multiple organ failure (multiple organ dysfunction syndrome) is defined as
the presence of altered organ function in an acutely ill patient such that
homeostasis cannot be maintained without intervention.
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1.5.4 Factors involved in the initiation of SIRS and sepsis
The last decade or so has seen considerable advancement in our understanding
of the initiation of SIRS and sepsis. Previously considered to be a simple
systemic inflammatory response to invading microorganisms, our ideas of how
SIRS, sepsis and their associated sequelae occur have been refined to include
an understanding of the multi-factorial nature of the inititation of these events
(reviewed in Oberholzer et al 2001).
Agents now recognised as being capable of inducing a systemic inflammatory
response (SIRS) include not only components from bacteria, yeast and viruses
but also host-derived products of necrotic cells and tissue damage. Thus, SIRS
and its related sequelae may be initiated not only by almost any kind of infection
but also by ischaemia-reperfusion injury, thermal injury, soft tissue injury or
haemorrhagic shock (Bone et al 1997, Bone et al 1989). Indeed, studies of SIRS
patients in some clinical settings have routinely demonstrated a high percentage
of cases in which no obvious source of infection can be found - for example the
study of Bone et al which demonstrated that only around 45% of patients
diagnosed with SIRS could demonstrate a positive blood culture (Bone 1991).
Sepsis, on the other hand, is defined as the subset of SIRS patients whose
symptoms can be directly traced to a source of infection (Bone et al 1997). In
surgical and burns cases in particular, it is becoming increasingly clear that by
far the most common source (>90%) of these infections is the hosts own normal
microbial flora (Munford et al 2001). More specifically, evidence is beginning to
accumulate to suggest that the most significant source of these commensals is
the host gastrointestinal tract, as disruption of the gut barrier has been seen to
be readily capable of initiating the septic state (Saadia et al 1990, Gough et al
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1992), and is often seen to be compromised in patients suffering from sepsis
syndrome (Haglund et al 1975).
The significance of the gut barrier should not be underestimated, as it is this
mucosal surface which serves to divide the rest of the body from the large
amounts of Gram-positive and Gram-negative bacteria, yeasts, digestive
enzymes, lipoproteins, endotoxins and other stongly pro-inflammatory mediators
present in the lumen of the gut. Damage of this barrier and release of the
contents into the surrounding tissues or circulation is termed 'translocation' and
is thought to be initiated following a range of potential insults. These include
haemorrhagic shock, thermal injury, malnutrition, jaundice and even simple
intestinal obstruction (Saadia et al 1990, Heidecke et al 1999, Baker et al 1988,
Bynum et al 1984). The tissues of the gut appear to be particularly sensitive to
both ischaemia and reperfusion injuries (Chiu et al 1970, Baker et al 1988,
Bynum et al 1984, Haglund et al 1975). For example, a decrease in splanchnic
blood has been shown to directly damage the gut mucosa in human patients
suffering from shock (Chiu et al 1970, Haglund et al 1975). Further, it has even
been suggested that dysregulation or defect of the host immune system may be
enough to intitate translocation (Deitch et al 1986). While the exact mechanism
for this translocation of bacteria and toxins remains as yet unclear, it has been
postulated that tight junctions between the cells of the gut epithelia are critical in
maintaining this function (Bounos et al 1977, Rhodes et al 1973).
Finally, it should be pointed out that while gut barrier function clearly has a role
to play in sepsis syndrome, breakdown may act as both a cause and as a result
of sepsis syndrome.
1.5.5 Pathology of SIRS and sepsis syndrome
Both SIRS and sepsis syndromes are thought to be precipitated by the same
basic mechanism.
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In the main, it is thought that both conditions are initiated by a systemic release
of pro-inflammatory cytokines from the cells of the innate immune system. In
particular, it is thought that overproduction of the cytokines TNF-a, IL-113, IL-8
and IL-6 are the principal mediators of the initital insults of both SIRS and
sepsis, though IFN-y, IL-12 and IL-18 have also been shown to play a role
(Oberholzer et al 2001).
These mediators may be elicited in response to any of the infectious agents or
products of tissue damage listed above and their effects on the body both locally
and systemically are mediated in three main ways:
(i) They induce local inflammation - properties and permeabilities of local blood
vessels are changed. Phagocytes, other immune cells and molecules are
recruited to the site of infection.
(ii) They induce the production of acute phase proteins by the liver, which bind to
bacterial surface molecules enhancing both the activation of complement and
phagocytosis.
(iii) They can elevate body temperature, reduce the hosts' spontaneous activity
and induce behavioural changes called "sickness syndrome" - all of which are
thought to be deleterious for the growth or spread of the organism.
In local foci of infection, these pro-inflammatory mediator-driven responses
serve to enhance defence against the organism, limit its spread from that
location and ultimately initiate a "clean up" and repair of the damaged area.
However, when activation of the innate immune system is severe enough, the
host response itself can propel the patient into a systemic inflammatory
response syndrome (termed SIRS), or even shock and multiple organ failure
(MOF) (Oberholzer et al 2001). These two more serious pathologies are
precipitated as a result of the ability of released cytokines to promote: (i)
progressive dysfunction of the endothelial surfaces leading to increased
microvascular permeability (Tracey et al 1988, Stephens et al 1988), (ii) platelet
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sludging leading to blockage of the microcirculation causing maldistribution of
blood flow and possibly ischaemia (Sigurdsson et al 1992), which in turn may
cause reperfusion injury (Cipolle et al 1993) and induction of heat shock proteins
(Rinaldo et al 1990), (iii) massive consumption of clotting proteins, thereby
removing the patient's ability to clot properly (Oberholzer et al 2001), (iv)
activation of the coagulation system and impairment of the protein C-protein-S
inhibitory pathway (Levi et al 1993) and (v) profound vasodilation, fluid
transudation and maldistribution of blood flowwhich may result in profound
shock (Gomez-Jiminez et al 1995, Miyauchi et al 1990). These consequences
may ultimately lead to organ dysfunction and failure unless homeostasis is
quickly restored. Further, approximately 40% of patients with sepsis go on to
develop shock, a condition which adversely affects prognosis (Kreger et al
1980).
The critical roles of proinflammatory cytokines in these pathologies are
confirmed by studies observing a correlation between the magnitude of plasma
IL-1 p, IL-6 and TNF-a levels and negative outcome of septic and burns patients
(Drost et al 1993, Casey et al 1993). However, it should be pointed out that
more recent studies have also shown correlations between adverse outcome
and high levels of anti-inflammatory mediators such as IL-10 and TGF-p and
poor outcome in adult respiratory distress syndrome (Neidhardt et al 1997) and
sepsis (Sherry et al 1996).
1.5.6 Role of LPS in sepsis syndrome
As mentioned above, it appears that the critical event in the initiation of SIRS is
the widespread and overwhelming production of pro-inflammatory cytokines.
Many agents are capable of eliciting these molecules from the cells of the innate
immune system, but by far the most extensively studied in terms of its role in the
initiation and pathology of sepsis syndrome is endotoxin. Capable of inducing
aggressive release of pro-inflammatory mediators from the cells of the innate
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immune system at concentrations as low as several picograms per millilitre,
endotoxin has been shown capable of inducing all of the symptoms of sepsis
syndrome on administration to human volunteers (Michie et al 1988). Indeed,
proof that LPS alone can induce all of the characteristic features of septic shock
in humans came from a laboratory worker who self-administered 1mg of purified
Salmonella minnesota LPS intravenously, resulting in severe shock and organ
failure within 3 hours (Taveira daSilva et al 1993). Further evidence for its
involvement comes from the observation of its presence (at least transiently) in
the plasma of at least 86% of patients with sepsis syndrome (Goldie et al 1995).
The main source of endotoxin in these patients is thought to be translocation
from the gut (Saadia et al 1990, Wells et al 1986), though it should be borne in
mind that it may also occur in conjunction with Gram-negative infection from
other routes.
Indirect evidence for the role of LPS in sepsis syndrome also exists. For
example, investigations of antibody responses to LPS have demonstrated an
association between low preoperative serum anti-endotoxin antibody levels and
adverse outcome following surgery (Bennett-Guerrero et al 1997, Freeman and
Gould 1985, Gould et al 1989, Hamilton-Davies et al 1997). Low or falling levels
of anti-endotoxin have also been shown to correlate with adverse outcome in
patients diagnosed with abdominal sepsis (Wakefield et al 1998) and
pancreatitis (Windsor et al 1993).
Together these lines of evidence suggest that LPS may have a strong role to
play in the initiation of sepsis syndrome.
1.5.7 Sepsis and immunological hyporeactivity
Although most patients survive the initial SIRS insult, these patients remain at
increased risk of developing secondary or opportunistic infections because of
the frequent onset of a secondary phase of immune hyporeactivity (Oberholzer
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et al 2001, Bone et al 1997). This phase is seen to be characterised by a
depression mainly in the production of Th1 cytokines (IL-2, IFN-y) whereas the
production of Th2 cytokines (IL-4, IL-10) remains largely unchanged or even
upregulated (Cavaillon et al 2001, Oberholzer et al 2002). This was shown after
vascular surgery (Berguer et al 1999), cardiopulmonary bypass (Naldini et al
1998), cholecystectomy (Brune et al 1999) and in burn and trauma patients
(O'Sullivan et al 1995). Further cellular effects of this phase include a shift of
CD8 cells towards the Type 2 phenotype, increased IL-4 production and a
decrease in expression of FILA-DR (Kox et al 1997).
The first observation of PBMC hyporeactivity in sepsis patients came with the
study of Wood and colleagues in 1984, showing that PBMC from these patients
exhibited decreased IL-2 production in response to PHA stimulation (Wood et al
1984). Subsequent studies by many groups have noted specific defects in every
population of immune cells from patients in this hyporeactive state. Monocytes,
for example, have been shown to have a diminished capacity to release TNF-a,
IL-1a, IL-13, IL-6, IL-10 and IL-12 in response to LPS (Ertel et al 1987, Munoz et
al 1991, Sekatrian et al 1994, Van Deuren et al 1994) whereas this is not the
case for IL-1 receptor antagonist (Van Deuren et al 1994). Similar observations
were reported in human volunteers after LPS injection: the capacity to produce
IL-1, TNF-a and IL-6 were all all significantly reduced independently of the
nature of the activating agent (ie LPS, IL-1 {3, staphylococcal toxic shock
syndrome toxin-1) (Granowitz et al 1993). Neutrophils are similarly affected, with
those extracted from septic patients demonstrating a reduced capacity to
release IL-13, IL-1 ra and IL-8 upon activation with LPS (McCall et al 1993).
Aberrant T-cell function in septic patients has also been reported. The study of
Heidecke et al (1999), for example, looked at T-cell function in patients with
post-operative sepsis due to intra-abdominal infection and showed that T-cell
proliferation and production of IL-2 were seen to be severely suppressed in the
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non-survivors, while survivors were shown to have normal levels of proliferation
and IL-2 release. As a result of their findings, they suggest a significant role for
T-cells in the response to post-operative infection.
Animal models of sepsis too, often reveal a phase of hyporeactivity similar to
that seen in humans. Martineau and coileauges have used the rat infusion
model of intra-abdominal infection to show temporary functional defects in B and
T-cells consistent with those seen in patients with peritonitis (Martineau et al
2000). Further, Gough et al have used the murine model of sepsis (caecal
ligation and puncture), to show a systemic immunosuppression that eventually
reverts to normal (Gough et al 1992).
1.5.8 The CARS hypothesis
The phenomenon of anergy following a pro-inflammatory episode has led to a
number of hypotheses being put forward to explain it. The longest running of
these, initially put forward by Bone et al (1997), holds that the primary phase of
systemic production of pro-inflammatory cytokines is eventually countered and
replaced by a systemic compensatory anti-inflammatory response (CARS). In
this model, the initial over-zealous activation of the innate immune response is
thought be countered with anti-inflammatory and Type 2 cytokines such as IL-
10, TGF-|3 and IL-4 (Cavaillon et al 2001). Widespread upregulation of these
secondary cytokines leads to macrophage deactivation, T-cell anergy and the
rapid apoptotic loss of many lymphoid tissues throughout the body, all of which
contribute to the development of the CARS syndrome and its associated
morbidity and mortality (Oberholzer et al 2001). Such a 'two-wave' model is
depicted in Figure 1 9a, and Bones proposed list of immunological definitions of
the SIRS and CARS phases, based on the cytokine levels observed in patient








(a) The "Two Wave" model, proposed by Bone et al [2781
Predominating in the tissues:
Particularly alveolar macrophages,
lung neutrophils and liver cells.
Time
CARS ► Predominating in the blood compartment:
insult Reduced responsiveness of blood PBMC
and neutrophils to in vitro stimuli.
(b) The"Compartmentalised" model, proposed by Cavaillon et al
(Inflammation)
Period of stress:
Initiates and perpetuates a
state of immunosuppresion
Inflammation:
May occur at a local site of infection,
as a result of immunocompromised
host being at risk of infectious challenge
Time
(Immunosuppression)
(c) The"Stress Induced" model, proposed by Munford et al
Figure 1.9 Proposed models of immunological status in sepsis patients
68
Table 1.4: Possible immunological definitions of SIRS and CARS from patient
plasma (from Oberholzer et al 2001)
SIRS: IL-6 > 1000pg/ml, IL-ip (detectable), TNF-a (detectable), IL-8 > 100pg/ml,
E-selectin > 150 ng/ml.
CARS: IL-10 (detectable), IL-1ra > 1500 pg/ml, sTNF-R I (p55) > 1500 pg/ml,
sTNF-R II (p75) > 1500 pg/ml, PBMC HLA-DR < 30%.
However, since its initial proposal in 1997, numerous studies have revealed
inconsistencies in the basic assumptions behind this so called 'two wave' model
of sepsis (Hassoun et al 2001). In particular, it has been seen that while cells
from individual patients may be hyporesponsive to one stimulus, they may be
normally reactive to another (Heidecke et al 1999, Cavaillon et al 2001, Zedler et
al 1999, Christou et al 1984, Tellado et al 1990). Further, particular cell types
purified from sepsis patients may exhibit conflicting inflammatory mediators
(Bone et al 1997, Oberholzer et al 2002, Heidecke et al 1999, Cavaillon et al
2001). Such a mixed response has been termed MARS (mixed anti¬
inflammatory response syndrome) which some hypothesise as a transitional
phase between SIRS and CARS phases (Bone et al 1997).
In order to explain these discrepancies, at least two further models of the
immunological events precipitating and perpetuating this phase of
immunological hyporeactivity have been proposed. The first of these was
proposed by Jean-Marc Cavaillon and colleagues (Cavaillon et al 2001) and
brings forward the idea of compartmentalisation. In this model, the authors
suggest that while cells extracted from the blood of patients may be
hyporesponsive to certain stimuli, cells derived from the tissues are normally
responsive or even primed to the same stimuli at all stages of sepsis. This
partitioning of the two responses, they suggest, allows a vigorous inflammatory
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response to remain at the site of infection, while sites distant from the infection
are protected from the damaging effects of pro-inflammatory molecules by the
concomittant release of systemic anti-inflammatory molecules such as IL-10 and
TGF-p. Such a 'biphasic' model of immune hyporeactivity is depicted in Figure
1.9b.
However, recent advances in our understanding of the strong interactions
between neurological and immunological functions have led to the proposal of a
more radical model. In particular the observation that stress hormones such as
catecholamines can suppress the activity of immune cells (Jones et al 1989),
inhibiting production of TNF-a (Severn et al 1992) and promoting a state
favouring production of the anti-inflammatory IL-10 (Suberville et al 1996, van
ser Poll et al 1996), have led Munford and colleagues to suggest a third model
of sepsis related hypo-reactivity (Munford and Pugin 2001a, Munford and Pugin
2001b).
In this model, (Figure 1.9c) it is proposed that the systemic anti-inflammatory
response seen in patients is not merely a compensatory reaction in response to
systemic pro-inflammatory cytokines, but a much more generalised response of
the body to stress. Stresses as diverse as cold exposure, strenuous exercise,
major injury and even psychological stress is sufficient, they assert, to induce a
systemic anti-inflammatory state via cytokines, the HPA axis and the
sympathetic-adreno-medullary axis (Munford and Pugin 2001a, Munford and
Pugin 2001b).
Such systemic anti-inflammation, they further suggest, would be able to prevent
potential damage of uninvolved tissues, while concentrating white blood cells
towards sites of infection, and may therefore be considered a normal reaction to
microbial challenge. However they also point out that while this state may induce
favourable outcome in dealing with a local point of infection, the associated
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systemic immunosuppression may also lead to secondary infection from viruses,
bacteria or fungi. Thus it is possible, they surmise, that a stress-induced phase
of immunosuppression may in fact precede and even precipitate an episode of
SIRS.
This idea that a period of immunological hyporeactivity may precede an episode
of SIRS or sepsis gains support from the many studies of immunological status
in pre-surgical patients. It has often been reported that patients entering hospital
may be in an immunologically hyporeactive state before they undergo surgery or
any SIRS episode. So called 'walk-in anergic' patients are seen to be at
considerably more risk from poor outcome when compared to patients exhibiting
normal immune function on admission (Christou et al 1984, Christou et al 1989,
Johnson et al 1979, Adami et al 1980, Christou et al 1983).
For example, in 1984 Christou et al prospectively measured the delayed type
hypersensitivity (DTH) reaction of patients admited for elective surgery. Patients
were considered anergic if they responded to one or less of five skin test recall
antigens. Intriguingly, while no major episodes of sepsis occurred in the control
group of immunocompetent patients, 25% of the anergic patients showed
evidence of sepsis (p<0.05) (Christou et al 1984). Moreover, mortality in the
anergic group was seen to be much higher than among the immunocompetent
controls (6% vs 40%, p<0.05), a correlation which was also borne out in a larger
study of the correlation between DTH reaction and clinical outcome (Christou et
al 1989).
However, as for which of these three models most accurately reflects the true
immunological picture in these patients remains to be verified. Only examination
of the cellular and cytokine responses from a wide range of tissue types, taken
at a wide range of time points from the many different patient subgroups will
begin to shed light on this complex matter.
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1.6 Aims of Thesis
The immunological responses of human beings to lipopolysaccharide may
confer on the host either beneficial or deleterious effects depending on the
context and magnitude of endotoxin challenge. The objective of this thesis was
to investigate the role of the different arms of the human immune system in
dealing with LPS challenge.
The three main areas of research included:
1) The innate immune responses to LPS and a liposomal LPS-based vaccine
were assessed. The kinetics and requirement of serum-based lipid shuttle
proteins in the mediation of these responses were also investigated.
Capacity of cells carrying a common mutation in the TLR4 gene to mount
effective responses to a wide range of LPS types were assessed.
2) The responses of human and murine T-cells to LPS challenge were
assessed. The LPS of different species and strains of bacteria were
compared in terms of their capacity to activate T-cells. Responses of human
T-cells to different types of LPS were assessed over time. The hypothesis
that the lipid presentation molecule CD1 may be involved in the T-cell
recognition of LPS was tested.
3) T-cell and antibody responses to LPS were compared between healthy
volunteers and patients admitted to hospital with suspected endotoxaemia.
Clinical scores, TLR4 mutations, white blood cell counts, patient length of





2.1 General cells, media and materials
2.1.1 General chemicals
Unless otherwise stated, all chemicals used were of AnalAR grade. Aqueous
solutions were made up in either distilled water or pyrogen free water (Millipore,
Billerica, MA, USA). Phosphate buffered saline (PBS) used in all experiments
was made by dissolving one tablet of PBS (Oxoid, Basingstoke, UK) per 100mls
of pyrogen free water and autoclaved before use.
2.1.2 General media
Bacteria were grown in nutrient broth (filter-sterilized, Gibco, Paisley, UK).
Mammalian tissue culture cell lines were maintained in either RPMI-1640
(Sigma, Gillingham, UK) supplemented with 1% ready-mixed penicillin/
streptomycin / glutamine (PSG, Sigma) and 5% foetal calf serum (Gibco, Sigma
or Imperial laboratories, Andover, UK), hereafter refered to as RPMI/5%FCS, or
DMEM (Sigma) supplemented with 1% PSG (Sigma) and 5% foetal calf serum
(Gibco), hereafter refered to as DMEM/5%FCS. Primary mammalian cell
cultures were maintained in either RPMI/5%FCS or RPMI supplemented with
1% readymixed PSG and 10% pooled human AB serum (Sigma), hereafter
refered to as RPMI/10%HS.
2.1.3 Bacterial strains
Heat-killed bacteria required for murine immunization protocols were either
Escherichia coli K12 or E, coli 018 K\ Bacteria were grown from -70°C bead
aliquot in 100mls nutrient broth in shaking incubator overnight at 37°C. After
harvesting and washing (15 minutes, 500g) three times in normal saline (0.85%
NaCI in distilled water) they were resuspended in 10mls normal saline and heat-
killed by incubation in a 100°C boiling water bath for 10 mins. Samples was
allowed to cool and aliquots plated on blood agar to confirm complete killing.
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Cells were counted by haemocytometer microscopy then diluted to 1 x 109 per
ml in normal saline and stored in glass bijoux at -20°C before use in
immunization or antigen challenge protocols.
2.1.4 Mammalian cell lines
Cell lines employed in various assays included the murine macrophage cell line
J774 (ECACC no: 85011428), the human monocyte cell line THP-1 (ECACC no:
88081201) and the murine fibroblast cell line L929 (ECACC no: 85011425).
J774.1 and THP-1 cells were grown in RPMI/5%FCS. L929 cells were grown in
DMEM/5%FCS. Maintenance of all cell lines was as described in section 2.3.1
below.
2.1.5 Lipopolvsaccharides
Lipopolysaccharides from a wide variety of species and strains of bacteria were
used. Of these, only the smooth LPS of E.coli 018 K~ was prepared by the
author, all others were made up from aliquots taken from the Microbial
Pathogenicity Research Laboratory (MPRL, Edinburgh University Department of
Medical Microbiology, Teviot Place, Edinburgh, EH8 9AG) -20°C stocks of LPS,
or were kind gifts from colleagues (listed in Table 2.1). Each LPS was
resuspended to a final concentration of 1mg/ml in pyrogen-free water
supplemented with 0.1% triethylamine (Sigma) to ensure complete solubility.
For murine vaccinations with native LPS, only E.coli 018 K" and E.coli K12 were
used. For comparisons of LPS and liposomal LPS, native or liposomal
preparations of either E.coli K12 LPS or "cocktail" LPS (an equimolar mixture of
E.coli R1, E.coli K12, Bacteroides fragilis rough LPS and Pseudomonas
aeruginosa PAC 608 LPS) were employed. ForT-cell proliferation experiments,
the LPS from E.coli R1, E.coli R2, E.coli R3, E.coli R4, E.coli K12, B. fragilis,
Pseudomonas aeruginosa PAC 611, Klebsiella aerogenes, K.friedlander,
K.pneumoniae, Salmonella typhimurium and S.minnesota were used. For
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measurements of endogenous core antibody (EndoCAb) titre measurements,
ELISA plates were coated with LPS from E.coli K12, P.aeruginosa PAC 611,
K.aerogenes KaM10b and S.typhimurium 878. Finally, Toll-receptor 4
polymorphism experiments included analysis of the responses to LPS from
E.coli R1, Neisseria meningitidis, B.fragilis rough, Porphyromonas gingivalis,
Yersinia pestis, Chlamydia trachomatis and P.aeruginosa PAC 611. The exact
strain, source and extraction method of each of these LPS is listed in Table 2.1.






E.coli 018 K - - phenol/H20 S C. Erridge
E.coli R1 32 MPRL 2316, NCTC 13114 pep R R. Brown
E.coli R2 17 - pep R F. Mcloughlan
E.coli R3 18 - pep R F. Mcloughlan
E.coli R4 20 - pep R F. Mcloughlan
E.CO//K12 26 MPRL 1899, NCTC 13116 pep R R. Brown
B.fragilis R 69 MPRL 1504, NCTC 9343 pep R D. Delahooke
B.fragilis S 68 MPRL 1504, NCTC 9343 phenol/H20 S D. Delahooke
P. aeruginosa 50 PAC 608, NCTC 13124 pep R R. Brown
P. aeruginosa 49 PAC 611, MPRL 1091 pep R C. Currie
S.typhimurium 43 878 pep R F. Mcloughlan
S.minnesota 33 R60 pep R F. Mcloughlan
K.aerogenes 57 KaM10b pep R F. Erikkson
K.friedlander 60 MPRL 4334 phenol/H20 S L. Millar
K.pneumoniae 58 MPRL 4332 phenol/H20 S L. Millar
N.meningitidis 101 MPRL 2843 Triton/MgCI2 LOS R. Brown
P.gingivalis 102 MPRL 1675 phenol/H20 S R. Brown
C. trachomatis - LGV-1 phenol/H20 LOS A. Eley
Y.pestis - - phenol/H20 S P. Oyston
Notes to Table 2.1: PCP refers to the phenol / chloroform / petroleum extraction
technique of Galanos et al as described by Hancock and Poxton (1998). LPS
extracted by the pep method is predominantly of the rough form. Triton/MgCl2
refers to the triton detergent based extraction of Uchida et al (1987). Phenol/H20
refers to the phenol water extraction technique as described below. LPS type: R
- rough form, S - smooth form, LOS - lipooligosaccharide.
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2.2 Preparation of Stimuli
2.2.1 Extraction of LPS
Extraction of smooth LPS from E.coli 018K" was based on the aqueous phenol
method ofWestphal and Luderitz (1954). Two 2 litre flasks containing 1 litre of
nutrient broth (filter sterilised, Gibco) were inoculated with 2.0ml of an overnight
preculture grown in nutrient broth. The flasks were then incubated in an orbital
incubator (120rpm) at 37°C overnight. Bacterial cells were harvested by
centrifugation at 10,000g then washed twice in PBS by centrifugation at 10,000g
for 10 minutes. The bacterial pellet was frozen at -20°C, freeze dried and
weighed.
This pellet was subsequently ground, resuspended to a concentration of 5% wv
in pyrogen free water and heated to 67°C in a water bath in a fume cupboard.
Meanwhile 90% w/w aqeuous phenol was prepared by dissolving 90g phenol
(BDH, New York, USA) in 10 ml of distilled water at 45°C and then making the
volume up to 100ml in distilled water. A volume of phenol solution equal to that
of the bacterial suspension was heated to 67°C in a water bath. The prewarmed
bacterial suspension and phenol solution were mixed and stirred with a glass
rod for 15 minutes at 67°C. Following this, tubes were transferred to an ice bath
to allow separation of the phenol and aqueous phases. The tubes were then
centrifuged at 10,000g for 15 minutes to complete separation of the phases. The
upper (aqueous) phase containing the LPS was carefully removed using a glass
pipette and the extraction procedure repeated on the lower phenol phase. The
two aqueous phases were pooled, transferred to dialysis tubing (previously
washed and boiled for 10 minutes in distilled water) and dialysed against
running tapwater overnight, until the smell of phenol could not be detected.
Insoluble deposits were then removed by two further centrifugation steps (15
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minutes, 10,000g). The dialysed extract was then concentrated by rotary
evaporation to approximately one-fifth of its original volume. At this stage LPS
should be beginning to precipitate, so the solution was transferred to
ultracentrifuge tubes and spun at 10,000g for 3 hours. The gelatinous pellet
obtained was resuspended in distilled water using a syringe fitted with a blunted
needle and recentrifuged as before. The final pellet was then suspended in a
small volume of pyrogen free water, freeze dried and weighed. Glass bijoux
were used to store the dried LPS at -20°C until required.
2.2.2 Repurification of LPS
In experiments to determine the TLR usage of different LPS types, removal of all
trace of lipoprotein was desired, so the phenol re-extraction method of
Hirschfield et al (2000) was applied to a selection of LPSs. At room temperature,
5mg of each LPS was individually resuspended in 1 ml of endotoxin-free water
containing 0.2% tri-ethylamine. Each sample was split into two 500pl aliquots,
with one remaining stored at -20°C without further manipulation to serve as an
"unextracted" control. Deoxycholate (Sigma) was added to the remaining aliquot
to a final concentration of 0.5%, followed by the addition of 500pl of water
saturated phenol. The samples were then vortexed intermittently for 5 minutes,
and the phases allowed to separate at room temperature for 5 minutes.
Samples were placed on ice for 5 minutes, followed by centrifugation at 4°C for
2 minutes at 13,000x g. The top aqueous layer was transferred to a new tube,
and the phenol phase was subjected to re-extraction with 500pl of 0.2%
TEA/0.5% DOC. The aqueous phases were pooled and re-extracted with 1ml of
water saturated phenol. The pooled aqueous phases were adjusted to 75%
ethanol and 30mM sodium acetate and were allowed to precipitate at -20°C for
1 hour.
The precipitates were then centrifuged at 4°C for 10 minutes at 10,000xg,
washed in 1ml of cold 100% ethanol, and air dried. Finally, these pellets were
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resuspended in the original volume (500pl) of 0.2% TEA without deoxycholate.
One hundred percent recovery was assumed for the purified LPS samples.
2.2.3 Preparation of liposomal LPS
Liposomes containing "cocktail" LPS (ie an equimolar mixture of E.coli R1, E.coli
K12, B.fragilis rough LPS and P.aeruginosa PAC 608 LPS) were kind gift of Drs.
E. Guerrero and T. Mcintosh (Department of Anesthesiology, Columbia
University College of Physicians & Surgeons, New York, USA and Department
of Cell Biology, Duke University, Durham, NC, USA). Liposomes containing
E.coli K12 LPS were prepared by myself with the assistant of honours student
Sarah McPhee.
Liposomes were prepared using depyrogenated glassware and reagents
according to the method of Dijkstra et al (1988) incorporating the modifications
of Guerrero et al (2000). Phospholipids were obtained from Avanti Polar Lipids
(Alabaster, AL, USA) and consisted of dimyristoyl phosphatidyl choline (DMPC),
dimyristoyl phosphatidyl glycerol (DMPG) and cholesterol in a 4:1:4 molar ratio.
A phospholipid / cholesterol stock was prepared and dissolved in chloroform
(55.3mg DMPC + 14.1mg DMPG + 31.6mg Cholesterol in 10mls Chloroform)
before being evaporated to dryness at 50°C in a rotary evaporator. 10mg of
E.coli K12 LPS resuspended in 10mls pyrogen free water supplemented with
0.1% Triethyiamine was then added to the dried lipid film. The LPS/lipid
suspensions were then rigorously vortexed and sonicated using a bath sonicator
for not less than 5 minutes. The preparations were then rotovapped again to
dryness and resuspended with vigorous vortexing in PBS. The resulting
multilamellar liposomes containing LPS were spun down in a bench centrifuge at
13,000x g, to be stored at -20°C or 4°C.
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2.3 Preparation of animals and cells
2.3.1 Maintenance of mammalian cell lines
L929 cells were cultured in RPMI/5%FCS (section 2.1.2) and split every three to
four days, or when confluence was reached, using either trypsin/EDTA
treatment or mechanical disaggregation. For trypsin/EDTA splits, existing
medium was poured off and the adherent cells washed twice in PBS before
exposing them to 25mls of proprietary Trypsin/EDTA mix (Gibco) for
approximately 5 minutes at 37°C. Disaggregated cells were then washed twice
(5 minutes, 300g) in RPMI/5%FCS to remove residual trypsin before plating at a
concentration of between 1/5 and 1/20 of the original cellular concentration in
standard 75ml tissue culture flasks (Greiner, Longwood, FL, USA). For routine
splits (ie non-experimental) not requiring fine separation of the cells, cells were
scraped from the bottom surface of the flask using sterile plastic scrapers (Nunc)
before washing and re-seeding as described above. J774 cells were split in an
identical fashion, with the exception that re-seeding occured at a concentration
of between 1/3 and 1/7 of the confluent concentration.
THP-1 cells grow in suspension and were split by taking an aliquot of between
1/3 and 1/10 of the confluent population and reseeding into a fresh 75ml tissue
culture flask containing RPMI/5%FCS medium.
2.3.2 Separation of peripheral blood mononuclear cells from blood or buffy
coats
Venous blood was obtained via venepuncture and collected in sterile
heparinised tubes. Buffy coats (a byproduct of the blood transfusion process
containing large numbers of white cells) were obtained by arrangement from the
Scottish National Blood Transfusion Service (Lauriston Place, Edinburgh).
Peripheral blood mononuclear cells (PBMC) were extracted from both samples
using the same technique.
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10mls of blood or buffy coat was diluted 1:3 in PBS and layered gently onto
10mls of pre-warmed (37°C) Histopaque-1077 (Sigma) in a 50ml Falcon tube,
being careful to ensure that the two layers did not mix. Tubes were centrifuged
at 300g for 30 minutes to allow red blood cells and granulocytes to separate
from the PBMC. Following centrifugation, the layer of cells created at the
interface between the two layers was carefully removed by sterile pastette.
These PBMC were then washed twice (7 mins, 300g) in PBS or RPMI/5%
before being resuspended in appropriate medium at the desired concentration.
2.3.3 Counting of white cells
Pelleted PBMC or splenocytes were resuspended in a small volume of medium
(2-10mls). 10(il of this suspension was removed using a sterile tip and carefully
mixed with 90(.il of white cell diluting fluid (0.01% Gentian violet in 1% acetic
acid). A haemocytometer (Hawksley, London) was then assembled and a
portion of the sample allowed to fill one chamber. For experiments requiring
plating of monocytes, only monocytes (characterised by an irregular nucleus and
a prominent extended cytoplasm) were counted.
2.3.4 Separation of monocytes from PBMC
In order to separate monocytes from PBMC, monocytes were counted as
described above and the entire population resuspended at 2x105 monocytes per
ml. The entire population was then plated at either 10Optl per well of a 96 well
plate (Iwaki, Stone, UK), 500pil per well of a 24 well plates (Iwaki), or 50mls into
a 75ml flat bottomed tissue culture flask (Greiner). Cells were left to adhere for 1
hour at 37°C. Non-adherent cells were then removed with moderate shaking and
washing with 3-4 washes of PBS. Remaining adherent cells represent the
monocyte fraction of the PBMC.
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2.3.5 Thioqlycollate stimulation of mice
All animal manipulations were performed by Mr. M. Kerr (Animal House,
University of Edinburgh Medical School). A 10% w/v solution of brewers'
thioglycollate (Sigma) was prepared in pyrogen free distilled water and
autoclaved before storage at 4°C. C3H/HeN mice were then injected with 1ml of
this solution into the peritoneal cavity using a 23 gauge needle. Mice were killed
after four days and 5mls of sterile PBS injected into the peritoneal cavity using a
25 gauge needle and the area gently palpitated to release cells. Intraperitoneal
fluid containing cells was then recovered using a 21 gauge needle.
2.3.6 Vaccination of mice
All animal manipulations were performed by staff of the Animal House,
University of Edinburgh Medical School. C3H mice were immunised with either
heat killed bacteria (E.coli K12 or E.coli 018K~), LPS (E.coli K12 or E.coli 018K")
or sheep red blood cells. LPS samples were adjusted to 0.1mg/ml in normal
saline and heat-killed bacteria to 1x108 cells per ml in normal saline. Sheep red
blood cells were washed twice in PBS then resuspended in normal saline at a
concentration of 2x108 cells/ml before being mixed with an equal amount of
Freunds complete adjuvant (Difco, Franklin Lakes, NJ, USA). Mice received
duplicate tail base injections of 50pl of each preparation and spleens or lymph
nodes were harvested at time points ranging between 3 and 14 days.
2.3.7 Plating of murine peritoneal macrophages
Suspensions of peritoneal cells were washed three times in 25mls of PBS (five
minutes, 300g). Cells were then resuspended in a small volume of
RPMI/5%FCS, counted and adjusted to 2x106 cells per ml by further addition of
RPMI/5%FCS. 1 ml of this suspension was then added to each well of a sterile
24 well plate (Greiner) and incubated for one hour (37°C, 5% CO2) to allow the
macrophages to adhere. Following this, the cells were gently washed using
sterile pastettes containing PBS to remove non-adherent cells.
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2.3.8 Preparation of murine splenocytes
Spleens of naive or immunised C3H/HeN mice were removed intact and
transferred to a sterile universal containing PBS. Sterile agar plates were then
opened and a sterile nylon 100pm cell strainer (Falcon, Crowley, UK) placed on
top. Spleens were diced with autoclaved scissors and placed on top of the cell
strainer membrane. A sterile 200pl pippete tip was then used to diaggregate the
cells, while RPMI/5%FCS was constantly washed through to collect cells. The
cell strainer and remaining splenic residue were then removed and discarded.
Cells washed through to the plate were transferred to a sterile universal for three
washes in RPMI/5%FCS at 300g for five minutes before counting and
resuspension at the desired concentration.
2.3.9 MACS selection of cells
Antibody selection/depletion of cells from murine derived populations was
achieved using the MiniMACS system (Miltenyi Biotech, Bisley, UK). The
manufacturers instructions were followed, but in brief a MiniMACS separation
column was placed onto the magnet of a MiniMACS separation unit and
prepared by passing through 500pl of proprietary buffer. Cells of interest were
then stained with antibody (a-murine CD19, Serotec, Oxford, UK, for splenic B-
cell depletion experiments) and labeled by incubation with MACS anti-IgG
magnetic beads. Following this, a maximum of 107 labelled cells in 109
unlabelled cells was added to the top of the column and allowed to flow through,
followed by three washes of 500pl buffer. Eluant was collected as the depleted
cell population. The column was then removed from the magnet and flushed
through with 1ml of buffer to elute the positively labelled cells. Cells were
counted and washed to resuspend at appropriate conentrations in
RPMI/5%FCS.
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2.3.10 Creation of CD1a,b,c +ve dendritic cell populations
Human moncytes were allowed to adhere in 75ml tissue culture flasks and
washed as described above. Cells were then incubated in 10mls of
RPMI/5%FCS containing 200 lU/ml of IL-4 and GM-CSF (Peprotech, Rockyhill,
NJ, USA) and harvested after 3-4 days incubation at 37°C/5%CC>2.
2.4 Biological Assays
2.4.1 Challenge of cells with LPS/LTA or heat killed bacteria for cytokine
measurement
Ten fold dilutions of LPS or Staphylococcus aureus lipoteichoic acid (Sigma)
were created by adding 450pl of RPMI/10%HS or RPMI to each well of a 24 well
plate (Greiner). 4.5pil of defrosted stock (1mg/ml) samples of LPS or LTA were
then added to the first well and mixed thoroughly with a fresh pipette tip to
provide a concentration of lOpg/ml. A further fresh tip was used to transfer 50pil
of this dilution to the next well. It was found that in order to obtain reliable
results, a fresh tip must be used for every mixing and transfer step.
For experiments investigating responses to heat killed bacteria, stock samples
of heat killed bacteria were diluted to a primary concentration of 1x106 bacterial
cells per ml in RPMI/5%FCS and subsequent dilutions made as described
above.
Human monocytes were resuspended at 2x106 monocytes/mi in RPMI/10%HS
or RPMI without serum and plated at 100pl per well in a 96 well plate (Iwaki).
After one hours incubation at 37°C, non-adherent cells were carefully washed off
and the medium replaced with 10Opil of the LPS dilutions described above.
Murine peritoneal macrophages were plated as described (section 2.3.7) and
the medium replaced with 500ptl of appropriate dilutions of LPS or heat killed
bacteria. In all experiments other than those investigating signalling kinetics,
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supernatants were measured for TNF-a production at 4 hours, IL-13 production
at 18 hours and nitric oxide production at 24 hours, as described below. These
timepoints were chosen because peak TNF-a release is seen to occur at around
4 hours (Delahooke et al 1996) while IL-1 p and nitric oxide remain clearly
detectable in supernatants following an overnight incubation.
For experiments investigating the role of the serum proteins LBP and sCD14 in
LPS signalling, fixed concentrations of 100ng/ml LPS or 10pg/ml liposomal LPS
were used. Serum free RPMI was supplemented with 1 pg/ml purified human
plasma lipopolysaccharide binding protein (HBT, Uden, Netherlands) or 1pg/ml
recombinant human soluble CD14 (R&D).
For experiments investigating the capacity of the monoclonal antibodies TL2.1
(Cascade bioscience, Winchester, MA, USA) and HTA125 (Serotec) to block
TLR signalling, 96 well plates were seeded at 1x105 monocytes per well. 50pl of
RPMI/10%HS supplemented with 20(j.g/ml antibody was added to the cells and
allowed to block at room temperature for one hour. 50pl of double concentrated
stimulus was then added to each well and incubated overnight at 37°C.
Supernatants were harvested and assayed for IL-113 content 18 hours later.
2.4.2 Griess assays for nitric oxide
24 or 96 well plates containing challenged cells were spun at 300g for 7 minutes
before carefully decanting 100j.il volumes of culture supemates from each well
(taken 24 hours after stimulation of cells) into a fresh 96 well plate. A standard
curve was prepared using doubling dilutions of a stock solution of Sodium Nitrite
(128pM) in blank culture medium. 100pl of Griess reagent (Sigma) was then
added to each well and incubated at room temperature for 15 minutes. Griess
reagent consisted of sulphanilamide and N-1-napthylethylenediame




A bioassay was chosen over ELISA based methods of TNF-a measurement on
the basis of cost and the ability to measure functional TNF-a. A modified version
of the technique of Delahooke et al (1996) was employed. L929 cells were
disaggregated using the trypsin/EDTA method as described above (mechanical
disaggregation was seem to lead to poor reproducibility) and resuspended at
4x106 cells/ml in DMEM/5%FCS. 100j.il of this suspension was then added to
each well of a 96 well tissue culture plate and left for 3-4 hours to adhere.
Supernatants were then carefully removed from each well and replaced with
90j.il (sample wells) or 10Opil (standard curve wells) of DMEM/5%FCS containing
1pg/ml Actinomycin-D. To create the standard curve, 10j.il of medium was
removed from well number 1 and replaced with 10pil of 10,000 lU/ml
recombinant TNF-a in PBS (Peprotech). From this well, 3.2 fold dilutions were
performed along the standard curve row by taking 45j.il along and mixing into the
100j.il already present. The final 45pl was discarded from the last well in the row.
For sample measurement, 10jal of fresh supernatant from challenged cells was
added to the 90jil of DMEM/5%FCS/ActD already present in each sample
measurement well. Plates were then incubated at 37°C, 5% CO2 overnight.
The following day, plates were inverted vigorously to remove medium from the
cells. 50pl of crystal violet (0.5% Crystal violet in 20% methanol in dH20, filtered
through Whatman no1 paper) was added to each well and left to stain for 3-4
minutes. Each well was washed thoroughly under the tap. Following a brief
drying spell on tissues to remove the excess water, 50jil of acetic acid (20%
Acetic acid in dFI20) was added to each well to solubilise the cells. Absorbance
was read at at 540nm.
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2.4.4 Limulus Amoebocyte Lysate (LAL) assays
The Pyrochrome LAL kit (Associates of Cape Cod, Falmouth, MA, USA) was
used according to manufacturers instructions. In brief however, Pyrochrome
reagent was reconstituted in 3.2mls of pyrochrome buffer and kept on ice. A vial
containing 0.2ng of control endotoxin was reconstitued in 2mls of Pyrogen free
water to achieve a 1.0 EU/ml concentration. A seven point standard curve was
created using doubling dilutions from 1 EU/ml (0.1ng/ml) downwards.
Samples of LPS (10pg/ml) or liposomal LPS (1ng/ml) resuspended in pyrogen-
free water (PBS interferes with the assay) were added at 50pl per well in a 96
well plate. Pyrogen-free water alone was included as a control. 50pl of
reconstituted pyrochrome reagent was then added to each sample or control
and the plate was shaken gently before incubating at 37°C for 30 minutes. To
stop the reaction, 25pl of 50% acetic acid in pyrogen free water was added to
each well. Absorbance values were read at 405nm on an Anthos 2001
automated plate reader.
2.4.5 Measurement of human 1L-1B secretion
Supernatant levels of the human cytokine IL-1 p were measured using the
Duoset ELISA development system (R&D) according to the manufacturers
instructions. Briefly, high-binding ELISA strips (Maxisorp type, Nunc, Rochester,
NY, USA) were assembled in ELISA frames and 10Opil of capture antibody
diluted 1:180 in PBS was added to each well. Plates were sealed and incubated
overnight at room temperature. The following day, wells were washed three
times in ELISA wash buffer (PBS containing 0.05% Tween-20) using an
automated ELISA plate washer (Dynatech, Chantilly, UA, USA) and the last
remaining liquid removed by blotting on paper towels.
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Wells were then blocked with 300pl of blocking solution (PBS supplemented
with 1% BSA, 5% sucrose and 0.05% NaN3) at room temperature for one hour
before washing as described above. Plates were then dried thoroughly by
blotting and either used immediately or stored at 4°C for later use.
50-1 OOpil of tissue culture supernatant was added to each well, with one strip
providing a dilution curve created by doubling dilutions of 250pg/ml recombinant
IL-1(3 in blank tissue culture medium. Plates were incubated at room
temperature for 2 hours before washing (as above). 10Opil of detection antibody
diluted 180 fold in reagent diluent (PBS supplemented with 1% BSA, sterile
filtered at 0.2pm) was then added to each well and the plate allowed to incubate
at room temperature for a further 2 hours. Plates were washed as above before
adding 1OOpI of streptavidin conjugated to horseradish peroxidase diluted 200
fold in reagent diluent. Plates were incubated for 20 minutes at room
temperature and washed as described. 100pl of substrate solution (one tablet of
Tetramethylbenzadine (Sigma) dissolved in 10mls 0.05M phosphate/citrate
buffer, pH 5.0 (308mg citric acid and 482mg Na2HP04 dissolved in 100mls
distilled water), supplemented with 2pl of fresh 30% hydrogen peroxide) was
then added to each well and the plate covered and incubated at room
temperature for a further 20 minutes. Finally, 50pl of stop solution (2N H2SO4)
was added to each well and the plates gently tapped to encourage complete
mixing. Optical densities of each well were read at 450nm using an automated
plate reader. The blank well OD was subtracted from each value and a standard
curve created from the recombinant cytokine values to provide a measure of the
amount of cytokine in each sample.
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2.4.6 Preparation of endogenous core antibody (EndoCAb) ELISA plates
Stock 1mg/ml (approximately 0.2mM) solutions of LPS from the following strains
were prepared using pyrogen free water:
(i) E.coli K12 (ii) P.aeruginosa PAC611 (iii) K.aerogenes KaM10b (iv)
S.typhimurium 878.
Each solution was sonicated for 30s at 5 microns amplitude using a Sanyo
Soniprep 150 sonicator. A 1mg/ml solution of polymyxin-B sulphate (~1mM) in
pyrogen free water was then prepared. 1ml of each LPS solution was aliquoted
to a new bijoux and mixed with 1ml of 1mM polymyxin-B before sonicating as
before for another 30s. The resulting four mixtures were then transferred to
cellulose dialysis tubing with a 2000 mwt cut off (Spectrum Medical Industries
Inc, Los Angeles, USA) and dialysed against distilled water overnight to remove
unbound polymyxin.
Dialysis tubes were then carefully cut and the floccular LPS/polymyxin-B
complexes resuspended thoroughly before removing with pipette and storing in
fresh glass bijoux at -20°C.
To coat ELISA plates or strips with complex, 100pl of each of the four
complexes was combined in a glass universal and then diluted 1:50 by addition
of 20mls of coating buffer (see below). After vortexing, this mixture was rapidly
plated at 100pl per well of 96 well ELISA plate strips (Nunc, Intermed, Kaastrup,
Roskilde, Denmark). Strips were left to coat overnight at 37°C, then washed four
times with wash buffer (see below) using an ELISA plate washer (Dynatech).
Wells were then post-coated with 10Opil of post-coat buffer (see below) and left
to incubate at 37°C overnight. After 4 further washes with wash buffer, strips
were rinsed with distilled water and allowed to dry thoroughly before storing in
foil at -20°C.
Coating buffer (pH=9.6): 0.05M carbonate/bicarbonate buffer (6.2g/l
Na2C03.H20, 4.2g/l NaHCCb) plus 0.05% w/v sodium azide.
Post coat buffer: PBS containing 2% w/v BSA and 0.05% sodium azide.
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Wash buffer: PBS containing 0.05% v/v Tween-20 (Sigma).
Dilution buffer: PBS containing 0.05% v/v Tween-20, 4% w/v polyethylene glycol
6000 (Sigma) and 0.05% sodium azide.
Alkaline phosphatase substrate solution: 0.05M sodium carbonate buffer
(pH=9.8), 1.0mM Magnesium chloride, made up as follows: Solution A=4.24g
Na2CC>3 in 200mls dH20, Solution B=3.36g NaHC03 in 200mls dH20. Mix 55mls
of A with 70mls of B and 375mls of dH20. Check pH is 9.8. Add 102mg of
MgCI2, and dispense into 50ml screw capped bottles. All solutions are stored at
4°C.
2.4.7 Endogenous core antibody (EndoCAb) ELISA
Sufficient strips for a complete experiment were taken from -20°C storage and
placed in a frame with dummy strips to complete the plate. Plasma samples
were diluted 1:400 in dilution buffer (section 2.4.6) and added at 10Optl per well
in triplicate. A standard curve was created using doubling dilutions of a stock
sample of serum found in a previous study (Barclay et al, 1987) to contain a high
titre of anti-core LPS antibodies. A well containing dilution buffer only was also
included as a negative control. Plates were then wrapped in foil and incubated at
37°C for 90 minutes before washing 4 times with wash buffer (section 2.4.6).
Monoclonal antibodies against heavy chains of human IgG or IgM (Sigma)
conjugated to alkaline phosphatase were diluted 1:2000 in dilution buffer and
added at 100pl per well before incubating for a further 90 minutes at 37°C.
The plates were then washed four times with wash buffer before addition of
10Opil alkaline phosphatase substrate to each well made up by the addition of
one alkaline phosphatase substrate tablet (Sigma) per 5mls of the buffer
described above. Plates were then left to develop at room temperature before
reading at 405nm on an Anthos 2001 automated plate reader every 5 minutes or
so. The final reading was recorded when the highest optical density value on the
plate approached a value of 1.0.
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2.4.8 T-cell proliferation assays
Splenocytes extracted from mice or PBMC purified from human blood or buffy
coats (section 2.3.4) were resuspended at a concentration of 1x106 cells per ml
in RPMI/5%FCS or RPMI supplemented with 20% autologous plasma in some
human PBMC experiments. 200pl of this suspension was added to each well of
a 96 well plate and 10Optl of each LPS dilution (prepared as described in section
2.4.1) or 1pg/ml Concanavalin A (Sigma) added directly on top. Cells were then
incubated for 2-14 days at 37°C. 18 hours before harvesting, 10pil of PBS
containing 1 jaCi of tritium labelled thymidine (Amersham, Piscataway, NJ, USA)
was added to each well being careful not to cross-contaminate wells. Cells were
then harvested onto filter mats (Camo, Newmarket, Suffolk), and thymidine
incorporation measured by scintillation in a Packard 1900CA p-counter.
In experiments to block proliferation with antibodies against CD1a,b or c
(Serotec), azide was removed from stock antibodies by dialysis in proprietary
dialysis cassettes (Serotec) against a large volume of PBS in a stirred container
overnight. Final concentrations of anti-CD1a and CD1b were 0.05mg/ml, while
the concentration of anti-CD1c was 1mg/ml. Following plating of PBMC and LPS
as described above, 10pl of undiluted stock azide free antibody was added to
each culture (final concentration of antibodies: 2.5pg/ml a-CD1a,b,d or 50pg/ml
a-CD1c).
2.4.9 Staining of cells for flow cytometry
Cells were washed and adjusted to ~5x106 cells per ml. 100pl was then added
to each well of a V-bottom 96 well plate, supplemented with 25pl of neat normal
rabbit serum and placed on ice for 20 minutes. Meanwhile, 20mls of PBS was
freshly supplemented with 2% normal rabbit serum (Serotec) and used to dilute
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primary antibodies to working concentrations according to manufacturers
instructions (typically 1:100).
The plate was then centrifuged at 300g for 7 minutes to pellet the cells and
thrown over a sink to expel the supernatant. Cells were resuspended in 200pl
PBS/NRS and washed twice further in this fashion before resuspension in 10-
20pl of each antibody and incubation on ice for a further 45 minutes. Plates
were washed a further three times. Cells were then resuspended in 25pl of
secondary antibody (conjugated to PE or FITC) diluted according to the
manufacturers instructions. Following a final 30 minute incubation on ice in the
dark, plates were washed three times in 200gl PBS/NRS and resuspended in
PBS supplemented with 1% paraformaldehyde (BDH). Fixed cells were stored at
4°C in the dark until the flow cytometer became available.
2.5 Protein and DNA analysis
2.5.1 Immunoprecipitation
The Mammalian SiezeX immunoprecipitation kit (Pierce, Rockford, IL) was used
to immunoprecipitate proteins from cellular preparations. Manufacturers
instructions were adhered to, though a brief description of the protocol used
follows. Immobilised antibody columns were created using protein-G conjugated
resin cross linked to user supplied antibody (CD1a,b,c or d) using disuccinimidyl
suberate. Mammalian cells were then lysed using kit supplied lysis reagent,
mixed gently for 10 minutes and transferred to the column for a ten minute
incubation. Columns were then washed through with proprietary buffer before
elution of purified proteins using proprietary elution buffer. For PAGE analysis of
lysate protein content, 20pl of eluant was mixed with 5pl of proprietary sample
buffer, boiled for 5 minutes and allowed to cool before loading on a PAGE gel.
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2.5.2 Preparation of samples for polvacrvlamide gel electrophoresis
(PAGE)
Protein samples were prepared as described in section 2.5.1. LPS samples
were adjusted to 1.0mg/ml and 10pil of sample added to 10ptl of single strength
PAGE sample buffer (below) and heated for 10 minutes in a 100°C water bath.
20pl of this mixture (10pg total LPS) was run on each track of the gel. Single
strength PAGE sample buffer: 0.0625M Tris (BDH) pH 6.8 supplemented with
2.0% w/v SDS (BDH), 10% v/v glycerol (BDH), 1% v/v 2-mercaptoethanol (BDH)
and 0.001% bromophenol blue (BDH)
2.5.3 PAGE
PAGE of protein and LPS samples was performed according to the method of
Laemmli (1970). PAGE of samples for subsequent immunoblotting was carried
out as described below with the exception that SDS was omitted from each of
the buffers. The following buffers and solutions were used:
1) Electrode buffer (pH8.3) consisted of 0.025M Tris (BDH), 0.192M glycine
(BDH chromatographically homogeneous) and 0.1% w/v SDS (BDH).
2) Separating gel buffer (double strength, pH 8.8) consisted of 0.75M Tris-HCI
at pH 8.8 to which 0.2% w/v SDS was added (omitted for immunoblots).
3) Stacking gel buffer (double strength, pH 6.8) consisted of 0.25M Tris-HCI at
pH6.8 to which 0.2% w/v SDS was added (omitted for immunoblots).
4) Acrylamide stock solution (40% w/v) contained 100g acrylamide (BDH) and
2.7g methylene bis acrylamide (BDH) and made up to 250ml with distilled
water.
5) Ammonium persulphate (15mg/ml) prepared by addition of 300mg
ammonium persulphate (BDH) to 20 mis pyrogen free water. Stable for 14
days at 4°C.
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The separating gel was prepared according to the proportions described in
Table 2.2 and degassed under vacuum prior to addition of 50pl TEMED
(NNN'N-tetramethyi-1,2-diaminoethane, BDH) and 1.75 ml ammonium
persulphate (BDH). The gel solution was poured between two assembled gel
electrophoresis glass plates (160mmx125mmx1.5mm) previously cleaned with
methanol and sealed at sides and bottom with vaseline. The gel was overlayed
with water saturated butan-2-ol (BDH) and allowed to set. The butan-2-ol was
then discarded and the stacking gel, prepared according to the proportions
described in Table 2.2, was poured onto the separating gel. A comb was
inserted and the gel allowed to set. On removing the comb the gel was fitted into
an electrophoresis tank (Jencons Scientific Ltd, Beds.) and electrode buffer
added to brim the wells of the gel.
Each well was then loaded with either sample (prepared as described in
sections 2.5.1 and 2.5.2) or an equivalent volume of single strength sample
buffer. The gel was then run at an initial voltage of 60V, before switching to run
at 150V as the samples passed into the separating gel. After electrophoresis,
LPS samples were analysed by silver staining (section 2.5.4) and protein
samples by coomassie blue staining (section 2.5.5) or by immunoblotting after
transfer to nitrocellulose (section 2.5.6).
Table 2.2 Reagents required for preparation of PAGE gels
Reagent: 12% Separating gel 4% Stacking gel
Distilled Water 5.2 ml 3.5 ml
Separating buffer 17.5 ml -
Stacking buffer - 5.0 ml
Acrylamide solution (40%) 10.5 ml 1.0 ml
TEMED 50 pi 20 pi
Ammonium persulphate (15mg/ml) 1.75 ml 0.5 ml
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2.5.4 Silver staining of PAGE gels for LPS
Ari adaptation of the methods of Tsai & Frasch (1982) and Hitchcock & Brown
(1983) was used to visualise LPS in PAGE gels. The following reagents and
solutions were used in the silver staining procedure:
1) Fixative consisted of 7% v/v acetic acid (BDH) and 25% propan-2-ol (BDH) in
distilled water.
2) Oxidising solution consisted of 1.05g periodic acid (BDH) made up in 150ml
of distilled water and 4ml of the above fixative solution.
3) Ammoniacal silver nitrate solution was prepared freshly by placing 1,4ml of
ammonia solution (BDH, specific gravity 0.88) and 21 mis of 0.36% NaOH in
a dedicated 100ml flask and adding in a dropwise fashion with continual
mixing 4mls of 19.4% silver nitrate solution. Volume was made up to 100ml
with distilled water.
4) Developing solution, prepared just before use, consisted of a 0.019% v/v
formaldehyde (BDH) solution containing 0.005% w/v citric acid.
PAGE gels were placed in fixative and left overnight at room temperature on a
slowly shaking platform (used for all of the following steps). Fixative was poured
off and the gel oxidised for 5 minutes with a freshly prepared solution of periodic
acid. The gel was then washed in at least four changes of 200ml distilled water
over 4 hours. Ammoniacal silver nitrate solution, freshly prepared as above, was
then added to the gel. After staining for 10 minutes, the gel was washed with at
least four changes of distilled water (200ml) over 40 minutes. Samples were
visualised with the addition of 200ml of freshly made developing solution. Once
the desired staining intensity had been obtained (5-10 minutes) the gel was
washed repeatedly in large volumes of distilled water and stored in water in the
dark before digital scanning and recording.
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2.5.5 Coomassie blue staining of PAGE gels for protein
The coomassie blue stain described by Hancock and Poxton (1988) was used.
The solutions used were made up in distilled water and included:
Solution (1) - 25% v/v propan-2-ol (BDH), 10% v/v acetic acid (BDH) and 0.05%
w/v Coomassie brilliant blue R-250 (BDH).
Solution (2) -10% v/v propan-2-ol, 10% v/v acetic acid and 0.005% w/v
Coomassie blue.
Solution (3) -10% v/v acetic acid and 0.0025% w/v Coomassie blue.
Solution (4) - 40% v/v methanol (BDH) and 10% v/v acetic acid.
Solution (5) -10% v/v acetic acid.
PAGE gels were placed in solution 1 overnight and then sequentially through
solutions 2-5, for 45-60 minutes each at room temperature with gentle shaking
throughout, before digital scanning and recording.
2.5.6 Immunoblottinq
Cellular protein extracts (prepared as described in section 2.5.1) were separated
by PAGE and transferred to nitrocellulose (NIC) paper for immunochemical
analysis. A modification of the method of Towbin et al (1979) was followed.
The following reagents and solutions were used:
1) Electrode transfer buffer (pH8.3) - contained 6.1g Tris (BDH), 28.8g glycine
(BDH chromatographically homogeneous) and 400mls methanol (BDH)
made up to 2000mls with distilled water.
2) Tris buffered saline (pH7.5) (TBS) - consisted of 4.84g Tris (BDH) and
58.48g sodium chloride (BDH) made up to 2 litres with distilled water.
3) Tween-Tris-buffered saline (pH 7.5) (TTBS) - was made as TBS with the
addition of 0.025% v/v Tween-20 (Sigma).
4) Blocking solution - was made as for TBS with the addition of 3% w/v gelatin
(BioRad EIA grade).
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5) Antibody/conjugate diluent - was made as for TBS with the addition of 1 %
w/v gelatin (BioRad EIA grade).
6) Horse radish peroxidase (HRP) colour developer was made just before use
by the mixing of two solutions. Solution A: 60mg 4-chloro-1-napthol (BioRad
HRP colour reagent) dissolved in 20mls methanol. Solution B: 100ml TBS
containing 60pl hydrogen peroxide (BDH, 30% w/v).
Transfer of antigens from PAGE gels to nitrocellulose
PAGE gels were removed from the electrophoresis apparatus and placed into a
Scotchbrite blotting cassette. The gel was then covered with a sheet of NIC
presoaked in electrode transfer buffer, then two sheets (either side) of
presoaked blotting paper. The cassette was then closed sandwiching the gel,
NIC paper and blotting paper between the two Scotchbrite porous foam pads.
The assembly was then placed into the immunoblotting tank containing
electrode transfer buffer, ensuring that the gel was placed towards the cathode
and the NIC towards the anode. A constant current of 40mA was applied
overnight at 4°C.
Visualisation of antibody-antigen reactions
After electrophoretic transfer of antigens the NIC was removed and washed in
TBS for 10 minutes before placing in blocking solution for 45 minutes (with
gentle shaking, as used for all subsequent steps). Once blocked, the NIC was
transferred into antibody dilution buffer containing 1gg/ml of antibody (a-
CD1a,b,c or d, Serotec) and incubated for 3 hours at room temperature. The
NIC was then rinsed briefly in distilled water and washed for two 10 minute
periods in TTBS, following which it was incubated with HRP-conjugated anti-
mouse IgG (Serotec) diluted in antibody diluent for 60 minutes followed by
rinsing in distilled water and washing in TTBS (as above). The binding of
antibody to separated antigenic determinants was visualised by addition of HRP
colour developing solution to the NIC. The colour was allowed to develop for up
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to 30 minutes and then stopped by washing in several changes of distilled water.
The blot was dried before digital scanning and recording.
Dot-blot protocol
In order to determine if a particular antibody/protein interaction could be
detected in the context of NIC fixation, dot blots were performed. Small sections
of NIC (1cm x 4cm) were prepared using a sharp scalpel and washed in TBS
with gentle shaking (employed for all subsequent steps) for 10 minutes before
drying thoroughly. 1 to 2 pi of protein extract was then placed on the NIC and
allowed to dry completely at 37°C. Samples were then washed in TBS for 10
minutes as before. Blocking solution (prepared as above) was then applied for
45 minutes followed by a 2pg/ml solution of antibody (a-MHC-ll, CD3 or
CD1a,b,c or d, Serotec) diluted in antibody diluent for 3 hours. The NIC was
washed twice in Tween-TBS for 10 minutes each then incubated with HRP-
conjugated anti-mouse IgG (Serotec) diluted in antibody diluent for 1 hour. NIC
were washed two further times in Tween-TBS as before then rinsed with three
brief changes of tap water. Developing solution was freshly prepared (as above)
and applied to the NIC. Development was stopped by washing the NIC several
times in tap water. The NIC was then dried before digital scanning and
recording.
2.5.7 Preparation of genomic DNA for polymerase chain reaction fPCR)
The ReadyAmp genomic DNA purification system (Promega, Southampton, UK)
was used to extract genomic DNA from whole blood or stored PBMC samples.
Manufacturers instructions were followed but in brief consisted of the following.
50pl of stored PBMCs (2x106/ml) or 100pl of heparinised blood was made up to
1ml with nuclease free water and vortexed occasionally for 10 minutes. Cells
were pelleted by centrifugation at 13,000g for 2 minutes, then 200jil of kit
supplied resin was added and vortexed. Suspensions were then incubated at
56°C for 20 minutes, followed by 8 minutes at 100°C in a water bath. Samples
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were vortexed, then centrifuged and the supernatant containing the isolated
single stranded DNA carefully decanted for storage in fresh tubes at -20°C.
2.5.8 PCR of Toll receptor mutations
Patient and volunteer genomic DNA samples were screened for the presence of
two mutations in the Toll like receptor 4 gene (Asp299Gly and Thr399lle)
according to the method of Lorenz et al (2001). Briefly, 5pl of genomic DNA was
added to 25pl of ReadyTaq PCR mix (Sigma) supplemented with 0.2pl (20pmol)
of each primer and 19.6pl of PCR grade nuclease free water. Thermal cycling
was applied according to the following protocol: 95°C for 4 minutes, then 30
cycles of 95°C for 30s, 55°C for 30s and 72°C for 30s, followed by a final
completion stage of 72°C for 4 minutes and a 4°C hold phase.
Primers were designed to incorporate a missense mutation to provide a
restriction enzyme site (underlined bases). The positions of the primers in
relation to the mutations in the cDNA sequence of TLR-4 are shown in Figure
2.1. The mutation sites are indicated by capital letters and occur immediately
following the 299For and 399For primers.
Asp299Gly forward primer: 5' -GATTAGCATACTTAGACTACTACCTCCATG -3'
Asp299Gly reverse primer: 5'-GATCAACTTCTGAAAAAGCATTCCCAC-3'
Thr399lle forward primer: 5'-GGTTGCTGTTCTCAAAGTGATTTTGGGAGAA-3'
Thr399lle reverse primer: 5'-ACCTGAAGACTGGAGAGTGAGTTAAATGCT-3'
PCR products were visualised by running on a 1.5% ethidium-stained agarose
gel against 2pl of 100 base pair ladder (Promega).
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2.5.9 Genotypinq of Toll receptor mutations
Restriction of PCR products was also achieved according to the method of
Lorenz et al (2001). Asp299Gly and Thr399lle products were screened with A/col
(restriction site: C/CATGG, Promega, UK) and Hint] (restriction site: G/ANTC,
Promega, UK) restriction enzymes respectively. Briefly, 10pil of each PCR
product was added to 2\x\ of appropriate proprietary restriction enzyme buffer,
0.7pl of respective enzyme, 0.2pl of 1mg/ml bovine serum albumin and 7.1 pi of
nuclease free water, mixed and incubated for 4 hours at 37°C.
Digest products were run on a 3% high resolution agar gel (Nusieve 3.1,
Flowgen, Ashby de la Zouch, UK) at low voltage (65volts), alongside 2pl of 100
base pair ladder (Promega). Cut products indicated presence of the mutation.
2.6 Patient recruitment
2.6.1 Patient recruitment
A prospective series of patients presenting with inflammatory disease arising
from a suspected infectious origin were asked to participate in the following
study. Each diagnosis was made on the basis of judgement of clinical variables
by an experienced clinician. Over the course of 14 months, venous blood
samples (20mls) were taken from a total of 40 patients enrolled at the Royal
Infirmary of Edinburgh Surgical Admissions Unit. Of these patients, six agreed to
follow up blood sampling on either one or two occasions. 40 healthy controls
were also enrolled.
Patients were enrolled if a clinical diagnosis was confirmed consistent with
abdominal inflammation together with a documented source of infection. Written
informed consent was obtained from each participant. On enrolement each
patient was scored for systemic inflammatory response syndrome (SIRS score,
Bone et al 1992), sepsis related organ failure assesment (SOFA score, Vincent
et al 1996) and if presenting with acute pancreatitis or Crohn's disease the
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modified Glasgow score (Blarney et al 1984) or simple index of Crohn's activity
(Harvey et al 1980) respectively.
For each sample, PBMC were assessed for capacity to proliferate in response to
LPS or LTA (section 2.4.8), or stored at -20°C for subsequent genetic analysis
(section 2.5.9). Plasma samples were also retained for each sample for anti-LPS
antibody measurements (section 2.4.7).
Approval for the study was granted by the Lothian Research Ethical Committee
(LREC No. 2000/5/35). An example consent form is included in Appendix I.
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CHAPTER 3
INNATE IMMUNE RESPONSES TO LIPOPOLYSACCHARIDE
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3.1 introduction
A novel liposomal lipopolysaccharide vaccine has been proposed for the
prophylactic treatment of pre-surgical patients at risk of endotoxaemia. As one of
the key attributes of the vaccine is that it must demonstrate low toxicity, the
biological activity of the formulation was compared in the present study with that
of native LPS and with heat killed bacteria. Murine macrophages and human
monocytes were challenged with various concentrations of each preparation and
the resulting release of nitric oxide or TNF-a measured to allow comparison of
the different preparations. The mechanism for liposomal LPS signalling was
investigated using reconstitution of the serum proteins LBP and sCD14.
Toll receptor usage of different LPS types was investigated using antibody
blocking of TLR-2 and TLR-4. Then, as two point mutations in the TLR4 gene
have been shown to exist in the Caucasian population at a frequency higher
than that expected by chance (6-10%), experiments were performed to
determine whether individuals expressing mutant LPS receptors exhibit either
more or less sensitive recognition of LPS from particular strains and species of
bacteria.
3.2 Results
3.2.1 Murine nitric oxide responses to LPS, liposomal LPS and heat killed
bacteria
In order to determine the biological activity of a liposomal LPS vaccine,
experiments were performed to compare the response of murine thioglycollate
elicited peritoneal macrophages to native LPS, liposomal LPS and heat killed
bacteria. Peritoneal macrophages were challenged with varying concentrations
of either E.coli K12 LPS, heat killed E.coli K12 bacteria, liposomal E.coli K12
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LPS or medium alone (control) and supernatants were assayed for production of
nitric oxide after a period of 18 hours incubation.
In all experiments, a high level of background expression of nitric oxide was
observed. This was initially considered to be as a result of the activated state of
the peritoneal macrophages, though alteration of the protocol for thioglycollate
stimulation of the mice was found to be unable to reduce this spontaneous
activity. As a result, in order to observe a clear point of dilution for the different
LPS preparations, the results from many experiments had to be combined.
However, since the peak value of nitric oxide produced varied from mouse to
mouse (roughly 20 to 125pM), the maximum expression of NO in each
experiment was normalised to a value of 100% and all other data points re-
scaled proportionally. Collation of normalised data from the many experiments
performed was then able to provide an indication of the probable point of dose
response for the various stimuli.
Figure 3.1a shows that NO release from murine macrophages challenged with
native LPS is maximal in response to 100ng/ml LPS, with this response falling in
a dose dependent fashion such that below concentrations of LPS around
0.01ng/ml, no release of NO significantly different from background can be
measured. Figure 3.1b shows a similar dose dependent release of NO in
response to challenge of cells with liposomal LPS, though the concentration of
LPS required to initiate release of NO from cells is 32ng/ml or above. Figure
3.1c shows that the NO response of murine macrophages to heat killed E.coli is
maximal at 1,000,000 bacteria per ml, reducing in a dose dependent fashion
such that concentrations of less than 3,200 bacteria per ml do not stimulate cells
to release nitric oxide. These results are summarised in Table 3.1.
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Figure 3.1 Murine macrophage nitric oxide release in response to challenge with (a) native E.coli
K12 LPS (b) liposomal E.coli K12 LPS or (c) heat-killed E.coli K12 bacteria
Results are normalized means +/-SEM of 4 independent experiments for LPS, 8 independent
experiments for liposomal LPS and 9 independent experiments for heat killed bacteria. * Indicates
data point representing lowest concentration at which response is significantly different from
control (p<0.05). Ctrl represents response of cells incubated in medium alone. Maximum NO
production varies between experiments with a range of 20 to 125p.M.
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Log [Heat killed bacteria / ml]
Figure 3.1 Murine macrophage nitric oxide release in response to challenge with (c) heat-killed
E.coli K12 bacteria
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Table 3.1 Comparison of capacity of LPS, liposomal LPS and heat killed
bacteria to induce nitric oxide production in murine peritoneal macrophages
Stimulant Minimum concentration required
to stimulate macrophages *
Native E.coli K12 LPS 1 x 10"2 ng/ml
Liposomal E.coli K12 LPS 32 ng/ml
Heat killed E.coli K12 bacteria 3.2 x 104 bacteria/ml
* Minimum concentration represents the lowest concentrations at which native
E.coli K12 LPS, liposomal E.coli K12 LPS or heat killed E.coii K12 bacteria
stimulate murine macrophages to release significantly more nitric oxide (p<0.05)
than medium alone.
The data (Table 3.1) suggest that, weight for weight, LPS contained within
liposomes is at least 3,200 fold less capable of inducing a nitric oxide response
from murine peritoneal macrophages than native LPS alone. Further, as it has
been calculated that 106 whole E.coli bacteria contain approximately 100ng of
membrane bound LPS, it is clear that the liposomal formulation is also 10 times
less stimulatory than heat killed bacteria containing the equivalent amount of
LPS.
3.2.2 Murine TNF-g responses to LPS, liposomal LPS and heat killed
bacteria
As the cytokine TNF-a has often been implicated in the pathogenesis of severe
sepsis, the production of this cytokine in response to LPS, liposomal LPS and
heat killed bacteria was investigated. Murine thioglycollate elicited peritoneal
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macrophages were challenged with various concentrations of either E.coli K12
LPS, heat killed E.coli K12 bacteria, liposomal E.coli K12 LPS or medium alone
(control). Supernatants were assayed for TNF-a production after a 4 hour
incubation using a bioassay based on the L929 murine fibroblast cell line.
As the early results generated from this assay demonstrated extreme variablity,
the results from a great many experiments had to be discarded. Only extensive
modification of the original bioassay protocol was eventually able to result in a
relatively reliable protocol (described in section 2.4.3), such that reproducible
data could be obtained. Despite these improvements, however, a high
background production of TNF-a was observed in all experiments which could
not be removed by modulation of the thioglycollate stimulation protocol (a finding
mirroring that seen in previous nitric oxide experiments - section 3.2.1).
For this reason, the results from many experiments were combined using the
data normalisation procedure previously described for the nitric oxide
experiments (section 3.2.1). Figure 3.2a shows that TNF-a release from murine
macrophages is maximal in response to concentrations of native LPS ranging
from 0.1 to 100ng/ml. Below 0.1ng/ml LPS, TNF-a release is reduced in a dose
dependent fashion, until concentrations less than 10~5 ng/ml LPS which do not
reveal any signalling significantly different from background. Figure 3.2b shows
that murine macrophages release TNF-a in response to 100ng/ml liposomal
LPS, but no signalling is observed in response to concentrations below 10ng/ml.
Figure 3.2c shows that murine macrophage TNF-a release is maximal in
response to both 1,000,000 and 320,000 heat killed E.coli per ml, then reduces
in a dose dependent fashion, such that concentrations below 10,000 bacteria
per ml do not stimulate significant release of TNF-a. These results are
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Figure 3.2 Murine macrophage TNF-g release in response to challenge with (a) E.coli K12 LPS (b)
liposomal E.coli K12 LPS or (c) heat-killed E.coli K12 bacteria
Results are normalized means +/-SEM of 4 independent experiments for LPS, 5 independent
experiments for liposomal LPS and 4 independent experiments for heat killed bacteria. * Indicates
data point representing lowest concentration at which response is significantly different from control
(p<0.05).
Ctrl represents response of cells incubated in medium alone. Peak TNF-a release varied between









Figure 3.2 Murine macrophage TNF-a release in response to challenge with (a) E.coli K12 LPS (b)
liposomal E.coli K12 LPS or (c) heat-killed E.coli K12 bacteria
Log [Heat killed bacteria/mil
Table 3.2 Comparison of capacity of LPS, liposomal LPS and heat killed
bacteria to induce TNF-g production in murine peritoneal macrophages
Stimulant Minimum concentration required
to stimulate macrophages *
Native E.coii K12 LPS 1 x 10^ ng/ml
Liposomal E.coii K12 LPS 10 ng/ml
Heat killed E.coii K12 bacteria 1 x 104 bacteria/ml
* Minimum concentration represents the lowest concentrations at which native
E.coli K12 LPS, liposomal E.coii K12 LPS and heat killed E.coii K12 bacteria
stimulate murine macrophages to release significantly more TNF-a (p<0.05)
than medium alone.
The data (Table 3.2) suggest that, weight for weight, LPS contained within
liposomes is roughly 1,000,000 fold less capable of inducing a TNF-a response
from murine peritoneal macrophages than the equivalent amount of native LPS.
3.2.3 Human TNF-a responses to lipopolvsaccharide
The proposed vaccine consists of a liposomal formulation containing equal
amounts of complete core LPSs from the following four organisms: Escherichia
coli K12, Escherichia coli R1, Bactericides fragHis and Pseudomonas aeruginosa
(collectively refered to as 'cocktail' LPS). Experiments were therefore performed
to compare the biological activity of each of these native LPS with the liposomal
preparation by measuring the release of TNF-a from human monocytes
challenged with each preparation.
In a manner similar to that found in preceding murine investigations (sections
3.2.1 and 3.2.2), high backgound levels of TNF-a production from unchallenged
monocytes were observed in all early experiments. Much trial and error
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eventually traced this problem to the use of foetal calf serum in these
experiments since use of serum-free medium, or medium supplemented with
human serum ablated all spontaneous TNF-a responses. Foetal calf serum from
three different manufacturers (Gibco, Sigma and Imperial laboratories) was
tested, but all were found to induce high background production of TNF-a from
otherwise unchallenged monocytes. It was later learned that endotoxin
contamination of foetal calf serum is a very common occurrence. For this
reason, all data generated from experiments using foetal calf serum were
abandoned, and experiments were repeated using pooled human AB serum.
Donor to donor variability in the peak value of TNF-a released in the assay was
somewhat marked, so normalisation of the data was employed to allow collation
of multiple data sets (as described in section 3.2.1).
Figure 3.3 shows the relative amounts of TNF-a released from human
monocytes challenged with native Escherichia coli K12, Escherichia coli R1,
Bacteroides fragilis, Pseudomonas aeruginosa and 'cocktail' LPS. Responses to
Escherichia coli K12, Escherichia coli R1 and cocktail LPS are similar, each
stimulating cells maximally at all concentrations of LPS between 1,000 and
1ng/ml, with the response then falling in a dose dependent fashion such that all
three preparations fail to stimulate cells at concentrations less than 0.01ng/ml.
B. fragilis and P.aeruginosa LPS are also seen to stimulate cells in a dose-
dependant fashion, though B.fragilis LPS appears to be approximately 10,000
fold less toxic than the E. coli and mixed LPSs while P. aeruginosa LPS shows
an ability to stimulate monocytes only at concentrations 105 - 106 times more
than that obtained with E. coli derived LPS.
Figure 3.4 shows that the liposomal cocktail LPS also stimulates cells in a dose
dependent fashion with the minimum signalling concentration being around
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Figure 3.3 TNF-a release from human monocytes challenged with native Escherichia coli K12,
Escherichia coli R1, Bacteroides ffagilis. Pseudomonas aeruginosa or 'cocktail' LPS
Results are normalized means +/-SEM of five independent experiments. * Indicates data point
representing lowest concentration at which response is significantly different from control (p<0.05).
Ctrl represents response of cells incubated in medium alone. CT = cocktail, K12 = E.coli K12, R1
= E.coli R1, Bf = B.fragilis, Pa = P.aeruginosa. Peak TNF-a release varied between 52-810
pg/ml.
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Figure 3.4 TNF-a release from human monocytes challenged with 'cocktail' LPS containing liposomes
Washed liposomes were centrifuged five times further than freshly prepared (unwashed) liposomes.
Results are normalized means of four independent experiments +/- SEM. * Indicates lowest
concentration at which response is significantly different from control (p<0.05). Peak TNF-a release
varied between 120 - 435 pg/ml.
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stimulatory than the equivalent mixture of unincorporated LPS. Null liposomes
(ie containing no LPS) did not stimulate production of TNF-a from the
monocytes at any concentration (data not shown).
In order to investigate whether or not it was possible to lower the biological
activity of the liposomes further, an experiment was performed in which stock
LPS containing liposomes were washed five additional times by bench
centrifugation and resuspension in PBS, and the resulting activity of this
preparation compared with that of unwashed liposomes. Figure 3.4 shows that
these additional washing steps were unable to alter the biological activity of the
liposomes.
Table 3.3 summarises the lowest concentrations at which the preparations are
able to stimulate human peripheral monocytes to release significantly more
(p<0.05) TNF-a than medium alone.
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Table 3.3 Comparison of capacity of native and liposomal LPS preparations to
induce TNF-g production from human monocytes
LPS type: Minimum concentration Activity compared to
required to stimulate liposomes (liposomes=1)
monocytes *
E.coli R1 0.01 ng/ml 100,000
E.coli K12 0.01 ng/ml 100,000
B. fragilis 100-1,000 ng/ml ** 1 -10
P.aeruginosa 1,000-10,000 ng/ml** 0.1 - 1
Cocktail (CT) LPS 0.01 ng/ml 100,000
Liposomal CT LPS 1,000 ng/ml 1
Washed liposomes 1,000 ng/ml 1
Recovered LPS 0.1 ng/ml 10,000
* Data point taken as lowest value significantly different (p>0.05) from control,
and hence lowest concentration at which preparation is capable of stimulating
cells
** Monocytes from certain individuals responded to different degrees with B.
fragilis and P. aeruginosa LPS so a range of sensitivities is given.
Then in order to rule out the possibilty that the lowered biological activity of the
liposomal formulation of the vaccine was merely due to a delayed release of the
LPS slowly over time, an experiment was performed to investigate the
timecourse of TNF-a release from the monocytes. Figure 3.5 shows that the
kinetics of TNF-a release in response to the liposomal LPS is very similar to that
of the native LPS. Production of TNF-a in response to both stimuli increases
quickly over the first four hours to reach a peak between 8-24 hours and then
diminishes to background levels at around sixty hours.
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To rule out the possibility that the liposomes merely contained very low
concentrations of LPS due to inefficient incorporation of LPS during
manufacture, a sample of liposomal LPS was subjected to phenol re-extraction
and the resulting LPS assayed for capacity to induce TNF-a. Figure 3.6 reveals
that LPS re-extracted from the liposomes displays greatly more activity (-10,000
fold) than the equivalent amount of unextracted liposomal LPS, indicating that
the low biological activity of the vaccine is not due to low LPS content.
In order to investigate further how this reduction in biological activity was
achieved, the extracellular signalling pathways of LPS and liposomal LPS were
investigated. Figure 3.7 shows the relative dependencies of native LPS and
liposomal LPS on the extracellular signalling proteins soluble CD14 (sCD14) and
LPS binding protein (LBP). Signalling of 100ng/ml native LPS was seen to be
reduced to approximately half of the normal response on removal of serum from
the medium. This could be partially restored by addition of purified LBP or
completely restored with soluble CD14. Liposomal LPS signalling is completely
abolished on removal of serum, yet can also be recovered to approximately two
thirds of maximum activity by restoration of either LBP or soluble CD14, with




















Figure 3.5 Timecourse of TNF-a production from human monocytes exposed to liposomal LPS
and native LPS
The amount of TNF-a produced in response to 100ng/ml of pure LPS and 10jj.g/ml of liposomal
LPS was measured at various time points. Results show the mean of triplicate readings ±SEM
from one experiment and are representative of three similar experiments.
Figure 3.6 TNF-a production from human monocytes exposed to LPS re-extracted from
liposomal LPS
LPS was re-extracted from liposomes by phenol extraction. Results are normalized mean +/-
SEM of five independent experiments. * Indicates lowest concentration at which response is
significantly different from control (p<0.05).
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Figure 3.7: Dependence of LPS signalling on serum factors
Human peripheral blood monocytes were challenged with 100ng/ml LPS or lOpg/ml liposomal
LPS with human serum (+HS), without serum (-HS) and without serum but supplemented with
1pg/ml human LBP (+LBP) or 1pg/ml soluble CD14 (+CD14). Results are representative of
three similar experiments, error bars are SEM. CT LPS = 100ng/ml cocktail LPS. CT Lipo =
Liposomes containing 10p.g/ml cocktail LPS.
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3.2.4 Limulus amoebocyte lysate assay of LPS and liposomes
To further clarify the reduced biological activity of the liposomal LPS, the limulus
amoebocyte lysis (LAL) assay was employed. As this is an extremely sensitive
assay, concentrations of LPS and liposomal LPS were chosen to represent a
point in between saturation and background levels from the dilution curves
extrapolated from the human TNF-a assays. As a result, the concentrations
chosen were 1 ng/ml for the liposomal LPS and 0.01 ng/ml for the native LPS.
Figure 3.8 shows a typical standard curve produced by the kit created by
measuring serial dilutions of kit supplied standard (8EU/ng) E.coli 0111 LPS.
The high coefficient of correlation between optical density and LPS
concentration indicates a satisfactory accuracy for the assay.
The capacity to induce LAL activation of 0.01 ng/ml E.coli R1, E.coli K12,
B.fragilis, P.aeruginosa and cocktail native LPS and 1 ng/ml liposomal cocktail
LPS are shown in Figure 3.9. At these concentrations, both E.coli R1 and E.coli
K12 are seen to elicit a very similar LAL response. However, neither B.fragilis
nor P.aeruginosa LPS are able to stimulate the LAL reaction at this
concentration. The equimolar cocktail of all four LPSs exhibits a LAL activity
approximately half that of the E.coli R1 and E.coli K12 LPS. Interestingly, 1 ng/ml
liposomal cocktail LPS is seen to exhibit a LAL activity approximately three
times that of the 0.01 ng/ml native cocktail LPS, suggesting that at least in this
assay, the liposomal formulation is only ~30 fold less active than the equivalent
amount of native LPS.
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Figure 3.8 LAL assay calibration curve
Typical response of LAL assay standard curve showing linear relationship between LAL assay activity
and LPS concentration (OD=optical density). R2 = coefficient of correlation.
Figure 3.9 LAL assay measurement of biological activity of E.coli R1, E.coli K12, B.fraailis, P.aeruginosa
and 'cocktail' native LPS and liposomal cockiaii LPS
LAL assay activity (EU/ml) of 0.01ng/ml native LPS and 1ng/ml liposomal cocktail LPS. R1= E.coli R1
LPS, K12 = E.coli K12 LPS, Bf = B.fragilis LPS, Pa = P.aeruginosa LPS, CT = cocktail LPS. CT lipo =
liposomal cocktail LPS. H20 = Pyrogen-free distilled water (control).
122
3.2.5 Toll receptor utilisation of LPS and LTA
As some LPS are capable of signalling via TLR-2 instead of TLR-4, experiments
were performed to determine if antibody blocking of TLR-2 or TLR-4 was
capable of reducing signalling in response to further LPS types. Two monoclonal
antibodies proposed to be able to block the signalling function of TLR2 or TLR4
are currently commercially available. HTA125 is sold as a TLR4 blocking
reagent and TL2.1 as a TLR2 blocking reagent.
However, three separate experiments in this laboratory failed to demonstrate the
capacity of either antibody to block human monocyte recognition of either LPS
or LTA. Figure 3.10 shows the typical IL-1 (3 responses seen when challenging
human monocytes with E.coli LPS, P.gingivalis LPS and S.aureus LTA while
blocking with 20pg/ml of either TL2.1, HTA125 or the isotype matched control
antibody anti-keyhole limpet haemocyanin (a-KLH). In these experiments,
HTA125 does not significantly reduce monocyte signalling in response to any
stimulus. Moreover, TL2.1 not only fails to block signalling in response to any of
these stimuli, it also proves capable of stimulating cells to produce large
amounts of IL-p independently of any other stimulus. The isotype matched
control antibody anti-keyhole limpet haemocyanin (a-KLH) had no effect on
signalling.
3.2.6 Comparison of wild type and mutant TLR-4 recognition of LPS
Two mutations in the TLR4 gene (Asp299Gly and lle399Thr) have been shown
to exist at a relatively high frequency (at least 6%) in the Caucasian population.
This high frequency of TLR4 mutation in the general population prompted an
investigation to determine whether individuals expressing these genotypes
exhibit either more or less sensitive recognition of LPS from particular strains






Figure 3.10 Effect of anti-TLR -2 and TLR-4 antibodies on human monocyte recognition of
E.coli LPS, P.ainaivalis LPS and S.aureus LTA
IL-1(3 secretion of monocytes incubated with 20pg/ml antibodies (aKLH = isotype matched
control anti-keyhole limpet heamocyannin, aTLR2 = TL2.1, aTLR4 = HTA125, Ctrl = medium
alone) and 100ng/ml E.coli LPS, P.gingivalis LPS, S.aureus LTA or medium alone (Ctrl).
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PCR and restriction fragment length polymorphism (RFLP) analysis of the Toll-
receptor 4 gene of 40 healthy volunteers and 40 patients presenting with
abdominal inflammation revealed the presence of 8 individuals heterozygous for
both mutations (sections 2.5.8 and 2.5.9). Interestingly, every individual carrying
the Asp299Gly mutation was also seen to carry the lle399Thr mutation. No
individual was found to carry only one of the mutations and no individuals were
found to be homozygous for either mutation.
Figure 3.11a shows an example gel of the PCR products created from the
amplification of the two sections of the TLR-4 gene investigated. Figure 3.11 b
shows the results of restriction analysis of the PCR products. The higher
molecular weight (upper) band represents the presence of the wild type allele,
while double bands indicate individuals heterozygous for the mutation at that
locus. Three wild type and three heterozgous individuals are shown.
Then in order to determine whether or not these mutations altered the ability of
these individuals to recognise particular types of LPS, a panel of LPS
representing a wide range of Lipid-A structures was investigated. Figures 3.12 a
- f show the mean IL-1 (3 responses of three wild type and three heterozyogous
mutant volunteers to LPS of E.coli, N.meningitidis, Y.pestis, C.trachomatis,
B.fragilis, P.aeruginosa, P.gingivalis and S.aureus LTA respectively. It can be
seen that the responses of both wild type and mutant monocytes to all stimuli
tested are remarkably similar. All LPS show dose dependent curves, though the
minimum concentration of LPS required to stimulate cells varied between the
different LPS types. Responses to E.coli LPS occur at a minimum concentration
of around 0.01ng/ml, while those to N.meningitidis LPS occur at around
0.1ng/ml. Responses to B.fragilis LPS occur at a minimum concentration of
around 1ng/ml. Responses to P.gingivalis and Y.pestis LPS occur at a minimum
concentration of around 10ng/ml. C.trachomatis and P.aeruginosa LPS and
S.aureus LTA are recognised only at concentrations equal to or 100ng/ml.
125
Slightly more inter-individual variability is seen in the responses to LPS of
B.fragilis, and Y.pestis, though these are not statistically significant. These
results are summarised in Table 3.4.
Table 3.4 Comparison of wild type and mutant TLR4 bearing monocyte
recognition of various LPS
Stimulus Minimum concentration Minimum concentration
activating wild type activating TLR4 +/-
monocytes [ng/ml] * monocytes [ng/ml] *
E.coli LPS 0.01 0.01
N.meningitidis LPS 0.1 0.1
B.fragilis LPS 1 1
P.gingivalis LPS 10 10
Y.pestis LPS 10 10
C.trachomatis LPS 100 100
P.aeruginosa LPS 100 100
S. aureus LTA 100 100
* Minimum concentration represents the lowest concentration at which the
individual stimuli induce production of significantly more IL-1 p (p<0.05) than
cells incubated with medium alone.
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Figure 3.11 PCR products of amplification of two sections of the TLR-4 gene and digest products
following RFLP analysis of wild type and mutant TLR-4 alleles
(a) Lanes 1+14, 100 base pair marker. Lanes 2-7, PCR of 299 section of TLR gene from three
wild type donors and three heterozygotes. Lanes 8-13, PCR of 399 section of TLR gene from
three wild type donors and three heterozygotes. (b) Restriction products following digest with the
enzymes Nco\ (299) or Hinfl (399). Lanes 1+14, 100 base pair marker. Lanes 2-7, RFLP of 299
section of TLR gene from three wild type donors and three heterozygotes. Lanes 8-13, RFLP of
399 section of TLR gene from three wild type donors and three heterozygotes. Upper band







Figure 3.12 Comparison of wild type and mutant TLR-4 recognition of LPS and LTA
(a-h) IL-ip production from human monocytes (1x105 per well) challenged with varying
concentrations of E.coli, N.meningitidis, Y.pestis, C.trachomatis, B.fragilis, P.aeruginosa,
P.gingivalis LPS or S.aureus LTA respectively. Open circles represent mean results +/- SEM
from three wild type donors. Filled squares represent mean results +/- SEM from three donors


































Figure 3.12 Comparison of wild type and mutant TLR-4 recognition of LPS and LTA
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3.3 Discussion
3.3.1 Potential benefits of lipopolvsaccharide based vaccines
Several studies have suggested that high titres of anti-core LPS antibodies
provide protection from adverse outcome following a number of disease
processes or surgical procedures (Freeman et al 1985, Bennett-Guerrero et al
1997, Hamilton-Davies et al 1997, Bennett-Guerrero et al 2001). For this reason,
it has been suggested by several authors that pre-surgical vaccination with LPS
might benefit patients by increasing their anti-LPS antibody titre prior to surgery
(Bennett-Guerrero et al 2000, Campbell et al 1996, DeMaria et al 1988,
Baumgartner et al 1991 b). To avoid repetition, the wider impact of these studies
and previous proposals for the designs of such vaccines will be discussed in
further detail in section 6.2.
In brief, however, there are two main priorities that must be borne in mind in the
design of any lipopolysaccharide based vaccine. The first is that the vaccine
formulation must display a greatly reduced toxicity when compared to that of
naturally occuring LPS, as administration of as little as several nanograms of
LPS is enough, when administered to a human subject, to induce all of the
symptoms of systemic inflammation (Suffredini et al 1989, Martich et al 1993,
Taveira daSilva et al 1993). The second is that the vaccine must also remain
highly immunogenic, as induction of an antibody response to the widest possible
range of LPS core types has been shown to offer the best protection from Gram-
negative bacterial challenge (McCabe et al 1977, Ziegler et al 1979, Heumann
et al 1991, Cross et al 1988).
In order to fulfill these two briefs, a novel liposomal complete core
lipopolysaccharide vaccine has been described (Bennett-Guerrero et al 2000)
which, it is hoped, will display both low toxicity and high immunogenicity in
human clinical trials.
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3.3.2 Previously reported properties of the vaccine
In order to induce a broadly cross reactive antibody response, the vaccine
contains a mixture of the complete core (Ra-chemotype) LPSs from four
different Gram-negative bacteria - Escherichia coli K12, E. coli R1,
Pseudomonas aeruginosa PAC 608 and Bacteroides fragHis. In rabbits that
displayed little or no detectable antibodies to LPS by ELISA or dot-blotting prior
to vaccination, the vaccine was shown capable of eliciting an antibody response
towards a wide range of LPS types. These included LPS of E.coli serotypes 01,
04, 06, 08, 015, 075, 086 and 0111; P.aeruginosa Fischer types 1, 2 and 3,
K.pneumoniae serotypes 01, 02ab and 03, B.fragilis and B.vulgatis (Bennett-
Guerrero et al 2000).
Vaccination with the complex was also seen to provide significant protection in a
mouse lethality model of endotoxaemia. Galactosamine-treated mice challenged
with a lethal dose of E.coli 018 LPS showed 70% survival in the pre-vaccinated
cohort, compared with only 9% survival in the non-vaccinated cohort (Bennett-
Guerrero et al 2000).
The toxicity of the vaccine was also investigated using the rabbit pyrogenicity
assay. While administration of free LPS was seen to induce a pronounced
pyrogenic response in the rabbits (weight loss, lethargy, altered breathing,
increased core body temperature), administration of up to 500pg of liposomal
LPS did not display significant pyrogenicity (Bennett-Guerrero et al 2000).
3.3.3 Murine nitric oxide responses to LPS and liposomal LPS
In order to further understand how the reduced biological activity of liposomal
LPS is achieved, the present study began by looking at the response of murine
peritoneal macrophages to liposomal E.coli K12 LPS. As it has already been
proposed that heat killed bacteria could also be used as a vaccine for the
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production of anti-LPS antibodies (Ziegler et al 1982, Baumgartner et al 1991b,
DeMaria et al 1988), the responses of the cells to this antigen were compared
with those of both native and liposomal LPS.
Due to its ease of measurement, the effector molecule nitric oxide was chosen
as the marker of cellular activation in early experiments. However, two problems
hampered initial attempts to compare the biological activities of
LPS preparations. The first of these was that in every experiment performed, a
high background level of nitric oxide production was seen to be produced from
unchallenged cells. It was initially thought that the highly activated state of the
peritoneal macrophages was responsible for this, though alteration of the
protocol for thioglycollate stimulation of the mice was found to be unable to
reduce this spontaneous activity (data not shown).
The second problem concerned the mouse to mouse variation seen in the peak
level of nitric oxide produced - which at this stage was thought to reflect the high
level of activation of the murine cells. For these reasons, the results from many
experiments had to be normalised to a percentage of the peak value obtained
from each experiment and combined (as described in section 3.2.1).
Figure 3.1a shows that native E.coli K12 LPS is capable of inducing release of
nitric oxide from murine thioglycollate elicited peritoneal macrophages over a
wide range of concentrations, with a strong response to concentrations of LPS
around 100ng/ml that diminishes to levels not significantly different from
background at concentrations below around 0.01 ng/ml. In contrast, the lowest
concentration at which liposomal E.coli K12 LPS is able to stimulate a significant
release of nitric oxide is 32ng/ml (Figure 3.1b). These data suggest that
liposomal LPS is at least 3,200 fold less capable of inducing a nitric oxide
response from murine peritoneal macrophages than the equivalent amount of
native LPS.
134
Analysis of the nitric oxide response of these cells to heat killed E.coli K12
bacteria revealed that the lowest concentration capable of inducing a response
significantly higher than background was 32,000 bacterial cells per ml (Figure
3.1 c). Assuming that an average E.coli cell weighs 5pg, and 2% of the weight of
the bacteria is LPS, it follows that 106 bacteria contain approximately 100ng
LPS. Using this conversion factor, it appears that cell associated LPS is only
able to stimulate cells at a minimum concentration of around 3.2 ng/ml LPS,
making it at least 320 fold less biologically active than free LPS.
No other studies of murine nitric oxide release in response to liposomal LPS are
available for comparison with these findings.
3.3.4 Murine TNF-g responses to LPS and liposomal LPS
Many studies have implicated the pro-inflammatory cytokine TNF-a as a
significant mediator in the ill effects of endotoxin administration (Calendra et al
1990, Glauser et al 1991, Waage et al 1987). For this reason, production of
TNF-a from murine peritoneal macrophages in response to native E.coli K12
LPS, liposomal E.coli K12 LPS and heat killed E.coli K12 bacteria was
investigated.
Early attempts at these comparisons were impeded by extreme variablity in
TNF -a measurements of supernatants both between and within experiments.
Reliable data was only obtained following extensive modification of the original
bioassay protocol (section 2.4.3) and normalisation and collation of the results
from many experiments as previously described (section 3.2.1). Nevertheless,
high background production of TNF-a was seen in the control cultures of all
experiments which could not be removed. (This was later found to be due to a
contaminant of the foetal calf serum used in the preparation of the culture
medium - section 3.2.3).
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Native LPS is seen to induce maximal production of TNF-a from all
concentrations ranging between 0.1ng/ml and 100ng/ml (Figure 3.2a). The
lowest concentration at which native E.coli K12 LPS is capable of inducing
significantly more TNF-a than control cultures is 10 ° ng/ml. This concentration is
roughly one million fold lower than the concentration of liposomal LPS required
to activate cells (Figure 3.2b). Assuming that the molecular weight of complete
core LPS is around 5,000, this suggests that the lowest concentration of LPS
capable of inducing cellular activation (10 ° ng/ml) is equivalent to approximately
600 LPS molecules per cell. The responses of the monocytes to such low
concentrations of LPS may be enhanced by the synergistic effects of pro¬
inflammatory cytokines released from neighbouring macrophages.
Heat killed E.coli K12 bacteria induce activation of cells at a minimum
concentration of 10,000 cells/ml (Figure 3.2c), which is equivalent (according to
the calculation previously described) to approximately 1 ng/ml LPS. This
suggests that cell-associated LPS is roughly 100,000 fold less biologically active
than free LPS, though still at least ten fold more toxic than liposomal LPS.
Of note is the fact that murine macrophage release of TNF-a is seen to occur in
response to lower concentrations of all stimuli tested than those necessary to
stimulate release of nitric oxide (eg. 10"5ng/ml LPS vs 10"2ng/ml LPS). This may
represent the fact that nitric oxide is an effector molecule of the innate immune
response, whereas TNF-a is a signalling molecule and may therefore be more
readily released by cells in response to lower levels of endotoxin.
3.3.5 Human TNF-a responses to LPS and liposomal LPS
Having established the reduction in activity of a single LPS incorporated into
liposomes, the response of human monocytes to the mixed LPS based vaccine
were investigated. Cells were challenged with complete core R-form LPS of
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Escherichia coli K12, Escherichia coli R1, Bacteroides fragHis, Pseudomonas
aeruginosa or with an equimolar mixture of these LPS (refered to as 'cocktail'
LPS). Responses of the cells to these individual LPS were then compared with
responses to the vaccine - itself a liposomal formulation of the cocktail LPS
described.
Figure 3.3 shows that the biological activities of E.coli R1, E.coli K12 and
cocktail LPS are largely similar when considering human TNF- a responses.
Each shows a plateau of maximum response from around 1ng/ml up to 1,000
ng/ml and a lowest activating concentration of 0.01 ng/ml. Inter-individual
responses to these LPS were closely similar, but responses to B.fragilis and
P.aeruginosa LPS were quite variable between donors (as evidenced by the
larger error bars in Figure 3.3). These two LPS types were seen to demonstrate
much lower biological activity than the E.coli or cocktail LPS, with B.fragilis
stimulating cells only at concentrations around 100-1,000ng/ml and
P.aeruginosa around 1,000-10,000ng/ml. The amount of TNF-a produced in
response to each of these stimuli varied between 52 and 810 pg/ml, a figure
approximately 10 fold higher than the concentration of normal circulating levels
of TNF-a but still roughly 25 fold less than the maximum doses of TNF-a used in
early trials of TNF-a as an anti-cancer agent (Mittelman A et al 1992).
By comparison, liposomal cocktail LPS is seen to stimulate cells only at
concentrations equal to or above 1,000ng/ml. This represents a reduction in
biological activity when compared to native cocktail LPS of around 100,000 fold.
Then in order to ascertain whether or not it was possible to lower the biological
activity of the liposomes further, stock liposomal cocktail LPS was washed five
times by bench centrifugation and resuspension in PBS. Figure 3.4 shows that
these additional washing steps were unable to alter the biological activity of the
liposomes.
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It was suggested that the reduced activity of the vaccine may be due to very low
concentrations of LPS being contained within the liposomes due to inefficient
incorporation of LPS at manufacture. To rule out this posibility, a sample of
liposomal LPS was subjected to re-extraction of incorporated LPS using the
aqueous phenol method (section 2.2.2). LPS resulting from this extraction was
assayed for capacity to induce TNF-a from human monocytes and shown to
exhibit an activity ~10,000 fold more than the equivalent amount of liposomal
LPS (Figure 3.6). The low biological activity of the vaccine is therefore not due to
low LPS content.
3.3.6 Kinetics of LPS and liposomal LPS signalling
Another possible explanation for the low biological activity of the liposomal
formulation was that LPS was merely being released from the liposomes slowly
over time, with the possibility that at a later time than the 4 hour timepoint
investigated, sufficient amounts of incorporated LPS may have been released to
induce a much stronger release of TNF-a.
In order to rule out this possibility, the kinetics of TNF-a release in response to
challenge with native and liposomal cocktail LPS were compared. Figure 3.5
shows that both preparations induce production of significant amounts of TNF- a
after as little as one hours incubation. Peak production of TNF- a is seen to
occur for both preparations between 8 and 24 hours, with supernatant
concentrations of TNF-a gradually diminishing to background levels after
around 60 hours, indicating that no delayed peak in LPS release from the
vaccine occurs in vitro. These kinetics show a largely similar pattern to that
described by Delahooke et al for E.coli and B.fragilis native LPS (Delahooke et
al 1996), and provide further support for the safety of the vaccine for use in
human trials.
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3.3.7 Role of serum proteins in LPS and liposomal LPS signalling
In order to further investigate how this reduction in biological activity was
achieved, the extracellular signalling pathways of LPS and liposomal LPS were
investigated. Experiments were performed in which cells were challenged with
LPS or liposomal LPS resuspended in serum free medium reconstituted with
recombinant LPS binding protein (LBP) or soluble CD14 (sCD14). The relative
dependencies of native LPS and liposomal LPS on the extracellular signalling
proteins sCD14 and LBP for efficient signalling are depicted in Figure 3.7.
Signalling of native LPS is seen to be reduced to about half the normal output
when serum is removed from the medium. Addition of LBP led to partial
restoration of this signal, while supplementation with purified sCD14 led to
complete restoration of signalling capacity. Signalling of liposomal LPS, on the
other hand, was seen to be entirely ablated on removal of serum from the
medium, though this was restored to approximately two thirds of maximal activity
by supplementation with either LBP or sCD14. Thus at the concentrations tested
(100ng/m! native LPS and 10pg/ml liposomal LPS), presence of LBP or sCD14
is absolutely required for liposomal LPS signalling but not for native LPS
signalling. This capacity of high concentrations of native LPS to activate cells in
the absence of serum-derived lipid shuttling proteins has been documented
before (Beckman et al 1994), and is likely to reflect the ability of membrane
bound CD14 present on monocytes to catalyse transfer of monomeric LPS from
micelles to the LPS receptor. This is supported by the finding that sensitive
responses to LPS in vivo also require the presence of CD14 (Wurfel et al 1997,
Wright et al 1990).
Interestingly, while the CD14 knockout mouse exhibits an almost complete
impairment of LPS signalling (Wright et al 1990), the LBP knockout mouse is
only mildly hyporesponsive to LPS (Wurfel et al 1997). By contrast, these
139
experiments have shown that human LBP and sCD14 possess a broadly similar
capacity to restore LPS signalling. An explanation for this difference may lie in
the concentrations of LBP and sCD14 chosen for use in these experiments.
1 [ig/ml of each protein was used as this was calculated to be roughly equivalent
to the amount present in the 10% human serum-supplemented medium (Pugin
et al 1993, Wurfel et al 1997). However, as LBP is present in mouse serum at
concentrations -100 fold lower (~100ng/ml - Jack et al 1997) than that seen in
human serum (5-10pg/ml - Pugin et al 1993), it is possible that the murine LPS
recognition system is therefore much less dependent on LBP than the human
system.
3.3.8 LAL assay of LPS and liposomal LPS
LAL assay of 0.01 ng/ml E.coli R1 and E.coli K12 LPS show a LAL activity of
approximately 0.05 EU/ml (Figure 3.9). This is slightly lower than the 0.08 EU/ml
demonstrated by the same amount of kit supplied standard E.coli 0111 LPS,
possibly indicating that smooth LPS is a slightly stronger activator of the LAL
system than rough LPS. B.fragilis and P.aeruginosa LPS do not stimulate the
LAL reaction at this concentration, reflecting their -10,000 - 100,000- fold lower
capacity to induce the activation of human LPS receptors in monocyte challenge
assays (section 3.2.3). Native cocktail LPS exhibits a LAL activity approximately
half that of the E.coli type LPS, presumably reflecting the fact that it contains (by
mass) 50% E.coli type LPS, while the remaining (less active) LPS do not provide
additional signalling activity at this concentration.
Surprisingly, the liposomal LPS is seen to be only around 30- fold less active
than the equivalent amount of native LPS (section 3.2.4). This reduction in
activity is starkly lower than that demonstrated in all of the cell based assays
and much less marked than that described by other workers measuring the LAL
activity of liposomal LPS. For example, Dijkstra et al (1988a) and Bennett-
Guerrero et al (2000) have shown a reduction in LAL activity of between 100
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and 1,000 fold when comparing liposomal LPS with native LPS. One explanation
for the difference between the present finding and that of previous workers may
be the choice of kit used to measure the LPS. Instructions supplied with the kit
preclude the use of PBS in the assay as it interferes with the readout. For this
reason, all LPS and liposomal LPS were diluted to working concentrations in
pyrogen-free distilled water which, while not greatly affecting the activity of
native LPS, may have induced lysis of the liposomes as a result of the osmotic
effects of distilled water on the PBS based liposomes. Internalised LPS may
therefore have been released into the sample medium, resulting in the higher
than expected activity seen.
3.3.9 Mechanisms for reduced toxicity of liposomes
Given the great reduction in toxicity of LPS by incorporation into liposomes, it
appears that the vast majority of the LPS present in the liposomes must be
shielded from both the cellular and humoral proteins responsible for LPS
signalling. The results from the serum protein experiments suggest that the
liposomal signalling is occuring as a result of removal of LPS monomers from
the outer membrane of the vesicles by serum proteins such as LBP and CD14.
In this model, all internal LPS, either incorporated into the bilayers of internal
lamellae or in solution between the lamellae, is therefore shielded from
interaction from these proteins and therefore do not get channelled to cellular
LPS receptor complexes.
Further, the timecourse experiments reveal that fusion of the internal lamellae of
the liposomes with the internal membranes of the cell are unlikely to lead to
much activation of the cells as the kinetic profile of liposomal LPS was seen to
be very similar to that of native LPS. Together these experiments suggest that
liposomal incorporation is an efficient method of delivering large amounts of LPS
to cells without inducing an overtly inflammatory response.
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Interestingly, while the biological activity of the LPS has been clearly diminished
by incorporation into liposomes, the immunogenicity of the vaccine has not
(Bennett-Guerrero et al 2000). This can perhaps be best explained by
suggesting that the liposomal LPS is processed in the cell via pathways that are
much more likely to result in antibody formation than the pathways used to deal
with native LPS (Figure 1.4).
3.3.10 Comparison with earlier descriptions of liposomal LPS
In these experiments, incorporation of LPS into liposomes has demonstrated a
reduction in biological activity in the region of 3,200-fold for murine NO release,
one million-fold for murine TNF-a release and up to 100,000-fold when
considering release of human TNF-a.
These findings indicate a biological activity lower than that described by
previous workers studying liposomal LPS. Dijkstra et al, for example, showed
that incorporation of S.minnesota Re LPS into liposomal vesicles was able to
reduce the capacity of the LPS to induce IL-1p from a murine macrophage cell
line by only 1,000-fold (Dijkstra et al 1987). The same preparation was shown to
reduce TNF-a release from murine macrophages by a factor of 100 -1000- fold
(Dijkstra et al 1988b). Actinomycin D sensitized mice have been shown to have
only a 10-fold reduction in lethality when challenged with liposomal lipid A
compared with native lipid A (Dijkstra et al 1989). Finally, encapsulation of
Neisseria meningitidis LPS into liposomes has been shown to reduce the
pyrogenicity of LPS in rabbits by up to 1,000 fold (Petrov et al 1992).
Quite why the liposomal LPS preparations created in this laboratory exhibit
biological activities so much lower than those previously described remains
unclear. Flowever, some explanation may lie in the fact that the techniques used
to prepare the vaccine are slightly different from those previously attempted. A
modified version of the method described by Dijkstra et al (1988a) was
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employed (Bennett-Guerrero et al 2000). Thus, in our hands, the liposomes may
contain more internal lamellae or may be larger than those previously described,
or perhaps the distribution of LPS molecules within the liposomes is different.
In summary, however, the data from these studies provide support for the safety
of the proposed vaccine, as the greatly reduced capacity of liposomal LPS to
induce pro-inflammatory cytokines from myeloid cells in vitro suggests that
administration of the vaccine to human subjects should result in a much more
limited inflammatory response than that generated by native LPS. The wider
potential of this vaccine and other lipopolysaccharide based vaccines is
discussed in more depth in section 6.4.
3.3.11 Previously described TLR2/4 liqands
As discussed in the introduction (section 1.2), it was thought for some time that
the Toll-like receptor critical for the recognition of all types of LPS was TLR4
(Qureshi et al 1999, Poltorak et al 1998, Hoshino et al 1999). This model was
questioned, however, when several groups demonstrated responses to their
LPS preparations that were independent of TLR4. In these experiments, it
appeared that another Toll-like receptor, TLR2, was critical in these responses.
In the majority of these cases, stringent purification protocols were able to
demonstrate that the LPSs being investigated were signalling solely through
TLR4, while the TLR2 signalling previously seen appeared to be due to
lipoprotein contamination of those preparations (Hirschfield et al 2000, Shimazu
et al 1999).
However, the LPSs from Porphyromonas gingivalis and Leptospira interrogans
have both been proven to signal exclusively through TLR2 and not TLR4
(Hirschfield et al 2001, Werts et al 2001). This differential signalling of the LPS
of some bacterial species via alterative Toll-like receptors may have some
influence on the progression of disease as it has recently been shown that while
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the ten human Toll-like receptors all induce a core set of inflammatory genes,
the different members of the family also induce expression of genes unique to
stimulation of that receptor (Hirschfield et al 2001). For example, macrophages
stimulated via TLR2 can be triggered to release TNF-a, IL-ip and MIP-2,
whereas macrophages stimulated via TLR4 are triggered to release all of these
cytokines, but also IL-12 p40, IFN-y and macrophage chemotactic protein 5
(Hirschfield et al 2001). This suggests that Gram-negative bacteria expressing
Toll-like receptor 2 agonist LPS may well be recognised and dealt with quite
differently in the human host than bacteria expressing LPS recognised by TLR4.
3.3.12 Antibodies for the investigation of TLR2 and TLR4 signalling
In order to determine if the LPSs from other bacterial species were capable of
signalling via TLR2 instead of TLR4, experiments were performed to determine
if antibody blocking of TLR2 or TLR4 could reduce signalling in response to
different types of LPS. Currently, two monoclonal antibodies are commercially
available that are proposed to be able to block the signalling function of TLR2
(TL2.1) or TLR4 (HTA125).
However, in contrast to earlier reports of the succesful use of these antibodies in
blocking TLR4 (Akashi et al 2000, Tabeta et al 2000) and TLR2 signalling (Flo et
al 2000, Lien et al 1999), three separate experiments in this laboratory failed to
demonstrate the capacity of either antibody to block human monocyte
recognition of either LPS or LTA. Figure 3.10 shows that the IL-113 secretion of
human monocytes in response to challenge with E.coli LPS, P.gingivalis LPS or
S.aureus LTA cannot be blocked with either TL2.1 or HTA125. Further, at the
concentration used (20pg/ml), the antibody TL2.1 is seen to be capable of
inducing cells to release IL-J3 independently of any other stimulus. This seems
contra-intuitive, as previous experiments involving homodimerisation of TLR2
have been shown by previous workers to result in no cellular signalling (Ozinsky
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et al 2000). Further, TLR2 mediated signalling appears to be dependent on the
formation of heterodimers with TLR1 or TLR6 (Ozinsky et al 2000). It is therefore
possible that TL2.1 demonstrates a cross reactivity with epitopes on TLR1 or
TLR6, thereby causing the heterodimerisation required for signalling of TLR2.
Why these antibodies have been unable to block the signalling of their target
receptors in this laboratory remains unclear, though their failure has been noted
by other laboratories (L. O'Neill, personal communication).
3.3.13 Structural motifs required for the discrimination of TLR2 and TLR4
liqands
The physical mechanisms by which the TLR2 and TLR4 agonist LPSs are
discriminated remain to be determined. However, some interesting differences
from the typical hexa-acyl bis-phosphorylated structure demonstrated by most
TLR4 agonist enterobacterial LPS have been seen in the structure of the TLR2
agonist lipid A of Porphyromonas gingivalis. In particular, P.gingivalis lipid A
contains only five acyl chains and is mono-phosphorylated (Kumada et al 1995).
The structure of Leptospira interrogans lipid-A has yet to be determined, though
it is tempting to speculate that it may share structural features with P. gingivalis
lipid A.
Circumstantial evidence exists to support the notion that other bacterial species
may express LPS capable of recognition by TLR-2. Cells from C3H/HeJ mice
are deficient in TLR-4 signalling, yet remain capable of eliciting responses to
LPS from both B.fragilis (Delahooke et al 1996) and Treponema denticola
(Rosen et al 1999). Interestingly, the LPS of B.fragilis has been shown to
express a lipid A of very similar structure to that of P.gingivalis, sharing both the
5 acyl chain and monophosphorylation motif (Figure 1.3). This general structure
is also present in the lipid A of C.trachomatis LPS (Kosma 1999), which may
also therefore represent a potential TLR2 agonist. Determination of the structure
of further TLR2 agonist LPSs will provide useful insight into which domains or
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particular three dimensional arrangements of LPS are differentiated by TLR2
and TLR4.
3.3.14 Wild type and mutant responses to LPS and LTA
Sequencing of the TLR4 gene from a large number of patients and healthy
volunteers has revealed a selection of polymorphisms present in the Caucasian
population (Smirnova 2001). While some of these were seen to be present only
very rarely, two mutations in particular, Asp299Gly and lle399Thr, have been
shown to exist at a relatively high frequency (at least 6%) (Lorenz et al 2001).
This high frequency of TLR4 mutation in the general population prompted an
investigation to determine whether individuals expressing these genotypes
exhibit either more- or less- sensitive responses to the LPS of particular strains
and species of bacteria.
In order to investigate this possibility, monocytes of three individuals
heterozygous for both mutations and three individuals homozygous for the wild-
type allele were challenged with a panel of LPS selected to represent a broad
range of lipid A structures. LPS from E.coli, Neisseria meningitidis, Bacteroides
fragilis, Yersinia pestis, Chlamydia trachomatis, Porphyromonas gingivalis and
Pseudomonas aeruginosa and lipoteichoic acid of Staphylococcus aureus were
applied to monocytes of wild type and heterozygote individuals and production
of the pro-inflammatory cytokine interleukin-ip compared.
It was expected that the responses to S.aureus LTA and P.gingivalis LPS should
be broadly similar as the signalling of these two molecules are not TLR-4-
dependent (Hirschfield et al 2001, Lien et al 1999). Surprisingly, however, it can
be clearly seen that the responses of both wild type and mutant monocytes to all
stimuli tested, including all TLR4 agonists, are remarkably similar (Figures
3.12a-h). Slightly more inter-individual variability exists in the response towards
LPS of B. fragilis and P.aeruginosa, though these are not statistically significant.
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Further, analysis of the minimum concentration of LPS required to activate
mutant and wild type monocytes also reveals near identical sensitivity of the two
versions of the receptor (Table 3.4).
3.3.15 Comparison with previous findings on TLR4 mutant phenotypes
These findings contrast with those of Schwartz and co-workers who have
reported several examples of associations between the presence of these
mutations and either hyporesponsiveness to LPS or increased susceptibility to
Gram-negative infection.
The first such study investigated the response of 83 humans to inhaled LPS,
and it was shown that presence of the mutation resulted in blunted responses to
inhaled LPS in humans (Arbour et al 2000). Further, transfection of THP-1 cells
with the Asp299Gly mutation was shown to blunt LPS signalling in vitro, while
the Thr399lle mutation was shown to have no effect on signalling (Arbour et al
2000).
Closely following this, another group reported no association between presence
of the Asp299Gly mutation and either susceptibility to or severity of
meningococcal disease in a study of over 1,000 patients (Read et al 2001).
Schwartz and colleagues continued to test various patient populations for
presence of both mutations and have reported the following associations. A
study investigating the course of disease in 91 patients with septic shock
compared the frequency of the Asp299Gly mutation with that of 73 healthy
controls and found the mutation exclusively in the patient group (Lorenz et al
2002a). This study also points out that a higher prevalence of Gram-negative
infections occurred in the patients with the Asp299Gly mutation. A study of 237
patients receiving haematopoietic stem cell transplantation were assessed for
presence of the mutation and graft-versus-host disease. Those expressing
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either of the mutations demonstrated a slightly higher suscepibility to Gram-
negative bacteraemia and a reduced risk of developing acute graft-versus-host
disease, but these results were not statistically significant (Lorenz et al 2002b).
The same group then compared the effect of the mutation on risk of
atherogenesis in an Italian cohort consisting of 810 individuals (Kiechl et al
2002). They found that the 55 individuals harboring the Asp299Gly mutation
showed lower serum levels of pro-inflammatory cytokines, acute-phase
reactants and fibrinogen. Also, these individuals were found to be more
susceptible to severe bacterial infections, but also demonstrated a significantly
lower risk of carotid atherosclerosis and a smaller intima-media thickness in the
common carotid artery - consistent with the hypothesis that inflammation
initiated by the innate immune response has a strong role to play in
atherogenesis. Finally, an investigation into the presence of the Asp299Gly
mutation in 351 normal term and 440 prematurely born Finnish infants revealed
a correlation between presence of the mutation and premature birth (p=0.024)
(Lorenz et al 2002c). This, the authors claim, is consistent with the current
understanding that Gram-negative urinogenital infection is a risk factor in
premature term.
Each of the studies reported by Schwartz and colleagues appear to demonstrate
that individuals heterozygous for the Asp299Gly mutation show altered
responses to LPS or Gram-negative infection. Flowever, the present study of
monocytes derived from individuals heterozygous for both the Asp299Gly and
Thr399lle mutations demonstrates that no reduction in ability to detect any of the
seven LPS tested can be detected in these subjects. This discrepancy may
perhaps be explained as follows.
Firstly, the rationale or interpretation of several of the studies may be criticised.
For example, in the study of 91 septic patients, the group note a higher
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frequency of the mutation in the patient group than in a group of healthy controls
and cite a p-value of 0.05 for this comparison. However, they have correlated
the frequency of mutation in the patient population with only a small number of
healthy controls (73), when the genotypes of much larger numbers of healthy
controls were available from separate studies being undertaken at the same
time in the same laboratory. Had the allele frequency of this group been used for
comparison in the study, any statistical significance would almost certainly have
been removed from their finding. In the study of patients receiving
haematopoietic stem cell transplantation, the results were not statistically
significant and no biological interpretation of how impaired TLR4 signalling might
be involved in graft-versus-host rejection was offered. Finally, in the study of the
role of the mutation as a risk factor in premature birth, multiple pregnancies were
excluded from analysis and the genotype of only 94 mothers was investigated.
Further, the statistically significant correlation quoted was obtained from analysis
of the genotypes of the infants, and no explanation was given as to how the
innate immunity of the fetus should affect bacterial challenge of the parent.
Statistical analysis of the genotypes of the mothers, whose Toll-receptors are
more likely to be involved in the detection of urinogenital infection, results in no
statistically significant association (p=0.580). For these reasons, and the lack of
any positive associations originating from other laboratories, the findings from
these studies must be interpreted with caution.
It may yet, however, be possible to explain the demonstration that transfection of
THP-1 cells with Asp299Gly mutant TLR4 results in blunted LPS
responsiveness (Arbour et al 2000). The present study does not rule out the
possibility that receptors homozygous for the Asp299Gly mutation may exhibit
blunted LPS responses. In the THP-1 transfection experiments it is possible that
the vector used in their transfection protocol induced larger than normal levels of
mutant TLR4, such that most receptors on the surface were homodimers of
TLR4 mutant molecules. Only measurement of responses from individuals
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homozygous for this mutation, or transfection of TLR4 null cells (such as the
human embryonic kidney derived 293 cell line) with the Asp299Gly TLR4
construct will shed some light on this matter.
CHAPTER 4
T-CELL RESPONSES TO L1POPOLYSACCHARIDE
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4.1 Introduction
In order to investigate the possibility that T-cells reactive towards LPS may exist,
a readily available source of large numbers of lymphoid cells was required.
Naive mouse splenocytes were therefore chosen for preliminary experiments as
a result of their ease of extraction and availability. Subsequent experiments
investigated proliferative responses of murine lymph node cells and human
peripheral blood mononuclear cells in response to LPS.
The optimum conditions for proliferation of human LPS-reactive T-cells were
determined, then applied to the PBMC of several healthy donors to investigate
whether T-cell clones reactive towards particular LPS core epitopes existed in
healthy donors. The response to these epitopes was then assessed at several
time points in these individuals. Finally, in order to determine whether CD1-
mediated presentation of LPS was required for T-cell recognition of LPS,
antibody blocking experiments and co-immunoprecipitation was attempted.
4.2 Results
4.2.1 Murine splenocyte response to LPS
The optimum concentration of LPS required to induce proliferation of murine
splenocytes was determined by incubating with varying concentrations of E.coli
R4 LPS for 3 days in culture. The proliferative responses of these splenocytes
were measured by radiolabeled thymidine incorporation and are summarised in
Figure 4.1. This experiment shows a strong proliferative response to all
concentrations of LPS above 100ng/ml, with a linear relationship appearing
between LPS concentration and splenocyte proliferation. Concentrations below
about 10ng/ml do not appear to stimulate proliferation in these cells. Further, it
can be seen that high concentrations of LPS are able to induce a stronger
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proliferative response in the splenocyte population than 1pg/ml of the T-cell
mitogen Concanavalin A (ConA).
Naive mouse splenocytes were then extracted and plated with E.coli K12 LPS at
various concentrations and incubated for between 4 and 7 days to investigate
the kinetics of this proliferative response beyond day 3. Figure 4.2 confirms the
dose-dependent nature of the proliferation seen in the first experiment, but also
reveal that the cells proliferate strongly to both E.coli K12 LPS and ConA at day
four, with this response diminishing daily such that by day seven practically no
proliferation can be seen.
Next, to determine whether there was any effect of LPS core type on the
strength of the proliferative response, E.coli R1, R2, R3 and R4 and Bacteroides
fragllis LPSs were added to splenocytes at equal concentrations by mass and
the proliferation measured at three days. Figure 4.3 shows that E.coli R3 and R4
LPS exhibit the strongest responses at 10,000ng/ml, with the LPS from R1 and
R2 core types slightly less active and that of B.fragilis much less active.
Next, in order to determine which cell type within the splenocyte population was
responsible for this proliferation, antibody conjugated magnetic beads were
employed to provide purified cellular sub-populations. Figure 4.4 shows the
effect of enrichment for CD19+ve, CD3+ve and CD1d+ve cells on splenocyte
proliferation in response to E.coli R4 LPS. These data show that while the
CD19+ve fraction responds strongly to the LPS, the CD3+ve and CD1d+ve
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Figure 4.1 Dependence of splenocvte proliferative capacity on LPS concentration
Murine splenocytes were plated at 2 x 10 cells per well and challenged with varying
concentrations of E.coli R4 LPS. Cells were pulsed with 3H radiolabelled thymidine (1pCi per
well) 18 hours before harvesting at three days. Control cultures received either medium alone
(Ctrl) or 1pg/ml concanavalin A (ConA). cpm = counts per minute.
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Figure 4.2 Kinetics of murine splenocvte proliferation in response to LPS and ConA
Murine splenocytes were plated at 2 x 10 cells per well and challenged with varying
concentrations of (a) E.coli K12 LPS or (b) 1 pg/ml concanavalin A (ConA). Cells were pulsed
with 3H-radioiabelled thymidine (1 pCi per well) 18 hours before harvesting at four, five, six or
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Figure 4.3 Murine splenocvte proliferation in response to different LPS types
Murine splenocytes were plated at 2 x 10 cells per well and challenged with either 100ng/ml or
10,000ng/ml of various types of LPS. R1 = E.coli R1, R2 = E.coli R2, R3 = E.coli R3, R4 = E.coli
R4, Bf = B.fragilis, Cells were pulsed with 3H-radiolabelled thymidine (1 pCi per well) 18 hours
before harvesting at three days. Control cultures received either medium alone (Ctrl) or 1 pg/ml
concanavalin A (ConA). cpm = counts per minute.
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Figure 4.4 Proliferative capacities of CD19+ve, CD3+ve and CD1d+ve cells in response to LPS
Murine splenocytes were sorted into CD19+ve, CD3+ve and CD1d+ve cellular fractions using
antibody conjugated magnetic beads. Subpopulations were then cultured with 10pg/ml E.coli R4
LPS or medium alone for three days, receiving 1p.Ci per well 3H-radiolabelled thymidine 18 hours
before harvesting, cpm = counts per minute.
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To further clarify the role of CD19+ve cells in splenocyte proliferation, the
experiment was repeated with the alteration that the CD19 depleted fraction was
retained for investigation. Figure 4.5 shows that while non-depleted splenocytes
respond strongly to E.coli R4 LPS, depletion of CD19+ve cells removes this
ability completely. Moreover, the cellular fraction consisting purely of CD19+ve
cells is seen to be capable of responding to LPS without help from accessory
cells. This fraction does not proliferate in response to ConA, indicating that it is
not highly contaminated with T-cells.
These data suggest that the murine splenocyte reactivity towards LPS is
mediated primarily by CD19+ve B-cells. Since it appeared that this mitogenic
response would probably mask any effect of LPS reactive T-cells present in the
splenocyte population, subsequent experiments focused instead on cells
extracted from murine lymph nodes.
4.2.2 Murine T-cell response to LPS
In the first instance, cells from the lymph nodes of naive animals were extracted
and incubated with varying concentrations of E.coli K12 LPS or the T-cell
mitogen ConA. This experiment was repeated three times, each time revealing
no proliferative response to LPS from the lymph node cells of naive animals
(Figure 4.6). It was therefore postulated that immunisation of mice with LPS or
bacteria prior to lymphectomy may be required in order to create a significant
memory T-cell population.
In the first of these experiments, mice were injected at the tail base with 10pg
E.coli K12 LPS, 10' heat killed E.coli 018K bacteria or 107 sheep red blood
cells in Freunds complete adjuvant. Inguinal and periaortic lymph nodes were
removed 8 days after incubation and the cells extracted. These cells were then
exposed to various concentrations of E.coli K12 LPS, heat-killed E.coli 018K"
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bacteria or sheep red blood cells in vitro and the proliferation of these cells
assessed after two, four or six days using thymidine incorporation. In these and
similar experiments using in vitro incubation times ranging from 2 days to 6
days, no appreciable proliferative response was seen to occur in response to
any of these three antigens, although positive control cultures incubated with
ConA always showed proliferation (Figures 4.7a - c).
Suspecting that the lack of proliferation may have had something to do with the
length of time between immunisation and harvesting of the lymph nodes, a panel
of mice were immunised as before with heat-killed E.coli 018K" bacteria. Lymph
nodes were excised from either naive mice, mice immunised 10 days pre-
harvesting or mice immunised 14 days before harvesting. Cells were then
incubated with heat killed E.coli 018K~ bacteria for four days, with the
proliferation being measured using thymidine incorporation as before. Figure 4.8
shows that proliferative responses to the recall antigen were still absent, despite
strong responses to the T-cell mitogen ConA. Larger responses to ConA were
observed from the later stage mice suggesting that a higher proportion of T-cells
exists in these fractions. Since the ConA controls had been working in these
experiments, it was assumed that the presence of viable T-cells was not lacking.
However, in order to boost the number of antigen presenting cells, splenocytes
were chosen as a feeder layer for the T-cells in the next series of experiments.
In order to rule out proliferative effects previously demonstrated to be exhibited
by the splenocytes themselves, these cells were treated transiently with the cell
division inhibitor mitomycin C and thoroughly washed to provide cells capable of
antigen presentation but not division. Figure 4.9 shows the effect of mitomycin-C
treatment on the capacity of murine splenocytes to proliferate in response to
E.coli R4 LPS. This initial experiment appeared to show that while mitomycin C
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Figure 4.5 Effect of CD19+ve cell depletion/enrichment on splenocvte response to LPS
Murine splenocytes were sorted into CD19+ve and CD19-ve cellular fractions using
antibody conjugated magnetic beads. Subpopulations were then cultured with 10p.g/ml
E.coli R4 LPS or 1p.g/ml concanavalin A or medium alone for three days, receiving 1p.Ci
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Figure 4.6 Proliferative response to LPS and ConA from naive mouse Ivmph node cells
Lymph node cells extracted from naive mice (2 x 105 per well) were incubated with varying
concentrations of E.coli K12 LPS or medium alone (control) or 1 pg/ml concanavalin A
(ConA), pulsed for 18hrs with 1 ptCi 3H-thymidine and harvested at five days. Results are
representative of three similar experiments, cpm = mean counts per minute of three
independent cultures +/- SEIVI.
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Figure 4.7 Proliferative responses of pre-immuriised murine Ivmph node cells to (a) E.coli
K12 LPS (b) heat killed E.coli Q18K- bacteria or (c) sheep red blood cells
Lymph node cells extracted from mice pre-immunised with each antigen were incubated with
medium alone (Ctrl), 1pg/ml concanavalin A (ConA) and varying concentrations of (a) E.coli
K12 LPS (b) heat-killed E.coli 018K- bacteria or (c) sheep red blood cells. Cultures were
pulsed for 18hrs with 1pCi JH-thymidine and harvested at six days (LPS and heat killed
bacteria) or 2 and 4 days (sheep red blood cells). Results are representative of three similar
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Figure 4.7 Proliferative responses of pre-immunised murine Ivmph node cells to (a) E.coli
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Figure 4.8 Comparison of times between immunisation and harvesting on lymph node cell
proliferation in response to antigen
Lymph node cells from either naive mice, mice immunised 10 days pre-harvesting or mice immunised
14 days before harvesting were challenged with various concentrations of heat-killed E.coli 018K-
bacteria or medium alone (Ctrl) or 1pg/ml concanavalin A (ConA), pulsed for 18hrs with 1pCi 3H-
thymidine and harvested at 4 days. Results are representative of three similar experiments, cpm =
mean counts per minute of three independent cultures +/- SEM.
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presence of mitomycin-C treated and washed cells did not inhibit the
proliferation of fresh splenocytes added on top of them (Figure 4.9).
Mitomycin C- treated splenocytes were then plated into 96 well plates and
supplemented with T-cells purified from autologous splenocytes using the MACS
magnetic bead purification system (methods, section 2.3.9). Following this,
E.coli R4 LPS, ConA or medium alone was added to the cells and incubated for
4 days. Figure 4.10 shows that untreated splenocytes proliferate strongly in
response to both E.coli R4 LPS and ConA, while the response of mitomycin C
treated splenocytes is strongly blunted. However, addition of purified naive T-
cells to mitomycin C treated splenocytes does not enhance the proliferative
response to either E.coli R4 LPS or ConA.
As the yield of T-cells from the MACS purification system was relatively low,
passage of murine splenocytes over nylon wool was employed in the next series
of experiments to provide larger numbers of purified T-cells. This purification
method employs the principle that T-cells exhibit less adhesion to nylon than B-
cells or monocytes, and is capable of providing greater numbers of T-cells than
the MACS system as it can be easily scaled upwards. Splenocytes were treated
with mitomycin C as before, and plated alone or supplemented with nylon wool
selected autologous T-cells. Untreated splenocytes were also included in the
assay as positive control. Figure 4.11 shows that splenocytes in these
experiments respond vigorously to E.coli R4 LPS and ConA stimulation, while
mitomycin C-treated splenocytes respond only poorly. Purified T-cells exhibit no
proliferative response to either stimulus, but, surprisingly, are seen to be able to
remove completely the residual proliferative capacity of the mitomycin C-treated
splenocytes.
A repeat of the same experiment using longer treatment of the splenocytes with
mitomycin C is depicted in Figure 4.12a. The chart reveals that untreated
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splenocytes respond with strong proliferation in response to E.coli R4 LPS and
ConA stimulation. This response to LPS is reduced by the addition of nylon wool
purified T-cells, though the ConA response remains unaltered - a finding which
can probably be explained due to the fact that the splenocytes are plated at half
the usual concentration, with the remainder being made up with T-cells.
Mitomycin C-treated splenocytes in this experiment exhibit no proliferative
capacity whatsoever. The T-cell fraction retains residual proliferative capacity in
response to both LPS and ConA, possibly as a result of B-cell contamination of
these relatively crude preparations. However this response is lost when these
cells are mixed with the mitomycin C treated splenocytes. It was assumed at this
stage that the mitomycin C treated cells were still, despite careful washing,
removing the proliferative capacity of T-cells added to the preparation.
Concerned about potential B-cell contamination of the T-cell preparations, the
same experiment was repeated using freshly purchased nylon wool. Figure
4.12b shows that normal responses were seen from untreated splenocytes
towards both LPS and ConA. Mitomycin C treated splenocytes, purified T-cells
and a mixture of the two all failed to proliferate appreciably in response to the
two antigens.
As no proliferative T-cell response to LPS could be detected in any of the murine
systems investigated, subsequent experiments focused instead on the
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Figure 4.9 Effect of mitomvcin-C treatment on the capacity of murine splenocvtes to proliferate in
response to E.coli R4 LPS and ConA
Murine splenocytes were treated with mitomycin-C, washed then plated with medium alone
(MitC + 0), 1|j.g/ml Concanavalin A (MitC + ConA), lOpg/ml E.coli R4 LPS (MitC + R4 LPS) or
fresh splenocytes plus 10(a.g/ml E.coli R4 LPS (MitC + fresh cells + R4 LPS). Cultures were
pulsed for 18hrs with 1p.Ci °H-thymidine and harvested at 4 days, cpm = mean counts per minute
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Figure 4.10 Proliferative response of Mitomvcin-C treated splenocvtes supplemented with
MACS purified T-cells to E.coli R4 LPS and ConA
Murine splenocytes were treated with mitomycin-C, washed then plated with medium alone
(MitC + 0) or 10pg/ml E.coli R4 LPS (MitC + R4 LPS). Mixed cultures of mitomycin-C treated
splenocytes and MACS purified T-cells were cultured with medium alone (M+T+0),10p.g/ml
E.coli R4 LPS (M+T+R4LPS) or Ipg/ml Concanavalin A (M+T+ConA). Untreated splenocytes
(All spleen) were incubated with medium alone (0), 10p.g/ml E.coli R4 LPS (R4 LPS) or
1p.g/ml Concanavalin A (ConA). All cultures were pulsed for 18hrs with 1pCi 3H-thymidine and
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Figure 4.11: Proliferative response of Mitomvcin-C treated splenocvtes supplemented with nylon
wool purified T-cells to E.coli R4 LPS and ConA
Untreated murine splenocytes (Norm), mitomycin-C treated splenocytes (MitC), nylon wool
purified T-cells (T-cell), or mixed cultures of mitomycin-C treated splenocytes and nylon wool
purified T-cells (M+T) were cultured with medium alone (0), 10p.g/ml E.coli R4 LPS (R4) or
1 pig/ml Concanavalin A (ConA). All cultures were pulsed for 18hrs with 1p.Ci JH-thymidine and
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Figure 4.12 Proliferative response of Mitomvcin-C treated splenocvtes supplemented with nylon
wool purified T-cells to E.coli R4 LPS and ConA
(a) Untreated murine splenocytes (Spleen), nylon wool purified T-cells (T-cells), mitomycin-C
treated splenocytes (MitC Sp), mixed cultures of mitomycin-C treated splenocytes and nylon
wool purified T-cells (MitC Sp+T) or mixed cultures of untreated splenocytes and nylon wool
purified T-cells (Sp+T) were cultured with medium alone (0), lOpg/ml E.coli R4 LPS (LPS) or
1p.g/ml Concanavalin A (ConA). All cultures were pulsed for 18hrs with 1p.Ci 3H-thymidine and
harvested at 4 days, cpm = mean counts per minute of three independent cultures +/- SEM. (b)
Repeat of above experiment using fresh nylon wool for T-cell purification.
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4.2.3 Human T-cell responses to LPS
In order to investigate the possibility that human PBMCs may be able to
proliferate in response to LPS, human PBMCs extracted from buffy coats
(methods, section 2.3.2) were incubated with either E.coli K12 LPS or heat-killed
E.coli K12 bacteria for 3 days. Figure 4.13a shows that no proliferation occurred
in response to either LPS or heat-killed bacteria, though cultures challenged with
ConA exhibited strong proliferation. PBMCs derived from the buffy coats of
several different donors revealed the same lack of proliferation, so the same
experiment was repeated using a 5 day incubation period. Figure 4.13b shows
that proliferative responses were generated to ConA but not to either LPS or
heat killed bacteria.
It was considered that perhaps lack of prior exposure to this antigen may be
responsible for the lack of response seen. For this reason, the next series of
experiments investigated responses to LPS of E.coli R1, E.coli R2, E.coli R3,
E.coli R4 and B.fragilis - all of which may be commonly found in the gut or are
associated with infection. The proliferative responses to these antigens from the
buffy coats of several dozen individuals were tested using 3 days, 4 days or 6
days incubation. No response was seen to these antigens or to the LPS of
Klebsiella aerogenes, K.friedlander, K.pneumoniae, Salmonella minnesota or
S.typhimurium in many similar experiments (typical responses of individual
donors are represented in Figures 4.14-4.15).
At this stage it was postulated that perhaps upregulation of the antigen
presentation molecule CD1 was required to allow T-cell responses towards LPS.
For this reason, the next series of experiments investigated the response of T-
cells to LPS in the presence of CD1+ve cells. Figure 4.16a shows the
proliferation of buffy coat PBMCs exposed to either LPS alone or LPS
supplemented with 200IU/ml of the cytokines IL-4 and GM-CSF, which together
induce the expression of CD1a,b and c on human monocytes (Figure 4.29).
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Treatment of PBMC in this way did not result in induction of an LPS-specific
proliferative response at 4 days (Figure 4.16a) or at 6 days incubation (Figure
4.16b).
In another set of experiments, IL-4/GM-CSF was administered to buffy coat
PBMC first (for three days), with LPS being added afterwards (for a further three
days). Proliferation was then measured after six days total incubation. Figure
4.17 shows that once again, no difference in proliferation between LPS treated
and control cultures could be observed.
Concerned at the large variability seen in proliferation between identically
treated adjacent wells in this and previous experiments, an experiment was
performed to investigate whether this variability was due to problems in the
dispersion of LPS preparations or to an inherent property of the cells used. Buffy
coat PBMCs were incubated for 6 days in medium supplemented with 5% foetal
calf serum alone but without any other stimulus. Figure 4.18 shows that of the
12 wells, most exhibit a proliferation around 150cpm, while one exhibits a count
of around 2800. This inherent variabilty in the unstimulated cell population was
assumed to be responsible for the variability seen in previous experiments.
To further clarify the cause of the relatively high background proliferation seen in
all previous experiments, the role of the serum was investigated. Buffy coat
PBMC were plated with medium containing foetal calf serum or no serum and
challenged with LPS as before. Figure 4.19 shows that removal of serum from
the medium reduces proliferation of all cultures by a factor of approximately 10.
Foetal calf serum from three different manufacturers was tested (Gibco, Sigma
and Imperial laboratories) but none could remove the high (>1,000cpm)
background proliferation observed in all experiments. For this reason, a series of
experiments was performed using buffy coat PBMC supplemented with pooled
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Figure 4.13 Proliferation of human PBMCs exposed to LPS/heat-killed bacteria at (a) 3 days
and (bp 5 days
Human PBMC extracted from buffy coats were plated at 2 x 105 cells per well and challenged
with various concentrations of E.coli K12 LPS or heat-killed E.coli K12 bacteria (1e7/ml = 1 x
10' cells per ml) or medium alone (Control) or Ipg/ml Concanavalin A (ConA). Cultures were
pulsed for 18hrs with 1pCi °H-thymidine and harvested at (a) 3 days or (b) 5 days, cpm =
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Figure 4.14 Response of human PBMC to various LPS types at (a) 3 days and (b) 4 days
incubation
Human PBMC extracted from buffy coats were plated at 2 x 105 cells per well and challenged
with either 100ng/ml (100) or 10,000ng/ml (10,000) of LPS or medium alone (Control) or
1ug/ml Concanavalin A (ConA). R1 = E.coli R1, R2 = E.coli R2, R3 = E.coli R3, R4 = E.coli R4,
Bf = B.fragilis. All cultures were pulsed for 18hrs with 1pCi "H-thymidine and harvested at 3
















Figure 4.15 Response of human PBMC to various LPS types at 6 days incubation
Human PBMC extracted from buffy coats were plated at 2 x 10 cells per well and challenged with
either 10Ong/ml (100) or 10,000ng/ml (10,000) of LPS or medium alone (Control) or 1 pig/ml
Concanavalin A (ConA). R1 = E.coli R1, R2 = E.coli R2, R3 = E.coli R3, R4 = E.ooli R4, Bf =
B.fragilis, Ka = Klebsiella aerugines, Kf = Klebsiella friedlander, Kp = Klebsiella pneumoniae, Sm =
Salmonella minnesota, St = Salmonella typhimurium LPS. All cultures were pulsed for 18hrs with
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Figure 4.16 Effect of IL-4/GM-CSF treatment on PBMC proliferation in response to LPS at (a) 4
days and (b) 6 days
Human PBMC extracted from buffy coats were plated at 2 x 105 cells per well and challenged with
either 100ng/ml (100) or 10,000ng/ml (10,000) of LPS or medium alone (Control) or 1pg/ml
Concanavalin A (ConA). Culture medium contained either 5%FCS or 5%FCS + 200 lU/ml IL-4 and
GM-CSF. R1 = E.coli R1, R2 = E.coli R2, R3 = E.coli R3, R4 = E.coli R4, Bf = B.fragilis LPS.
Cultures were pulsed for 18hrs with 1p.Ci JH-thymidine and harvested at (a) 4 days or (b) 6 days,
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Figure 4.17 Effect of IL-4/GM-CSF pre-treatment on PBMC proliferation in response to LPS
Human PBMC extracted from buffy coats were plated at 2 x 10 cells per well and challenged
with either 100ng/ml (100) or 10,000ng/ml (10,000) of LPS or medium alone (Control) or
1(j.g/ml Concanavalin A (ConA). Culture medium contained either 5%FCS or 5% FCS for the
first 3 days then 5%FCS + 200 Ill/ml IL-4 and GM-CSF for the following 3 days. R1 = E.coli
R1, R2 = E.coli R2, R3 = E.coli R3, R4 = E.coli R4, Bf = B.fragilis LPS. All cultures were
pulsed for 18hrs with 1pCi 3H-thymidine and harvested at 6 days, cpm = mean counts per
minute of three independent cultures +/- SEM.
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Figure 4.18 Inherent variability in proliferation of unstimulated PBMC
Human PBMC extracted from buffy coats were plated at 2 x 10 cells per well in medium alone
(RPMI/5%FCS). Twelve identical cultures were were pulsed for 18hrs with 1p.Ci 3H-thymidine
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Figure 4.19 Proliferation of PBMCs exposed to LPS or LTA in (a) 5% foetal calf serum or (b)
serum free medium
Human PBMC extracted from buffy coats were plated at 2 x 105 cells per well and challenged
with either 100ng/ml (100) or 10,000ng/ml (10,000) of LPS or medium alone (Control) or
1 rig/ml Concanavalin A (ConA). Culture medium contained (a) 5%fetal calf serum or (b) no
serum. R1 = E.coli R1, R2 = E.coli R2, R3 = E.coli R3, R4 = E.coli R4, SA = S.aureus LTA. All
cultures were pulsed for 18hrs with 1 ptCi 3H-thymidine and harvested at 6 days, cpm = mean
counts per minute of three independent cultures +/- SEM.
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counts, they did not reveal any proliferative response to LPS significantly higher
than control cultures (data not shown).
To rule out the possibility that there was something wrong with the buffy coats
themselves, PBMCs were extracted from fresh venous blood obtained from
healthy human volunteers. Figure 4.20 show the results of the first attempt of
this experiment. Low background counts are observed and a strong proliferative
response is seen towards E.coli R1, E.coli R2, E.coli R3, E.coli R4, Klebsiella
aerogenes and K.friedlander LPS. The highest stimulation index of 35.6 is seen
in response to LPS of K. aerogenes.
Having demonstrated proliferation of human PBMC in response to LPS, a
number of experiments were performed in order to determine the optimum
experimental conditions required for the detection of LPS-reactive PBMC.
A time course experiment using timepoints of 2, 3, 4, 5, 6, 7, 8, 11, 14 and 17
days was performed to investigate the kinetics of proliferation of PBMC in
response to ConA, S.aureus lipoteichoic acid and E.coli R1 LPS. Figure 4.21 a+b
show that unstimulated PBMC do not proliferate greatly throughout the period of
incubation. Figure 4.21a shows that responses to ConA peak quickly to reach a
plateau of strong proliferation between days 3 and 5, before returning quickly to
background levels at around day 6. Responses to both LPS and LTA show
minimal proliferation before six days, then peak sharply at around day 7 to day 8
before slowly returning to background proliferation after a much longer period
than that seen for ConA-treated cultures.
An experiment was then performed to determine the optimum concentration of
cells required to detect an LPS specific response. Figure 4.22 shows the
response of fresh PBMC plated at 0.1, 0.5, 1, 3 and 5 x 105 cells per culture
well. Optimum proliferation is clearly obtained when using a cellular
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concentration of 3 x 105 cells per well, as this provides the highest stimulation
index (~18). Cellular concentrations higher than this are seen to result in much
higher background proliferation than that found when using lower
concentrations.
Then to determine the optimum concentration of LPS to use in subsequent
experiments, serial dilution experiments were performed using E.coli R1 LPS.
Figure 4.23 shows that a relatively linear relationship exists between LPS
concentration and proliferative response from human PBMC. The highest
response is seen to occur when using the highest dose tested (10pg/ml LPS),
with concentrations of LPS below 0.1ng/ml invoking little or no response.
Using the concentrations and times suggested by these experiments, PBMC
derived from the blood of six further healthy volunteers were investigated to
determine what proportion of people were able to respond to LPS in this way.
The responses of donors 2 - 7 to LPS from E.coli R1, E.coli R2, E.coli R3, E.coli
R4, B.fragilis, S.minnesota, S.typhimurium and LTA of S.aureus are shown in
Figures 4.24 a - f. It can be seen on comparison of these charts that while the
PBMC of some donors respond to most core types of LPS (eg. donor 3, Figure
4.24b), others respond to only a handful (eg. donor 5, Figure 4.24d) and one to
none of the LPS tested at all (donor 7, Figure 4.24f). This donor is considered a
non-responder because the counts from cultures incubated with LPS are not
significantly higher than those of the control cultures, despite the fact that the
actual counts for both cultures are quite high.
Then in order to determine which cellular subpopulation within the PBMC was
proliferating in these experiments, PBMCs were taken from one volunteer (donor
4), exposed to E.coli R3 LPS for 7 days and flow cytometry performed on the
markers CD3, CD14 and CD19 (markers for T-cells, monocytes and B-cells
respectively). Figure 4.25 shows that a small expansion (~15%) of CD3 and
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CD19+ve cells is seen following LPS stimulation, while CD14+ve cells are seen
to be slightly reduced (-10%) in number after LPS stimulation.
In order to determine whether the proliferation to different types of LPS varied
over time, the 7 volunteers were bled on either one or two further occasions and
the PBMC exposed to the same panel of LPS. Figures 4.26 a-f show how the
ability to respond to different types of LPS varies in each individual from day to
day. It can be seen that while some donors exhibited a very similar profile of
response on each occasion (eg. donor 2, Figure 4.26a), others varied
considerably (eg. donor 5, fig 4.26d). The non-responder displayed a stimulation
index less than 7 in response to LPS on each of the three occasions tested,
once again as a result of a high background proliferation, and is therefore
classed as a non-responder on each of these three days (Figure 4.26f).
As a more general measure of day to day LPS reactivity, an average score was
calculated as the mean proliferative response to the entire panel of LPS on the
day tested. This mean value was then plotted against the different days. Figure
4.27 shows that on different days, the overall capacity of some individuals to
respond to LPS may rise or fall, with one (donor 1) showing a clear transition
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Figure 4.20 Fresh human PBMC proliferation in response to LPS supplemented with human serum
Human PBMC extracted from fresh venous blood (donor 1) were plated at 2 x 10" cells per well and
challenged with 10p.g/ml of LPS or medium alone (Control). Culture medium contained 10%
autologous human serum. R1 = E.coli R1, R2 = E.coli R2, R3 = E.coli R3, R4 = E.coli R4, Ka =
Klebsiella aerogenes, Kf = Klebsiella friedlander, SA = S.aureus LTA. All cultures were pulsed for
18hrs with 1 p.Ci "H-thymidine and harvested at 8 days, cpm = mean counts per minute ot three




Figure 4.21 Kinetics of proliferation of human PBMC in response to (a) ConA or (b) LPS and LTA
Human PBMC extracted from fresh venous blood (donor 5) were plated at 2 x 10 cells per well
and challenged with 1p.g/ml of Concanavalin-A (ConA) or 10pg/ml E.coli R3 LPS or 10p.g/ml
S.aureus LTA or medium alone (Ctrl). All cultures were pulsed for 24hrs with 1 piCi JH-thymidine
and harvested at 2,3,4,5,6,7,8,11,14 or 17 days, cpm = mean counts per minute of three
independent cultures +/- SEM.
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Figure 4.22 Effect of cell number on human PBMC proliferation in response to LPS
Human PBMC extracted from fresh venous blood (donor 5) were plated at 0, 0.1, 0..5,1, 3 or 5 x
105 cells per well and challenged with 10^g/ml E.coli R3 LPS (LPS) or medium alone (Ctrl). All
cultures were pulsed for 18hrs with 1pCi 3H-thymidine and harvested at 7 days, (a) cpm = mean




Figure 4.23 Dilution curve for R1 LPS
Human PBMC extracted from fresh venous blood (donor 5) were plated at 2 x 105 cells per well
and challenged with 10"6 to 104 ng/ml E.coli R3 LPS or medium alone (Ctrl). All cultures were
pulsed for 18hrs with 1 jj.Ci 3H-thymidine and harvested at 7 days, cpm = mean counts per minute










Figure 4.24 Profile of responses of PBMCs from six healthy donors to LPS and LTA
Human PBMC extracted from fresh venous blood were plated at 2 x 10b cells per well and
challenged with 10pg/ml (1e4) or 100ng/ml (100) of LPS or medium alone (Control). R1 =
E.coli R1, R2 = E.ooli R2, R3 = E.coli R3, R4 = E.coli R4, BfR = B.fragilis rough LPS, BfS =
B.fragilis smooth LPS, Sm = S.minnesota, St = S.typhimurium, SA = S.aureus LTA. All
cultures were pulsed for 18hrs with 1pCi 3H-thymidine and harvested at 7 days, cpm = mean
counts per minute of three independent cultures +/- SEM. Figures a - f represent to the
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Figure 4.24 Profile of responses of PBMCs from six healthy donors to LPS and LTA
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Figure 4.24 Profile of responses of PBMCs from six healthy donors to LPS and LTA
Donors 6 + 7.
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Figure 4.25 Profile of cell subpopulation expansions following LPS stimulation
PBMC extracted from fresh human venous blood (donor 4) were plated in either medium
alone (RPMI/10%HS) or medium supplemented with 10pg/ml E.coli R3 LPS. Cells were
stained for CD3, CD14 and CD19 expression after 7 days incubation and percentage of
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Figure 4.26 Variation of PBMC responses of donors to different LPS types on different days
Human PBMC extracted from fresh venous blood (a-f = donors 2-7 respectively) were plated
at 2 x 105 cells per well and challenged with 10p.g/ml of LPS or medium alone (Ctrl). R1 = E.coli
R1, R2 = E.coli R2, R3 = E.coli R3, R4 = E.coli R4, SA = S.aureus LTA, BfR = B.fragilis rough
LPS, BfS = B.fragilis smooth LPS, Ka = K.aerogenes,Sm = S.minnes ta, St = S.typhimurium.
All cultures were pulsed for 18hrs with 1pCi JH-thymidine and harvested at 7 days, cpm =
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Figure 4.26 Variation of PBMC responses of donors to different LPS types on different days
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Figure 4.26 Variation of PBMC responses of donors to different LPS types on different days
Donors 6 + 7.
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Figure 4.27 Variation of mean PBMC responses to all LPS on different days
Day to day variation in the mean responses of PBMC from 7 healthy donors to panel of
LPS. Mean response was calculated as average stimulation index calculated for each
individual LPS looked at. Panel included LPS of: E.coli R1, E.coli R2, E.coli R3, E.coli
R4, B.fragilis rough strain, B.fragilissmooth strain, K,aerogenes, ,
S.typhimurium. All responses were measured at 7 days incubation.
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4.2.4 Human T-cell responses to liposomal LPS
As an appropriate T-cell response is generally thought to be required to induce
class switching for the formation of IgG antibodies, the capacity of the liposomal
LPS vaccine described in section 3.2.3 to induce a T-cell response was
investigated.
Liposomal cocktail LPS (methods, section 2.1.5) was added to human PBMC
and the resulting proliferative response compared with that of native cocktail
LPS. Figure 4.28 shows that PBMC proliferation is observed in response to
liposomal LPS at all concentrations between 10ng/ml and the highest dose
tested (lOpg/mi). The proliferative response is seen to be roughly equivalent to
that generated towards 0.01ng/ml native cocktail LPS.
4.2.5 Role of CD1 in T-cell responses to LPS
Experiments were performed to investigate the possibility that T-cell proliferation
in response to LPS involves presentation of lipid via molecules of the CD1
family. Determination of the expression levels of CD1 a,b,c and d molecules
revealed no significant expression of these molecules on freshly isolated
untreated PBMC (Figure 4.29). Similarly, monocytes cultured in 10% serum for 7
days do not express any CD1 isotype (Figure 4.29). However, treatment of
monocytes with 200IU/ml of each of the cytokines IL-4 and GM-CSF is clearly
seen to induce strong expression of the group I CD1 molecules (CD1a,b and c)
but not group 2 CD1 molecule CD1d (Figure 4.29). Treatment of monocytes with
these cyokines is also seen to have little impact on expression of MHC-I and
MHC-II while CD14 expression is significantly reduced (Figure 4.30).
It was then investigated whether expression of CD1 isotypes could be initiated
on PBMC by exposure to LPS. Figure 4.31 shows that exposure of PBMC to
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Figure 4.28 Proliferative response of human PBMC to liposomal LPS
Human PBMC extracted from fresh venous blood (donor 1) were plated at 2 x 105 cells per
well and challenged with 10pg/mi of cocktail LPS or 10pg/ml to 0.01ng/ml cocktail LPS (lipo)
containing lipsomes or 10p.g/ml empty liposomes or medium alone (Ctrl). All cultures were
pulsed for 18hrs with 1p.Ci 3H-thymidine and harvested at 7 days, cpm = mean counts per



































Figure 4.29 Expression of CD1 a.b.c and d on fresh monocytes and monocytes cultured for 7
days with or without IL-4/GM-CSF
Monocytes extracted from fresh venous blood (donor 2) were plated in either medium alone
(Ctrl) or medium supplemented with 200!U/ml IL-4 and GM-CSF. Cells were stained for
CD1a,b,c or d expression immediately (Fresh monos) or after 7 days incubation and




Figure 4.30 Expression of CD14, MHC-I and MHC-II on monocytes treated with 1L-4/GM-CSF
Monocytes extracted from fresh venous blood (donor 5) were plated in either medium alone
(Ctrl) or medium supplemented with 200IU/ml IL-4 and GM-CSF. Cells were stained for CD14,
MHC-I and MHC-II expression after 7 days incubation and percentage of positively staining
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Figure 4.31 CD1 expression on human monocytes exposed to LPS for 7 days
Monocytes extracted from fresh venous blood (donor 1) were plated in either medium alone
(Monocytes) or medium supplemented with 10pg/ml E.coli R3 LPS (Monocytes + LPS). Cells
were stained for CD1a,b,c or d expression after 7 days incubation and percentage of positively
staining cells compared with unstained cells (Ctrl) by flow cytometry.
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Then to investigate whether antibodies against CD1 could block PBMC
proliferation in response to LPS, fresh human PBMC were plated with LPS and
antibodies specific for each of the CD1 isotypes. Data from several individuals
were combined for each antibody to provide a mean stimulation index. Figure
4.32 shows that blocking with monoclonal antibodies specific for CD1a,b and c
has no significant effect on proliferation, while the monoclonal antibody specific
for CD1d appears to actually increase the proliferative response of the PBMC to
LPS.
Experiments were then performed to determine whether or not LPS could be
seen to bind to CD1. In the first series of experiments, expression of exposed
presented LPS core structures on the surface of CD1-expressing cells was
attempted to be visualised using a monoclonal antibody reactive to the core
structures of many types of enterobacterial LPS: Wnt-1. Human monocytes were
plated with or without IL-4/GM-CSF treatment to induce CD1a,b and c
expression and with or without E.coli R1 LPS followed by staining with Wnt-1 at
7 days. Figure 4.33 shows that using this method, no LPS can be seen bound to
the cell surface after seven days incubation. Treatment of cells with IL-4/GM-
CSF appears capable of inducing some binding of the Wnt-1 antibody
regardless of LPS treatment, as evidenced by the relatively high fluoresence
displayed by these cultures.
As a result of this failure to detect LPS core structures on the surface of CD1+ve
cells, autoradiography of immunoprecipitated CD1 was planned, such that
radiolabeled LPS could be used to determine if CD1 could bind LPS.
IL-4/GM-CSF treated human monocytes were pulsed with LPS and the proteins
extracted. Figure 4.34 shows that abundant proteins are present in these
extracts. While distinct banding patterns are difficult to make out, it is clear that a
200
large amount of proteins are migrating in the region expected to contain all CD1
isotypes (41-55 kDa).
However, immunoblots of these gels using anti-CD1 monoclonal antibodies
continually failed to reveal the presence of CD1 (data not shown). For this
reason, dot blots were performed to determine whether the antibody could
detect CD1 in the context of nitrocellulose.
Figure 4.35a shows that MHC-II molecules present in the extract from these
cells are readily detected while the isotype matched negative control antibody
(anti-CD3) shows that non-specific staining is not occurring. However, Figure
4.35b shows that the presence of CD1 isotypes cannot be detected using this
protocol. As detection of CD1 isotypes using these antibodies failed to occur in
several similar experiments, planned experiments using radiolabeled LPS were
abandoned.
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Figure 4.32 Effect of anti-CD1 mAbs on proliferation of PBMC exposed to E.coli R3 LPS
PBMC extracted from fresh venous blood of various donors were plated in either medium
alone or medium supplemented with 10|ig/ml E.coli R3 LPS or medium supplemented with
lO^g/ml E.coli R3 LPS and 2.5p.g/ml a-CD1a,b,d or 50p.g/ml a-CD1c. Stimulation index was
calculated as LPS treated cell proliferation divided by control cell proliferation. Mean
stimulation indices for several individuals were combined for each antibody. a-CD1a
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Figure 4.33 Expression of LPS core structures on cell surface of PBMC exposed to LPS and
1L-4/GM-CSF
PBMC extracted from fresh human venous blood (donor 3) were plated in either medium alone
(RPMI/10%HS) or medium supplemented with 200 lU/ml IL-4 and GM-CSF. Both cultures were
supplemented with lOpg/ml E.coli R1 LPS. Cells were stained with either no primary antibody or the
LPS core reactive monoclonal antibody Wnt-1 after 7 days incubation. Percentage of cells staining





Figure 4.34 Coomassie blue stained ael of protein extract from IL-4/GM-CSF treated PBMC
Proteins were extracted from fresh human PBMC treated with 200IU/ml IL-4/GM-CSF for seven
days, separated by PAGE electrophoresis and stained using Coomassie blue. Lanes 1+5,
molecular weight markers (120kDa, 84kDa, 60kDa, 39kDa, 28kDa, 18kDa). Lanes 2-4, protein
extracts from three separate experiments. CD1a,b,c or d if present should migrate at 41-55 kDa.
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Figure 4.35 Dot blot of (a) MHC-II and CD3 and (b) CDIa.b.c.d proteins extracted from IL-
4/GM-CSF treated monocytes
Proteins were extracted from fresh human monocytes treated with 200IU/ml IL-4/GM-CSF for
seven days. Extracts were blotted in duplicate onto nitrocellulose and stained with (a) a-MHC-




4.3.1 Why look at T-cell responses to LPS?
While the response towards LPS of other immune cells such as neutrophils,
monocytes and B-cells have been well characterised (reviewed in Martich et
1993, Rietschel et al 1994, Peavy et al 1970 respectively), much less is known
of the role of T-cells in immune responses to LPS. For some time it was
considered that human T-cells were incapable of proliferating in response to
LPS (Peavy et al 1970, Greaves et al 1974, Ellner et al 1989, Fauci et al 1976),
though this has now been shown not to be true (Mattern et al 1994). Since it is
understood that T-cells have a strong role to play in both the orchestration and
class switching of antibodies in any immune response, an understanding of the
T-cell response to LPS was desired in order to further our understanding of how
antibody responses to LPS are made. Information derived from such studies
could provide insights that may be of use in the design of lipopolysaccharide-
based vaccines.
4.3.2 Murine splenocvte responses to LPS
Several studies have demonstrated the ability of murine splenocytes to
proliferate in response to LPS (Peavy et al 1970, Andersson et al 1977,
Morrison et al 1981, Glode et al 1976). This has typically been considered to be
mediated primarily by B-cells, with one estimate suggesting that 1 in 3 splenic B-
cells are capable of proliferating in response to LPS (Andersson et al 1977).
However, evidence also exists for the presence of LPS reactive T-cells in mice.
In particular, murine T-cell proliferative responses have been reported to occur
in response to both in vitro (Vogel et al 1983, Miller et al 1983) and in vivo
(Tough et al 1997) LPS challenge. Of particular interest to the following study,
however, is the observation by Vogel et al that a small subpopulation of T-cells
purified from murine splenocytes (approximately 3%) were capable of
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proliferating in response to LPS challenge. For this reason, early experiments
investigated the response of murine splenocytes to LPS challenge.
Challenge of murine splenocytes with LPS resulted in dose dependent
proliferation (Figure 4.1). Viable T-cells were clearly present within the
splenocyte population as evidenced by the strong proliferative response to the
T-cell mitogen ConA (Figure 4.1). The kinetics of this proliferation indicate strong
responses at 4 days, with proliferation diminishing daily to background levels by
day 7. Such kinetics are reminiscent of the proliferative responses of
lymphocytes to other polyclonal mitogens (Peavy et al 1970, Greaves et al 1974,
Fauci et al 1976).
Then in order to determine whether there was any effect of LPS core type on the
strength of the proliferative response, E.coli R1, R2, R3 and R4 and B.fragilis
LPSs were added to splenocytes at equal concentrations and the proliferation
measured at three days. Figure 4.3 shows that the strongest responses are
developed against E.coli R3 and R4 LPS, with responses to E.coli R1 and R2
LPS slightly reduced and responses to B.fragilis LPS much lower. The latter
finding is consistent with the previously reported observation of the lower
capacity of B.fragilis LPS to stimulate activation of monocytes (Delahooke et al
1996, Lindberg 1990, Erridge et al 2002).
In order to determine which cell type within the splenocyte population was
proliferating in response to these antigens, purified cellular sub-populations were
assessed for capacity to proliferate in response to LPS. Figure 4.4 shows that
CD19+ve cells (B-cells) proliferate strongly in response to LPS, while the
CD3+ve cells (T-cells) proliferate slightly and the CD1d+ve fraction do not
proliferate at all. CD1d was chosen as one of the marker molecules as it has
been implicated in the response of other immune cells to lipid antigens
(Beckman et al 1994, Schofield et al 1999, Park et al 2000). However, the
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proliferation seen in the CD3+ve cell fraction in this experiment most likely
represents B-cell contamination of this fraction, as it was seen in a second
experiment that depletion of CD19+ve cells from splenocytes was seen to result
in complete abrogation of proliferation in response to LPS (Figure 4.5).
These experiments suggest that the murine splenocyte reactivity towards LPS is
mediated entirely by CD19+ve B-cells. The splenic T-cell preparations reported
by Vogel et al (1983) to be capable of responding to LPS may well have also
been contaminated with B-cells. Their study employed an antibody affinity
purification approach similar to the one used in this study. Further, they noted
that FACS analysis of their preparations indicated a 98% purity of their T-cell
preparations. No characterisation of the remaining 2% of cells was reported. In
the light of the current study, it is likely that this impurity contained a
contaminating B-cell population which imparted the proliferative response on
preparations. For these reasons, subsequent attempts to identify the presence
of LPS reactive T-cells in mice focused instead on cells extracted from murine
lymph nodes.
4.3.3 Murine lymph node responses to LPS
In several experiments, cells from the lymph nodes of naive mice did not show
any proliferative response to either E.coli K12 LPS or the T-cell mitogen ConA
(Figure 4.6a). For this reason, the cells from lymph nodes of pre-immunised
mice were used in subsequent experiments.
Mice were initially immunised with either E.coli K12 LPS, heat killed E.coli 018K"
bacteria or sheep red blood cells complexed with Freunds complete adjuvant.
Lymph node cells were removed 8 days post immunisation and exposed to
E.coli K12 LPS, heat-killed E.coli 018K" bacteria or sheep red blood cells in
vitro. Figure 4.7 reveals that no proliferation occurs in response to these
antigens at two, four or six days incubation in vitro.
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It was thought that the 8 day delay between immunisation and harvesting of
cells may not have been long enough to generate a significant T-cell response
to these antigens, so lymph nodes from either naive mice, mice immunised 10
days pre-harvesting or mice immunised 14 days before harvesting with heat-
killed E.coli 018K" bacteria were assessed. Figure 4.8 shows that incubation of
the cells with heat-killed E.coli 018K" bacteria resulted in no appreciable
response to this antigen, though a strong response to ConA was seen at all time
points, suggesting that the presence of viable T-cells is not lacking in these
experiments. The response to ConA was seen to be strongest in day 14
animals, less in day 10 animals and least strong in naive animals. This suggests
that the immunisation protocol has increased either the number or the
responsiveness of the T-cells in the lymph nodes of these animals.
As viable T-cells were not seen to be lacking in these assays, it was considered
that perhaps the number of antigen presenting cells was limiting, so subsequent
experiments attempted to supplement cultures with autologous splenocytes. In
order to ensure that proliferation of the splenocytes did not occur and mask any
T-cell response, these cells were transiently treated with the cell division
inhibitor mitomycin C. Figure 4.9 shows that treatment of murine splenocytes
with mitomycin C is capable of significantly blunting their capacity to proliferate
in response to E.coli R4 LPS or ConA. Further, co-culture of untreated
splenocytes with mitomycin-C treated cells is not seen to result in inhibition of
the responses of untreated cells to LPS (Figure 4.9).
Figure 4.10 shows that addition of antibody purified naive T-cells to mitomycin C
treated splenocytes does not enhance the proliferative response to either E.coli
R4 LPS or ConA. As the yield of T-cells from the magnetic bead purification
system was relatively low, passage of murine splenocytes over nylon wool was
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employed in the next series of experiments to provide larger numbers of purified
T-cells.
Figure 4.11 shows that nylon wool-selected autologous T-cells do not proliferate
in response to either LPS or ConA. Supplementation with mitomycin C-treated
splenocytes does not rescue this phenotype. Further, addition of T-cells to
mitomycin C-treated splenocytes is seen to completely remove the residual
proliferative capacity of the mitomycin C-treated splenocytes. This is most likely
explained by the fact that the concentration of mitomycin C-treated splenocytes
in these wells are at half the concentration of unsupplemented welis, and may
be below a critical cellular concentration required for measurable activity in this
assay.
The same experiment was repeated using longer treatment of the splenocytes
with mitomycin C. In this experiment, the T-cell fraction is seen to retain residual
proliferative capacity in response to LPS, a finding which may reflect the
possibility of B-cell contamination of these relatively crude preparations (Figure
4.12a). Mitomycin C-treated splenocytes do not respond to either stimulus, but
are seen to remove the capacity of the T-cells to display their residual
proliferation in response to LPS, suggesting that despite thorough washing,
these cells retain some toxicity post treatment in this experiment.
In an attempt to reduce the potential B-cell contamination of the T-cell
preparations, freshly purchased nylon wool was used in the next series of
experiments. Figure 4.12b shows that the activity of the T-cell fraction in
response to LPS is reduced, but since the response to ConA is also severely
blunted, the viability of these cells is questionable. Supplementation with
mitomycin C-treated antigen presenting cells does not rescue their ability to
proliferate.
210
As consistent results from these experiments could not be obtained, the focus of
the search for LPS reactive T-cells shifted towards the proliferative response of
human peripheral blood mononuclear cells (PBMC). However, the success of
previous workers in demonstrating the presence of LPS reactive T-cells in mice
may perhaps be explained by the following observations. Positive responses of
splenic T-cells to LPS (Vogel et al 1983, Miller et al 1983) may have occurred as
a result of contamination of these preparations with responding B-cells (as
described above). The demonstration of a murine T-cell line (CT6) capable of
responding to LPS challenge in vitro reports that the cell line did not have this
property when first isolated. This property was spontaneously acquired after
repeated passages approximately two years post-cloning, and therefore most
likely represents a long term tissue culture adaptation resulting in expression of
TLR4. The report of in vivo LPS mediated T-cell proliferation most likely occurs
as a result of indirect activation. Antigen presenting cells secrete a wide range of
cytokines on exposure to LPS, several of which have been shown to induce
proliferation of memory T-cells. In particular, IFN-a and 3 stimulate T-cell
proliferation (Tough et al 1997), as do the cytokines IL-ip (Vogel et al 1983) and
IL-15 (Grabstein et al 1994). Finally, since the in vivo proliferation of T-cells is
absent in mice of the C3H/HeJ strain, and since functional TLR-4 is not required
for presentation of antigens to T-cells, it is most likely that the response is
occuring as a result of TLR4 mediated recognition of LPS, ana not from antigen
presentation of LPS to T-cells.
4.3.4 Human buffv coat PBMC responses to LPS
In order to attempt a large number of experiments, a readily available source of
human PBMC was required. As buffy coats derived from the blood transfusion
service had reliably provided viable monocytes for investigations of innate
immunity in earlier experiments, these were chosen as the source of human
cells in the first series of experiments looking for LPS-reactive human T-cells.
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Figure 4.13 shows that while viable T-cells are clearly present in these
preparations (there is strong proliferation in response to ConA), there is no
proliferation in response to either LPS or heat-killed E.coli at either 3 days or 5
days incubation. PBMC from several different donors revealed the same lack of
reactivity.
It was then considered that since E.coli K12 is a laboratory strain not widely
encountered in the natural setting, perhaps lack of prior exposure to this antigen
may be responsible for the lack of response seen in these individuals. For this
reason, the next series of experiments investigated responses to LPS of E.coli
R1, E.coli R2, E.coli R3, E.coli R4 and B.fragilis - all of which may be commonly
found in the gut or are associated with infection (Gransden et al 1990, Patrick
1993). Figures 4.14 + 4.15 show the profile of response to these antigens,
displayed by one such donor and which is broadly representative of all similar
experiments. Proliferation in response to these antigens was seen to be no
different from that of control cultures incubated for 3, 4 or 6 days. Challenge with
the LPS of Klebsiella aerogenes, K.friedlander, K.pneumoniae, Salmonella
minnesota or S.typhimurium in many similar experiments also revealed no
significant proliferative response.
As the molecule CD1 has been shown capable of mediating T-cell recognition of
other lipids (discussed later), it was considered that perhaps the presence of
CD1+ve cells was required for T-cell proliferation in response to LPS. This was
achieved in the next series of experiments by supplementing the culture medium
with 200IU/ml of the cytokines IL-4 and GM-CSF, which together induce the
expression of CD1a,b and c on human monocytes (Beckman et al 1994 and
Figure 4.29).
Treatment of whole PBMC in this fashion did not result in the proliferation of
cells in response to LPS at 4 days (Figure 4.16a) or at 6 days (Figure 4.16b).
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Preincubating cells with the two cytokines for 3 days before LPS challenge also
resulted in no proliferation (Figure 4.17), despite clear evidence of high levels of
expression of the type I CD1 molecules (ie CD1a,b and c) on similarly treated
cells (Figure 4.29).
Then, as concurrent experiments had revealed that use of foetal calf serum was
capable of stimulating production of cytokines from unchallenged monocytes,
foetal calf serum from three different manufacturers was tested (Gibco, Sigma
and Imperial laboratories). None of these could remove the high (>1,000cpm)
background proliferation observed in all experiments (Figure 4.19).
Suspecting that trace amounts of endotoxin may be present in the foetal calf
serum that was activating both a cytokine and a proliferative response, further
experiments were performed using buffy coat PBMC supplemented with pooled
human serum. These experiments demonstrated much lower background
counts, but did not reveal any responses to LPS higher than unstimulated cells.
4.3.5 Comparison with earlier studies
At this stage, a reference was found in the literature that demonstrated human
T-cell proliferation in response to LPS. In contrast to previously held dogma,
Mattern and colleagues had shown that a small proportion of human T-cells are
capable of responding to LPS (Mattern et al 1994). Their explanation for the
reason that this had not been seen before (Peavy et al 1970, Greaves et al
1974, Ellner et ai 1989, Fauci et al 1976) was because other groups had
measured proliferation at the more usual timepoint of 3-4 days, whereas the
proliferation they measured was reached after seven days incubation.
This response seemed to be mediated by antigen presentation, as T-cell
proliferation was absolutely dependent on contact with accessory monocytes
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and the frequency of responding T-cells of between 1:400 and 1:1100 was in the
range of antigen (not mitogen) specific T-cells.
Only 50% of the healthy volunteers they tested, however, responded with an
appreciable proliferation in response to LPS - a finding they later related to the
presence or absence of CD34+ blood stem cells (Mattern et al 1999).
As the same experimental conditions used by Mattern to demonstrate LPS
reactive T-cells (seven days incubation and use of human serum) had already
been tried several times in the present study, it was concluded that some
property of the buffy coats may be hindering response to LPS. With hindsight, it
is possible that the CD34+ blood stem cells that are required for this proliferation
are absent from or unviable in buffy coat preparations, either as a result of the
purification method of the cells at source, or the storage system employed
following purification.
For this reason, subsequent experiments investigated the responses of PBMC
freshly isolated from human venous blood.
4.3.6 Human PBMC responses to LPS
Figure 4.20 shows that freshly isolated PBMC are capable of mounting a strong
proliferative response towards the LPS of E.coli R1, E.coli R2, E.coli R3, E.coli
R4, Klebsiella aerogenes and K.friedlander. This figure also shows that a slight
proliferative response can also be made by human PBMC to the lipoteichoic
acid of the Gram-positive organism S.aureus, a finding which has not been
documented before.
Figure 4.21b shows that human PBMC proliferation in response to LPS is
minimal before six days incubation, reaching a maximum proliferative response
between days 7 ana 8, then tailing off with residual activity remaining after
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almost two weeks incubation. The kinetics of this response are therefore starkly
different to the response made by PBMC to the mitogen ConA, which
demonstrates maximum proliferation by day 3, but tails off quickly to background
levels by days 6-7 (Figure 4.21a). This provides further evidence for the fact that
LPS acting as an antigen, not as a mitogen in these cells.
T-cell responses to LPS occurred in a dose dependent manner, with all
concentrations above 0.01ng/ml inducing proliferation (Figure 4.23). This is of a
similar order to the concentration of LPS required to initiate a TNF-a response
from human monocytes (Table 3.4), and therefore does not preclude the
possibility that both cell types may be employing the same type of receptor for
recognition of LPS.
Flowever, if this was the case and the monocyte receptor for LPS (TLR4) was
responsible for the proliferation observed in the PBMC, it follows that the
responses to LPS of different core types should all be largely similar, as only the
presence of lipid A is recognised by TLR4 (Heine et al 1999, Medzhitov et al
1997). By contrast, Figures 4.24 a-f show that PBMC responses to LPS from
E.coli R1, E.coli R2, E.coli R3, E.coli R4, B.fragilis, S.minnesota, S.typhimurium
and LTA of S.aureus vary considerably between the six healthy volunteers
tested. For example, while the PBMC of some donors respond to most core
types of LPS (e.g. donor 3, Figure 4.24b), others respond to only a handful (e.g.
donor 5, Figure 4.24d). These results suggest that an antigen specific reaction is
occuring that is not dependent on the lipid A component of the LPS.
In order to verify Matterns finding that the cells proliferating in these assays are
T-cells (Mattern et al 1994), PBMCs were taken from one volunteer (donor 4),
exposed to E.coli R3 LPS for 7 days and flow cytometry performed on the
markers CD3, CD14 and CD19 (markers for T-cells, monocytes and B-cells
respectively). Figure 4.25 shows that a small expansion (~15%) of the CD3 and
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CD19+ve cells is seen following LPS stimulation, while CD14+ve cells are seen
to be slightly reduced in number after LPS stimulation. However, as the staining
of the control culture is also increased following LPS incubation, the significance
of this assay might be questioned. Repeat of Matterns transwell experiments
involving plating of antibody purified monocytes and T-cells would be the best
way to verify the fact that T-cells are responsible for the proliferation observed in
PBMC exposed to LPS.
It was then determined whether the proliferative responses to different LPS core
types varied from day to day. The same 7 healthy volunteers were assayed on
either one or two further occasions. Figures 4.26 a-f show that while some
donors exhibit a very similar profile from day to day (eg. donor 2, Figure 4.26a),
others varied somewhat (eg. donor 5, fig 4.26d). The non-responder did not
respond on any of the three days, once again as a result of a high background
proliferation (Figure 4.26f). One possible explanation for the observation that
responses to particular core types may rise and fall with time is that individuals
may be constantly exposed to these antigens. Recent exposure to particular
core types, either as a result of asymptomatic infection or translocation of
specific LPS/bacteria from the gut may result in amplification of memory T-cells
specific for these epitopes. Some dynamic interplay may also exist between the
expansion of these cells and the establishment of gut-mediated tolerance which
may ultimately result in down-regulation of responses to certain epitopes.
Further work is required to establish the clinical relevance of T-cell reactivities
towards individual core types.
Next, as immunological status has been shown to have a strong impact on the
outcome of pre-surgical patients (Christou et al 1984, Christou et al 1989,
Johnson et al 1979, Adami et al 1980, Christou et al 1983), an average of all of
the stimulation indexes for each LPS tested was calculated to provide a more
general measure of the day to day variation of overall LPS responsiveness
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among the volunteers. Figure 4.27 shows that the overall responsiveness of
individuals may either rise or fall with time, in some cases quite dramatically.
Donor 1, for example, makes a clear transition from responder status to non-
responder status. This observation prompted the hypothesis that should LPS-
reactive T-cells turn out to play a protective role in either Gram-negative
infection or endotoxaemia, then individuals may enter phases of LPS
hyporeactivity during which they are at greater risk of complications from these
pathologies. Should the mechanism be found for this particular
immunosuppression, then therapeutic interventions may be devised to help
reduce the likelihood of such episodes. This hypothesis is discussed in detail in
the following chapter.
4.3.7 Human T-cell responses to liposomal LPS
As there is a role for T-cells in the regulation of antibody formation (Stavnezer
1996, Fujieda et al 1998), the capacity of the vaccine to induce a T-cell
response was assessed. Figure 4.28 shows that the vaccine is capable of
inducing T-cell proliferation at LPS concentrations as low as 10ng/ml. This
concentration is approximately 100 fold lower than that seen capable of initiating
a cytokine response in human monocytes (Table 3.3). This finding provides
further evidence that T-cell recognition of LPS is not dependent on the same
receptor utilised by monocytes to detect LPS - TLR4. Instead, presentation of
internalised liposomal LPS by antigen presenting cells to T-cells is the more
likely explanation for this enhanced sensitivity to liposomal LPS.
4.3.8 Role of CD1 in T-cell responses to LPS
In order to further investigate the possibilty that LPS or processed fragments of
LPS were being presented to T-cells, the role of CD1 was investigated. The CD1
family of molecules share striking sequence and structural homology to the MFIC
class of molecules (Park et al 2000) and have been found to be present in every
mammalian species so far examined (Calabi et al 1989). Humans, for example,
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are seen to possess genes for five CD1 molecules (CD1 a,b,c,d and e which is
not expressed) and mice only CD1d (Cattoretti et al 1989, Balk et al 1991).
CD1 molecules are now regarded as having a key role in generating T-cell
immunity against mycobacterial lipid antigens (Pamer et al 1999). Several
studies have demonstrated CD1 mediated presentation of lipid antigens to T-
cells including the mycobacterial lipids mycolic acid (Beckman et al 1994,
Porcelli et al 1992), lipoarabinomannan (Sieling et al 1995), glucose
monomycolate (Moody et al 1997), phosphoisoprenoids (Moody et al 2000),
human self ceramides (Shamshiev et al 1999) and, curiously, the marine sponge
lipid a-galactosylceramide (Natori et al 1994). Interestingly, all CD1-presented
lipids have been shown to share a common general architecture. This can be
broadly characterised as a di-acyl hydrophobic region attached to a strongly
polar headgroup - the only exception so far documented being the monoacyl
nature of the CD1c ligand glucose monomycolate (Park et al 2000).
4.3.9 Can LPS bind to CD1?
In order to answer the question of whether or not CD1 -mediated presentation of
LPS is possible, the question of whether or not LPS is capable of binding to CD1
must be answered first. Structurally speaking, the general architecture of LPS is
similar to that displayed by the other CD1 ligands: namely a hydrophobic region
attached to a highly polar headgroup. However, as a result of the substitution of
the diglucosamine backbone with between 5 and 7 acyl chains, it is likely that
unmodified LPS monomers will be too bulky to fit inside the di-acyl adapted
groove of CD1. This conflict is further borne out by the observation that
enterobacterial LPS monomers have been estimated to have a width of
approximately 20-24A and a length of roughly 12-14A (Alexander et al 2001).
This compares with the hydrophobic binding pocket of CD1 which is
approximately 30A long by 10-15A wide (Zeng et al 1997). Thus, it appears that
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while LPS molecules are not too long to fit inside the CD1 binding groove, they
are too wide.
However, enzymatic degradation of LPS within cells may well be capable of
trimming sufficient acyl and glycan groups to form a ligand of the appropriate
structure and size for binding to CD1 (as discussed in section 1.4). Such
enzymes have certainly been reported to be present in the intracellular
compartments through which LPS trafficks (Prigozy et al 1997, Sugita et al
1996, Ernst et al 1998, Thiemblemont et al 1998, Detmers et al 1996).
Mattern et al dismissed the possibility of CD1 -mediated T-cell recognition in their
studies of LPS-dependent T-cell proliferation, citing a lack of expression of CD1
of either monocytes or CD34+ blood stem cells (Mattern et al 1999). However,
as more recent studies have suggested that CD1 may be expressed
constitutively at least at low levels on monocytes (Porcelli et al 1999), and
CD1a,b and c on cytokine differentiated monocytes (Porcelli et al 1992, Kasinerk
et al 1993), the possibility that CD1 presentation of LPS may be responsible for
the T-cell proliferation seen in earlier experiments was investigated in the
following study.
Expression of CD1 was not detected on resting monocytes (Figure 4.29), but all
type I CD1 molecules were seen to be strongly expressed on IL-4/GM-CSF-
treated monocytes (Figure 4.29). This induction could not be achieved using
stimulation of PBMC with E.coli R3 LPS (Figure 4.30). This may be because the
cytokines produced by PBMC in response to LPS are typically Th1 biased,
whereas IL-4 and GM-CSF are more commonly associated with a Th2
response, which may be more likely to occur in response to a natural infection
with bacteria.
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Attempts to block the proliferation of PBMC in response to LPS using antibodies
directed against CD1 isomers failed (Figure 4.31). Curiously, the monoclonal
antibody specific for CD1d appears to actually increase the proliferative
response of the PBMC to LPS. This antibody may exhibit cross binding activity
with other activating molecules on these cells. The failure of a-CD1a,b,c mAbs
to block proliferation may be due to internalisation of CD1-bound antibody due to
cycling of membrane proteins over the relatively long seven day incubation, or
the antibodies may target epitopes on the CD1 molecules that do not sterically
hinder their interaction with either antigen or T-cells.
In order to determine whether or not LPS could bind to CD1, E.coli R1 LPS was
added to human monocytes treated with cytokines to induce expression of
CD1a,b and c. Presence of bound LPS on the surface of cells was probed for
with a monoclonal antibody previously demonstrated to bind to the core
structures of a wide range of enteric LPS, including E.coli R1 core structures (Di
Padova et al 1993). This method did not reveal the presence of LPS on the
surface of the cells after seven days incubation (Figure 4.33). The monoclonal
antibody used also shows non-specific binding to cells that have been treated
with IL-4 and GM-CSF. It remains possible, however, that the reason no core
epitopes were detected on the surface of the cells by this antibody is that
enzymic processing of internalised LPS may have resulted in alteration or
removal of core epitopes that are required for antibody binding to unprocessed
LPS molecules.
Protein extracts of IL-4/GM-CSF treated monocytes were then assessed for
CD1 content. Figure 4.34 shows that abundant proteins are present in these
extracts, particularly in the 41-55 kDa range expected to contain all CD1
isotypes, though repeated immunoblots of these gels using the same anti-CD1
monoclonals used in blocking experiments and flow cytometry could not reveal
the presence of CD1.
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Dot blots of the same protein extracts revealed the expected high expression of
MHC-II and lack of expression of CD3, but no expression of CD1a,b,c or d could
be seen in these assays (Figure 4.35). These antibodies clearly work in flow
cytometry (Figure 4.29) but appear incapable of binding to CD1 in the context of
nitrocellulose. This technical difficulty could not be overcome, and as a result co-
immunoprecipitation experiments of LPS and CD1 could not be performed.
In summary, there is evidence that LPS or fragments of LPS are presented to T-
cells. The fact that T-cell proliferation in response to LPS is dependent on cell
contact with accessory cells (Mattern et al 1994), and that these cells are
present only at frequencies typical of antigen specific T-cells (~1:1,000) support
this hypothesis. The finding of this study that responses appear to be directed
against core epitopes of LPS and not lipid A appear to rule out TLR4-mediated
activation of the T-cells, as does the observation that T-cell responses to
liposomal LPS occur at concentrations approximately 100-fold lower than those
recognised by monocytes. However, the mechanisms by which presentation of
LPS to T-cells is achieved remain unknown, and further work is required to
determine whether or not LPS or breakdown products of LPS are capable of
being presented by CD1.
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CHAPTER 5
IMMUNE RESPONSES TO LIPOPOLYSACCHARIDE IN SEPSIS
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5.1 Introduction
In order to understand the role played by the host immunological responses to
LPS in outcome from disease, a prospective series of patients presenting with
inflammatory disease associated with endotoxin exposure were recruited into
the following study.
The capacity of patients' PBMC to proliferate in response to a panel of LPS was
measured, as was the ability to proliferate in response to lipoteichoic acid of
S.aureus and the T-cell mitogen ConA. Toll receptor-4 genotype was analysed
and measurements of antibodies of the IgG and IgM subclass specific for the
core structures of LPS were also made. Clinical parameters investigated
included diagnosis, length of stay, whole blood neutrophil and lymphocyte
counts, SIRS score, SOFA score, Glasgow score and presence or absence of
sepsis on admission.
The following chapter investigates the possible relationships between these
biological and clinical indicators and compares the responses of these patients
with those of a control group of healthy volunteers.
5.2 Results
5.2.1 Patient and control recruitment
Over the course of 14 months, emergency surgical patients were enrolled for
the following study if a clinical diagnosis was confirmed consistent with
abdominal inflammation together with a documented source of infection. In total,
40 patients were enrolled with six patients agreeing to follow up blood sampling
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on either one or two occasions. Five of the patients enrolled in the study had to
be excluded from subsequent analysis on the grounds of more generalised
inflammatory conditions. These diagnoses included 1 torted ovarian cyst, 1
hiatus hernia, 1 probable urinary tract infection, 1 case of pelvic inflammatory
disease and 1 case that was undiagnosed.
Of the 35 remaining patients, a largely complete data set is only currently
available for 27 patients. This cohort consists of 10 cases of appendicitis, 8
cases of pancreatitis, 5 cases of cholecystitis, 2 cases of diverticulitis and 2
cases of Crohn's disease. In the following analysis, data from the patients
diagnosed with appendicitis, cholecystitis or diverticulitis have been pooled to
form a further patient grouping, hereafter refered to as the A+C+D cohort. Data
from these diagnoses in particular have been pooled since all of these cases
involve inflammation of a lumenal organ and a likely resultant Gram-negative
infection. Forty healthy controls were also enrolled.
5.2.2 Patient and control demographics
The 27 patients enrolled had a median age of 39 years (range 13-80 years),
which was not significantly different from the median age of the control cohort
(32 years, range 21-63). Only the 2 diverticulitis and 2 Crohn's patients showed
significantly different mean age than the control population (diverticulitis
patients were older at mean age 68, p<0.05; and Crohn's patients younger at
mean age 16, p<0.05). The sex ratio of the whole patient group (17 males to 10
females) was not significantly different from the sex ratio of the control group
(18 males to 22 femaies). These data are summarised in Tabie 5.1.
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Table 5.1 Patient and control demographics
Patient n Median Age Sex *P **p
Group: (range): (M:F)
Controls: 40 32 (21-63) 18:22 - -
All: 27 39 (13-80) 17:10 0.490 -
Appendicitis: 10 32 (18-52) 8:2 0.489 0.238
Cholecystitis: 5 53 (20-68) 1:4 0.626 0.795
Diverticulitis: 2 68 (63-73) 1:1 0.021 0.132
Crohn's: 2 16 (13-20) 1:1 0.020 0.093
Pancreatitis: 8 62 (19-80) 6:2 0.055 0.223
A+C+D: 17 39 (18-73) 10:7 0.675 0.791
A+C+D subgroup represents data pooled from appendicitis, cholecystitis and
diverticulitis patients. * p-values represent comparison of the median age of
each group with the control population using the Mann-Whitney U-test. ** p-
values represent comparison of the median age of each patient subgroup with
that of the entire patient group using the Mann-Whitney U-test.
5.2.3 Patient clinical scores
On enrolment each patient was assessed for systemic inflammatory response
syndrome (SIRS score), sepsis-related organ failure assessment (SOFA score)
and if presenting with acute pancreatitis or Crohn's disease the modified
Glasgow score or simple index of Crohn's activity respectively. As a result of
incomplete filling in of forms, Glasgow scores are only available for 4 of the 8
pancreatitis patients and only one of the 2 Crohn's patients was assessed on
the Crohn's index. Data relating to the concentrations of neutrophils and
lymphocytes in patients whole blood were also recorded from the routine
hospital blood analyses of 12 patients.
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5.2.4 Patient SIRS scores
All patients were assessed on enrolment for systemic inflammatory response
using the SIRS score of Bone et al (1992). Scores ranged from 0 to a maximum
score of 4 (median score 1). 13 patients had a score of 2 or more and since all
patients enrolled had a documented source of infection, are hence defined as
suffering from sepsis. SIRS scores and frequency of diagnosis of sepsis for
each patient group are summarised in Table 5.2. No individual patient subgroup
had a SIRS score significantly higher or lower than the whole group median.
The number of patients with a SIRS score of 2 or more was approximately half
of the whole group number for each patient subgroup.
Table 5.2 Patient SIRS scores by subgroup
Patient group: n Median SIRS score (range): * p SIRS score > 1
All: 27 1 (0-4) - 13
Appendicitis: 10 2 (0-4) 0.442 5
Cholecystitis: 5 2 (0-3) 0.876 3
Diverticulitis: 2 1 (0-2) 0.606 1
Crohn's: 2 0 (0-0) - 0
Pancreatitis: 8 2 (0-3) 0.798 4
A+C+D: 17 2 (0-4) 0.763 9
A+C+D subgroup represents data pooled from appendicitis, cholecystitis and
diverticulitis patients. SIRS > 1 column shows number of patients diagnosed
with sepsis within each subgroup. * p-values represent comparison of the SIRS
scores of each patient subgroup with the whole patient population using the
Mann-Whitney U-test. Number of patients with SIRS scores greater than 1
represent subset diagnosed with sepsis.
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5.2.5 Patient SOFA scores
All patients were assessed on enrolment for systemic organ failure using the
SOFA score of Vincent et al (1996). Scores ranged from 0 to a maximum score
of 5 (median score 1). The maximum possible score on the SOFA scale is 24.
No individual subgroup of patients showed a significantly higher or lower organ
failure score than the group average. SOFA scores of each patient subgroup
are summarised in Table 5.3.
Table 5.3 Patient SOFA scores by subgroup
Patient group: n Median SOFA score (range): * p
AN: 27 1 (0-5) -
Appendicitis: 10 1 (0-3) 0.811
Cholecystitis: 5 0 (0-0)
Diverticulitis: 2 2 (1-3) 0.366
Crohn's: 2 1 (0-1) 0.636
Pancreatitis: 8 2 (0-5) 0.336
A+C+D: 17 0 (0-3) 0.655
A+C+D subgroup represents data pooled from appendicitis, cholecystitis and
diverticulitis patients. * p-values represent comparison of the SOFA scores of
each patient subgroup with the whole patient population using the Mann-
Whitney U-test.
5.2.6 Patient length of stay
As mortality was low in this cohort (1 pancreatitis patient), length of stay was
chosen as an objective measurement of patient outcome. In the whole patient
group, length of stay ranged from 2 days to 31 days with a median stay of 4
days (Table 5.4). Only the group of appendicitis patients stayed a sigificantly
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shorter time in hospital than the median time stayed by the entire patient cohort
(2-5 days, median stay 3 days).
Table 5.4 Patient length of stay by subgroup
Patient group: n Median Stay (range): *P
All: 27 4 (2-31) -
Appendicitis: 10 3 (2-5) 0.017
Cholecystitis: 5 5 (4-13) 0.406
Diverticulitis: 2 11 (8-13) 0.245
Crohn's: 2 14 (12-15) 0.121
Pancreatitis: 8 4 (3-31) 0.409
A+C+D: 17 4 (2-13) 0.341
A+C+D subgroup represents data pooled from appendicitis, cholecystitis and
diverticulitis patients. * p-values represent comparison of the lengths of stay of
each patient subgroup with the whole patient population using the Mann-
Whitney U-test.
5.2.7 Glasgow scores of pancreatitis patients
Pancreatitis patients were assessed for severity of disease using the modified
Glasgow score of Blarney et al (1984). Of the 8 pancreatitis patients enrolled,
scores are available for 4 and were seen to have a range of 0-4 and a median
of 1. The maximum possible score on the Glasgow scale is 8.
5.2.8 Crohn's index scores of Crohn's patients
Of the 2 Crohn's' patients enrolled in the study, only one was assessed for
severity of disease using the simple index of Crohn's activity proposed by
Harvey et al (1980). This patient showed a score of 7 (maximum possible 33) on
this scale.
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5.2.9 Patient whole blood neutrophil and lymphocyte counts
Neutrophil and lymphocyte count data are available for 12 of the 27 patients.
Median cellular concentrations recorded for each patient subgroup are
summarised in Table 5.5. Each patient subgroup is seen to have a substantially
raised concentration of neutrophils when compared to that of the healthy
population (normal range 2.0 - 7.5 cells/pl), and a slightly reduced
concentration of lymphocytes (normal range 1.5 - 4.0 cells/pl). Comparison
between patient subgroups revealed no individual subgroup to have
significantly higher or lower neutrophil and lymphocyte counts than the group
average.
Table 5.5 Neutrophil and lymphocytes counts of patient subgroups
Patient Group: n Neutrophils * p Lymphocytes ** p
(range): (range):
All: 12 13.7 (6.1-17.4) - 0.82 (0.4-2.3) -
Appendicitis: 7 13.9 (9.8-17.4) 0.352 1.07 (0.4-2.3) 0.353
Cholecystitis: 0 - - - -
Diverticulitis: 1 9.4 - 0.4 -
Crohn's: 1 6.1 - 0.7 -
Pancreatitis: 3 13.5 h-"srpCOS- 0.773 0.7 (0.6-1.0) 0.564
A+C+D: 8 13.9 (9.4-17.4) 0.563 1.0 (0.4-2.3) 0.671
All counts are represented in cells / pi. A+C+D subgroup represents data
pooled from appendicitis, cholecystitis and diverticulitis patients. * p-values
represent comparison of the neutrophil counts of each patient subgroup with the
whole patient population using the Mann-Whitney U-test. ** p-values represent
comparison of the lymphocyte counts of each patient subgroup with the whole
patient population using the Mann-Whitney U-test.
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5.2.10 Patient and control proliferative responses to LPS
PBMC from patients and controls were exposed to E.coli R1, E.coli R2, E.coli
R3, Bacteroides fragilis, Klebsiella pneumoniae and Salmonella typhimurium
LPS and the proliferation of the cells in response to these stimuli measured by
thymidine incorportion. Additionally, cells of some patients and controls were
incubated with lipoteichoic acid (LTA) of Staphylococcus aureus or the T-cell
mitogen concanavalin-A (ConA). As the number of cells obtained from the blood
of patients was not always sufficient to provide cultures for a complete set of
experiments, the various stimuli were ranked in order of priority. Priority was
given to E.coli R1 LPS, with the following being plated in order as availability of
cells allowed: E.coli R2 LPS, E.coli R3 LPS, S.aureus LTA, B.fragilis LPS,
K.pneumoniae LPS and S.typhimurium LPS. In the rare cases where sufficient
cells were available for further cultures than these listed, a separate plate was
set up to measure the capacity of the T-cells to respond to ConA after three
days incubation.
Proliferative responses of patients cells to each stimuli were compared by
calculation of the stimulation index (SI) for each antigen. This was calculated as
the proliferative response (measured in counts per minute) of the challenged
cell cultures divided by the background proliferative response (also measured
in counts per minute) of unchallenged cell cultures.
5.2.11 Patient and control mean responses to all LPS
A generalised score was derived to represent the overall ability of each subject
tested to mount a proliferative PBMC response to LPS. This index was
calculated as the average of the stimulation indices for all the Gram-negative
LPS tested for that individual. Table 5.6 summarises the mean responses to
LPS of each patient and control subgroup tested. Using this measure, the
median response of the whole patient group was 3.6, which was not
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significantly less than the median response of 7.1 demonstrated by the cohort
of 40 healthy controls (p=0.15). Responses of cholecystitis and diverticulitis
patients to all LPS were higher than control responses (median SI 9.3 and 10.1
respectively), but this was not a significant difference. The most blunted
responses were seen in the appendicitis, pancreatitis and Crohn's patient
subgroups (scores of 2.2, 2.1 and 2.3 respectively), though no patient subgroup
demonstrated an overall PBMC reactivity towards LPS significantly different
from controls.
Patients and controls were then further subdivided into groups of high and low
reactivity towards LPS. According to the convention of Mattern et al (1994),
those demonstrating a stimulation index greater than 7 were classed as
responders while those with a stimulation index of less than 7 were classed as
non-responders. Using this test, 50% of healthy controls were classed as
responsive to LPS in general (Table 5.6). Frequencies of responders within the
various patient subgroups were then compared with the frequency of
responders in the healthy control population using the Chi-squared test. The
whole patient group shows a frequency of responders of 26% which, due to the
small sample size, is not significantly different from controls (p=0.086).
Similarly, despite the fact that only 10% of appendicitis patients were classed
as overall responders, this frequency is not significantly different from controls
(p=0.053).
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Table 5.6 Patient and control mean responses to all LPS
Patient Group: n Median SI (range) *P >7 <7 **p
Controls 40 7.1 (0.1-46.1) - 20 20 -
All 27 3.6 (0.4-66.4) 0.150 7 20 0.086
Appendicitis 10 2.2 (0.4-13.8) 0.085 1 9 0.053
Pancreatitis 8 2.1 (0.6-7.2) 0.054 2 6 0.364
Cholecystitis 5 9.3 (1.6-66.4) 0.448 3 2 0.958
Crohn's 2 2.3 (0.8-3.8) 0.226 0 2 0.512
Diverticulitis 2 10.1 (3.8-16.5) 0.658 1 1 0.469
A+C+D 17 3.7 (0.4-66.4) 0.469 5 12 0.254
A mean response to each of the LPS tested was derived for each individual
patient to obtain a measure of overall responsiveness. Median SI represents
the median of these scores for each of the patient groups examined. A+C+D
subgroup represents data pooled from appendicitis, cholecystitis and
diverticulitis patients. *p-values represent comparison of the mean responses
to all LPS tested for each patient subgroup with the control population using the
Mann-Whitney U-test. >7 or <7 indicates number of individuals within each
subgroup with a stimulation index greater (or less) than 7 in this assay. ** p-
values represent comparison of the frequencies of responders within each
patient subgroup and the control population using the Chi-squared test.
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5.2.12 Patient and control best response to any LPS
As it was seen that a number of patients classed as overall non-responders
showed clear responses to particular individual types of LPS, a record was kept
of the best response to any of the panel of LPS applied to the cells of each
patient. The median best response to any LPS for the control group was 12.7
(range 0.2 - 87), while that of the whole patient group was 4.6 (range 0.7 -171).
No significant difference in median stimulation index or frequency of responders
was observed between the various patient subgroups and the control cohort
(Table 5.7).
Table 5.7 Patient and control best response to individual LPS types
Patient Group: n Median SI (range) * P >7 <7 ** p
Controls 40 12.7 (0.2-87.0) - 24 16 -
All 27 4.6 (0.7 -171.0) 0.156 11 16 0.194
Appendicitis 10 4.6 (0.7-20.7) 0.152 3 7 0.178
Pancreatitis 8 4.0 (0.8-32.6) 0.158 3 5 0.435
Cholecystitis 5 9.7 (2.8-171.0) 0.600 3 2 0.628
Crohn's 2 2.7 (1.0-4.4) 0.165 0 2 0.347
Diverticulitis 2 17.9 (8.5-27.2) 0.637 2 0 0.696
A+C+D 17 6.7 (0.7-171.0) 0.536 8 9 0.542
A+C+D subgroup represents data pooled from appendicitis, cholecystitis and
diverticulitis patients. * p-values represent comparison of the best responses to
all LPS tested for each patient subgroup with the control population using the
Mann-Whitney U-test. >7 or <7 indicates number of individuals within each
subgroup with a stimulation index greater (or less) than 7 in this assay. ** p-
values represent comparison of the frequencies of responders within each
patient subgroup and the control population using the Chi-squared test.
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5.2.13 Patient and control responses to E.coli R1 LPS
27 patients and 40 controls were assessed for PBMC proliferation in response
to E.coli R1 LPS. The median response for the control population was 5.6
(range 0.1 - 43.4), while the median response of the whole patient group was
significantly lower at 1.8 (range 0.3 - 25.6, p=0.006). Every patient subgroup
demonstrated a lower response to E. coli R1 LPS than healthy controls, though
only the appendicitis, pancreatitis and A+C+D subgroups demonstrated
significantly lower responses to E.coli R1 LPS than healthy controls (Table 5.8).
The frequency of reponders in the whole patient group was also significantly
lower than that of the control population (p=0.035).
Table 5.8 Patient and control PBMC response to E.coli R1 LPS
Patient Group: n Median SI (range) * P >7 <7
**
p
Controls 40 5.6 (0.1 -43.4) - 15 25 -
All 27 1.8 (0.3-25.6) 0.006 3 24 0.035
Appendicitis 10 1.3 (0.4-6.5) 0.028 0 10 0.054
Pancreatitis 8 0.9 (0.4-18.3) 0.028 1 7 0.338
Cholecystitis 5 1.9 (0.3-25.6) 0.613 2 3 0.704
Crohn's 2 2.7 (1.0-4.4) 0.425 0 2 0.746
Diverticulitis 2 2.6 (2.2-3.1) 0.359 0 2 0.746
A+C+D 17 1.9 (0.3-25.6) 0.035 2 15 0.104
A+C+D subgroup represents data pooled from appendicitis, cholecystitis and
diverticulitis patients. * p-values represent comparison of the responses to
E.coli R1 LPS of each patient subgroup with the control population using the
Mann-Whitney U-test. >7 or <7 indicates number of individuals within each
subgroup with a stimulation index greater (or less) than 7 in this assay. ** p-
values represent comparison of the frequencies of responders within each
patient subgroup and the control population using the Chi-squared test.
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5.2.14 Patient and controi responses to E.coli R2 LPS
26 patients and 39 controls were assessed for PBMC proliferation in response
to E.coli R2 LPS. The median response for the control population was 7.6
(range 0.1 - 74.6), while the median response of the whole patient group was
2.7 (range 0.3 - 73.9). Responses of cholecystitis and diverticulitis patients to
E.coli R2 LPS were higher than control responses (median SI 9.5 and 11.1
respectively), but this was not a significant difference. No significant differences
were observed between patient subgroup and control responses to LPS when
considering either median response or frequency of responders (Table 5.9).
Table 5.9 Patient and control PBMC response to E.coli R2 LPS
Patient Group: n Median SI (range) * P >7 <7
**
p
Controls 39 7.6 (0.1 -74.6) - 20 19 -
All 26 2.7 (0.3-73.9) 0.258 8 18 0.167
Appendicitis 10 1.7 (0.3-20.0) 0.121 2 8 0.156
Pancreatitis 7 2.7 (0.6-18.2) 0.321 2 5 0.486
Cholecystitis 5 9.5 (2.8-73.9) 0.318 3 2 0.914
Crohn's 2 2.6 (1.0-4.3) 0.238 0 2 0.490
Diverticulitis 2 11.1 (2.0-20.2) 0.856 1 1 0.490
A+C+D 17 2.8 (0.3-73.9) 0.575 6 11 0.417
A+C+D subgroup represents data pooled from appendicitis, cholecystitis and
diverticulitis patients. * p-values represent comparison of the responses to
E.coli R2 LPS of each patient subgroup with the control population using the
Mann-Whitney U-test. >7 or <7 indicates number of individuals within each
subgroup with a stimulation index greater (or less) than 7 in this assay. ** p-
values represent comparison of the frequencies of responders within each
patient subgroup and the control population using the Chi-squared test.
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5.2.15 Patient and control responses to E.coli R3 LPS
25 patients and 39 controls were assessed for PBMC proliferation in response
to E.coli R3 LPS. The median response for the control population was 7.6
(range 0.1 - 40.6), while the median response of the whole patient group was
3.6 (range 0.3 -171.0). Responses of cholecystitis and diverticulitis patients to
E.coli R3 LPS were higher than responses of healthy controls (median SI 11.4
and 17.9 respectively), but this was not a significant difference. No significant
differences were observed between patient subgroup and control responses to
LPS when considering either median response or frequency of responders,
despite the very low response of the appendicitis patient subgroup to E.coli R3
LPS (median SI 1.6; Table 5.10).
Table 5.10 Patient and control mean PBMC response to E.coli R3 LPS





Controls 39 7.6 (0.1 -40.6) - 20 19 -
All 25 3.6 (0.3-171.0) 0.259 9 16 0.347
Appendicitis 10 1.6 (0.3-20.7) 0.076 2 8 0.156
Pancreatitis 8 3.6 (0.6-29.4) 0.359 2 6 0.333
Cholecystitis 5 11.4 (3.4-171.0) 0.268 3 2 0.914
Crohn's 2 1.6 (0.5-2.6) 0.155 0 2 0.490
Diverticulitis 2 17.9 (8.5-27.2) 0.318 2 0 0.535
A+C+D 17 6.4 (0.3-171.0) 0.611 7 10 0.685
A+C+D subgroup represents data pooled from appendicitis, cholecystitis and
diverticulitis patients. * p-values represent comparison of the responses to
E.coli R3 LPS of each patient subgroup with the control population using the
Mann-Whitney U-test. >7 or <7 indicates number of individuals within each
subgroup with a stimulation index greater (or less) than 7 in this assay. ** p-
values represent comparison of the frequencies of responders within each
patient subgroup and the control population using the Chi-squared test.
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5.2.16 Patient and control responses to B.fraailis LPS
16 patients and 37 controls were assessed for PBMC proliferation in response
to B.fragilis LPS. The median response for the control population was 5.0
(range 0.1 - 85.5), while the median response of the whole patient group was
2.9 (range 0.3 - 23.6). Responses of cholecystitis patients to B.fragilis LPS were
higher than responses of healthy controls (median SI 22.1 vs 5.0), but this was
not a significant difference. The lowest median SI was once again displayed by
the appendicitis patient subgroup (2.2, not significant). No significant
differences were observed between other patient subgroup and control
responses to LPS when considering either median response or frequency of
responders (Table 5.11).
Table 5.11 Patient and control PBMC response to B.fraailis LPS
Patient Group: n Median SI (range) *P >7 <7 ** p
Controls 37 5.0 (0.1 -85.5) - 14 23 -
All 16 2.9 (0.3-23.6) 0.854 6 10 0.775
Appendicitis 7 2.2 (0.7-9.0) 0.847 2 5 0.969
Pancreatitis 5 2.9 (0.3-9.2) 0.484 1 4 0.776
Cholecystitis 3 22.1 (7.7 -23.6) 0.057 3 0 0.137
Crohn's 0 - - - - -
Diverticulitis 1 1.9 - 0 1 0.782
A+C+D 11 2.9 (0.7-23.6) 0.492 5 6 0.918
A+C+D subgroup represents data pooled from appendicitis, cholecystitis and
diverticulitis patients. * p-values represent comparison of the responses to
B.fragilis LPS of each patient subgroup with the control population using the
Mann-Whitney U-test. >7 or <7 indicates number of individuals within each
subgroup with a stimulation index greater (or less) than 7 in this assay. ** p-
values represent comparison of the frequencies of responders within each
patient subgroup and the control population using the Chi-squared test.
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5.2.17 Patient and control responses to K.oneumoniae LPS
16 patients and 36 controls were assessed for PBMC proliferation in response
to K.pneumoniae LPS. The median response for the control population was 5.0
(range 0.1 - 36.1), while the median response of the whole patient group was
2.2 (range 0.2 - 55.3). The appendicitis patient subgroup showed the lowest
proliferative response to K.pneumoniae LPS (SI = 1.0), which was significantly
lower than that seen in the healthy controls (p=0.048). Responses of
cholecystitis patients to K.pneumoniae LPS were higher than responses of
healthy controls (median SI 11.5 vs 5.0), but this was not a significant
difference. No significant differences were observed between other patient
subgroup and control responses to LPS when considering either median
response or frequency of responders (Table 5.12).
Table 5.12 Patient and control PBMC response to K.pneumoniae LPS
Patient Group: n Median SI (range) * P >7 <7 ** p
Controls 36 5.0 (0.1 -36.1) - 12 24 -
All 16 2.2 (0.2-55.3) 0.234 4 12 0.783
Appendicitis 7 1.0 (0.2-11.2) 0.048 1 6 0.579
Pancreatitis 5 1.4 (0.3-20.8) 0.449 1 4 0.930
Cholecystitis 3 11.5 (2.5-55.3) 0.268 2 1 0.596
Crohn's 0 - - - - -
Diverticulitis 1 4.4 - 0 1 0.704
A+C+D 11 2.5 (0.2-55.3) 0.309 3 8 0.994
A+C+D subgroup represents data pooled from appendicitis, cholecystitis and
diverticulitis patients. * p-values represent comparison of the responses to
K.pneumoniae LPS of each patient subgroup with the control population using
the Mann-Whitney U-test. >7 or <7 indicates number of individuals within each
subgroup with a stimulation index greater (or less) than 7 in this assay. ** p-
values represent comparison of the frequencies of responders within each
patient subgroup and the control population using the Chi-squared test.
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5.2.18 Patient and control responses to S.tvphimurium LPS
16 patients and 36 controls were assessed for PBMC proliferation in response
to S.typhimurium LPS. The median response for the control population was 6.0
(range 0.1 - 87.0), while the median response of the whole patient group was
3.8 (range 0.4 - 50.2). The lowest response to S.typhimurium LPS was
observed in the appendicitis patient subgroup (SI = 1.5), but this was not
significantly lower than the response of the healthy controls (p=0.122).
Responses of cholecystitis patients to S.typhimurium LPS were higher than
responses of healthy controls (median SI 19.8 vs 6.0), but this was not a
significant difference. No significant differences were observed between other
patient subgroup and control responses to LPS when considering either median
response or frequency of responders (Table 5.13).
Table 5.13 Patient and control PBMC response to S.tvphimurium LPS
Patient Group: n Median SI (range) * P >7 <7 **p
Controls 36 6.0 (0.1 -87.0) - 16 20 -
All 16 3.8 (0.4-50.2) 0.736 6 10 0.870
Appendicitis 7 1.5 (0.4-17.9) 0.122 1 6 0.284
Pancreatitis 5 9.0 (0.8-32.6) 0.661 3 2 0.861
Cholecystitis 3 19.8 (2.4-50.2) 0.225 2 1 0.889
Crohn's 0 - - - - -
Diverticulitis 1 2.6 - 0 1 0.890
A+C+D 11 2.6 (0.4-50.2) 0.474 3 8 0.506
A+C+D subgroup represents data pooled from appendicitis, cholecystitis and
diverticulitis patients. * p-values represent comparison of the responses to
S.typhimurium LPS of each patient subgroup with the control population using
the Mann-Whitney U-test. >7 or <7 indicates number of individuals within each
subgroup with a stimulation index greater (or less) than 7 in this assay. ** p-
values represent comparison of the frequencies of responders within each
patient subgroup and the control population using the Chi-squared test.
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5.2.19 Patient and control responses to S.aureus LTA
23 patients and 32 controls were assessed for PBMC proliferation in response
to S.aureus LTA. The median response for the control population was 2.6
(range 0.1 - 20.6), while the median response of the whole patient group was
1.8 (range 0.2 - 47.1). The cholecystitis patient subgroup showed a significantly
higher median response (21.6, range 5.0 - 47.1) to S.aureus LTA than the
healthy controls (p=0.0127). Diverticulitis patients also expressed a proliferative
response to S.aureus LTA higher than that of the healthy control cohort
(Sl=6.1), though this was not a significant difference. The appendicitis and
pancreatitis patient subgroups shared the lowest responses to S.aureus LTA
(Sl=1.4), though neither was significantly different from the response of healthy
controls. Other than the cholecystitis patient subgroup, no significant
differences were observed between patient subgroup and control responses to
LPS when considering either median response or frequency of responders
(Table 5.14).
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Table 5.14 Patient and control PBMC response to S.aureus LTA
Patient Group: n Median SI (range) *P >7 <7 ** p
Controls 32 2.6 (0.1 -20.6) - 8 24 -
All 23 1.8 (0.2-47.1) 0.805 6 17 0.824
Appendicitis 10 1.4 (0.2-10.3) 0.238 1 9 0.570
Pancreatitis 8 1.4 (0.4-12.6) 0.237 0 8 0.277
Cholecystitis 5 21.6 (5.0-47.1) 0.013 3 2 0.286
Crohn's 0 - - 0 0 -
Diverticulitis 2 6.1 (2.1 -10.1) 0.558 1 1 0.961
A+C+D 17 2.1 (0.2-47.1) 0.648 5 12 0.994
A+C+D subgroup represents data pooled from appendicitis, cholecystitis and
diverticulitis patients. * p-values represent comparison of the responses to
S.aureus LTA of each patient subgroup with the control population using the
Mann-Whitney U-test. >7 or <7 indicates number of individuals within each
subgroup with a stimulation index greater (or less) than 7 in this assay. ** p-
values represent comparison of the frequencies of responders within each
patient subgroup and the control population using the Chi-squared test.
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5.2.20 Patient and control PBMC response to ConA
Only 2 pancreatitis patients and 12 healthy volunteers provided enough cells for
measurement of proliferation in response to ConA (Table 5.15). The median
response for the control population was 88.3 (range 7.5 -151.3), while the
median response of the patient group was 1.0 (range 0.8 -1.3). In terms of both
median response and frequency of responder these two patients show
significantly lowered capacity to respond to ConA (p=0.036 and p=0.008
respectively).
Table 5.15 Patient and control PBMC response to Concanavalin-A
Patient Group: n Median SI (range) * p >7 <7 ** p
Controls 12 88.3 (7.5-151.3) - 12 0 -
Pancreatitis 2 1.0 (0.8-1.3) 0.036 0 2 0.008
A+C+D subgroup represents data pooled from appendicitis, cholecystitis and
diverticulitis patients. * p-values represent comparison of the mean proliferative
responses to ConA for each patient subgroup with the control population using
the Mann-Whitney U-test. >7 or <7 indicates number of individuals within each
subgroup with a stimulation index greater (or less) than 7 in this assay. ** p-
values represent comparison of the frequencies of responders within each
patient subgroup and the control population using the Chi-squared test.
5.2.21 Post recovery patient PBMC responses to LPS
Six patients agreed to follow up blood sampling for measurement of PBMC
responses to LPS after a period of between one and twelve weeks recovery.
Table 5.16 summarises the changes in overall responsiveness to all LPS tested
of these patients following recovery. Five of the six patients sampled showed an
increased capacity to mount a proliferative response to LPS, with a post-
recovery : pre-recovery response ratio (calculated as the post-recovery SI
divided by the SI measured at admission) ranging from 1.7 to 37.2. One
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cholecystitis patient who was a responder on admission (Sl=9.3) showed a
lower proliferative response to LPS post recovery (Sl=1.9).
Table 5.16 Post recovery patient proliferative responses to LPS
Patient Diagnosis Age Average SI Average SI Response ratio
(admission) (recovery) (recovery / admission)
1 Appendicitis 26 0.7 2.1 3.0
2 Cholecystitis 68 1.6 59.5 37.2
3 Cholecystitis 20 9.3 1.9 -4.9
4 Diverticulitis 73 1.2 16.5 13.8
5 Pancreatitis 72 1.1 1.9 1.7
6 Pancreatitis 53 1.6 4.5 2.8
5.2.22 Patient and control endogenous core IqG antibody responses to
LPS
Heparinised plasma was separated from all blood samples collected and stored
at -20°C before measurement of antibodies specific for the core epitopes of
enteric LPS (endogenous core antibodies - EndoCAb) as described in Materials
and Methods sections 2.4.6 and 2.4.7.
27 patients and 40 healthy volunteers were assessed for plasma titre of
endogenous core antibodies of the Immunoglobulin-G (IgG) isotype. The control
population was seen to have a median antibody titre of 192 median units
(MU)/ml (range 74 - 345) while the whole patient group showed a significantly
lower IgG EndoCAb titre of 154 MU/ml (range 97 - 359, p<0.05). Table 5.17
shows that the diverticulitis patients demonstrated the highest IgG EndoCAb
titre among the patient subgroups (198 MU/ml), but this was not significantly
243
different from either controls or the remainder of the patient group. Other patient
subgroups showed quite similar median IgG EndoCAb titres, ranging from 146
MU/ml (appendicitis) to 158 MU/ml (Crohn's).
Table 5.17 Median endogenous core loG antibodies of patients and controls
Patient group: n Median IgG *p
(range)
Controls 40 192.0 (74- 345) -
All 27 153.8 (97- 359) 0.0497
Appendicitis 10 145.8 (101 -223) 0.102
Pancreatitis 8 155.9 (97- 243) 0.262
Cholecystitis 5 147.1 (107 -359) 0.312
Crohn's 2 158.1 (130 -166) 0.425
Diverticulitis 2 198.2 (146 -251) 0.906
A+C+D 17 147.1 (101 -359) 0.086
A+C+D subgroup represents data pooled from appendicitis, cholecystitis and
diverticulitis patients. * p-values represent comparison of the endogenous core
IgG antibody titre for each patient subgroup with the titres of the control
population using the Mann-Whitney U-test.
5.2.23 Patient and control endogenous core IqM antibody responses to
LPS
27 patients and 40 healthy volunteers were assessed for plasma titre of
endogenous core antibodies of the Immunoglobulin-M isotype (Table 5.18). The
control population was seen to have a median antibody titre of 89 MU/ml (range
35 -159) while the whole patient group showed a lower (but not statistically
significant) IgM EndoCAb titre of 69 MU/ml (range 19-181). Every patient
subgroup was seen to have lower median levels of IgM EndoCAb when
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compared to controls, though this was not significant. In contrast to IgG
EndoCAb titre, diverticulitis patients showed the lowest IgM EndoCAb titres of
the patient subgroups (52 MU/ml).
Table 5.18 Median endogenous core IgM antibodies of patients and controls
Patient group: n Median IgM
(range)
*P
Controls 40 89.1 (35- 159) -
All 27 69.2 (19- 181) 0.117
Appendicitis 10 76.9 (22 - 181) 0.734
Pancreatitis 8 57.5 (47- 164) 0.430
Cholecystitis 5 69.2 (19--90) 0.080
Crohn's 2 73.0 (56--90) 0.637
Diverticulitis 2 52.4 (23--82) 0.204
A+C+D 17 70.4 (19- 181) 0.138
A+C+D subgroup represents data pooled from appendicitis, cholecystitis and
diverticulitis patients. * p-values represent comparison of the endogenous core
IgM antibody titre for each patient subgroup with the titres of the control
population using the Mann-Whitney U-test.
5.2.24 Post recovery patient antibody responses to LPS
Five patients agreed to follow up blood sampling on either one or two
occasions. Tables 5.19 and 5.20 summarises the changes in EndoCAb IgG and
IgM antibody titres of these patients following recovery. It can be seen that
antibodies to LPS of both the IgG and IgM isotype may increase or decrease
following recovery, with no obvious trend apparent.
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Table 5.19 Post recovery patient IqG antibody responses to LPS
Patient Diagnosis Age ti I2 ^3
Patient 1 Appendicitis 26 119 90 66
Patient 2 Cholecystitis 68 147 328 -
Patient 3 Cholecystitis 20 107 146 -
Patient 4 Diverticulitis 73 251 335 -
Patient 5 Pancreatitis 72 158 227 212
T1 = EndoCAb IgG titre at admission to hospital. T2 = First measurement of
EndoCAb IgG titre following recovery from illness. T3 = Later measurement of
EndoCAb IgG titre following recovery from illness. All titres are expressed in
EndoCAb median units/ml.
Table 5.20 Post recovery patient IqM antibody responses to LPS
Patient Diagnosis Age lgM-1 lgM-2 lgM-3
Patient 1 Appendicitis 26 60 33 38
Patient 2 Cholecystitis 68 19 61 -
Patient 3 Cholecystitis 20 76 15 -
Patient 4 Diverticulitis 73 82 93 -
Patient 5 Pancreatitis 72 58 43 40
lgM-1 = EndoCAb IgM titre at admission to hospital. lgM-2 = First measurement
of EndoCAb IgM titre following recovery from illness. lgM-3 = Later
measurement of EndoCAb IgM titre following recovery from illness. All titres are
expressed in EndoCAb median units/ml.
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5.2.25 Patient and control antibody responses to individual LPS core types
As materials allowed, titres of antibodies specific for the core epitopes of
several enteric LPS were measured in the plasma of 17 patients and 6 healthy
controls as described in Materials and Methods sections 2.4.6 and 2.4.7.
Antibodies of the IgG isotype directed against the following LPS were
measured: E.coli R1, E.coli R2, E.coli R3, E.coli R4, B.fragilis rough and smooth
LPS, K.aerogenes and S.typhimurium. Optical densities were compared with
that of the same standard high titre serum used to calibrate the EndoCAb IgG
and IgM measurements, assuming it to have the same median units/ml for each
antibody as demonstrated for EndoCAb IgG (392 MU/ml).
The antibody responses to each LPS were then sorted in descending order of
magnitude according to the response profile of patient 1, leading to the
following order of presentation in Figure 5.1: EndoCAb, B.fragilis rough, E.coli
R1, B.fragilis smooth, K.aerogenes, S.typhimurium, E.coli R4, E.coli R2, E.coli
R3. This allowed easier comparison of the antibody response profiles of each
individual to the panel of LPS used.
It can be seen that the profile of response to each LPS is remarkably similar in
all patients and controls, with only occasional deviations from the typical profile
of response in response to particular core types. Of particular note, however, is
the occasional high response to S.typhimurium LPS, as displayed by patients 4,
7 and 16 and healthy volunteer number 4. There was no significant difference
between patient and control mean titres of any of the antibodies investigated.
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5.2.26 Frequencies of TLR4 mutations in patients arid controls
Patient and control genomic DNA samples were screened for the presence of
the mutations Asp299Gly and Thr399lle in the Toll-like receptor 4 gene using
the restriction enzyme digest method described in Materials and Methods
section 2.5.8.
27 patients and 40 controls were screened for the presence of either mutation.
Four individuals were found in each group to be heterozygous for both the
Asp299Gly and the Thr399lle mutation. No individual was seen to carry only
one of the mutations and no individuals were found to be homozygous for either
mutation. Analysis of the allele frequencies of the mutation in both groups (10%
of controls vs 15% of patients) revealed that this difference was not significant.
The four heterozygote patients included two appendicitis and two pancreatitis
patients.
5.2.27 Effect of TLR4 mutations on proliferative responses to LPS
Proliferative responses to LPS were compared between TLR4 heterozygotes
and wild types within the patient and control populations. Heterozygous patients
exhibited slightly lower responses to LPS than wild-type patients (median SI 2.2
vs 3.7), though heterozygous controls exhibited slightly higher responses to
LPS than wild-type controls (median SI 10.9 vs 7.1). A similar pattern was
observed for best proliferative responses to LPS and median proliferative
responses to LTA though none of these differences were statistically significant,
most likely reflecting the very small sample size (n=4) of the heterozygote
groups available for comparison (Table 5.21).
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Table 5.21 Effect of TLR4 mutations on proliferative responses to LPS
Patients TLR4 ++ TLR4 +- * p
All LPS average 3.7 2.2 0.918
Best SI for any LPS 5.0 4.1 0.920
S.aureus LTA 1.8 1.3 0.441
Controls TLR4 ++ TLR4 +- ** p
All LPS average 7.1 10.9 0.499
Best SI for any LPS 12.7 16.5 0.620
S.aureus LTA 2.7 4.6 0.576
TLR4++ = homozygous, wild-type cohort. TLR4+- = heterozygous cohort, p
represents statistical comparison of the wild type and heterozygote population
proliferative responses to LPS or LTA using the Mann-Whitney U-test.
5.2.28 Effect of Toll-receptor 4 mutations on antibody responses to LPS
EndoCAb antibody responses to LPS were then compared between TLR4
heterozygotes and wild types within the patient and control populations.
Heterozygote IgG was lower than wild type IgG for the patient group (141 vs
157 MU/ml), though this trend was reversed in the control group (219 vs 186
MU/ml). Heterozygote IgM was higher than wild type IgM in both the patient
(102 vs 62 MU/ml) and control groups (108 vs 87 MU/ml). None of these
differences were statistically significant, most likely reflecting the very small
sample size (n=4) of the heterozygote groups available for comparison (Table
5.22).
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Table 5.22 Effect of TLR4 mutations on antibody responses to LPS
Patients: TLR4 ++ TLR4 +- * p
EndoCAb IgG 156.8 141.5 0.585
EndoCAb IgM 61.9 101.6 0.065
Controls TLR4 ++ TLR4 +- *P
EndoCAb IgG 186.4 219.0 0.379
EndoCAb IgM 86.6 108.2 0.380
TLR4++ = homozygous wild type cohort. TLR4+- = heterozygous cohort, p
represents statistical comparison of the wild type and heterozygote population
antibody responses to LPS using the Mann-Whitney U-test.
5.2.29 Statistical analysis of potential risk factors in sepsis
In order to assess which biological and clinical indicators had the strongest
impact on patient outcome from abdominal inflammation, data from each assay
was correlated against length of stay for each patient. Biological indicators
investigated included proliferative responses to LPS and LTA, IgG and IgM
antibody responses to LPS and Toll-receptor 4 genotype. Clinical indicators
investigated included SIRS score, SOFA score and neutrophil and lymphocyte
whole blood counts.
5.2.30 Correlation of patient PBMC responses to LPS with length of stay
Patient PBMC proliferative responses to the antigens E.coli R1 LPS, E.coli R2
LPS, E.coli R3 LPS, B.fragilis LPS, S.typhimurium LPS, K.pneumoniae LPS and
S.aureus LTA were plotted against length of stay (Figures 5.2a-i). Linear
regression analysis was applied to each plot to assess the coefficient of
correlation (R2).
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Figure 5.2b: Patient best stimulation index vs length of stay
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Figure 5.2e: Patient T-cell responses to E.co// R3 LPS vs length of stay
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Figure 5.2f: Patient T-cell responses to B.fraailis LPS vs length of stay
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Figure 5.2a: Patient T-cell responses to S.tvohimurium LPS vs length of stay
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Figure 5.2i: Patient T-cell responses to S.aureus LTA vs length of stay
No statistically significant correlation was observed between patient length of
stay and proliferative responses to any of the LPS or LTA tested except that of
K.pneumoniae. Figure 5.2h shows that within this group of 16 patients, higher
proliferative responses to K.pneumoniae LPS at admission tend to correlate
with longer stay in hospital (R2=0.384, p<0.01). This correlation is not nealy as
clearly seen in the scatter plots of other LPS, which show a much wider
scattering of points (R2 for overall response to all LPS tested =0.06, best
response to LPS =0.04, E.coli R1 LPS =0.06, E.coli R2 LPS =0.02, E.coli R3
LPS =0.05, B.fragilis LPS =0.01, S.typhimurium LPS =0.111, S.aureus LTA =
0.01). The strong correlation coefficient for K.pneumoniae LPS most likely
reflects the fact that two patients who stayed a relatively long time in hospital
(13 days) happened to demonstrate much higher proliferative responses to
K.pneumoniae LPS than the other patients, and has therefore most likely
occurred by chance.
Then, according to the protocol of Mattern et al (1994), patients were stratified
according to responsiveness to each antigen. Those displaying a stimulation
index greater than 7 were classed as responders while those displaying a
stimulation index less than 7 were classed as non-responders. Table 5.23
summarises the median lengths of stay of the responding and non-responding
patient populations with respect to each antigen. Non-responders in the context
of each LPS stay a median of only 3.5 - 4 days in hospital. Median length of
stay is longer and more variable among the groups classed as responders for
each antigen (4.5 days to 13 days). This ionger stay seen in the responding
group is only a significant difference when considering the ability to respond to
S.typhimurium LPS (median length of stay 13 days vs 3.5 days for non-
responders, p=0.045).
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Table 5.23 Effect of responder status on patient length of stay
Proliferative response Responder Non-responder P
median stay median stay
Mean response to all LPS 13 4 0.121
Best response to any LPS 8 4 0.139
E.coli R1 LPS 13 4 0.203
E.coli R2 LPS 8.5 4 0.291
E.coli R3 LPS 8 4 0.174
B. fragHis LPS 4.5 4 0.704
K.pneumoniae LPS 8.5 4 0.396
S.typhimurium LPS 13 3.5 0.045
S.aureus LTA 8.5 4 0.195
p represents statistical comparison of the responding and non-responding
populations responses to LPS using the Mann-Whitney U-test.
5.2.31 Correlation of patient antibody responses to LPS with length of stay
Patient antibody responses to the LPS core epitopes were plotted against
length of stay (Figures 5.3 a-b). Linear regression analysis was applied to each
plot to assess the coefficient of correlation (R2). The coefficient of correlation
between patient length of stay and igG anti-core LPS antibodies was (0.0013).
The coefficient of correlation between patient length of stay and IgM anti-core
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Figure 5.3a: Patient anti-core LPS laG antibodies vs length of stay
Figure 5.3b: Patient anti-core LPS loM antibodies vs length of stay
5.2.32 Effect of Toll receptor mutation on length of stay and clinical scores
Patients were stratified according to Toll-like receptor 4 genotype into those
harboring the Asp299Gly and Thr399lle mutations (heterozygotes) and those
without (wild types). Heterozygotes were younger than wild types (23years vs
48years) but this was not a significant difference (p=0.082). Heterozygotes
stayed slightly longer in hospital (4.5days vs 4 days) and exhibited lower
median SIRS scores (1 vs 2), lower median SOFA scores (0.5 vs 1) and a
reduced incidence of sepsis (25% vs 52%), though none of these differences
were of any statistical signicance, presumably reflecting the small sample
number of heterozygotes available for study (n=4, Table 5.24).
Table 5.24 Effect of TLR4 mutations on patient clinical indicators and outcome
Clinical indicator: TLR4 ++ TLR4 +- p
Age 48.1 22.7 0.082
Length of stay 4 4.5 0.838
(median)
SIRS (median) 2 1 0.865
SOFA (median) 1 0.5 0.633
Sepsis (frequency) 12/23 1/4 0.644
TLR4++ = homozygous wild type cohort. TLR4+- = heterozygous cohort, p
represents statistical comparison of the wild type and heteroygote population
antibody responses to LPS using the Mann-Whitney U-test or chi-squared test
of equal variance if comparing frequencies.
5.2.33 Correlation of clinical indicators with length of stay
The patient clinical indicators SIRS score, SOFA score, whole blood neutrophil
count and whole blood lymphocyte count were plotted against length of stay
(Figures 5.4 a-d). Linear regression analysis was applied to each plot to assess
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the coefficient of correlation (R2). SIRS score showed no correlation at all
(R2=0.000) with length of stay. However, higher SOFA scores on admission
were seen to correlate quite clearly with increased length of stay (R2=0.156,
p<0.05, Figure 5.4b). Lower lymphocyte counts were also seen to exert a
statistically significant detrimental effect on length of stay (R2=0.141, p<0.05,
Figure 5.4d). Lower neutrophil counts also correlated with longer hospital stay,
though this was not statistically significant (R2=0.130, Figure 5.4c). Additionally,
patients were stratified into those diagnosed with sepsis at admission (ie, those
presenting with a SIRS score >=2) and those not. Both septic patients and non-
septic patients stayed the same median length of time in hospital (4 days).
5.2.34 Correlation of clinical scores with PBMC and antibody responses to
LPS
Since high scores in the SIRS and SOFA scales have been associated with
increased morbidity and mortality, associations were sought between these
scores and the proliferative and antibody responses to LPS. Figures 5.5 a-f
show linear regression analyses of the two scores plotted against overall
proliferative responiveness to LPS, anti-core LPS IgG antibodies and anti-core
LPS IgM antibodies. No statistically significant correlation was observed when
comparing SIRS scores with overall proliferative responses to LPS (R2=0.023,
Figure 5.5a), SOFA scores with overall proliferative responses to LPS
(R2=0.045, Figure 5.5b), SIRS scores with EndoCAb IgG (R2=0.031, Figure
5.5c), SOFA scores with EndoCAb IgG (R2=0.044, Figure 5.5d), SIRS scores
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Figure 5.4a: Patient SIRS scores vs length of stay
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Figure 5.4b: Patient SOFA scores vs length of stay
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Figure 5.4d: Patient whole blood lymphocyte counts vs length of stay
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Figure 5.5e: Patient SIRS scores vs anti-core LPS IgM antibodies
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Figure 5.5f: Patient SOFA scores vs anti-core LPS laM antibodies
5.2.35 Correlation of proliferative and antibody responses towards LPS
As the proposed liposomal LPS vaccine had been seen to induce a proliferative
PBMC response, the question was asked whether proliferative responsiveness
to LPS had any impact on titres of IgG or IgM anti-core LPS antibodies. Patient
and healthy control overall proliferative responses to LPS were plotted against
levels of antibodies to core LPS structures (Figures 5.6 a-d). Linear regression
analysis was applied to each plot to assess the coefficient of correlation (R2).
No statistically significant correlation was observed between proliferative
response to LPS and EndoCAb IgM in patients (R2=0.000) or controls
(R2=0.111). Levels of EndoCAb IgG strongly correlated with overall PBMC
responses to LPS in the patient group (R2=0.319, p<0.01), but this trend was
completely absent in the analysis of the control population (R2=0.016).
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Figure 5.6b: Patient anti-core LPS laM antibodies vs overall T-cell response to LPS
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Figure 5.6c: Control anti-core LPS laG antibodies vs overall T-cell response to LPS
Figure 5.6d: Control anti-core LPS laM antibodies vs overall T-cell response to LPS
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5.3 Discussion
5.3.1 Why investigate this patient group?
The aim of the current study was to evaluate the role of PBMC proliferative and
antibody responses to LPS in endotoxin-related disease. For this reason,
patients admitted to hospital suffering from abdominal inflammation arising from
an infective source were enrolled. These entry criteria led to the recruitment of
diagnoses comprising appendicitis, cholecystitis, diverticulitis, Crohns' disease
and pancreatitis - all of which are thought to involve either or both of Gram-
negative infection and endotoxaemia (Prof. K. Fearon, personal
communication). As each of these ailments are associated with different
initiating pathologies, time courses and severities of disease, the following
analysis of the results has been considered in terms of the different disease
subgroups. Additionally, since the cases of appendicitis, cholecystitis and
diverticulitis all relate to inflammation of a lumenal organ likely caused by Gram-
negative infection, data from these patients have been collated into a further
grouping (A+C+D) for analysis.
5.3.2 Patient and control demographic and clinical data
Healthy volunteers were chosen to match the age spread of the patient group
as closely as possible. However, the slight difference of median age between
the two groups (32 for controls vs 39 for patients) is unlikely to affect analysis of
proliferative responses as there was seen to be no correlation between age and
proliferative response to LPS (data not shown). This finding is surprising in itself
as a clear trend was observed correlating increased age with reduced
proliferative responsiveness to ConA in 12 healthy controls (data not shown).
This may indicate that certain components of the human immune system are
less affected by the human ageing process than others.
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5.3.3 Patient clinical scores
The SIRS and SOFA scores of the various patient subgroups are seen to be not
significantly different from the median scores exhibited by the whole group. This
is almost certainly due to the low patient numbers present in the current study
as there is a clear difference in the severity of disease between the different
diagnoses. For example, while cholecystitis patients typically present with mild
disease, pancreatitis patients often present with more severe symptoms (Prof.
K. Fearon, personal communication).
A similar picture is seen when considering the iengths of stay of the various
patient subgroups. Only the appendicitis cases are revealed to have
significantly reduced hospital stay when compared with the mean stay for the
whole group (Table 5.4), reflecting the acute nature of this condition. With
greater patient numbers, it is almost certain that the other patient subgroups
would show significantly longer or shorter lengths of stay in hospital.
5.3.4 Patient and control proliferative responses
When considering overall proliferative responsiveness to LPS, the entire
patient group shows a median score approximately half that of the healthy
controls. Further, while 50% of controls were considered responders, only 26%
of patients were. These results are not significantly different however (p=0.15),
once again as a result of the small sample number of the current study.
Of more interest, however, are the diffences in overall LPS responsiveness of
the different patient subgroups. The appendicitis and pancreatitis patient
subgroups in particular show a trend towards reduced responsiveness to LPS
(Table 5.6). The cholecystitis group, on the other hand, shows a median overall
responsiveness to LPS greater than that of the control group and therefore
stands out from the rest of the patient group in this respect. This may reflect the
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mildness of disease occuring in the cholecystitis patients, as their immune
systems may not be as suppressed as the more severely ill patients such as the
appendicitis and pancreatitis patients. This picture is largely similar when
considering patient best responses to any LPS (Table 5.7).
Of patient responses to the individual LPS, the first thing to note is that overall
responses of the whole patient group are reduced in response to every LPS
tested when compared with the healthy controls (Tables 5.8-5.13). Interestingly,
however, the strongest reduction in responses occurs with E.coli R1 LPS (5.6 vs
1.8 median SI, p=0.06) and K.pneumonlae LPS (6.0 vs 3.8). This may reflect a
defecit of T-cells responsive to the core epitopes of these LPS in these patients,
perhaps as a result of gut mediated tolerance towards particular organisms in
these individuals. Further work will be required to investigate the mechanism
responsible for this clonal deletion.
Of secondary interest is the fact that the appendicitis and pancreatitis patient
subgroups are once again seen to suffer the greatest reductions in
responsiveness to these LPS, while the cholecystitis group has a higher
response than the control group to all LPS except E.coli R1, further suggesting
a strong role for the R1 core type of E.coli LPS in the modulation of the immune
response in these diseases (Tables 5.8-5.13).
Also of interest is the fact that the three components of the A+C+D cohort
(appendicitis, cholecystitis and diverticulitis) show quite different responses to
each LPS, despite the fact that they originate from a similar pathology. In
general, appendicitis patients present the most blunted responses, while
diverticulitis patients show iess blunted responses and the responses of
cholecystitis patients are either only mildly blunted or are enhanced when
compared to the median control response (Tables 5.8-13). This suggests that
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the progression or severity of the disease may have a significant impact on the
pattern of resulting immunocompromise. In particular, the timecourse may have
significance, as the length of time between onset of symptoms and admission to
hospital is quite different between these subgroups. The course of appendicitis,
for example, is typically very rapid, with patients being admitted to hospital
sometimes within 24 hours of initial symptoms. Diverticulitis and cholecystitis,
on the other hand, may progress more slowly with the inflammatory response
proceeding at a similarly reduced rate. Thus, it may be that either the severity of
the initial insult in the appendicitis patients is larger than that seen in the other
groups, leading to stronger immunosuppression. Or it may be that the length of
time between initial insult and admission to hospital allows some restoration of
an earlier, more pronounced immunosuppression in the diverticulitis and
cholecystitis patients. Further work will be required to answer this question.
Proliferative responses to the Gram-positive lipid lipoteichoic acid are, on the
other hand, not nearly as markedly reduced in the patient group as those
towards LPS (Table 5.14). The strong immune responses of the cholecystitis
subgroup are once again highlighted by the significantly stronger response to
S.aureus LTA than controls (median SI 21.6 vs 2.6). There are two possible
explanations for this finding. The first is that an expanded memory T-cell pool
reactive for LTA may exist in cholecystitis patients, implying that the course of
their ailment has allowed them time to generate a significant cellular response
to a Gram-positive infection. The second is that some feature of the pathology
of cholecystitis produces an immunological priming effect that leads to a more
generalised enhancement of T-ceil capacity to respond to all antigens. Such an
effect has been shown to be induced by the cytokine IFN-y, itself secreted by
LPS reactive T-ceils (Mossman et al 1989, Morel et ai 1998), though the
mechanism responsible for the priming in this case remains to be determined.
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Responses to the T-ceii mitogen ConA show a much clearer difference between
patients and controls. While only two ConA scores from within the 27 patient
subgroup are available for comparison with controls at this time, 4 remaining
patients with incomplete data sets show similarly blunted responses to ConA
(data not shown), suggesting that these two results are statistically relevant.
Indeed, comparison of these 2 ConA scores alone with controls demonstrates a
highly significant (p=Q.036) reduction in capacity to respond to ConA (control SI
88.3 vs patient SI 1.0). An explanation for the severity of the
hyporesponsiveness of these patients to ConA may be found in the kinetics of
proliferation in response to these antigens (Figure 4.21). ConA responses were
measured at 3 days, while responses to LPS and LTA were measured at 7
days. Thus, it is possible that the agent responsible for the immunosuppression
present in these patients continues to affect PBMC proliferative capacity over a
3 day incubation in vitro, while the effect is lost by the seven day timepoint at
which LPS responses are measured. Further experiments, including for
example challenge of cells in heterologous serum, would be required to
determine what this factor is.
The findings of the present study are not the first observation of PBMC
hyporeactivity in septic patients. Blunted responses of PBMC have been
reported by previous authors examining similar patient groups. For example,
PBMC of septic patients have been shown to exhibit significantly decreased IL-
2 production in response to PHA stimulation (Wood et al 1984). Monocytes from
similar patients have been shown to have a diminished capacity to release
TNF-a, IL-1a, IL-1(3, IL-6, IL-10 and IL-12 in response to LPS (Ertel et al 1997,
Munoz et al 1991, Sekatrian et al 1994, Van Deuren et al 1994) and human
volunteers injected with endotoxin show significantly reduced capacity to
subsequently produce IL-1, TNF-a and IL-6 in response to various activating
factors (Granowitz et ai 1993). Severely blunted T-cell responses to activating
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factors have been described in patients with post-operative sepsis due to intra¬
abdominal infection (Heidecke et al 1999). Similarly, animal models of intra¬
abdominal infection show temporary functional defects in B- and T-cells
consistent with those seen in patients with peritonitis (Gough et al 1992,
Martineau et ai 2000).
Studies such as these and the present study may be interpreted in two different
ways. On the one hand, it is possible that the immunosuppression observed is
occuring as a result of the systemic response to infection. On the other hand, it
is possible that immunological hyporesponsiveness present in the general
population is a strong risk factor for the development of sepsis and is therefore
present in a high percentage of sepsis patients before the onset of disease.
Evidence to support both hypotheses exists.
In support of the former is the observation that caecal ligation and puncture of
mice results in a systemic immunosuppression that eventually reverts to normal
(Gough et ai 1992). Similarly, rats inoculated intra-abdominaliy with bacteria
show temporary functional defects in both B and T-cells (Martineau et al 2000).
Immunosuppressive cytokines are seen to be released rapidly in response to
both injury (Neidhardt et al 1997, O'Sullivan et al 1995) and minor surgery
(Brune et ai 1999, Hensler 1997) in humans and the long iived cytokine IL-6
released in response to infection in humans which has long been considered a
pro-inflammatory cytokine is now realised to express anti-inflammatory
properties (Xing et al 1998). Thus, the combined stresses of infection and
inflammation in sepsis patients may resuit in the downreguiation of the immune
response observed.
In support of the latter hypothesis, however, are the many reports of a strong
correlation existing between immunological hyporeactivity and poor outcome
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following surgery. Patients displaying an immunologically hyporeactive state on
admission before surgery or any episode of sepsis (so called 'walk-in anergic'
patients) are seen to be at considerably more risk from poor outcome when
compared to patients exhibiting normal immune function on admission (Christou
et al 1984, Christou et al 1989, Johnson et al 1979, Adami et al 1980, Christou
et al 1983). In particular, measurements of the delayed-type hypersensitivity
(DTH) reaction in response to five common recall antigens have shown that
anergic patients are much more likely to suffer an episode of sepsis or poor
outcome (Christou et al 1984 & 1989). Low pre-operative proliferative
responses of PBMC to PHA and ConA were also seen to correlate with post
surgical episodes of sepsis and adverse outcome in thoracic esophagectomy
patients (Takagi et al 2001).
This hypothesis is compiemeted by the hypothesis of Munford and Pugin that
the immunological hyporeactivity seen in sepsis patients may result as a natural
reaction of the body to stress (Munford and Pugin 2001a and 2001b). They cite
evidence that stress factors as diverse as major injury, strenuous exercise, cold
exposure and even psychological stress are sufficient to induce stress
hormones such as catecholamines which in turn have been shown capable of
suppressing the activity of immune cells (Jones et al 1989), inhibiting
production of TNF-a (Severn et al 1992) and promoting a state favouring
production of the anti-inflammatory cytokine IL-10 (Suberville et al 1996, van
der Poll et al 1996). While this response has obviously evolved to afford
protection to the host in some way, (it may promote better focussing of immune
resources to a localised point of infection), they point out that the associated
systemic immunosuppression may also iead to secondary infection from
viruses, bacteria or fungi.
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The hypothesis that immunological status may rise and fall in health is also lent
support by the findings from the current study, as summarised in Figure 4.27.
This examination of the overall PBMC responsiveness to LPS of healthy
volunteers clearly shows that this measure of immune status rises and falls with
time. Indeed, it is seen that at least one individual (donor 1) makes a clear
transition from responder status to non-responder status. Further, 5 of 6
patients assessed for post-recovery ability to demonstrate a proliferative
response to LPS were seen to demonstrate improved immune function (Table
5.16), suggesting that the immunosuppression observed in this patient group
may be quite transient.
Thus the question remains of whether the immunological hyporesponsiveness
observed in the current study is initiated before or during an episode of sepsis.
Unfortunately, this can only be answered from the testing of patients
responsiveness to LPS at regular timepoints before, during and after an
episode of sepsis. As this is obviously an impractical proposition, animal
models of these diseases must be examined, though it should be pointed out
that the responses of mice (which are often used to simulate sepsis related
conditions - Spinas et al 1992, Gough et al 1992) to endotoxin are quite
different from those of humans (Martich et al 1993, Alexander et al 2001), and
caution should therefore be urged in the interpretation of such studies.
Nevertheless, regardless of when the immunosuppression occurs, the question
remains of which mechanisms are responsible for its initation and perpetuation.
On the one hand, it is possible that these T-cells have been rendered anergic
via a mechanism that is retained cellularly. Alternatively, since autologous
plasma has been used to supplement the medium in all cultures in the current
study, it is possible that the cells are in fact capable of activation, but their
responses are blunted due to the activity of immunomodulating factors present
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in the plasma. Evidence certainly exists that stress hormones and certain
cytokines can have immunosuppressive effects on diverse cell types in vitro
(Randowet al 1995, Munford and Pugin 2001a and 2001b, Opal et al 1998). In
particular, the observation that the responsiveness of neutrophils to endotoxin
can be restored in septic patients to near normal levels if the patients plasma is
treated extracorporeally provides strong support for this hypothesis (Tetta et al
2002). As this method of plasmafiltration has been shown to remove (by
adsorption) multiple cytokines, activated complement components and lipid
mediators from patient plasma (Tetta et al 2002), the study therefore lends
support to the attractive hypothesis that alteration of cytokine concentrations in
immunosuppressed patients may be able to restore immunological competence.
As for what possible role LPS-reactive T-celis have, the original hypothesis that
they may help in assisting with antibody formation is not made any clearer by
the present study. Leveis of anti-core IgM antibodies do not correlate with
PBMC responses to LPS in either the patient group (R^=0.000) or in the control
group (R2=0.111). This might be expected as IgM responses are typically
considered to be T-cell independent (Stavnezer 1996). However, while levels of
EndoCAb IgG strongly correlated with overall proliferative responses to LPS in
the patient group (R2=0.319, p<0.01), this trend was completely absent in the
control group (R2=0.016). One possible explanation for this paradox may be that
there is no correlation in health, but patients exposed to LPS suffer antibody
depletion and concurrent T-cell immunosuppression, thereby resulting in the
positive correlation seen.
Instead, the role of these T-cells may lie in their production of cytokine. It is
clear that on ligation with their ligand, they do not release type II cytokines such
as IL-4, IL-5 or IL-10 (Mattern et al 1994), but produce significant amounts of
the type I cytokine IFN-y (Mattern et al 1999). This cytokine is seen to be
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capable of inhibiting the activation of Th2-cells and stimulating cell-mediated
immunity (Mossman et al 1989, Morel et al 1998). Interestingly, many studies
have observed this cytokine to be blunted during the phase of immunological
hyporeactivity often seen in patients following an episode of sepsis (Cavaillon
et al 2001, Oberholzer et al 2002, Berguer et al 1999, Naldini et al 1998, Brune
et al 1999, O'Sullivan et al 1995). Thus, the role of these T-cells may simply be
to address this imbalance by secreting this cytokine in sepsis, infection or
endotoxaemia. A lack of LPS-reactive T-cells in patients may therefore
predispose them to overzealous immunosuppression and resultant poor
outcome.
5.3.5 Patient and control endogenous core antibody responses to LPS
Antibodies directed against the core epitopes of LPS have been shown to offer
the best cross reactivity with a wide range of LPS (Poxton 1995, Barclay 1990,
Chedid 1968), and possibly also cross protection against infection with
heterologous strains of bacteria (Braude et al 1972, McCabe et al 1972, Cross
et al 1988), as discussed in greater detail in the Introduction (section 1.3).
Levels of antibodies to the core structures of LPS have also been seen to
correlate with outcome in studies of a number of patient groups. For example,
anti-core antibodies were seen to be depleted during episodes of
endotoxaemia, then restored in 2 of 3 patients studied with septic shock
(Barclay et al 1989). Studies of anti-core antibodies in the sera of pre- and post-
surgery patients have also revealed a correlation between high endogenous
levels of anti-core LPS antibodies and protection from adverse post-operative
outcome (Freeman et al 1985, Bennett-Guerrero et al 1997, Hamilton-Davies et
al 1997, Bennett-Guerrero et al 2001). Further, non-survivors of intra-abdominal
sepsis were seen to have depressed levels of IgG anti-endotoxin (Wakefield et
al 1998), as were non-survivors of intensive care (Goldie et al 1995). Falling
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titres of IgG anti-core LPS antibodies have also been reported to correlate with
the development of multiple organ failure in acute pancreatitis (Windsor et al
1993).
While no correlation was observed between patient antibody titres and patient
length of stay in the present study (Figure 5.3), IgG anti-core LPS antibodies
are significantly lower in patients than in healthy controls (median titre 154 vs
192 MU, p<0.05, Table 5.17). A lower level of IgM anti-core LPS antibodies is
also seen in the patient group when compared to controls, though this is not a
significant difference (median titre 69 vs 89 MU, Table 5.18). The small
differences in antibody levels observed between the different patient subgroups
are not statistically significant in the present study, though a much larger study
may provide useful insights.
In general though, the results of this study appear to agree with the previous
studies listed above. However, caution must be urged in the interpretation of
these data as at least two possible interpretations are possible from these
findings.
The first is that LPS released during the disease processes in the patient group
in this study is depleting LPS-specific antibody from the serum. However,
mindful of the recent observations of the critical role of immunosuppression in
these conditions, it is also possible that the depletion of anti-LPS antibodies are
merely symptomatic of falling IgG titres in the more general sense. Thus, low
levels of humoral immunity may also be a risk factor in the initiation or
progression of these infections, thereby explaining the increased frequency of
depleted titres in our study sample. Certainly, anti-LPS antibody levels can vary
somewhat in healthy controls, varying from 74 to 345 MU in the forty controls
tested here (Table 5.17), and an even wider range has been reported in studies
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of larger numbers of healthy donors (Barclay 1990). Similarly, the study of
Goldie et al (1995) point out that their measurements of both IgG and IgM
EndoCAb levels are highly significantly correlated (IgG, r=0.5, p<0.001; IgM,
r=0.65, p<0.001) to plasma levels of whole antibody as measured by the
standard hospital method of laser nephelometry. Further experiments
measuring the whole IgG and IgM content of the patients plasma samples of the
current study will be required to shed some light on this matter.
5.3.6 Patient and control antibody responses to individual LPS core types
Looking at the order of the peak titres listed in Figure 5.1, it is tempting to
speculate that an order of frequency exists for antibodies specific for individual
LPS core types in the general population. In particular, it appears that the most
common antibodies exist towards B.fragilis core, then E.coli R1 core, then
B.fragilis O-polysaccharide, then K.aerogenes core LPS etc (as listed in legend
at right). Flowever, this conclusion cannot be made from this experiment alone.
The reason for this is that the serum used to calibrate the experiment was a
high EndoCAb titre serum from one individual, and all antibodies are measured
relative to that particular individuals profile of response. Thus, only one main
point may be extracted from consideration of the profiles presented in Figure
5.1 - antibodies present in the serum of each patient and control seem to show
a similar profile of response between donors, with each individual showing
similar proportions of antibody specific for each LPS. Only occasionally are
individuals seen to deviate greatly from this pattern, for example, the strong
antibody response to S.typhimurium LPS shown by control number 4 and
patient number 7. These occasional 'spikes' may reflect recent challenge with
an organism expressing similar LPS core structures to S.typhimurium LPS
which has resulted in these specific high titres. Examination of T-cell responses
to proteins specific to these organisms may be able to add further support to
this hypothesis.
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5.3.7 Toll-receptor 4 mutations in patients and controls
In the present study, 4 of the 27 patients studied were found to be heterozygous
for the co-segregating mutations Asp299Gly and Thr399lle in the TLR4 gene.
This frequency is not significantly different from the frequency of the mutation
found in 40 healthy controls, and indeed in the entire original group of 40
patients, the frequency is also 4 out of 40 patients.
Presence of the mutation had no significant effect on the length of stay of
patient carriers (Table 5.24), nor on the strength of proliferative or antibody
responses to LPS (Tables 5.21 & 5.22). Further, presence of the mutation did
not adversely affect SIRS or SOFA clinical scores (Table 5.24).
These findings are consistent with the earlier finding of this study that
monocytes from individuals heterozygous for both mutations show absolutely no
impairment of response to LPS (Figure 3.12). The numbers of patients used in
this study are obviously too low for any statistically significant findings to
emerge, though they certainly do not add support to the recent study of the
mutation in sepsis patients of Lorenz et al (2002a). That study of 91 septic
shock patients compared the frequency of the Asp299Gly mutation with that of
73 healthy controls and found the mutation exclusively in the patient group
(Lorenz et al 2002a). The group also noted a higher prevalence of Gram-
negative infections occurred in the patients carrying the Asp299Gly mutation.
Flowever, the frequency of the mutation in the patient group was not compared
with the frequency of the mutation in the wider population - data which was
both created in and available to the same laboratory (Arbour et al 2000, Lorenz
et al 2002b), raising some doubts as to the validity of their statistical tests.
However, it remains possible that individuals homozygous for the mutation have
altered responses to LPS that affect the progression of disease in these
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pathologies. Only a much larger study will be able to determine whether these





6.1 Is there a role for LPS in sepsis syndrome?
One of the most significant questions we can ask in the context of the current
study is simply "Does LPS have a role to play in the pathogenesis of sepsis?" If
the answer is yes, then investigations into the role of LPS in sepsis may
ultimately lead to valuable new options for therapy. If not, our efforts are best
directed at trying to understand and then influence the other pertinent aspects
of sepsis syndrome. In order to answer this question, there are three main lines
of evidence which we must look towards to make our assessment of the viability
of this hypothesis.
The first of these is the observation that administration of LPS or even purified
lipid A to humans is capable of inducing all of the clinical features characteristic
of sepsis syndrome (Michie et al 1998), shock (Suffredini et al 1989) and even
multiple organ failure (Taveira daSilva et al 1993, Martich et al 1993).
Countering this, however, is the observation that sepsis and resultant episodes
may be initiated from no infective source or other obvious source of LPS
whatsoever. Cases of severe trauma, for example, are often seen to result in a
systemic inflammatory response and clinical course very similar to that of sepsis
syndrome, with no obvious sign of infection (Faist et al 1987, Abraham et al
1985, O'Sullivan et al 1995, Baker et al 1988). This may perhaps be explained
by the observation that products of host tissue damage resulting from these
injuries such as host heat shock protein 60 and fibronectin extra domain A have
been shown to be capable of signalling via TLR4 and inducing expression of
exactly the same genes upregulated on LPS recognition (Okamura et al 2001,
Vabulas et al 2002). Thus, it is possible that a systemic inflammatory response
could be initiated under certain circumstances in the absence of any bacterial
products. However, the argument remains that LPS may still have a role to play
in these cases of sepsis too. Several studies have demonstrated that the gut is
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extremely sensitive to loss of splanchnic biood flow, and cite evidence that gut
hypoperfusion can result in translocation of both bacteria and LPS into the
systemic circulation of the host (Saadia et al 1990, Haglund et al 1975, Chiu et
al 1970, Baker et al 1988, Bynum et al 1984, Haglund et al 1975). Thus it
remains possible that the ili effects seen in the patient groups exhibiting no
obvious infective source could yet be attributable to LPS, in these cases
derived from gut commensals as a result of injury to the gut mucosal barrier.
The second line of evidence comes from the observation of the presence of
LPS in the plasma of many patients with sepsis syndrome (Goldie et al 1995,
Opal et al 1999, Casey et ai 1993, Danner et al 1991, Barclay et al 1989,
Dofferhoff et al 1992). However, the question remains, of course, of whether
this plasma-borne LPS is responsible for the initiation of the septic state, or
whether it is simply a marker for gut barrier break down caused by systemic
inflammation brought on by some other (non-LPS mediated) pathology.
Finally, there is the evidence arising from the studies of antibodies specific for
LPS in human plasma. Associations have been observed, for example, between
low pre-operative serum anti-endotoxin antibody levels and adverse outcome
following surgery (Bennett-Guerrero et al 1997, Freeman et al 1985, Gould et al
1989, Hamilton-Davies et al 1997, Nys et al 1993). Low or falling levels of anti-
endotoxin have also been shown to correlate with adverse outcome in patients
diagnosed with abdominal sepsis (Wakefield et al 1998) and pancreatitis
(Windsor et al 1993). However, most of these studies have not correlated their
EndoCAb findings with whole IgG levels, and it remains possible that low levels
of antibodies specific for LPS merely reflect a more generalised depletion of all
immunoglobulin in the patient. Indeed, one study has shown an almost absolute
correlation (p<0.001) for levels of LPS-specific antibodies and whole IgG and
IgM levels in septic patients (Goldie et ai 1995). Thus it remains possible that
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lowtitres of anti-LPS antibodies may simply reflect a more general compromise
of the immune system.
These lines of evidence suggest that LPS may have a role to play both in the
initiation and the pathology of sepsis and its related sequelae, though the
hypothesis has yet to be proven. Only extensive sampling of patients blood
before septic episodes or effective neutralisation of LPS in the plasma of pre-
septic patients will be able to provide more substantial evidence for the role of
LPS in these conditions.
6.2 Antibody treatments for sepsis - can they work?
The history of research into the potential of LPS-specific antibodies in the
treatment of disease has something of a chequered past at best (discussed in
detail in section 1.3). Certainly evidence exists that antibodies specific for the
core structures of LPS become depleted in patients exposed to LPS, and
associations have been made between low or falling levels of these antibodies
and poor outcome in patient groups (Pollack et ai 1983, Nys et al 1993,
Freeman et al 1985, Gould et al 1989, Bennett-Guerrero et al 1997).
Nevertheless, hard evidence for a beneficial effect of passive transfer of
antibodies to either patients or animal models of sepsis is scarce.
Indeed, the most promising reports of such evidence came in the late 1970s
with the efforts of McCabe and Ziegler, whose studies appeared to demonstrate
that passive transfer of anti-LPS antibodies conferred a protective benefit on
rats challenged with live bacteria (McCabe et al 1977, Ziegler et al 1979).
However, these findings could not be repeated by later researchers
(Baumgartner et al 1990, Baumgartner et al 1991a). Similarly, several human
clinical trials of passive transfer of hyperimmune serum have provided initially
encouraging results (Ziegler et al 1982, Baumgartner et al 1985, Teng et al
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1985), but all have since been heaviiy criticised in terms of either the
interpretation or general methodology of the study (Baumgartner 1994,
Baumgartner et al 1987, Baumgartner et al 1991c, Wenzel 1992 - summarised
in section 1.3). Further, two large clinical trials of supplementation of the plasma
of septic patients with two different monoclonal antibodies purported to bind to
LPS (E5 and HA1A) have shown no protective benefit whatsoever and have led
to widespread criticism of the methods used in assessment of such antibodies
for clinical use (Wenzel et al 1991, Various authors 1991, Baumgartner 1994,
Baumgartner et al 1991c).
For the researcher considering the application of anti-LPS antibodies as a
therapeutic agent in sepsis, the first question that must be answered is "What
led to the failure of these trials?" In essence there are two main possibilities that
may explain these failures.
The first is that antibodies specific for LPS have very littie role in dealing with
either endotoxaemia or disease. However, the study of Burd et al (1993)
showed that an igG monoclonal antibody specific for E.coli 0111 LPS not only
enhanced uptake of that LPS by macrophages but also inhibited TNF-a
secretion in response to that LPS. The extension of their hypothesis, that IgG-
bound LPS is internalised via Fc receptors thereby bypassing the signalling
receptors, suggests that high ievels of these antibodies in septic patients may
serve to reduce the burden of pro-inflammatory cytokine produced in response
to a certain amount of LPS. The question has not yet been answered, however,
of how significant this effect should be in humans in vivo.
The second possibility is that antibodies specific for LPS may well provide
benefit, but the binding specificity of the antibodies towards the LPS used in
each study was not broad enough to deal with the bacteria or LPS the animals
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or patients were exposed to. In support of this idea is the report of a monoclonal
antibody (termed WN1-222.5), which is capable of binding to all smooth and
most rough LPS from all E.coii and Salmoneiia strains so far investigated (Di
Padova et al 1993). This antibody has been shown capable of inhibiting release
of pro-inflammatory cytokines such as TNF-a and IL-6 from LPS-challenged
murine peritoneal macrophages. Of most interest, however, is the
demonstration that its administration neutralises the pyrogenic response to LPS
in rabbits and protects D-galactosamine-treated mice from lethal challenge with
both E.coii and S.abortus-equi. These data are certainly encouraging, and
suggest that broadly cross-reactive antibodies may yet offer therapeutic value
to patients at risk of exposure to endotoxin. However, WN 1-222.5 has not been
shown capable of binding to LPS of Enterobacter, Klebsiella, Serratia, Proteus
or Pseudomonas spp. This suggests that for a monoclonal antibody-based
approach to offer significant benefit to patients, it will have to be a cocktail of
several monoclonals, each with a specificity as broad as that demonstrated by
WN1-222.5. Acting together, they should be designed such that their activities
overlap and are able to bind and neutralise the LPS of a much wider range of
clinically relevant organisms.
6.3 Prospects of the vaccine
Attempts to boost human anti-LPS antibody titres have so far revolved around
the prophylactic transfer of either hyperimmune plasma or monoclonal
antibodies to patients (Ziegler et al 1982, McCutchan et al 1983, Baumgartner
et ai 1985, Teng et al 1985, Caiandra et al 1988, Ziegler et al 1991). However,
a vaccine-based approach may have several advantages over these therapies.
These include low cost and the ability to generate high titre endogenous
antibodies in recipients. Further, prophylactic vaccination may be more effective
than passive immunisation in challenged patients, as it is clinically difficult to
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detect the eariy signs of endotoxaemia in time to intervene effectively with a
specific anti-endotoxin therapy (Cross et al 1994, Opal et al 1995).
The idea of using LPS O-chain or core epitopes as part of a vaccination
strategy to induce anti-LPS antibodies has received a great deal of interest
(Cryz et ai 1987, Barclay et al 1986, Cryz et al 1991, Bhattercharjee et al 1996,
McCabe et al 1972, McCabe et al 1977, Bhattacharjee et al 1999). However, in
order to avoid problems associated with the inherent toxicity of lipid A, most of
these studies have focused on the properties of protein-saccharide conjugates
(Cryz et al 1987, Schiff et al 1993, Cryz et al 1991, Bhattacharjee et al 1994,
Bhattacharjee et al 1996).
The present study shows that a liposomal vaccine containing complete core
LPS of Escherichia coli K12, Eschehchia coli R1, Bacteroides fragilis and
Pseudomonas aeruginosa is capable of being added to human monocytes and
inducing no inflammatory response (in terms of TNF-a release, at least) at
concentrations up to 100,000 fold higher than the equivalent amount of native
LPS. A previous study (Bennett-Guerrero et al 2000) has shown the vaccine
capable of providing significant protection from lethality in galactosamine-
sensitised mice exposed to lethal doses of E.coli 018 LPS and inducing broadly
cross-reactive antibody responses in immunised rabbits. However, the
concentration of liposomal LPS used to vaccinate rabbits in this study was
16pg/ml - a concentration which this study has shown results in considerable
release of TNF-a from human monocytes (Figure 3.4). If minimum release of
TNF-a is desired for the safety of vaccine administration, the highest
concentration that can be applied to humans in its current form is around
0.1pg/ml (Figure 3.4).
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However, while the vaccine has been shown to display low toxicity and an
ability to generate a broadly cross reactive antibody response in rabbits,
experiments involving animal models of sepsis need to be performed before any
idea of how useful the preparation is in the prevention of disease. In particular,
challenge of mice with clinically relevant bacteria should be performed, as
should murine caecal ligation and puncture (the standard murine model of
sepsis) to determine whether vaccinated animals fare better than non-
vaccinated ones. Only if studies such as these demonstrate a positive effect
shouid the vaccine continue to human trials in its current form.
6.4 Other potential therapies for sepsis.
The last fifty years has seen an increase in the incidence of sepsis syndrome
while outcome has not improved (Wheeler et al 1999, Various authors 1990).
Unsurprisingly this has led to some frustration among physicians, keen to apply
new therapies to reverse this trend. To this end, more than a dozen clinical
trials using antagonists of either the initial stimulators of the pro-inflammatory
state or the pro-infiammatory mediators themselves have been attempted in
order to try to improve outcome in this patient group (reviewed in sections 1.3
and 1.5). Unfortunately none of these have met with clear success.
These disappointing results suggest that a much more thorough understanding
of the pathological processes underlying sepsis syndrome will be required. In
particular, acknowledgements of a number of key facts must be borne in mind in
these considerations. The first of these is that sepsis is an extremely
heterogeneous disease. It may be initiated by a number of primary causes:
physical trauma (Faist et al 1987), reperfusion injury (Bone et al 1997), infection
(Martineau et al 2000), gut barrier failure (Saadia et al 1990) and possibly even
immunocompromise resulting from a wide variety of potential stresses (Munford
and Pugin 2001b). The nature and particularly the timecourse of these different
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initiators of sepsis may weii have some bearing on the underlying processes
present in those patients (as evidenced by the quite different immunological
profiles of the different patient subgroups examined in the present study).
The next fact that must be considered is that in very general terms, there are
two main pathologies that lead to the mortality of septic patients. The first of
these is the effect on the host of the systemic inflammation characteristic of
sepsis - the problem being in particular the multiple organ failure catalysed by
the presence of widespread cytokine-induced coagulation, vasodilation and
aggressive proteolysis of endothelial surfaces (Oberholzer et al 1997). The
second major cause of mortality in septic patients is the frequently observed
phase of immunosuppression, which leaves some patients unable to defend
against otherwise non-threatening nosocomial infections (Hensler et al 1997).
Any approach to treat septic patients must, therefore, be capable of addressing
both of these concerns.
Attempts to stem the damage resulting from systemic inflammation have so far
revolved around blockade of the pro-inflammatory cytokines TNF-a (Fisher et al
1993), and IL-ip (Fisher et ai 1994). Unfortunately, these large scale studies
have failed to demonstrate any improvement in survival of treated patients
despite the initial promise of animai studies (Tracey et al 1987, Ziegler et al
1987, Ohlsson et al 1990). It may therefore be the case that these cytokines are
required by the host to halt the spread of and ultimately clear the infection
underlying the septic episode. With this in mind, a better approach may be to
target not the signalling molecules which have a multitude of roles to play in
protecting the host from the underlying infection, but the particular mediators
causing most organ damage. Protease inhibitors and anti-coagulants in
particular may allow some protection of organ vasculature from the deleterious
effects of systemic inflammation. For patients at risk of sepsis, such as trauma
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patients and those undergoing major surgery, such medications may prove of
some use in a prophylactic capacity.
However, it should be noted that such interventions will only be useful within a
particular window of opportunity. Patients surviving this phase should be
considered at risk of immunological hyporeactivity, and this abnormality should
then be targeted for treatment. As discussed in section 1.5, by far the most
often reported predictor of favourable outcome in septic patients is a strong
immunological status prior to sepsis (Christou et al 1984, Heidecke et al 1999,
Christou et al 1989, Johnson et ai 1979, Adami et al 1980, Christou et al 1983).
This suggests that augmentation of the patients immune system may well
provide some benefit in these patients.
Theoretically this may be achieved in a number of ways, it has been suggested
by Oberholzer and colleagues, for example, that the excessive lymphocyte
apoptosis often observed during sepsis (Hotcnkiss et al 1999a & 1999b) may
represent a potential target for therapy of this condition (Oberholzer et al 2001).
Not only wouid blockade of such apoptosis lead to higher numbers of circulating
lymphocytes, it could also reduce the amount of anti-inflammatory cytokines
such as IL-10 released by macrophages in response to phagocytosis of
apoptotic bodies (Voll et al 1997).
The present study has shown that T-ceil responses to LPS and ConA are
blunted in patients suffering from abdominal inflammation arising from an
infective source. Therefore it is possible that modulation of the function of T-
cells may offer an attractive prospective target for the therapeutic treatment of
patients at risk of, or suffering from, sepsis.
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The role played by the LPS reactive T-cells examined in the present study has
yet to be established, though some interesting points can be made out. The first
is that on exposure to LPS these cells secrete the type I cytokine IFN-y (Mattern
et al 1994), a cytokine capable of inhibiting the activation of Th2-cells and
stimulating cell-mediated immunity (Mossman et al 1989, Morel et al 1998). As
previously discussed, the role of these T-cells may therefore be to balance the
excessive production of type II cytokines in the phase of immunological
hyporeactivity typically seen during or following sepsis. Interestingly, treatment
of sepsis patients with native IFN-y has been shown to restore not only HLA-DR
expression on monocytes but also their ability to secrete IL-6 and TNF-a (Bone
et al 1996). Further, administration of IFN-y has also been shown to result in
fortification of host cell-mediated immunity (Reed et al 1988). For this reason,
restoration of the activity of these cells may benefit patients.
As for how an increase in the abundance or activity of such cells might be
achieved, it is interesting to note that the accessory cell type required for
presentation of LPS to these cells is the rare CD34+ blood stem cell (Mattern et
al 1998). T-cells from non-responding donors were shown capable of
responding when supplemented with CD34+ cells (Mattern et al 1998), so it may
be possible that supplementation of patients blood with CD34+ cell populations
may provide the LPS-reactive T-cell response required. This may be achieved
by prophylactic drug treatment, or, as the interaction between these cells and T-
cells is not dependent on MHC-molecules, donor cells could be sourced from
either cord blood (in which the CD34+ population is particularly abundant) or
from healthy responding donors.
Of further interest is the observation that the liposomal LPS vaccine described
in this study is capable of inducing expansion of LPS reactive T-cells in vitro at
concentrations lower than that required to stimulate release of pro-inflammatory
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cytokines from human monocytes (sections 3.4 and 4.5). This suggests that a
proliferative response can be generated to liposomal LPS at concentrations
lower than the threshold required for detection by the innate immune response,
and by extrapolation, TLR-4. This observation provides further weight to the
hypothesis that the proliferation observed is not mediated via TLR-4 or other
innate mechanisms, but may be due instead to presentation of LPS to T-cells,
and resultant clonal expansion. Therefore, in addition to inducing high titres of
LPS reactive antibodies, the vaccine may also provide a protective benefit in
recipients from the resulting expansion of LPS-reactive T-cells.
6.5 Future work
Further investigation of the potential of the proposed liposomal LPS vaccine will
require evaluation of its efficacy in animal models of sepsis. In particular,
challenge of immunised mice with a wide range of clinically relevant bacteria
should be performed, as should the effect of the vaccine on outcome in caecal
ligation and puncture experiments. The low toxicity of the formulation
demonstrated in this study and others (Bennett-Guerrero et al 2000) already
lends support for its use in phase I trials in human volunteers.
The high frequency of the Asp299Gly and Thr399lle alleles of the Toll-like
receptor 4 gene in the European population also merits further investigation.
The present study has shown that heterozygous expression of the mutant
receptor has no effect on LPS signalling. TLR4 deficient cell lines (such as 293
cells) should therefore be transfected with constructs coding for each mutation
and LPS signalling investigated. Additionally, challenge of mutant receptors
with other TLR4 agonists, such as heat shock protein and respiratory syncytial
virus F-protein should be investigated, as the high frequency of these mutations
in the general population may yet indicate that some advantage exists in the
recognition of these alternative TLR4 ligands.
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The role of LPS reactive T-cells in the wider immune response to pathogens
has yet to be determined. As this study has shown the murine model to be
inappropriate for investigation of these cells, studies of human cellular
preparations must continue. In particular, despite strong circumstantial
evidence from this and other studies (Mattern et al 1994, 1998, 1999), cell
surface molecule-mediated presentation of LPS to T-cells has not yet been
confirmed. Co-immunoprecipitation of radiolabeled LPS with such a
presentation molecule may yet be achieved should monoclonal antibodies be
found capable of functioning in this assay.
Lastly, the role of immunological hyporeactivity in healthy patients and in septic
patients requires investigation. In particular, as it has been shown in this study
that the immunological status of healthy individuals varies considerably with
time, the responses of cells from anergic and immunocompetent donors to
various stimuli should be compared. The capacity of the serum from anergic
patients to modulate the response of cells from immunocompetent individuals
should be investigated, as this will determine whether such immunosuppression
can be reversed by alteration of factors present in the serum. If this is the case,
attempts should then be made to restore the function of anergic cells in vitro.
These should begin with an investigation into the efficacy of blockade of type II
and anti-inflammatory cytokines, followed by treatment with drugs blocking the
immunosuppressive effects of stress hormones. Treatment of anergic cells with
other cytokines should be perfomed, as should supplementation with CD34+
cells, as the capacity of these cells to modulate the wider immune response has
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A vaccine that induces humoral immunity to lipopolysaccharide (LPS), while remaining non-
pyrogenic should be beneficial, as high levels of antibodies against LPS are associated with a
reduced risk of adverse outcome. However, pure LPS or bacteria expressing LPS are generally
considered too toxic to be used as vaccines. Recently, a novel, immunogenic complete core
lipopolysaccharide vaccine has been described, which has been designed to prevent endotoxin-
related inflammatory reactions in surgical and high-risk hospitalized patients. In vivo studies have
shown that while administration of the vaccine to rabbits results in no toxicity over 7 days, it does
induce significantly enhanced antibody responses towards a broad range of clinically relevant
Gram-negative LPSs. Here we show that encapsulation of the four complete core LPS types
Escherichia coli K12, Escherichia coli Rl, Bacteroides fragilis and Pseudomonas aeruginosa into
liposomes greatly reduces the ability of a given amount of LPS to induce TNF-a production in vitro
from human monocytes. In contrast to previous studies of liposomal LPS, we demonstrate a
reduction in activity of approximately 100,000-fold; a reduction approximately 100-1,000-fold
more than that previously described. The signalling by the liposomal LPS appears to be entirely
dependent on serum factors, though this can be partially restored by soluble CD 14 or, to a lesser
extent, by lipopolysaccharide binding protein. Time-course experiments reveal that liposomal LPS
signalling shows similar kinetics to pure LPS signalling. Therefore, as well as inducing specific
antibody responses, liposomal LPS demonstrates characteristics suitable for use as a vaccine to be
used in human beings.
Introduction
It has been estimated that endotoxin-mediated toxicity
accounts for approximately 100,000 deaths per year in
the US alone,1 with a predisposition towards post-surgi¬
cal patients. In surgical and high-risk hospitalized
patients, it is thought that the gut barrier breaks down,
leading to release of whole Gram-negative organisms,
cell membranes or lipopolysaccharide (LPS: endotoxin)
into the portal circulation.2-3 Endotoxin-mediated toxic-
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ity is thought to occur as a result of the effect that LPS
has on the cells of the immune system, and in particular,
macrophages.4 Endotoxin is capable of inducing
macrophages to release a number of pro-inflammatory
mediators, including TNF-a, IL-6, IL-8 and IL-1(3. In
greater than normal physiological concentrations, these
mediators induce systemic pathological effects.5-8
Recent studies of anti-LPS antibodies in the sera of pre-
and post-surgery patients have revealed a correlation
between high endogenous levels of anti-core LPS antibod¬
ies and protection from adverse postoperative outcome.^12
Pre-surgical vaccination with LPS might benefit patients by
increasing their anti-LPS antibody titre before surgery.
However, even as little as several nanograms of LPS is
enough, when administered to a human subject, to induce
symptoms of systemic inflammation.13 This toxicity must
be reduced somehow if an LPS-based vaccine is to be
© W. S. Maney & Son Ltd
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viable, and for this reason the LPS used in the vaccine
has been incorporated into liposomes.
However, while demonstrating lower toxicity than
native LPS, the vaccine must also remain highly immuno¬
genic. Therefore, in order to achieve the widest possible
protective antibody response, the liposomal vaccine com¬
prises a mixture of four complete core LPSs (Escherichia
coli K12, E. coli Rl, Pseudomonas aeruginosa PAC 608
and Bacteroidesfragilis), since antibodies directed against
these core epitopes cross-react with many LPS
serotypes.14 In addition, this liposomal cocktail has been
shown to protectmice from challenge with a lethal dose of
E. coli 018 LPS.14
The objective of this study was to investigate the toxic¬
ity of the vaccine in human cell systems. We compared the
relative toxicity of the vaccine with the native unincorpo¬
rated cocktail of LPSs mixed in equal ratio but not incor¬
porated into liposomes. Measurement of TNF-a secretion
from challenged human monocytes reveals the potential
toxicity of the vaccine as applied to humans, as release of
this cytokine is a major contributor to the symptoms of
endotoxic shock.6 The kinetics of release of these molecules
was also investigated to determine whether the new prepa¬
ration shows a delayed peak release of cytokines due to its
encapsulation in the liposomes, or protracted cytokine
release over time. Finally, the dependence of liposomal sig¬
nalling on serum factors was investigated to determine
whether the pathway utilized by macrophages to detect the
liposomal LPS shared any similarities with the serum-
dependent pathways used to recognize pure LPS.
Materials andMethods
LPS/liposome preparation
LPSs used in experiments were extracted from rough
mutant E. coli K12 (NCTC 13116), E. coli Rl (NCTC
13114), P. aeruginosa PAC 608 (NCTC 13124), and B.
fragilis (NCTC 9343). Bacteria were grown in nutrient
broth (filter-sterilized, Gibco), overnight at 37°C. After
harvesting and washing 3 times in PBS, they were heat
killed (100°C, 10 min) and then frozen until LPS extrac¬
tion. LPS was extracted from lyophilized bacteria by the
phenol/chloroform/petroleum (PCP) method of Galanos
et al. as described by Hancock and Poxton.15 Purified
LPS was checked for protein impurities by the Lowry
assay (<1% protein) and silver-stained SDS-PAGE (no
visible bands), and for nucleic acid contamination by
spectrophotometry (< 0.2%), then dissolved at 1 mg/ml
in pyrogen-free water and stored at -20°C before use in
assays. Multilamellar liposomes, consisting of dimyris-
toyl phosphatidyl choline, dimyristoyl phosphatidyl
glycerol and cholesterol (4:1:4), containing 33 pg total
LPS per ml (one-quarter of each LPS core type by
weight, 10:1 lipid to LPS ratio w/w), were prepared accord¬
ing to the method of Dijkstra et al.,16 with some modifica¬
tions (as described by Bennett-Guerrero et a/.14) at Duke
University (Durham, NC, USA). For subsequent washes,
liposomes were centrifuged for 10 min at 13,000 g in a
bench centrifuge and resuspended in pyrogen-free PBS.
LPS was recovered from liposomal preparations in some
experiments by aqueous phenol extraction.15
Preparation ofhuman monocytes
Human peripheral blood was diluted 1:3 in PBS then
layered onto Histopaque 1077 (Sigma), centrifuged at
400 g for 30 min and the interface cells removed. Cells
were then washed twice in PBS and resuspended in
RPMI/10% human serum (HS; Sigma). Monocytes were
counted in white cell diluting fluid (0.01% Gentian vio¬
let in 1% acetic acid). Cells were plated at 2 x 105 mono¬
cytes per well of a 96-well plate. After 1-1.5 h, the cells
were washed with RPMI/10% HS to remove non-adher¬
ent cells, leaving a monolayer ofmonocytes.
Challenge with LPS preparations
LPS or liposome preparations were diluted to appropri¬
ate concentrations in RPMI/10% HS or RPMI without
serum and 100 pi of each dilution was then added to
monocytes in triplicate. In experiments using only one
concentration of LPS, either 100 ng/ml LPS or 10 pg/ml
liposomal LPS was chosen. Serum protein experiments
used serum-free medium supplemented with 1 pg/ml
purified human plasma lipopolysaccharide binding pro¬
tein (HBT, Uden, The Netherlands) or 1 pg/ml recombi¬
nant human soluble CD14 (R&D). Samples of
supernatant were collected and assayed for TNF-a con¬
tent at specific time points (4 h for single time-point
TNF-a experiments, various time-points for TNF-a
release time-course experiments).
Measurement of TNF-a
Supernatant TNF-a concentrations were measured by
bioassay as described by Delahooke et al.11 Briefly, 10
pi of supernatant was added to L929 cells plated at 2 x
104 per well of a 96-well plate together with 90 pi
DMEM/5% FCS/1 pg/ml actinomycin D. A standard
curve was prepared using TNF-a (Peprotech) at 3.2-fold
dilutions. After incubation at 37°C overnight, cell death
was measured by staining with crystal violet for 2 min
then releasing with 50 pi 20% (v/v) acetic acid. Values
were read at 590 nm on an Anthos 2001 automated plate
reader.
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Statistics
Due to interexperimental variation in the maximum
amount of TNF-a produced from each individual donor,
the values for each experiment were normalized such
that the maximum production of TNF-a in each experi¬
ment was taken to be 100. Data from 3-5 independent
experiments were then combined and each datum point
compared with control cell secretion by the Student's
paired f-test. The end-point of dose response was taken
as the first point that was not significantly different from
background (P > 0.05).
Results
Relative biological activity ofpure LPS and LPS-
liposome preparations
The capacity for macrophage stimulation by PCP-puri-
fied LPS and LPS in liposomes was estimated by deter¬
mining a dose-response curve for each preparation in
terms of its ability to induce TNF-a from human periph¬
eral blood monocytes. The end-point of dose response
was taken as the first datum point that was not signifi¬
cantly different from background (P > 0.05).
The activities of E. coli R1 and E. coli K12 LPS show
very similar levels of activity to the mixed (cocktail)
LPS (Fig. 1). B. fragilis LPS appears to be approxi¬
mately 10,000-fold less toxic than the E. coli and mixed
LPSs, while P. aeruginosa LPS shows an ability to stim¬
ulate monocytes only at concentrations 105—106 times
more than that obtained with E. co/f-derived LPS.
The sensitivity of the monocytes from each individual
donor to the different LPSs was very consistent for E.
co/i-derived and mixed LPS, but significant differences
were observed between donors in their ability to recog¬
nise B. fragilis and P. aeruginosa LPS, as evidenced by
Table 1. Comparative biological activities of LPS core types and liposomes
LPS type Minimum concentration Activity compared to
required to stimulate monocytes* liposomes (liposomes = 1)
(ng/ml)
E. coli R1 0.01 100,000
E.coli K12 0.01 100,000
B. fragilis 100-1000** 1-10
P. aeruginosa 1000-10,000** 0.1-1
Cocktail (CT) LPS 0.01 100,000
Liposomal CT LPS 1000 1
Washed liposomes 1000 1
Recovered LPS 0.1 10,000
*Datum point taken as lowest value significantly different (P > 0.05) from control, and hence concentration at which
preparation does not stimulate cells. **Monocytes from certain individuals responded to different degrees with B. fragilis and
P. aeruginosa LPS so range of sensitivity is given.
5 4 3 2 1 0 -1 -2 -3 -4 -5 -6 Ctrl
Log (ng/ml)
Fig. 1. Comparison of TNF-a production from monocytes exposed to free
(unincorporated) E. coli K12, E. coli R1, B. fragilis, P. aeruginosa and the
cocktail of these LPSs (CT). Results are normalized means ± SEM of five
independent experiments. *Datum point indicating lowest concentration at
which response is significantly different from control (P < 0.05). "For B.
fragilis and P. aeruginosa LPS, the minimum concentration of LPS
responded to was highly donor-dependent, so statistics were performed on
the individual data sets from these donors and not the mean values





Fig. 2. Comparison of TNF-a production from monocytes stimulated with
washed and unwashed liposomes containing cocktail LPS. Washed liposomes
were centrifuged 5 times further than freshly prepared (unwashed) liposomes.
Results are normalized means from four independent experiments ± SEM.
*Indicates lowest concentration at which response is significantly different
from control (P < 0.05).
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Fig. 3. TNF-a production from monocytes stimulated with LPS reclaimed
from liposomes by phenol extraction. Results are normalized mean ± SEM
of five independent experiments, indicates lowest concentration at which
response is significantly different from control (P < 0.05).
the larger error bars in those series. The liposomal cock¬
tail LPS proved to be ~105-fold less stimulatory than the
equivalent mixture of unincorporated LPS (Figs 1 & 2),
as summarised in Table 1. Liposomes containing no LPS
do not induce TNF-a release from monocytes at any
concentration.
Quantification ofLPS incorporated into liposomes
To determine how much of the LPS added to the liposo¬
mal lipids became incorporated into the liposomes, a LAL
assay was performed on the supernatant of centrifuged
liposomes. This showed that 96-99.8% of the LPS was
incorporated at this stage.14 Challenge of monocytes with
this liposomal supernatant and subsequent TNF-a mea¬
surement also revealed a biological activity in close
accordance with what might be expected if this amount of
LPS had been incorporated (data not shown).
However, to rule out the possibility that native LPS was
co-pelleting with the liposomes in this assay, we performed a
phenol extraction of the prepared liposomes and used the
resultant re-purified LPS to challenge monocytes as
described above. Figure 3 shows that the recovered LPS is
approximately 10,000-fold more toxic than the liposomes
(Fig. 2) - slightly less than might be expected if the recovery
of the LPS from the liposomes were 100% efficient. Then, to
determine whether subsequent washing steps could reduce
the activity of the liposomes yet further, liposomes (already
washed 5 times during manufacture) were washed a further 5
times. The activity of the liposomes following these addi¬
tional washes remained largely unchanged (Fig. 2). Finally,
in order to determine whether free LPS could co-precipitate
with the liposomes in these washing steps, centrifugation of
stock LPS was performed according to the same protocol. No
pellet was observed and supernatant retained biological
activity suggesting that centrifugation under these condi¬
tions is not sufficient to pellet soluble LPS.
Fig. 4. Time course ofTNF-a production by human monocytes in
response to pure LPS and liposomal LPS. The amount of TNF-a produced
in response to 100 ng/ml of pure LPS and 10 |ig/ml of liposomal LPS was
measured at various time points. Results show the mean of triplicate
readings ± SEM from one experiment and are representative of three
similar experiments.
Kinetics ofcytokine release and dependency on serum
factors
When human peripheral blood monocytes were incu¬
bated with 100 ng/ml pure LPS or 10 |ig/ml LPS com-
plexed in liposomes the release of TNF-a showed
similar kinetic profiles (Fig. 4). TNF-a production was
seen to peak at 8 h (LPS) and 24 h (liposomes) before
decreasing substantially in both cases by 48 h and
becoming undetectable by 60 h.
Removal of serum from the medium reveals the depen¬
dency of the signalling on substances within serum. Figure
5 shows the relative TNF-a produced from human mono¬
cytes exposed to either 100 ng/ml of pure LPS or 10 (J.g/ml
70 i
CT LPS CT Lipo Control
Fig. 5. Dependence of LPS signalling on serum factors. Human peripheral
blood monocytes were challenged with 100 ng/ml LPS or 10 |ig/ml
liposomal LPS with human serum, without serum and without serum but
supplemented with 1 |ig/ml human LBP or soluble CD14. Results are
representative of three similar experiments, error bars are SEM. CT LPS =
100 ng/ml cocktail LPS. CT Lipo = liposomes containing 10 pg/ml
cocktail LPS.
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liposomal LPS. On removal of serum, approximately one-
half of the serum response remained following challenge
of cells with native LPS preparations. This could be par¬
tially rescued by addition of purified LBP or to a greater
extent by soluble CD 14. The response towards liposomal
LPS is completely abolished on removal of serum, yet
this can also be recovered to approximately two-thirds of
maximum activity by restoration of either LBP or solu¬
ble CD 14, with each of these proteins having a similarly
restorative effect in this case.
Discussion
Evidence is now accumulating to support the hypothesis
that low endogenous levels of anti-LPS antibody is a sig¬
nificant risk factor in the outcome of high-risk hospital¬
ized patients. For example, a study of 86 cardiac surgery
patients revealed that those with detectable anti-LPS
antibodies before surgery had a lower incidence of
wound infection (3% versus 29%) and fever (30% ver¬
sus 64%).9 A later study revealed that patients with low
anti-LPS IgM levels had a higher incidence of post-
surgery complications, while those with high anti-LPS
IgM levels had a much lower incidence of post-surgical
complications.10 In light of these observations, several
groups have attempted to provide passive protection
from endotoxin-mediated complications by administra¬
tion of monoclonal anti-LPS antibodies to patients prior
to surgery, but these have met with limited success for a
variety of reasons (for a review see Baumgartner18). In
general, however, these problems were mainly con¬
cerned with the poor specificity for LPS or low cross
reactivity between different LPS core types of the mono¬
clonal antibodies used in these studies. An alternative
approach is active immunisation with a cocktail of LPS
preparations. In order to provide the widest possible pro¬
tective antibody response, a liposomal vaccine compris¬
ing a mixture of four complete core LPSs (E. coli K12,
E. coli Rl, P. aeruginosa PAC 608, and B.fragilis) was
developed. Antibodies directed against these core epi¬
topes cross-react with LPS from many potential patho¬
genic organisms.14 It should be noted that the antibodies
produced by the vaccine are against core epitopes rather
than specific O-antigens. The use of this cocktail of
complete LPS core molecules has resulted in an
immunogenic vaccine that produces a broadly cross
reactive response to a range of LPSs from a large panel
of Gram-negative bacteria. It has been shown to protect
mice from lethal challenge with E. coli 018 LPS.14
In addition to immunogenicity, however, any pro¬
posed LPS-based vaccine must first be shown to be sig¬
nificantly less toxic than native LPS. Administration of
pure LPS alone as a vaccine to hospitalized patients is an
impractical proposal, as even very small amounts of pure
LPS can elicit toxic reactions.13 Pure LPS is also
unlikely to produce an IgG T-dependent antibody
response. For this reason, we have compared the relative
toxicity of the cocktail LPS liposomal preparation with
that of the individual LPS components in soluble form
by looking at the TNF-a secretion of challenged human
monocytes.
In order to do this, the concentration of the LPS within
the liposomes had to be determined accurately. This was
achieved in principle by measuring the concentration of
LPS in a stock solution by LAL assay before incorporating
the whole amount into liposomes.14 Subsequently, the lipo¬
somes were centrifuged and the remaining supernatant and
the liposomes themselves re-checked by LAL assay to
ensure that negligible LPS remained in the supernatant. In
practice, 96-99.8% of the LPS was incorporated, and the
final LAL assay of the washed liposomes revealed an
activity of less than 0.1% of the native LPS.14
This small amount of endotoxin remaining in the
supernatant surrounding the liposomes was also con¬
firmed by measuring the TNF-a release from monocytes
challenged with the supernatant. This, therefore,
prompted an experiment to determine whether the activ¬
ity of the liposome preparations could be lowered yet
further through further centrifugation and washing steps
to remove this extra-liposomal endotoxin. Figure 2
shows that, in fact, the freshly manufactured liposomes
(already washed 5 times during manufacture) have a bio¬
logical activity largely similar to that of liposomes
washed a further 5 times. In addition, it was noted that
centrifugation of native, soluble LPS according to the
same protocol was unable to produce a pellet. These
findings suggest that the endotoxic activity existing in
the supernatant outside the liposomes cannot be sepa¬
rated from them in this way, possibly indicating that an
equilibrium exists between the liposomal and soluble
compartments such that a small amount of endotoxin
always remains in the medium.
However, to rule out the possibility that the low activ¬
ity of our liposomes was purely due to extremely poor
incorporation of LPS during manufacture, we performed
a phenol extraction of the prepared liposomes and used
the resultant re-purified LPS to challenge human mono¬
cytes. Figure 3 shows that, in terms of TNF-a produc¬
tion, the recovered LPS is approximately 10,000-fold
more toxic than the original liposomes (Fig. 2). This is
not quite the 100,000-fold difference that might be
expected if the initial incorporation and subsequent
extraction of the LPS had returned a 100% efficiency,
and given the LAL assay data are more likely to be a
reflection of the poor yield of the simple phenol extrac¬
tion method used rather than the incorporation protocol.
We then compared the biological activity of the liposo¬
mal cocktail LPS with that of the individual component
LPSs. Table 1 summarises the results ofour comparisons of
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the TNF-a release from human monocytes challenged with
free and liposomal LPS. E. coli Rl, E. coli K12 and 'cock¬
tail' LPS showed very similar biological activities in this
assay, all being easily detected by the monocytes at concen¬
trations down to around 0.01 ng/ml (Fig. 1). Interestingly,
however, while each of the five individual donors' mono¬
cytes responded similarly to the E. co/i-derived LPSs, a
much larger diversity was noted in their sensitivity to B.
fragilis and P. aeruginosa LPS. Responses to B. fragilis
LPS occurred from 100-1000 ng/ml and P. aeruginosa
from 1000-10,000 ng/ml. This may indicate a heterogene¬
ity in the sensitivity or expression of the receptor molecules
for these LPSs in these individuals that is not seen in the
largely TLR-4-dependent signalling process used by the
monocytes to detect E. coli type LPSs. Further experiments
will be required to determine how this heterogeneity in sen¬
sitivity to P. aeruginosa and B. fragilis LPS arises and
whether or not differential TLR usage is involved.
When comparing the activity of the liposomal LPS
with that of the equivalent free cocktail LPS, a reduction
in activity of at least 100,000-fold was observed (Table
1). This reduction in biological activity is approximately
100-1000-fold more than that seen previously by other
workers. For example, studies of Salmonella minnesota
rough (Re) and wild-type LPS showed that incorporation
of LPS into liposomes according to the method of
Dijkstra et al.16 results in reduction of IL-1 (3 secretion
from RAW 264.7 macrophages by 100-1000-fold,19 and
TNF-a release of 100-1000-fold.20 A reduction in activ¬
ity as measured by LAL assay has been observed to be in
the order of 100-1000-fold,16 and actinomycin D sensi¬
tized mice have been shown to have a 10-fold reduction
in lethality when challenged with liposomal lipid A
compared with native lipid A.21 Finally, encapsulation of
Neisseria meningitidis LPS within liposomes has been
shown to reduce the pyrogenicity of LPS in rabbits by up
to 1000-fold.22 Why our liposomal preparations demon¬
strate lower biological activities than those seen in ear¬
lier studies is unclear, though perhaps some explanations
may lie in the fact that the techniques used to prepare
them are slightly different. A modified version of the
method described by Dijkstra et a/.16 was employed.14
Thus, our liposomes might contain more internal lamel¬
lae or are larger than those previously described, or per¬
haps the distribution of the LPS within the liposomes is
different.
In order to understand how this reduction in activity is
conferred, the recognition pathways utilised by the
macrophages to recognise native LPS must be consid¬
ered. It is thought that proteins present in serum (such as
LBP and soluble CD 14) are able to catalyze transfer of
LPS from micelles or the outer membranes of bacteria to
the cell surface of macrophages.23-24 Here they appear to
be inserted into the plasma membrane for recognition by
Toll-like receptors (TLRs). It is not clear where this final
Toll-mediated recognition occurs, but evidence exists
that TLR-425-26 is involved in recognizing the presence of
LPS and mediates subsequent internalization and trans¬
port of the LPS molecules to the Golgi.24 Here, a poorly
defined signalling cascade leads to LPS recognition and
the stimulation of the macrophage, through NF-kB and
AP-1 transcription factors, to release molecules such as
TNF-a, IL-6, IL-8, and IL-lp.26 However, alternative
pathways exist for the uptake of LPS that do not elicit
secretory responses. Both CD 18 and scavenger receptor
are capable of binding LPS and, following either pinocy-
tosis of LPS or engulfment of whole bacteria, the LPS is
degraded in lysosomes without inducing strong cytokine
release.27 These pathways are utilized by spleen and liver
cells, for example, to detoxify LPS from the blood.
Bearing these pathways in mind, several possible
explanations for the reduced toxicity of the liposomal
LPS arise. First, it is possible that the multilamellar lipo¬
somes contain only a very small proportion of their LPS
in their outermost lipid leaflets, and hence only a small
proportion of the LPS is accessible to macrophage
receptor molecules to induce signalling. In this model,
the majority of the LPS would be contained within the
central layers of the liposomes where it is shielded from
interaction with proteins such as LBP or macrophage
CD 14. Alternatively, direct phagocytosis of the lipo¬
somes could direct them through less stimulatory
degradative pathways, and there is already evidence to
suggest that this is the case, as following endocytosis
liposomes appear to be quickly trafficked towards sec¬
ondary lysosomes.20 In this model, it may simply be that
the comparatively large size of the liposomes predis¬
poses them towards rapid engulfment by the
macrophages and hence non-stimulatory degradation of
LPS, while the LPS micelles may remain too small to be
dealt with efficiently in this manner. It may be also the
case that the small size of the LPS micelles (~0.01 pm)27
compared with the liposomes simply offers a much
increased surface area for interaction with serum lipid
transfer proteins in a fashion similar to the effect particle
size has on reaction kinetics. Finally, since we were
unable in our experiments to remove all endotoxic activ¬
ity from the liposomal supernatant, the possibility
remains that the larger part of the liposomal toxicity
comes from this compartment. In this view, the prepara¬
tion can then be seen as simply being a low concentra¬
tion solution of LPS with the liposomes playing little or
no role in monocyte activation.
The possibility that the liposomes might release the
LPS slowly over time leading to stronger and/or longer
lasting monocyte activation was investigated, as this
outcome could negate some of the benefits of the vac¬
cine. Such a delayed peak in TNF-a release could occur
by fusion of the internal liposomal lamellae with TLR-4
bearing intracellular vesicles or the plasma membrane.
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However, this seems unlikely given the data presented in
Figure 4, as both free and liposomal LPS were revealed
to show a similar kinetic profile. TNF-a production was
seen to peak at 8 h (LPS) and 24 h (liposomes) before
decreasing substantially in both cases by 48 h and
becoming undetectable by 60 h. This profile of mono¬
cyte activation suggests that the observed reduction in
biological activity of the liposomal LPS is not due sim¬
ply to a delayed response of the macrophages to the LPS,
but rather to a lack of availability of the LPS to the
macrophage recognition pathways.
To clarify further the role of serum proteins on liposo¬
mal LPS recognition, experiments were performed in the
absence of serum, since activation ofmacrophages under
these circumstances could indicate direct liposomal
fusion with the macrophage plasma membrane or with
subsequent internal vesicles linked to the LPS signalling
pathways. On removal of serum, approximately one-half
of the serum response remained following challenge of
cells with native LPS preparations (Fig. 5). This obser¬
vation (that high concentrations of pure LPS do not
require serum factors for monocyte activation) has been
made before.28 This activity could be restored partially,
however, by addition of purified LBP or entirely by
addition of an equivalent amount of soluble CD 14. By
contrast, the response towards liposomal LPS is seen to
be completely abolished on removal of serum, yet this
too can be restored to approximately two-thirds of maxi¬
mum activity by supplementation of the medium with
either LBP or soluble CD 14. However, in this case, both
proteins seem to have a similar restorative capacity.
These findings suggest that the biological activity of the
liposomes is occurring via the traditional LPS shuttle
proteins and receptors used to detect low concentrations
of soluble LPS. We are thereby unable to rule out the
possibility that most or all of the liposomal activity seen
comes from the small amount of endotoxin present in the
supernatant surrounding the liposomes.
Interestingly, while the biological activity of the LPS
has been clearly diminished by incorporation into lipo¬
somes, the immunogenicity of the vaccine has not. This
can perhaps be best explained by suggesting that the
liposomal LPS is processed in the cell via pathways that
are much more likely to result in antibody formation
than the pathways used to deal with native LPS. At pre¬
sent, however, these mechanisms remain largely unclear.
Conclusions
We have provided data in support of the potential bene¬
fits of this new liposomal LPS by showing it to have
greatly reduced macrophage stimulatory potential in
vitro. The immunogenicity of this new liposomal prepa¬
ration has been shown capable of inducing production of
broadly cross-reactive and protective anti-LPS antibod¬
ies in small animals14 and we await clinical trials in pre-
surgery patients.
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Abstract
The lipopolysaccharides of Gram-negative bacteria have a profound effect on the mammalian immune system and are of great
significance in the pathophysiology of many disease processes. Consideration is given in this review to the relationship between structure
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1. Introduction
Lipopolysaccharide (LPS) is vital to both the structural
and functional integrity of the Gram-negative bacterial outer
membrane. Ubiquitously expressed by all Gram-negative
bacteria, and containing several well-conserved domains,
LPS also serves as one of the primary targets of the innate
arm of the mammalian immune system. Recognition of the
presence of LPS by cells such as monocytes and macroph¬
ages has evolved over the millennia to provide the mam¬
malian host with a rapid recognition of and reaction towards
Gram-negative infection. This rapid, innate response against
LPS typically involves the release of a range of pro¬
inflammatory mediators, such as TNF-a, IL-6 and IL1 (3,
which in local sites of infection and in moderate levels
benefit the host greatly by promoting inflammation and
otherwise priming the immune system to eliminate the
invading organisms.
However, in conditions where the body is exposed to
LPS excessively or systemically (as when LPS enters the
blood stream), a systemic inflammatory reaction can occur,
leading to multiple organ failure, shock and potentially
death. Studies demonstrate that the majority of endotoxin
exposure in these patients does not originate from an
infection per se [1], but instead arises from translocation of
endotoxin from the gastrointestinal tract [2]. The LPS of
Gram-negative bacteria also shows quite a diversity of
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causative or modulating effects in a number of other disease
processes. As much of the pathophysiological potential of
these organisms derives directly from the exact structure of
the LPS they express, this review will focus on the
relationship between the structure and function of a number
of clinically significant LPSs.
2. General structure of LPS
In the early part of the last century, it was becoming clear
that endotoxin consisted of lipid and carbohydrate, and
hence the term 'lipopolysaccharide' came into usage. The
first main attempts at elucidation of the structure of the
molecule came in the 1950s with the efforts of Luderitz and
Westphal, whose acid treatment of LPS preparations yielded
the first carbohydrate-free portions of LPS (termed lipid A).
By the 1960s, it was becoming clearer that it was this lipid
portion of the molecule that contained the endotoxic activ¬
ity, as the so-called 'deep-rough' mutants (lacking the major
part of the oligosaccharide portion of the molecule) were
found to retain strong biological activity. Other experi¬
ments, such as mild alkali removal of fatty acids and protein
binding experiments, pointed towards the same conclusion.
However, it was only in the 1980s when free lipid A was
finally prepared synthetically by Tetsuo Shiba et al. in Japan
[3] that it was proven to be the endotoxic centre of the
molecule.
Today, with procedures such as NMR, HPLC and epitope
studies, the structures of the LPSs of many Gram-negative
organisms have been characterised, and they all conform, in
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Fig. 1. General structure of Gram-negative LPS.
the main, to a common general architecture (Fig. 1).
Modifications of this basic structure account for the endot¬
oxins of all Gram-negative organisms so far investigated
and can be formally classified as containing three separate
regions. Lipid A is the highly hydrophobic and endotoxi-
cally active part of the molecule. Covalently attached to this
is the core section of the molecule which can itself be
formally divided into inner and outer core. The inner core is
proximal to the lipid A and contains a high proportion of
unusual sugars such as 3-deoxy-D-manno-octulosonic acid
(Kdo) and L-glycero-D-manno heptose (Hep). The outer
core extends further from the bacterial surface and is more
likely to consist of more common sugars such as hexoses
and hexosamines. Onto this is attached, in most cases, a
polymer of repeating saccharide subunits called the
O-polysaccharide, or O-chain, also typically composed of
common hexoses. This O-chain is not ubiquitous, however,
as it is seen to be truncated or lacking in a number of
Gram-negative strains. Bacteria, which colonise mucosal
surfaces, for example, often express LPS with a truncated
non-repeating O-chain known as lipo-oligosaccharide
(LOS). In addition, certain strains carry mutations in the
otherwise well-conserved 'rfb' locus (which contains a
selection of genes involved in O-chain synthesis and attach¬
ment) and are termed Tough mutants' to differentiate them
from the wild-type 'smooth' strains which express O-chain-
bearing LPS.
2.1. O-polysaccharide
The repeating units of the O-polysaccharide region
consist between one and eight glycosyl residues and differ
between strains by means of the sugars, sequence, chemical
linkage, substitution, and ring forms utilised. As can be
expected, this leads to an almost limitless diversity of
O-chain structure and is verified in nature with the obser¬
vation of hundreds of serotypes for particular Gram-
negative species. In addition, the number of subunits used to
complete the chain varies between 0 and -50 and a single
organism will produce a wide range of these lengths as a
result of incomplete synthesis of the chain. This gives rise to
the classical ladder pattern of molecular weights seen when
smooth LPS is visualised by SDS-PAGE.
The O-polysaccharide is also the outermost part of the
LPS molecule expressed on bacteria and is therefore the
major antigen targeted by host antibody responses. These
responses can be highly O-chain specific, and for this reason
the O-chain is often also referred to as the 0-antigen. As a
result of this, serology of O-antigens has become a useful
tool in typing strains of organisms and LPS.
The O-polysaccharide region is also recognised by the
innate arm of the immune system, playing a role in both the
activation and inhibition of complement activation [4]. For
many organisms (e.g. Salmonella), the O-chain is essential
for survival in host serum as it prevents penetration of the
complement membrane attack complex [5].
2.2. Core polysaccharide
While the O-polysaccharide region of bacterial endotox¬
ins is extremely variable, the oligosaccharide structures in
the core part of the molecule are much more limited, with
some regions being highly conserved between different
strains and species. As an illustration, while there are now
over 160 identified O-serotypes for Escherichia coli, only
five unique core structures have so far been determined
(R1-R4 and K12) [6]. Fig. 2 shows some examples of the
range of core structures seen in a selection of wild-type and
'rough' strain Gram-negative bacteria.
The outer core typically consists of common hexose
sugars such as glucose, galactose, A-acetyl galactosamine
and A-acetyl glucosamine (hence alternatively referred to as
the hexose region) and is generally more variable than the
inner core.
The inner core is characterised by more unusual sugars,
particularly Kdo and heptose. The former of these is seen in
almost every LPS looked at to date, being a-bound to the
carbohydrate backbone of lipid A in every case. The only
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Fig. 2. Core structures of selected Gram-negative pathogens. Examples of core types from selected Gram-negative pathogens showing a variety of viable core
structures. The E. coli core shown is that of rough mutant Rl; the structure given for N. meningitidis relates to the entire LOS of the organism; all isolates
of C. trachomatis so far investigated have shown only the Kdo triplet depicted; and the deep rough mutant of H. influenzae (1-69 Rd~/b+) represents the
smallest core structure yet seen for any viable Gram-negative bacteria. NB: linkages of sugars shown in this scheme are for diagrammatic purposes only.
exceptions yet seen to this rule are Acinetobacter and
Burkholderia cepacia LPS which employ the alternative
2-keto-D-glycero-D-talo-octonic acid (Ko) in its place. The
bond between the lipid A and this first Kdo residue is
normally very acid labile with moderate pH (<4.4) easily
hydrolysing the bond to release the core (and with it the
O-antigen) from the lipid A.
Interestingly, while the O-chain and the majority of the
core can be dispensed with in some viable mutants, this Kdo
residue is always absolutely required for bacterial viability.
Evidence for this is seen in the fact that the smallest
saccharide component seen in the LPS of any organism is
that of a deep rough mutant of Haemophilus influenzae [7]
which has only one Kdo residue attached to its lipid A, and
of the naturally occurring bacteria, the smallest core yet
seen is that of Chlamydia spp., which consists of only a
triplet of Kdo units [8] (Fig. 2). This primary Kdo residue
always has a negatively charged substituent on it (such as
phosphate, typically at position 4) and it appears that this is
essential for viability too.
The fact therefore that Kdo synthesis is absolutely
essential for Gram-negative bacteria viability presents ratio¬
nal drug designers with a tantalising opportunity. Drugs
targeting the Kdo synthesis enzymes would show not only a
wide specificity towards Gram-negative organisms but
would also represent an entirely new class of antibiotics [9].
A second unusual sugar seen in the inner core is heptose,
typically in the L-glycero-D-manno configuration, but also
occasionally as D-glycero-D-manno heptose. Yersinia
strains, for example, use this isomer exclusively [10].
Both inner and outer core sugar residues can be substi¬
tuted with charged groups like phosphate, pyrophosphate,
2-aminoethylphosphate and 2-aminoethylpyrophosphate. In
the inner core, it is thought that these substituents maintain
a close association with the Ca2+ and Mg2+ ions that are
required for membrane structure and function [11].
Since the inner core is reasonably well conserved (the
structure is identical, for example, for all strains of E. coli
and Salmonella), this provides the possibility of an epitope
capable of inducing an antibody of broad enough specificity
to cross-react antigenically with the LPS of many different
strains of Gram-negative LPS. This thought has already
been applied in the consideration of a new vaccine to elicit
such widely cross-reactive antibodies in human sera [12]
and in the production of a monoclonal antibody capable of
binding to a wide range of E. coli and Salmonella LPSs
[13].
Finally, it should be pointed out that while the endotoxi-
cally active part of the molecule is lipid A, the nature and
number of attached saccharide residues and substituents do
have considerable impact on modulating this activity. The
mechanisms for this will be discussed later.
2.3. General structure of lipid A
In 1985, it was shown that synthetic lipid A exhibits
identical biological properties to E. coli lipid A. [14], thus
proving that lipid A is the part of the molecule responsible
for its endotoxic activity. Structurally, lipid A is typically
composed of a |3-D-GlcN-(l-6)-a-D-GlcN disaccharide car¬
rying two phosphoryl groups (at positions 1 and 4'). Both
phosphates can be further substituted with groups such as
phosphate, ethanolamine, ethanolamine phosphate, ethano-
lamine diphosphate, GlcN, 4-amino-4-deoxy-L-arabino-
pyranose and D-arabino-furanose.
To this structure are attached up to four acyl chains by
ester or amide linkage. These chains can then in turn be
substituted by further fatty acids to provide LPS molecules
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Fig. 3. Chemical structure of E. coli lipid A. The structural format of E. coli
lipid A is widely considered to be close to that optimally recognised by
human cellular LPS receptors. Deviations from this bisphosphorylated
diglucosamine backbone substituted with six acyl chains are typically seen
to result in molecules of lower biological activity.
with up to seven acyl substituents, which vary quite
considerably between species in nature, number, length,
order and saturation. These can be attached to the lipid A
either symmetrically (3 + 3, e.g. Neisseria meningitidis) or
asymmetrically (4 + 2, e.g. E. coli). Unsaturated fatty acids
are rarely seen in lipid A, but have been reported in
Rhodobacter sphaeroides and R. capsulatus LPS and in
enterobacteriaceae grown at low temperature. It is possible
though not yet proven that this helps the bacteria regulate
membrane fluidity.
The polysaccharide portion of the molecule is almost
invariably linked (see above) to the lipid A by means of a
linking Kdo residue at position 6' (Fig. 3). This portion of
the molecule therefore constitutes the most highly con¬
served region seen between LPS molecules: a phosphory-
lated diglucosamine backbone attached to at least one Kdo
(or Ko) residue. (Campylobacter jejuni LPS is the notable
exception to this rule, in which GlcN II is replaced by the
related molecule 2,3-diamino-2,3-dideoxy-D-glucose
(GlcN3N) [15].)
Some examples of lipid As from selected human patho¬
gens and chemically synthesised derivatives are depicted in
Fig. 4. These are the chemically elucidated complete struc¬
tures of lipid A, though it should be borne in mind that like
O-chain, extracted lipid A often possesses a considerable
proportion of partial or incomplete structures as a result of
incomplete biosynthesis.
3. Lipid A structure vs. function
In order to understand how the structure of lipid A affects
its endotoxic activity, much use has been made of chemi¬
cally synthesised and modified lipid As. In the main, these
lipid A partial structures were prepared to contain the typical
|3-(l-6)-linked D-GlcN disaccharide while differing in pat¬
terns of acylation and phosphorylation. To date, a wide
range of synthetic structures have been tested in biological
assays and much has been learned of the contribution of
individual parts of the molecule towards its overall toxicity.
From these studies, it has appeared that the major
contributing factors to endotoxicity are the number and
lengths of acyl chains present and the phosphorylation state
of the disaccharide backbone. For example, structures with
only one phosphate at either 1 or 4' appear, in most assays,
to be -1000-fold less active than E. coli lipid A [16,17] (as
is the naturally occurring monophosphoryl Bacteroides
fragilis lipid A). However, phosphates per se do not appear
to be essential, as substitution with phosphono-oxyethyl
does not alter the compound's activity [18], suggesting that
merely correctly placed negative charges can restore activ¬
ity.
GlcN monosaccharide preparations phosphorylated and
acylated in various positions lack activity in general [19],
suggesting that the disaccharide backbone is also required
for optimum recognition by humoral/cellular receptors.
Lipid A with GlcN3N replacing GlcN (as seen naturally in
C. jejuni) have similar activity to those expressing GlcN.
Naturally, much work has concentrated on the role of the
nature, number and lengths of acyl chains attached to the
lipid A. For example, structures similar to E. coli lipid A
with two phosphates but seven or five fatty acids are less
active by a factor of approximately 100 [6].
From these studies and many others, it appears that it is
the diphosphorylated E. coli-like hexa-acyl lipid A contain¬
ing two |3(l-6)-linked D-glucosamine (GlcN or GlcN3N)
residues which is optimally recognised by mammalian
receptors to express the full spectrum of endotoxic activi¬
ties. In almost all structures looked at, deviations from this
pattern reduce the activity of the molecule.
These predictive rules for toxicity tend to hold true when
looking at naturally occurring LPSs, as evidenced by the
structures recently obtained for endotoxins of lower activity
(cf. lipid As of B. fragilis, Pseudomonas aeruginosa,
Chlamydia trachomatis and R. sphaeroides depicted in
Fig. 4).
The excellent work of Rietschel et al. [11] has looked in
particular at the role of individual subunits within this
structure in conferring overall toxicity, and is summarised in
Fig. 5.
Interestingly, it appears that this optimum structure for
cellular activation is not the same as the optimum structure
for cell binding. Experiments have revealed that the opti¬
mum structure for binding to cells follows a much less strict
template, being merely a bisphosphorylated disaccharide,
together with some fatty acids (minimum 2) and in no
particular arrangement. Structures that bind very well to
cells do not necessarily induce strong monokine release,
further suggesting that it is the number, nature and distri¬
bution of fatty acids, i.e. the acylation pattern of the lipid A
which determines the endotoxic activity of these com¬
pounds.
In addition to providing a number of structures with
reduced biological activity, these studies have also produced
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Fig. 4. Selected Gram-negative lipid A and derivative structures. Structures shown are complete forms. Commonly seen partial substitutions (as a result of
incomplete biosynthesis) are indicated by dashed lines. NB. The endotoxic activities given for each compound are included as a qualitative guide only and
represent only a subjective appraisal of the results from the many disparate (and occasionally conflicting) in vitro studies—and therefore cannot be assumed
to reflect the overall in vivo endotoxicity of any structure shown. For LPS where no such data are available (indicated with a question mark), the activity
shown is an estimate based on the structure of that molecule.
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Fig. 5. Effect of structural modifications on lipid A bioactivity. Figures
shown represent factors by which modified structures are reduced in
bioactivity when compared to complete E. coli lipid A. Top: modifications
to hydrophilic section. Bottom: modifications to hydrophobic section.
Reproduced with permission from Rietschel et al. [11].
some compounds with pronounced inhibitory effects. One
of the most interesting of these is compound 406 (also
called precursor la, as it is a biological precursor to natural
lipid A) which is tetra-acyl (Fig. 4). This structure is
essentially the same as compound 506 (i.e. synthetic E. coli
lipid A) but with the two acyl-substituted fatty acids
removed. In a number of biological assays, this analogue
not only completely lacks endotoxic activity, but is also able
to inhibit normal lipid A signalling. Moreover, compound
406 is not antagonistic for other stimuli, such as lectins,
Gram-positive bacteria, lipoproteins or cytokines. Of per¬
haps yet more interest is the fact that this compound, while
exhibiting no endotoxicity in human assays, does show
moderate activity in murine monocytes. The implications of
this observation will be discussed later.
Additionally, it may be of note that on biodegradation of
E. coli lipid A by the enzyme 3-acyloxyacyl-hydrolase
within macrophages, the product yielded is essentially
identical to compound 406 [20], suggesting the possibility
that such a pathway may be utilised by the cells to detoxify
LPS and thus counteract subsequent lipid A recognition.
Finally, it should be pointed out that natural antagonists
to E. coli lipid A signalling also exist. LPS or lipid A from
R. capsulatus and R. sphaeroides have also been shown to
have antagonistic properties, as has LPS isolated from
B.fragilis [21,22].
4. Physical conformation and endotoxicity of LPS
LPS molecules like other amphipathic molecules will
aggregate into larger supra-molecular structures above a
particular critical concentration. The three-dimensional con¬
figuration of this structure depends to a large extent on the
shape of the individual contributing molecules and the
environment in which it forms. Much work has recently
been performed on how the structure of these aggregates
affects the endotoxicity of LPS preparations. From these
studies, some striking observations have been made as to the
relationship between these structures, the molecular archi
tecture of individual LPS molecules and resultant endotoxic
activity.
Early studies looked initially at the phase transition
temperature of lipid A and LPS preparations [23]. The acyl
chains of LPS can assume two main phase states: liquid
crystalline (a) or gel state ((3), and above or below a
particular temperature (Tc), this phase state can reverse. Tc
depends to a large extent on the length and degree of
saturation of the acyl chains and on the conformation and
charge density of the hydrophilic head group region. Of
note, while bacteria are able to alter the Tc of their plasma
membrane quite widely to adapt to the current growth
temperature, the LPS Tc cannot be altered by nearly as much
(perhaps lending a role to the partial structures and unsat¬
urated acyl chains occasionally seen in naturally occurring
LPS).
Seydel et al. have noted a striking correlation between Tc
and the biological activity of LPS preparations. In addition
to many other examples, they cite that for instance: (i) the
induction of leukotrine C4 (LTC4) release from mouse
peritoneal macrophages after stimulation with Salmonella
Minnesota LPS is highest with ReLPS (lowest Tc), lowest
for lipid A (highest Tc) and decreases with longer oligosac¬
charide (Tc increasing); and (ii) murine spleen cell prolif¬
eration is high for rough mutant LPS (Rd is best), with
responses to lipid A and smooth LPS significantly lower
(reviewed in [17]). From this point of view, it appears that
low Tc gives rise to high endotoxic activity.
However, other studies have taken an alternative ap¬
proach, looking instead at the physical superstructure of
LPS aggregates. It was initially observed that structural
presentation of the LPS to cell receptors must play a role,
following the work of Takayama et al. [24], who managed
to prepare solutions of LPS monomers by using concentra¬
tions below the critical micelle concentration. They found
that the activity of a given lipid is significantly increased
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Fig. 6. Shape of LPS molecules and resultant supra-molecular structures.
Three commonly seen conformations of LPS. The ratio between the upper
(hydrophilic) and lower (hydrophobic) surface areas has been proposed to
be the primary determinant of supra-molecular structure (see text). Repro¬
duced with permission from Seydel et al. [23].
In general, biologically active lipid A adopts (at physi¬
ological conditions of water content, pH, temperature and
Mg2+ concentration) exclusively non-lammelar structures
[25]. These are of either cubic or hexagonal conformation
(see Fig. 6). In contrast, biologically inactive lipid As adopt
lammelar structures (e.g. R. capsulatus).
These researchers then suggest that the superstructure
itself is purely a function of molecular shape. Effectively,
LPS can be viewed as having two easily measured surface
areas: that of the hydrophilic domain and the hydrophobic
domain. The ratio between these two parameters essentially
defines the shape of the molecule to be, for example, conical
or cylindrical, and it is these parameters that dispose the
LPS towards a particular type of superstructure, and hence
endotoxicity (see Fig. 6). Thus, from comparison of many
lipid A and LPS structures, they conclude that endotoxically
active lipid A is conical, whereas inactive lipid A is
cylindrical.
Of course it is quite possible that Tc and superstructure
are highly related, though the question of which structural
parameter of LPS (i.e. individual molecular shape or aggre¬
gate conformation) is being recognised by cellular receptors
has yet to be determined.
However, a word of caution should be inserted at this
stage. The assays used to determine the endotoxicity of
these lipid A preparations have in the main been in vitro
using highly chemically defined products. In the natural
setting, the LPS presented to cells would almost certainly
not be in this context. Instead, the LPS will be present in
both large and small aggregates, complexed with bacterial
proteins and other contaminants and would be heteroge¬
neous in composition. In addition, plasma proteins will be at
least partly complexed with the LPS and will also have a
strong influence on the in vivo endotoxicity of any given
preparation. Thus, while much can be said of the endotoxic
potential of any given LPS by analysis of its phosphate and
acyl composition, it does not necessarily follow that this
will be reflected in the natural setting.
5. Receptors for LPS
While it had been recognised for some time that the
molecule CD 14 was required by cells to confer sensitive
responses to LPS, it was seen that it could not function as
the sole receptor molecule for LPS. Being a GPI anchored
protein, CD 14 lacks a transmembrane domain with which to
facilitate intracellular signalling. In addition to this, it was
noted that CD14-deficient human cells could still respond to
LPS even in serum-free conditions lacking soluble CD 14
[261.
This mystery remained unsolved until 1999, when the Ips
gene responsible for the LPS hyporesponsive phenotype of
C3H/HeJ mouse was at last discovered and shown to code
for a mutated version of the protein TLR-4 (Toll-like
receptor, so called because of its homology with the
Drosophila Toll protein) [27,28]. Examination of the TLR-4
knockout mouse that same year revealed a phenotype
similar to that of the C3H/HeJ mouse, and thus the function
of TLR-4 as an essential component of the LPS receptor was
confirmed [29].
However, it was soon realised that this was not yet the
complete picture. Transfection of some TLR-4-deficient cell
lines with TLR-4 was not in itself sufficient to render them
sensitive to LPS [27,29]. Thus, at least one further molecule
was seen to be required to complete the LPS receptor
complex. This was discovered shortly afterwards to be the
protein MD-2 when it was seen that co-transfection of these
cells with MD-2 restored LPS sensitivity [30]. An extracel¬
lular protein lacking a transmembrane domain, MD-2 re¬
mains attached to the cell surface via its interaction with
TLR-4.
However, this picture of the TLR-4/MD-2 complex being
the sole signalling receptor for LPS went through a period
of some controversy. Many groups were able to show
responses to their LPS preparations that were independent
of TLR-4. Moreover, it appeared that another Toll-like
receptor, TLR-2, was critical in these responses. Only
stringent purification protocols capable of providing LPS
extracts free from protein contaminants were finally able to
reveal that the majority of LPSs signal solely through TLR4,
while the TLR-2 signalling previously seen appeared to be
due to lipoprotein contamination of those preparations [31].
Nevertheless, two very interesting exceptions to this rule
have recently been described. The LPSs from Porphyromo-
nas gingivalis and Leptospira interrogans have both been
shown to be recognised not by TLR-4, but by TLR-2
[32,33]. Interestingly, the five branched acyl chains and
mono-phosphorylated lipid A of P. gingivalis differs sub¬
stantially from the typical hexa-acyl diphosporylated E. coli
lipid-A-like template recognised by TLR-4. While the
structure of L. interrogans lipid A has yet to be determined,
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it is tempting to speculate that it may share structural
features with P. gingivalis lipid A. Further, it is interesting
to note that LPS extracted from B.fragilis has already been
shown capable of activating TLR-4 mutant mouse
(C3H/HeJ) cells and shares a lipid A of striking resemblance
(see Fig. 4) to that of P. gingivalis lipid A [22]. Determining
the chemical structures of lipid A from other organisms with
LPS capable of stimulating TLR-4-deficient cells (such as
that of Treponema denticola [34]) may well shed some light
on the matter of which domains or particular three- dimen¬
sional arrangements of LPS are differentiated by TLR-2 and
TLR-4.
5.1. Mechanisms for recognition of LPS by TLR-4/MD-2
Much evidence has recently emerged to shed some light
on the mechanisms by which the TLR-4/MD-2 complex
might recognise LPS. Firstly, it appears that the main role of
LPS binding protein in the serum is to deliver LPS to either
soluble or membrane-bound CD14 [35]. Then, as it is now
becoming clearer that CD 14 does not play an essential role
in the TLR-4/MD-2 receptor complex (see above), it seems
that the likely role of CD 14 is to catalyse insertion of LPS
molecules into either the plasma membrane (a function of
CD14 demonstrated by Wurfel and Wright [36]) or directly
into the receptor complex. In support of this hypothesis,
Ulevitch and co-workers have used photo-activated cross-
linking to reveal LPS in close proximity with both TLR-4
and MD-2, but only when in the presence of CD 14 [37]. In
addition, it has also been shown that LPS is transferred out
of mCD14 before it is internalised [38].
As for which of TLR-4 and MD-2 participates in the
discrimination of active lipid As, evidence is now emerging
to suggest a role for both of these proteins in this function.
For example, it has been shown that expression of murine
TLR-4 in human cells renders them sensitive to the partial
structure lipid IVa, whereas expression of human TLR-4 in
unresponsive C3H/HeJ mouse cells does not [39,40]. On the
other hand, Akashi et al. [41] have shown that while
transfection of Ba/F3 cells with murine TLR-4 and MD-2
allows them to respond to the partial structure lipid IVa,
replacement of the murine MD-2 with the human equivalent
removes this ability. In addition, this chimaeric complex
was seen to confer an antagonistic effect on lipid IVa, which
remains an agonist in cells expressing the purely murine
complex [41]. MD-2 has also been shown to have a direct
effect on the discrimination of another TLR-4 ligand, the
anti-mitotic compound Taxol. Signalling in response to
Taxol has been shown to be ablated following the mutation
of a single glycine residue in MD-2, whereas LPS signalling
remains unaffected [42]. Further, distinct differences have
been observed in the abilities of human and mouse MD-2
molecules to recognise Taxol [43].
Nevertheless, it seems clear that dimerisation of TLR-4
appears to be the key to activation of the complex, as
chimaeric constructs of TLR-4/CD4 have been shown to
dimerise at the cytosolic domains and induce cellular
activation [44]. However, the question of how LPS is able to
induce dimerisation of TLR-4 remains as yet unclear.
Depicted in Fig. 7 are three models which suggest how
particular types of LPS may result in dimerisation of TLR4
monomers and ultimately, cellular activation.
In the first (Fig. 7a), LPS is recognised within the
complex of MD-2 and TLR-4. MD-2 has been shown to
have a high affinity for LPS (Kd = 65 nM, similar to that of
CD 14 [45]) and may function to hold the LPS in place for
TLR-4-mediated pattern recognition. Alternatively, the in¬
corporation of the LPS into either molecule may induce a
conformational change which then promotes dimerisation of
TLR-4. In this model, LPS molecules are delivered directly
to the complex by CD 14.
Alternatively, since it has been shown that CD 14 rapidly
catalyses the insertion of LPS into the plasma membrane of
host cells [36], it may be possible that this is where TLR-4
and MD-2 encounter the LPS (Fig. 7b). In this scenario, the
shape of the lipid A is recognised by the transmembrane
domains of TLR-4, while the (exposed) charged head group
may be recognised by MD-2.
Finally, it is possible that disruptions to the physical
properties of the host cell membrane occurring as a result of
the incorporation of the unusual lipid A are recognised by
TLR-4/MD-2, as first suggested by Wright [46]. Evidence
Fig. 7. Possible mechanisms for LPS recognition by the TLR-4/MD-2 complex, (a) CD 14 delivers LPS molecules directly to the TLR-4/MD-2 complex
inducing dimerisation; (b) CD 14 catalyses insertion of LPS into the plasma membrane, where the hydrophobic domain interacts with the transmembrane
domain of TLR-4 and the head group with MD-2; (c) LPS inserted into the membrane by CD14 causes changes in the membrane architecture sensed by the
TLR-4/MD-2 complex.
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NF-kB MAP Kinases
Fig. 8. Proposed signalling complex of TLR-4/MD-2. Dimerisation of
TLR-4 in response to ligand occurs with the assistance of extracellular
MD-2 to form a signalling complex containing MyD88 (Myeloid differen¬
tiation factor 88), TIRAP (Toll/interleukin-1 -receptor-domain-containing
adaptor protein), TOLLIP (Toll interacting protein) and IRAKs (IL-1
receptor-associated kinases).
for this includes the striking correlation between lipid A Tc
and toxicity (discussed earlier) and the fact that the mem¬
brane active agent chlorpromazine is able to render cells
usually insensitive to lipid IVa, sensitive [47]. The effects of
lipid A antagonists can also be explained in this model by
functioning to counteract the physical changes in the mem¬
brane caused by lipid A. In this model, local membrane
architecture is altered in such a way as to dimerise the TLR
subunits with the assistance ofMD-2 resulting in signalling
(Fig. 7c).
5.2. Intracellular signalling of the TLR-4/MD-2 complex
The TLR-4 signalling pathway shows striking similari¬
ties to that employed by the IL-1 receptor. In both pathways,
the adaptor protein MyD88 (myeloid differentiation factor
88) is thought to be recruited to activated (i.e. dimerised)
IL-1R or TLR-4 cytosolic domains where it catalyses the
activation of serine/threonine kinases of the IL-1 receptor-
associated kinase (IRAK) family. These then act through
TRAF-6 (TNF-receptor associated factor 6) to promote both
MAP kinase cascades and the NF-kB-inducing cascade
(reviewed in [48]).
Recently, a protein has also been identified that interacts
both with the cytoplasmic tail of the IL1 receptor and with
IRAKs. Termed Tollip, this protein has also been shown to
co-precipitate with TLR-2 and TLR-4 [49], and is also
likely to play a role in recruiting IRAKs to the dimerised
Toll receptors (see Fig. 8).
Evidence is accumulating, however, to suggest that LPS
signalling may proceed along alternative parallel pathways.
For example, certain cellular responses towards LPS do not
require MyD88, and while the activation of NF-kB in
response to LPS is merely delayed in MyD88-deficient
cells, it is completely abolished in TLR-4-deficient cells
[50]. Another recently discovered protein TIRAP (or MAL)
has been shown to interact with both TLR-4 and IRAK-2
and on over-expression also activates NF-kB [51,52]. It is
therefore possible that this adaptor protein is responsible for
at least one MyD88-independent signalling pathway
[51,52], though its full function remains to be determined.
6. Comparison of Gram-negative LPS structures
While the endotoxicity of lipid A is certainly of great
significance in many disease processes, it is not the only
aspect of naturally occurring LPSs to affect the pathophysi¬
ology of Gram-negative infections. The saccharide domains
are also of great significance, and much variation occurs as
to the general role of LPS in infections. Most notably, the
O-polysaccharide portion of the molecule is often seen to
confer serum resistance on organisms [53]. It may act as a
cellular adhesion molecule, for example, Actinobacillus
pleuropneumoniae which utilises its LPS as a major adhesin
for lung tissue [54]. Finally, it may act either directly or
indirectly as a virulence factor in many disease processes.
Further consideration is now given to the roles played by
particular LPS types in the pathology of different Gram-
negative infections and to the relationship between structure
and function of these LPSs.
6.7. E. coli LPS
E. coli is the most common cause of urinary tract
infections and is also responsible for many different gas¬
trointestinal diseases including travellers' diarrhoea and
infantile diarrhoea. However, the LPS of E. coli alone can
be the causative agent of a number of diseases. Being a
major gut commensal, the human gut therefore contains
many grams of E. coli LPS. Under normal conditions,
limited diffusion of this into the portal circulation is dealt
with by Kupffer cells in the liver via non-stimulatory
degradative pathways. However, on release of larger
amounts of LPS into the blood stream (as can occur
following surgery or other causes of hypo-volaemic shock)
the resulting systemic inflammatory response syndrome can
lead to multiple organ failure, shock and potentially death.
In this respect, E. coli LPS is often regarded as the most
potent initiator of monokines.
The high toxicity of E. coli LPS can be explained to a
large extent by its structure. The hexa-acyl diphosphory-
lated lipid A with acyl chains of length C12-C14 is widely
believed to comprise or at least be very close to the structure
optimally configured to provide maximal activation of
TLR-4, and hence activation of monocytes. In vitro studies
of many different LPS types have shown that in the main,
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deviations from this structural format lead to sometimes
quite dramatic reductions in the endotoxic potential of a
molecule (cf. Figs. 4 and 5).
6.2. S. minnesota LPS
Salmonella spp. are a leading cause of gastroenteritis.
The LPS from Salmonella is typically regarded as having
almost as much endotoxic activity as E. coli LPS. This
could be expected of S. typhimurium LPS, which shares an
identical lipid A structure with that of E. coli, but might be
considered unusual of S. minnesota LPS, as hepta-acyl LPS
has been shown to have reduced activity when compared to
E. coli LPS. However, while the hepta-acyl structure given
for S. minnesota lipid A in Fig. 4 is the most complete
structure seen, it is not the most numerous. Studies of
S. minnesota Re595 LPS and lipid A have revealed that only
15% of structures are complete (i.e. hepta-acyl) with the
most abundant structure being a hexa-acyl analogue of the
E. coli arrangement [55]. This therefore provides the most
likely explanation for the high endotoxicity seen in naturally
occurring S. minnesota LPS.
6.3. Klebsiella pneumoniae LPS
K. pneumoniae is an opportunistic pathogen causing
bacteraemia, pneumonia and urinary tract infections in
humans. Often associated with nosocomial infections, it is
second only to E. coli as the culprit behind Gram-negative
sepsis syndrome and is a major cause of mortality in
hospital-acquired infections. Several O-antigens have now
been described with approximately 80% of K. pneumoniae
clinical isolates belonging to serotypes Ol, 02, 03 and 05
[56]. Properties of K. pneumoniae LPS include the unusual
observation of Kdo existing in the outer core and the
existence of homo-polysaccharides in some O-chains. It has
also been observed that K. pneumoniae LPS itself is a
significant virulence factor in these infections. For example,
injection of purified LPS significantly enhances K. pneumo¬
niae virulence in a mouse model of infection [57], though it
is not yet clear how this occurs. Characteristic lung damage
can also be seen in K. pneumoniae infections and is caused
by the release of a toxic complex from the bacterial cell
surface during growth of strains of K. pneumoniae serotypes
01:K1 and 01:K2. LPS is the critical component of this
complex.
In terms of endotoxicity, K. pneumoniae LPS is consid¬
ered to be strongly active—an observation in accordance
with its bisphosphorylated lipid A substituted with six acyl
chains of 12-16 carbon length, thereby making it close in
structure to the optimally recognised template.
6.4. P. aeruginosa LPS
P. aeruginosa is an opportunistic pathogen found ubiq¬
uitously in the environment and is capable of infecting
patients whose health is compromised. At least 20 sero-
groups of O-chain have been identified and at least four core
structures have now been determined [58]. Unusual features
of P. aeruginosa LPS include the presence of several
unusual diacetamido uronic acids of gluco-, manno-, and
gulo-configurations in the ^-polysaccharide region [59] and
the substitution of some of these sugars with amino acids.
Unusually, about 80% of the LPS expressed on the surface
of P. aeruginosa is of the rough variety [60,61]. P. aerugi¬
nosa LPS also contains an additional polysaccharide antigen
(sometimes called the A band LPS) which is common to
many serogroups. Composed primarily of D-rhamnose
monosaccharides, it is not clear if this polymer attaches to
the same core as the O-chain or to a different lipid A. Either
way, the O-polysaccharide region is required for virulence
as R-mutant P. aeruginosa tested in animal models of acute
infection are virtually avirulent [62].
However, P. aeruginosa infection in the cystic fibrosis
patient reveals an interesting exception to this rule. Strains
causing chronic infections are seen to lose the O-chain and
become serum sensitive [63]. The reason for this is unclear.
In healthy patients, functional CFTR is capable of binding
to the P. aeruginosa LPS core region [64], thus mediating
ingestion and removal of the bacteria. It has been proposed
that this CFTR-mediated uptake is a key component of host
innate defence against P. aeruginosa [65], as it appears to
be the only bacteria recognised by these receptors. Cystic
fibrosis patients expressing the defective CFTR dF508, on
the other hand, only poorly ingest these bacteria and are
therefore prone to chronic infection.
In structural terms, P. aeruginosa lipid A exhibits signifi¬
cantly less toxicity than E. coli and Salmonella lipid A,
presumably as a result of the penta-acyl format which at
C10-C12 is significantly shorter than the optimum E. coli-
like template (Fig. 4).
6.5. B. cepacia LPS
B. cepacia was first identified as a phytopathogen caus¬
ing soft rot in onions. Now, it is more widely recognised as
a significant nosocomial pathogen and an agent of recalci¬
trant respiratory infections in cystic fibrosis patients in
particular. B. cepacia LPS has been looked at as a possible
virulence factor [66], but the effect on pathophysiology and
colonisation remains unclear.
Nevertheless, B. cepacia LPS has some unusual struc¬
tural features which may affect its pathogenicity. The most
striking of these is the replacement of the otherwise very
highly conserved lipid attached Kdo with the related 2-keto-
D-glycero-D-talo-octonic acid (Ko). Of note, the bond of
Ko to lipid A is not nearly as acid labile as Kdo.
B. cepacia (9-chains are all linear with simple disaccha-
ride or trisaccharide repeating units often containing un¬
usual sugar residues (e.g. 2-amino-2-deoxy-L-glucose,
D-fucose, L-glycero-D-manno-heptose) and in several sero¬
types, the LPS is seen to contain two antigenically distinct
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polymers. B. cepacia LPS has a low anionic character as a
result of the limited phosphorylation and the presence of
4-amino-4-deoxy-L-arabinose in the core polysaccharide
[66]. This low anionic character may account for the high
resistance to (especially cationic) antibiotics of B. cepacia.
Antibody responses to B. cepacia are typically strong but do
not clear the infection [67]. In most environments, B. cepa¬
cia LPS is of the smooth form, though in a similar fashion
to P. aeruginosa isolates from cystic fibrosis patients, can
be either R- or S-form.
The fine structure of B. cepacia lipid A has not yet been
determined, though as it is seen to be strongly endotoxic in
vitro, it is likely that it does not share the penta-acyl format
of P. aeruginosa LPS, most likely adopting instead an
E. co/i-like hexa-acyl format.
6.6. Helicobacter pylori LPS
H. pylori is able to cause chronic infection of the human
gastric mucosa and is the primary cause of active chronic
gastritis. Structurally, H. pylori LPS has been well charac¬
terised. While R-LPS is tetra-acylated, S-LPS is seen to
contain some hexa-acylated LPS. In addition, while R-form
LPS is only mono-phosphorylated (at position 1 and par¬
tially substituted by ethanolamine), a second phosphate is
partially substituted at position 4'. The acyl chains are
longer than those seen in E. coli lipid A, averaging about
16-18 carbons long. Thus, it might be predicted that as a
result of this under-phosphorylation and under-acylation
H. pylori lipid A should display reduced endotoxic activity.
This is indeed found to be the case: pyrogenicity and
mitogenicity is 1000-fold less than that observed for S. ty-
phimurium LPS, lethal toxicity in mice is 500-fold lower
and LAL assay reveals an activity 100-500-fold less [68].
Of more interest, however, is the fact that H. pylori
O-antigens can share Lewis x and y blood group antigens
found in the gastric mucosa. Monteiro et al. [44] have
shown that H. pylori can express both type 1 and type 2
Lewis antigens and it has even been shown that H. pylori
derived from infected individuals express Lewis antigens
consistent with the erythrocyte phenotype of the host [69,
70], It has therefore been postulated that these structures are
present to minimise the risk of host attack on these
organisms [71].
6.7. B. fragilis LPS
Bacteroides spp. constitute the most numerous commen¬
sal bacteria in the human gut, outnumbering E. coli by at
least 100 to 1. B. fragilis is one of the most commonly
encountered anaerobic species in clinical specimens, ap¬
pearing to be more virulent than its close relatives. Tradi¬
tionally, the endotoxic activity of B.fragilis LPS (when
extracted from whole bacteria by the
petroleum/chloroform/phenol method for R-form LPS) is
considered to be low when compared to E. coli and Salmo¬
nella LPS: pyrogenicity, the ability to promote local
Shwartzman reaction and IL-113 induction from monocytes
are all reduced 100-1000-fold [72], This weak endotoxicity
has been proposed to be due to the mono-phosphorylated
(on the CI of the reducing amino sugar) lipid A, the
relatively long (C15-C17) acyl chains and the fact that there
is an average of only five fatty acids per molecule with some
of these showing unusual branching patterns.
However, when the LPS was extracted by the aqueous
phenol method (for S-form LPS), the resultant product was
much more highly endotoxic, being equivalent to that of
enterobacterial LPS in terms of Limulus activity and TNF
induction from mononuclear cells. It also appeared to
produce a fine ladder pattern on silver-stained SDS-PAGE
gels, reminiscent of smooth LPS [73,74].
6.8. C. jejuni LPS
C. jejuni is an increasingly recognised cause of intestinal
infection. Human Campylobacter infections are character¬
ised by intestinal mucosal invasion, haemorrhagic inflam¬
mation and crypt abscess formation. C. jejuni lipid A is
similar to that of related species, but has replaced one (or
both) of the glucosamine residues of the lipid A backbone
with the related sugar 2,3-diamino-2,3-dideoxy-D-glucose
(GlcN3N). Other than this, C. jejuni lipid A is antigenically
similar to enterobacterial lipid A, and has comparable
endotoxic activity in biological test systems [15],
Inner core oligosaccharides of C. jejuni strains share a
common unique tetrasaccharide (Glc-Hep-Hep-Kdo) and
also possess a trisaccharide that occurs in the inner core of
other bacterial species. The inner and outer core may be
substituted with sialic acid [15] in the form of ganglioside
mimicry. This is a common feature shared by a number of
but not all C. jejuni serotypes and may play a significant
role in the induction of autoantibodies in Guillain-Barre
syndrome following C. jejuni infection [75],
As with other LPSs, there is some heterogeneity in
naturally occurring lipid As. For example, at position 2' of
the lipid A backbone, 16:0 on 14:0 (3-OH) is only partially
(20%) substituted and non-stochiometric substitution of
phosphate groups occurs (pos. 1: ethanolamine or ethano¬
lamine phosphate; pos. 4': ethanolamine phosphate).
6.9. Yersinia pestis LPS
Less work has been performed on Y. pestis LPS, though
the following general points can be made. Rough and
smooth forms have been observed. Lipid A consists of the
typical (1-6) p-linked D-glucosamine disaccharide carrying
two phosphate groups—further substituted with either phos-
phoethanolamine, a 4-amino-4-deoxy-L-arabinosyl residue
or the rarely seen D-arabinofuranose [10]. The exact loca¬
tions of the acyl chains remain to be determined, though a
proposed structure [10] is given in Fig. 4. The chain lengths
(C12-C16) and presence of two lipid A bound phosphates
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suggest that if the lipid A of this species turns out to be
predominantly hexa-acylated, it is likely to show strong
endotoxic activity.
6.10. N. gonorrhoeae and N. meningitidis (LOS)
Not all Gram-negative LPSs have a long repeating
O-chain structure. Some bacteria express only core saccha¬
ride joined to a short non-repeating polysaccharide unit.
Such LPSs have been termed 'lipo-oligosaccharide' (LOS)
to differentiate them. Both N. gonorrhoeae and N. menin¬
gitidis express LOS—the latter of which is of particular
interest as most of the shock and complications involved in
meningococcal meningitis are due to N. meningitidis endot¬
oxin, which causes extensive vascular damage.
The LOS of N. meningitidis and N. gonorrhoeae is non¬
repeating and less than 10 residues in length (see Fig. 2).
Both are able to mimic carbohydrates present in the gly-
cosphingolipids of humans by sialylating their LOS by
means of host-derived enzymes [76], For example,
neuraminic acid (Neu5Nac) is often expressed at the termi¬
nal glycosyl residue. It has been hypothesised that this
allows Neisseria to evade host immune responses by mim
icking Neu5Nac-carrying host antigens [25]. This may be
achieved in a number of ways. Firstly, it has been seen that
the presence of sialic acid in membranes is able to down-
regulate the alternative complement pathway component C3
convertase, though it should be pointed out that strains
lacking this sialylation are not necessarily rendered sensi¬
tive to serum killing. Sialylation also inhibits phagocytosis
of cells by human neutrophils. Some reports suggest that
sialylation decreases adherence to human cells, while others
have pointed out that there is specific binding of gonococcal
LPS to ciliated epithelial cells, suggesting that a human
lectin may exist to recognise specific carbohydrate epitopes
on LOS. LOS receptors on human monocytes have also
been suggested. Other suggested roles for sialylated LOS
include intracellular survival and altered regulation of host
cells. Lastly, Neisseria LOS can also be modified in vivo by
host substances/secretions, thereby allowing it to be differ¬
entially expressed in different environments. (For literature
relating to all of these points, see [76].)
In terms of endotoxicity. Neisseria LOS is generally
agreed to be very strongly active, as might be predicted
from the C12-C14 hexa-acyl bisphosphorylated lipid A
structure which closely resembles that of E. coli lipid A.
6.11. H. influenzae (LOS)
H. influenzae is an exclusively human pathogen that
routinely colonises the upper respiratory tract [77]. The
capsular type B of the bacterium was the most frequent
agent ofmeningitis in children under 4 years of age and was
responsible for many hundreds of thousands of childhood
deaths around the world. However, this has been greatly
reduced since the introduction of the Hib conjugate capsular
vaccine. Like N. meningitidis, H. influenzae also expresses
an LOS. This is a critical component of the non-capsulated
strains which are a common cause of otitis media, sinusitis
and lower respiratory tract infections.
However, despite the lack of a long O-polysaccharide,
strong serological variations are still observed [77], H. in¬
fluenzae can change its LOS epitopes via phase (or anti¬
genic) variation by altering expression of the so-called
'contingency genes' [78],
In each type of H. influenzae LOS chemically identified
so far, there is a common inner core consisting of three
heptoses linked via a single Kdo to the lipid A (providing a
promising target for vaccine development). The remainder
of the core then tends to be composed of neutral hexoses
outwards. A complete core seems to be required for both
commensal and invasive behaviour. For example, the deep
rough mutant 169 of a type b strain (lacking much of the
core, Fig. 2) was found to be non-virulent in the infant rat
model of infection [79], and a minimum of five sugars
attached to lipid A are required for efficient intra-vascular
survival. Again like N. meningitidis, sialylation is often seen
on terminal sugar residues. This appears to be endogenous,
but is enhanced when NANA is supplied in the growth
medium.
Structurally speaking, the hexa-acyl, C12-C14 format of
H. influenzae lipid A suggests a strongly toxic molecule and
in vitro systems prove this to be the case. Indeed, the lipid
A region is seen to be associated with damage during
disease.
6.12. Bordetella pertussis (LOS)
B. pertussis, the agent of whooping cough, also produces
an LOS which has been directly implicated as being the
mediator behind whooping cough syndrome [80].
The lipid A of B. pertussis LOS is covalently linked to a
single Kdo residue and then to a branched chain oligo¬
saccharide, thereby making it unlike most other strains of
the genus, which produce a longer O-antigen [81]. Also,
unlike most other enteric bacteria, Bordetella LOS contains
several charged sugars, and can be further substituted with
other charged sugars such as TV-acetyl-A-methylfucosamine
(FucNAcMe), 2,3-dideoxy-2,3-di-(V-acetylmannosaminuro-
nic acid (2,3-di-NacManA) and A-acetylglucosamine
(GlcNAc). It has been noted that the distal tri- and penta¬
saccharide epitopes provide potentially good targets for
vaccine design [81],
In vitro challenge data are not available for the LOS of
B. pertussis, though it might be suspected to exhibit a low
activity as there are only five acyl chains, and while most
are of E. coli-like length (C14), one is relatively short at
CIO.
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6.13. Chlamydia LPS
Chlamydiae are obligate intracellular parasites respon¬
sible for a variety of clinical manifestations. For example,
strains of C. trachomatis affect between 300 and 500
million people in developing countries, causing trachoma
which can lead to blindness. In industrialised countries,
C. trachomatis is the most prevalent cause of sexually
transmitted uro-genital infections. C. pneumoniae is the
causative agent of~5-10% of pneumoniae and bronchitis
cases and has even been implicated in coronary heart
disease. (For literature see [82].)
Chlamydiae express LPS of a unique structure. While
species expressing LOS typically attach between 10 and 20
sugars to their lipid A, chlamydial LPS makes do with only
a Kdo tri-saccharide joined a-Kdo-2-8-a-Kdo-2-4-a-Kdo.
Chlamydial LPS is of low toxicity, and much of this can
be attributed to its unusual structural features. Long-chain
fatty acids (C14-C21) in a penta-acyl arrangement and
mono-phosphorylation of the diglucosamine backbone dif¬
fer greatly from the optimum structure of E. coli.
7. Summary
LPS is one of the most potent activators of the mamma¬
lian immune system, and is essential for the viability of all
Gram-negative bacteria. A wide variety of LPS types are
expressed in nature, but all share some common principles:
a phosphorylated diglucosamine backbone substituted with
several acyl chains and at least one Kdo residue.
Differences between species and strains exist in all parts
of the molecule, but most variation occurs in the
O-polysaccharide, followed by the core region and finally
the lipid A component. The endotoxicity of LPS molecules
is determined primarily by the number, nature and arrange¬
ment of acyl chains and phosphate groups on the lipid A part
of the molecule, with molecules displaying an acylation
pattern similar to that of E. coli being the ones optimally
recognised by human monocytes.
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